---
document_datetime: 2024-02-08 11:28:53
document_pages: 216
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/omjjara-epar-public-assessment-report_en.pdf
document_name: omjjara-epar-public-assessment-report_en.pdf
version: success
processing_time: 288.8352375
conversion_datetime: 2026-01-01 21:17:18.416173
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

09 November 2023 EMA/548646/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Omjjara

International non-proprietary name: momelotinib

Procedure No. EMEA/H/C/005768/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                            |                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................    | 6                                                                                                         |
| 1.2. Legal basis and dossier content............................................................................      | 6                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................          | 6                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                | ................................................... 6                                                     |
| 1.4.1. Similarity                                                                                                     | ....................................................................................................... 6 |
| 1.4.2. New active Substance status.............................................................................       | 7                                                                                                         |
| 1.5. Protocol assistance............................................................................................. | 7                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                    | ....................................................... 8                                                 |
| 2. Scientific discussion ................................................................................9            |                                                                                                           |
| 2.1. Problem statement.............................................................................................   | 9                                                                                                         |
| 2.1.1. Disease or condition.........................................................................................  | 9                                                                                                         |
| 2.1.2. Epidemiology                                                                                                   | .................................................................................................. 9      |
| 2.1.3. Aetiology and pathogenesis...............................................................................      | 9                                                                                                         |
| 2.1.4. Clinical presentation, diagnosis and prognosis....................................................             | 10                                                                                                        |
| 2.1.5. Management.................................................................................................    | 12                                                                                                        |
| 2.2. About the product ............................................................................................   | 13                                                                                                        |
| 2.3. Type of Application and aspects on development                                                                   | .................................................. 14                                                     |
| 2.4. Quality aspects ................................................................................................ | 14                                                                                                        |
| 2.4.1. Introduction                                                                                                   | ................................................................................................. 14      |
| 2.4.2. Active Substance...........................................................................................    | 14                                                                                                        |
| 2.4.3. Finished Medicinal Product ..............................................................................      | 17                                                                                                        |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                     | 21                                                                                                        |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                             | ..................... 21                                                                                  |
| 2.4.6. Recommendations for future quality development                                                                 | .............................................. 21                                                         |
| 2.5. Non-clinical aspects..........................................................................................   | 21                                                                                                        |
| 2.5.1. Introduction ................................................................................................. | 21                                                                                                        |
| 2.5.2. Pharmacology...............................................................................................    | 22                                                                                                        |
| 2.5.3. Pharmacokinetics ..........................................................................................    | 27                                                                                                        |
| 2.5.4. Toxicology.................................................................................................... | 29                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................              | 34                                                                                                        |
| 2.5.6. Discussion on non-clinical aspects....................................................................         | 34                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................           | 35                                                                                                        |
| 2.6. Clinical aspects                                                                                                 | ................................................................................................ 35       |
| 2.6.1. Introduction                                                                                                   | ................................................................................................. 35      |
| 2.6.2. Clinical pharmacology                                                                                          | .................................................................................... 38                   |
| 2.6.3. Discussion on clinical pharmacology .................................................................          | 58                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology                                                                           | ............................................................... 66                                        |
| 2.6.5. Clinical efficacy                                                                                              | ............................................................................................. 67          |
| 2.6.6. Discussion on clinical efficacy                                                                                | .........................................................................156                              |
| 2.6.7. Conclusions on the clinical efficacy..................................................................174      |                                                                                                           |
| 2.6.8. Clinical safety                                                                                                | ..............................................................................................175         |

<div style=\"page-break-after: always\"></div>

2.6.9. Discussion on clinical safety ...........................................................................  198

2.6.10. Conclusions on the clinical safety ..................................................................  202

2.7. Risk Management Plan  .....................................................................................  203

2.7.1. Safety concerns ...........................................................................................  203

2.7.2. Pharmacovigilance plan  .................................................................................  203

2.7.3. Risk minimisation measures  ...........................................................................  203

2.7.4. Conclusion  ...................................................................................................  204

2.8. Pharmacovigilance...........................................................................................  204

2.8.1. Pharmacovigilance system  .............................................................................  204

2.8.2. Periodic Safety Update Reports submission requirements ...................................  204

2.9. Product information  .........................................................................................  204

2.9.1. User consultation..........................................................................................  204

2.9.2. Additional monitoring  ....................................................................................  204

3. Benefit-Risk Balance............................................................................  205

3.1. Therapeutic Context ........................................................................................  205

3.1.1. Disease or condition......................................................................................  205

3.1.2. Available therapies and unmet medical need ....................................................  205

3.1.3. Main clinical studies  ......................................................................................  206

3.2. Favourable effects  ...........................................................................................  207

3.3. Uncertainties and limitations about favourable effects ..........................................  208

3.4. Unfavourable effects  ........................................................................................  209

3.5. Uncertainties and limitations about unfavourable effects .......................................  210

3.6. Effects Table ..................................................................................................  211

3.7. Benefit-risk assessment and discussion ..............................................................  213

3.7.1. Importance of favourable and unfavourable effects ...........................................  213

3.7.2. Balance of benefits and risks  ..........................................................................  214

3.7.3. Additional considerations on the benefit-risk balance .........................................  215

3.8. Conclusions  ....................................................................................................  215

4. Recommendations ...............................................................................  215

<div style=\"page-break-after: always\"></div>

## List of abbreviations

## Quality

AS

Active substance

BCS

Biopharmaceutics classification system

CHMP

Committee for Medicinal Products for Human use

CQA

Critical quality attribute

DoE

Design of experiments

EC

European Commission

EI

Elemental impurity

EMA

European Medicines Agency

EU

European Union

FP

Finished product

FT-IR

Fourrier transform infrared spectroscopy

GC

Gas chromatography

HDPE

High density polyethylene

ICH

International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

IR

Infrared spectroscopy

KF

Karl Fischer titration

LDPE

Low density polyethylene

MO

Major objection

NMR

Nuclear magnetic resonance

NOR

Normal operating range

PAR

Proven acceptable range

PDE

Permitted daily exposure

Ph. Eur.

European Pharmacopoeia

RH

Relative humidity

SDS

Sodium dodecyl sulfate

SmPC

Summary of product characteristics

TSE

Transmissible spongiform encephalopathy

UPLC

Ultra-high performance liquid chromatography

XRPD

X-ray powder diffraction

## Non-clinical; Clinical

ACVR1/ALK2

Activin A receptor type 1/activin receptor-like kinase-2

AML

Acute myeloid leukemia

AUC

Area under the plasma concentration-time curve

BAT

Best available therapy

BID

Twice daily

Cmax

Maximum plasma concentration

CHMP

Committee for Medicinal Products for Human Use

CL/F

Apparent clearance

CYP

Cytochrome P450

DAN

Danazol

DIPSS

Dynamic International Prognostic Scoring System

eGFR

Estimated glomerular filtration rate

ELN

European LeukemiaNet

EMA

European Medicines Agency

E-R

Exposure-response

ESMO

European Society for Medical Oncology

ET

Essential thrombocythemia

EU

European Union

FDA

Food and Drug Administration

FLT3

FMS-like tyrosine kinase 3

Hgb

Hemoglobin

HSCT

Hematopoietic stem cell transplantation

IPSS

International Prognostic Scoring System

ISS

Integrated Summary of Safety

ITT

Intent-to-treat

JAK

Janus kinase

LFS

Leukemia-free survival

LS

Least squares

MAA

Marketing Authorisation Application

MACE

Major adverse cardiovascular events

MCT

Meaningful change threshold

MF

Myelofibrosis

MFSAF

Myelofibrosis Symptom Assessment Form

MMB

Momelotinib

MMRM

Mixed model for repeated measures

MOMENTUM

Study SRA-MMB-301

MPN

Myeloproliferative neoplasm

MPN-SAF

Myeloproliferative Neoplasm Symptom Assessment Form

OS

Overall survival

P-gp

P-glycoprotein

PK

Pharmacokinetics

PMF

Primary myelofibrosis

PV

Polycythemia vera

RBC

Red blood cell

RUX

Ruxolitinib

SIMPLIFY-1

Study GS-US-352-0101

SIMPLIFY-2

Study GS-US-352-1214

SmPC

Summary of product characteristics

SRR

Splenic response rate

STAT

Signal transducer and activator of transcription

TD

Transfusion dependence or transfusion dependent

TI

Transfusion independence or transfusion independent

Tmax

Time to Cmax

TR

Transfusion requiring

TSS

Total symptom score

US

United States

XAP

Study SRA-MMB-4365

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Glaxosmithkline Trading Services Limited submitted on 9 November 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Omjjara, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 15 October 2020.

Omjjara, was designated on 05 August 2011 as an orphan medicinal product EU/3/11/886 in the following condition: post-polycythemia vera myelofibrosis; EU/3/11/887 in the following condition: post-essential thrombocythemia myelofibrosis and EU/3/11/888 in the following condition: primary myelofibrosis.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Omjjara as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara

The applicant applied for the following indication:

Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms, and anaemia in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with a JAK inhibitor.

## 1.2. Legal basis and dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) EMEA-001656-PIP01-14 and EMEA-001656-PIP02-19 on the granting of a (product-specific) waiver.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## 1.4.2. New active substance status

The applicant requested the active substance momelotinib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.5. Protocol assistance

The applicant received the following Protocol assistance on the development relevant for the indication subject to the present application:

| Date              | Reference                             | SAWP co-ordinators                                                      |
|-------------------|---------------------------------------|-------------------------------------------------------------------------|
| 19 July 2012      | EMEA/H/SA/2368/1/2012/PA/SME/III      | Dr Andre Elferink, Dr Christoph Unkrig and Dr Rembert Elbers            |
| 19 September 2013 | EMEA/H/SA/2368/1/FU/1/2013/PA/II      | Dr Joao Manuel Lopes de Oliveira and Dr Ferran Torres                   |
| 28 February 2019  | EMEA/H/SA/2368/1/FU/2/2019/SME/II     | Dr Adriana Andrić and Dr Karin Janssen van Doorn                        |
| 19 September 2019 | EMEA/H/SA/2368/1/FU/3/2019/PA/SME/I I | Dr Karin Janssen van Doorn, Dr Juha Kolehmainen and Dr Armando Magrelli |

The Protocol assistance pertained to the following non-clinical and clinical aspects:

## EMEA/H/SA/2368/1/2012/PA/SME/III:

- The adequacy of the non-clinical study package with regards to metabolism studies, identification of metabolites and toxicology studies, to support clinical investigation
- The conduct of comparative bioavailability studies to support a proposed switch from capsule to tablet formulation for the phase III clinical trials
- The design and timing of the TQT study
- Elements of the proposed phase III  clinical studies YM387-III-01 and YM387-III-02, including eligible population, sample size,  design, comparators, primary and secondary endpoints and related measuring instruments.
- The appropriateness of the clinical program to support the sought indication and to justify significant benefit in the context of the orphan medicinal product designation.

## EMEA/H/SA/2368/1/FU/1/2013/PA/II

- The design and key elements of study GS-US-352-0101 including population, sample size, endpoints and statistical analysis plan, in order to support a regulatory approval in the sought indication.

## EMEA/H/SA/2368/1/FU/2/2019/SME/II

- The design and key elements of study SRA-MMB-301 including  patient population, comparator, primary and secondary endpoints and related PRO instruments, as well as  statistical analysis.

## EMEA/H/SA/2368/1/FU/3/2019/PA/SME/II

<div style=\"page-break-after: always\"></div>

- The potential of the available clinical data, in particular considering studies  SIMPLIFY-1 and SIMPLIFY-2,  to  support an application for conditional marketing authorization in the sought indication.
- The relevance of the revised clinical study SRA-MMB-301 to provide comprehensive data postapproval in the context of a conditional marketing authorization.
- The adequacy of the clinical program to support the sought indication as well as to generate data to justify significant benefit in the context of the orphan medicinal product designation

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Christophe Focke

Co-Rapporteur:  Alexandre Moreau

| The application was received by the EMA on                                                                                                                                              | 9 November 2022   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                                | 1 December 2022   |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                            | 21 February 2023  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                            | 2 March 2023      |
| The CHMP Co-Rapporteur's assessment was circulated to all CHMP and PRAC members on                                                                                                      | 3 March 2023      |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                 | 30 March 2023     |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                     | 14 July 2023      |
| The CHMP and PRAC Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                | 25 August 2023    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 31 August 2023    |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                 | 14 September 2023 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 9 October 2023    |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 25 October 2023   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Omjjara on | 9 November 2023   |

<div style=\"page-break-after: always\"></div>

| The CHMP adopted a report on similarity of Omjjara with Inrebic on                                                                     | 9 November 2023   |
|----------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product | 9 November 2023   |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Myelofibrosis (MF) is a rare Philadelphia chromosome (Ph1)-negative myeloproliferative neoplasm (MPN) that may occur de novo as primary MF (PMF) or as secondary MF (SMF) when it evolves from other pre existing MPNs polycythaemia vera (PV) or essential thrombocythemia (ET) (post PV/ET MF). SMF is clinically indistinguishable from PMF and develops due to fibrotic transformation and progressive bone marrow fibrosis (Sangle, 2014).

## 2.1.2. Epidemiology

MF has an incidence of about 0.58 new cases per 100,000 person-years, but a higher prevalence of 6 per 100,000 person-years because of its chronic and disabling course. Median age at diagnosis is 67 years, without any significant difference in distribution between the sexes (Iurlo, 2017; Visser et al, 2021). The median survival for all patients with MF is approximately 6 years (Zahr, 2016).  Median survival is considerably worse for patients with PMF with intermediate 2 risk (4 years) or high risk disease (1.5 -2.5 years) (Passamonti, 2010; Cervantes, 2009).  The most frequent cause of death in patients with MF is transformation to acute myeloid leukaemia (20%). Most patients die because of other disease-related events, such as progression without transformation, infections, and thrombohaemorrhagic complications.

## 2.1.3. Aetiology and pathogenesis

MF is a rare, chronic, progressive disease caused by clonal proliferation of hematopoietic stem cells in the bone marrow that leads to cytokine release, myeloid hyperproliferation, bone marrow fibrosis, and over time, characteristic clinical features (O'Sullivan, 2018; Iurlo, 2017).  The etiology of anemia in MF is multifactorial, that could be distinguished as MF-associated anemia with contributions from bone marrow fibrosis, direct effects of inflammation on the bone marrow microenvironment, splenomegaly with splenic sequestration; treatment-related anemia (eg, following treatment with JAK inhibitors), and anemia due to other causes, such as indirect effects due to elevated hepcidin or concomitant factors or deficiencies that contribute to anemia.

Regardless of whether myelofibrosis is primary or secondary, the disease is characterized by a clonal haemopoietic stem cell proliferation associated with reactive bone marrow fibrosis, osteosclerosis, angiogenesis, extramedullary haematopoiesis (EMH) and abnormal cytokine expression. MPNs are considered to arise from a somatic mutation of a pluripotent haematopoietic progenitor cell, but the exact cause of pathogenesis is unknown.

<div style=\"page-break-after: always\"></div>

Almost all patients with PV and about one half of patients with ET and PMF have a Janus kinase 2 (JAK2) mutation, typically JAK2V617F mutation. Increased JAK2 signaling, evidenced by constitutively phosphorylated signal transducer and activator of transcription (STAT3), is not strictly dependent on the presence of JAK2V617F mutation. Other mutations in patients with PMF include calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) (Tefferi, 2012). About 10% of patients with PMF have no detectable mutation in JAK2, CALR, or MPL and are termed 'triple negative' (Tefferi, 2016). Mutations in JAK2, CALR, and MPL activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway (Romano, 2017), resulting in cell proliferation and inhibition of cell death and clonal expansion of myeloproliferative malignant cells.

It is less clear how the driver mutations that are present in earlier myeloproliferative neoplasms, such as essential thrombocythemia or polycythemia vera, evolve to the more advanced phases of myelofibrosis. Factors may include epigenetic changes; additional somatic mutations in other genes, such as additional sex combs like 1 (ASXL1), ten-eleven translocation-2 (TET2), and isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2); and contributions of the bone marrow microenvironment, particularly regarding inflammation. Cytokine elevations in MF occur regardless of mutational status or disease subtype and MF is considered to be a condition with a considerable inflammatory potential (Lussana, 20175).

## 2.1.4. Clinical presentation, diagnosis and prognosis

MF manifests with complex clinical features that differ from patient to patient. Up to 30% of patients may be asymptomatic at the time of MF diagnosis, which may follow a routine blood test or physical examination revealing splenomegaly (O'Sullivan, 2018).  As the disease progresses, all patients become symptomatic due to bone marrow fibrosis/failure, systemic inflammation, and/or organomegaly. Key clinical features include constitutional symptoms, anemia, and organomegaly, principally of the spleen, which can cause associated symptoms (eg, abdominal pain, early satiety). Patients may experience constitutional symptoms such as fatigue, night sweats, fever, cachexia, bone pain, and pruritus (Tefferi, 2021).

Overall, MF is an aggressive, chronic disease with symptomology that is often debilitating.

A diagnosis of MPN is based on the 2016 World Health Organization (WHO) diagnostic criteria and requires a combination of clinical, laboratory, cytogenetic, and molecular testing (O' Sullivan, 20186). This includes the presence of 1 of the 3 driver mutations (JAK2, CALR and MPL). In patients with triplenegative disease, the detection of one of the associated somatic mutations (eg, EZH2, TET2, IDH1/2, ASXL1, SRSF2, or SF3B1) suffices as the presence of a clonal marker for diagnostic purposes. Because the natural course of secondary MF (post-PV MF and post-ET MF) may differ from that of PMF, the diagnosis of post-PV or post-ET MF should adhere to criteria published by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (Barosi, 2008).

Several prognostic scoring systems have been developed to facilitate risk assessment for patients with MF. The prognostic scorings were originally developed for primary MF, but the same models and parameters are applied in post-PV and post-ET MF, partly because the therapeutic approach is quite similar. The International Prognostic Scoring System (IPSS) is used to predict survival at diagnosis, and the Dynamic International Prognostic Scoring System (DIPSS) is used to predict survival at any time during the disease. The IPSS, DIPSS, and DIPSS plus prognostic models for PMF used to stratify patients into risk groups for survival and to guide treatment decisions all include Hgb &lt; 10 g/dL as a risk factor. Transfusion dependence (TD) is included as an additional risk factor in the DIPSS plus model. Variables are included with a defined number of points in different scoring systems (with moderate and anaemia with haemoglobin level &lt; 10 g/dL scored as 1 or 2 points). IPSS included

<div style=\"page-break-after: always\"></div>

variables of age &gt; 65 years, constitutional symptoms, haemoglobin level &lt; 10 g/dL, white blood cell (WBC) counts &gt; 25 x 109/L and circulating blast frequency ≥ 1%. DIPSS puts more emphasis on anaemia. DIPSS Plus incorporates 3 additional independent risk factors: platelet count &lt; 100 x 109/L, red blood cell (RBC) transfusion need, and unfavourable karyotype (Gangat, 2011). A strong association between DIPSS Plus risk category and overall survival (OS) for MF patients has been reported; intermediate-1, intermediate-2, or high-risk disease has been associated with median survival of 6.5, 2.9, and 1.3 years, respectively (Gangat, 2011; Tefferi, 2016). Approximately 90% of individuals with MF are in the intermediate or high-risk categories according to DIPSS Plus (Gangat, 2011), comprising a large population with symptomatic disease and shortened survival and representing the greatest unmet medical need.

An increased risk of leukemic transformation and shortened survival are serious concerns for patients with MF (O'Sullivan, 2018; Gangat, 2011).  Although transformation to acute myeloid leukemia (AML) is the most frequent cause of death for patients with MF (20%; Iurlo, 2017), survival is more commonly shortened because of other disease related events such as complications from progressive bone marrow failure, infections, thrombohemorrhagic complications, portal hypertension, or cardiovascular complications.

## Anemia in MF

The etiology of anemia is multifactorial with contributions from bone marrow fibrosis, direct effects of inflammation on the bone marrow microenvironment, splenomegaly with splenic sequestration, treatment effects, and indirect effects due to elevated hepcidin (anemia of inflammation) and other causes.  Anemia and RBC TD are major negative prognostic factors for survival in patients diagnosed with MF. Elevated hepcidin levels have also been correlated with poor survival in patients with PMF (Pardanani, 2013). Many of the disease related conditions contributing to early death are exacerbated by anemia, RBC transfusion associated iron overload, or both (Naymagon, 2017).  Anemia and associated RBC transfusion need are also risk factors for leukemic transformation in MF (Dunbar, 2020).

The presence of TD assigns a patient to at least intermediate 2 risk in the DIPSS plus model.  All grades of anemia have been shown to adversely affect survival among patients with PMF (Nicolosi, 2018).  Severe anemia (defined as Hgb &lt; 8 mg/dL or TD) was associated with a &gt; 1.5 fold increase in the risk of death compared with moderate anemia (defined as Hgb 8 to &lt; 10 mg/dL) at the time of diagnosis.

In a study of 1000 consecutive patients with PMF, 38% had Hgb level &lt; 10 g/dL and 24% required RBC transfusions at the time of diagnosis (Tefferi, 2012).  Within 1 year after diagnosis, 58% had Hgb level &lt; 10 g/dL and 46% required transfusions.  Nearly all patients with MF eventually require RBC transfusions.  In addition to predicting poor survival, anemia and TD are inversely associated with quality of life (Naymagon, 2017).  Finally, RBC transfusions are associated with risk of acute and chronic complications (eg, infection, fluid overload, infusion reactions, iron overload), and they substantially burden patients, their families, and health care systems (Semple, 2019; Naymagon, 2017; Bartoszko, 2015; Shander, 2009). Therefore, all grades of anemia have been associated with shortened survival in patients with PMF (Nicolosi, 2018).

There is currently insufficient data to allow conclusion on prognosis worsening in patients with anemia post-JAK inhibitors exposure.

).  RBC transfusions are associated with risk of acute and chronic complications (eg, infection, fluid overload, infusion reactions, iron overload), reduced quality of life, and reduced survival, and they substantially burden patients, their families, and health care systems (Semple, 2019; Naymagon, 2017; Bartoszko, 2015; Shander, 2009).

<div style=\"page-break-after: always\"></div>

## 2.1.5. Management

Treatment of PMF and SMF is similar and requires an individualized approach, considering each patient's age, comorbidities, symptom profile, prognostic risk category, performance status, treatment preference, and other factors.  The selection of appropriate treatment is based on the risk score and presence of symptoms (European LeukemiaNet (ELN), Barbui, 2018; the European Society for Medical Oncology (ESMO) clinical practice guidelines, Vannucchi 2015).

· Allogeneic HSCT is the only curative therapy for MF (Robin, 2019).  However, the procedure is associated with high morbidity and mortality, particularly in older adults, and is thus generally considered for only a limited subset of patients aged &lt; 70 years with suitable donors, lack of significant comorbidities, and good performance status (Tiribelli, 2020).   Allogeneic stem-cell transplantation (SCT) is the only treatment that is potentially curative and can induce long-term remission in patients with MF (Barbui, 2018; Vannucchi, 2015). However, the majority of MF patients are not eligible for the procedure due to age, comorbidities and an overall frail condition (Stahl, 2017; Vannucchi, 2015). Therefore, the existing treatment options are primarily symptom oriented. Treatment goals include reduction of spleen size, improvement of cytopenias and symptom burden, reduction of bone marrow fibrosis, restoration of transfusion-independence, and prevention and delay of progression to acute myeloid leukemia (AML) (Stahl, 2017; Vannucchi, 2015).

· For many patients who are ineligible for allogeneic HSCT, the current standard of care includes treatment with an approved JAK inhibitor:

-Ruxolitinib.  RUX is a JAK1 and JAK2 inhibitor indicated for the treatment of disease related splenomegaly or symptoms in adult patients with PMF, post PV MF, or post ET MF (Jakavi SmPC, 2017).  RUX has been incorporated into international treatment guidelines, including the ESMO Practice Guidelines for Philadelphia chromosome negative chronic MPNs (Vannucchi, 2015), and has become the standard of care for patients with MF.  RUX reduces splenomegaly and MF associated symptoms in patients with MF and has been associated with improved OS.  Development/exacerbation of thrombocytopenia and anemia was common with RUX, necessitating frequent RUX dose modifications and/or RBC transfusions (Harrison, 2012; Verstovsek, 2012).  Mean Hgb levels were decreased from baseline with RUX.  After RUX discontinuation, patients experience relapse of symptoms, worsening splenomegaly, and poor survival.  For patients with intermediate-risk 2 or high-risk score and not eligible for alloSCT, ruxolitinib is the core treatment of MF. Ruxolitinib (Jakavi), a JAK1/2 inhibitor, which is centrally approved drug in the EU for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. It improves splenomegaly symptoms in patients with intermediate-2-risk and high-risk myelofibrosis (COMFORT-II study Cervantes, 2013). It is also used in patients with symptomatic intermediate-1-risk myelofibrosis who are not responding or are intolerant to hydroxyurea. Whether ruxolitinib improves survival is uncertain, as meta-analyses have not been able to conclude on estimates of survival advantage of ruxolitinib and the benefit of ruxolitinib is currently seen as controlling splenomegaly and constitutional symptoms (Barbui, 2018).

-Fedratinib.  Fedratinib is a JAK2 and FLT3 inhibitor indicated for the treatment of disease related splenomegaly or symptoms in adult patients with PMF, post PV MF, or post ET MF who are JAK inhibitor naïve or have been treated with RUX (Inrebic SmPC, 2021).  Fedratinib reduces splenomegaly and symptom burden in patients with MF but similar to RUX, does not provide anemia benefit and can cause or exacerbate cytopenias.  In the registrational phase 3 study JAKARTA, encephalopathy, including Wernicke encephalopathy, occurred in some patients treated with fedratinib (Pardanani, 2015).  Thus, thiamine levels are assessed in patients before and throughout fedratinib treatment to mitigate the risk of encephalopathy (Inrebic SmPC, 2021).

<div style=\"page-break-after: always\"></div>

- Other treatments.  Before JAK inhibitors were available for MF, treatment options were limited.
- -Hydroxycarbamide (hydroxyurea), a cytoreductive agent, has been widely used to reduce constitutional symptoms and symptomatic splenomegaly.  However, responses are not durable and exacerbation of anemia is common (Iurlo, 2017; Martínez Trillos, 2010).
- -Other supportive treatments for splenomegaly include splenectomy, splenic irradiation, and partial splenic artery embolization (Tremblay, 2020).  However, these treatments are limited to select patients.
- -Supportive therapies for MF associated anemia include androgens (eg, testosterone, DAN), corticosteroids (eg, prednisone), immunomodulators (eg, lenalidomide), erythropoiesis stimulating agents, and RBC transfusion (Iurlo, 2017; Naymagon, 2017).  However, the efficacy, durability, and tolerability of these therapies are limited.  Notably, the ELN could not issue any evidence-based recommendations for treating MF associated anemia (Barbui, 2018).  Other therapeutic options for MF include erythropoiesis-stimulating agents (ESAs), corticosteroids, danazol, and immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide) for improvement of anaemias and hydroxyurea and interferon for the treatment of splenomegaly and/or constitutional symptoms (Stahl, 2017). Hydroxyurea (HU) is the only approved on a national basis in a few countries (e.g. France, Italy, Sweden and Spain) in the EU. Splenectomy and splenic irradiation are treatment options in refractory disease and disease specific complications (Tefferi 2016).

## Unmet medical need in MF patients with anemia

The approved JAK inhibitors for MF do not improve anaemia, a cardinal feature of this progressive disease and an important risk factor for poor survival.  RUX and fedratinib can exacerbate cytopenias (thrombocytopenia, anemia, neutropenia) due to myelosuppressive effect attributed to JAK2 inhibition, necessitating dose modification, interruption, or discontinuation.  Compromised dose intensity can limit treatment effects on disease related splenomegaly and symptoms.

Although ruxolitinib and fedratinib are not contraindicated in patients with anemia and TD, anaemia is a common reason for discontinuation or one of the factors considered at the initiation of JAK inhibitors. Consequently, management of the clinical manifestations of MF in patients who present with or develop anemia and/or thrombocytopenia remains an ongoing challenge (Naymagon, 2017 There is currently no approved JAK inhibitors specifically for management of anaemia along with other disease manifestations, such as symptoms and splenomegaly.

## 2.2. About the product

Momelotinib is a potent, orally bioavailable, small molecule inhibitor of the Janus kinases (JAK) JAK1 and JAK2 and the activin A receptor type 1 (ACVR1)/activin receptor like kinase 2 (ALK2).

It belongs to the pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors.

Like other JAK inhibitors (eg, ruxolitinib, fedratinib), MMB interferes with the JAK STAT (signal transducers and activators of transcription) signaling pathways, which are dysregulated in MF as a key component in the pathogenesis and clinical manifestations of the disease.  Distinct from other molecules in its class, MMB also inhibits the ACVR1 SMAD (mothers against decapentaplegic) signaling pathway resulting in reduced hepcidin expression in the liver, thereby increasing iron availability for erythropoiesis.  This unique attribute of MMB confers a differentiated benefit on anaemia and red blood cell (RBC) transfusion dependence, which are important negative prognostic factors for MF and inversely correlate with quality of life.  Further, transfusion independence has been shown to be associated with improved overall survival in MMB treated patients with MF.

<div style=\"page-break-after: always\"></div>

The initially proposed indication is as follows:

'Omjjara is indicated for the treatment of disease related splenomegaly or symptoms, and anaemia in adult patients with primary myelofibrosis (MF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with a JAK inhibitor.'

The recommended dose of Omjjara is 200 mg once daily.

A complete blood cell count must be performed before initiating treatment with Omjjara, periodically during treatment, and as clinically indicated.

Note: Momelotinib is also known as CYT387, GS-0387, SRA 0387, MMB

## 2.3. Type of application and aspects on development

Several rounds of scientific advice have been sought for momelotinib development (see section 1.5).

With regards to paediatric requirements, momelotinib was granted a product-specific waiver for primary myelofibrosis indication (EMEA-001656-PIP02-19) and for treatment of essential thrombocythaemia, post-essential thrombocythaemia myelofibrosis, polycythaemia vera and postpolycythaemia vera myelofibrosis (EMEA-001656-PIP01-14) on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

## 2.4. Quality aspects

## 2.4.1. Introduction

The  finished  product  is  presented  as  film-coated  tablets  containing  100,  150  and  200  mg  of momelotinib (as momelotinib dihydrochloride monohydrate) as active substance.

Other ingredients are:

Tablet  core:  propyl  gallate,  microcrystalline  cellulose,  lactose  monohydrate,  sodium  starch  glycolate (type A), colloidal anhydrous silica and magnesium stearate.

Tablet coating: polyvinyl alcohol, macrogols, titanium dioxide, talc, iron oxide yellow and iron oxide red.

The  product  is  available  in  white,  high-density  polyethylene  (HDPE)  bottles  with  child-resistant polypropylene  cap  and  induction-sealed,  aluminium  faced  liner.  Each  bottle  contains  a  silica  gel desiccant and polyester coil.

## 2.4.2. Active substance

## 2.4.2.1. General information

The INN of the active substance (AS) is momelotinib and the chemical name is N -(cyanomethyl)-4-(2{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide. The structure is shown in Figure 1.

<div style=\"page-break-after: always\"></div>

Figure 1. active substance structure

<!-- image -->

The molecular formula of the free base is C23H22N6O2; The molecular formula of the active substance is C23H22N6O2·2HCl·H2O.

The relative molecular mass of the free base is 414.47. The relative molecular mass of the active substance is 505.40.

The chemical structure of momelotinib dihydrochloride monohydrate (MMB diHCl) was elucidated by a combination of elemental analysis, mass spectrometry,  1 H- and  13 C-NMR spectroscopy, FT-IR spectroscopy, UV, counter ion content and X-ray crystallography. The solid-state properties were investigated by XRPD, melting point, thermogravimetric analysis and dynamic vapour sorption.

MMB diHCl appears as light yellow to brown to reddish-brown not hygroscopic crystalline solid which may contain differently coloured solids within the same colour range. In its base form is practically insoluble in water. The equilibrium aqueous solubility of momelotinib dihydrochloride monohydrate cannot be accurately assessed due to disproportionation of the dihydrochloride salt in non-acidified aqueous media. The salt form shows an initial kinetic solubility of &gt; 60 mg/mL in water at 25 °C followed by a decrease in solubility over 30 to 45 minutes along with formation of a monohydrochloride salt form in the solid phase.

No chiral centres exist in the molecule.

One polymorphic form for momelotinib dihydrochloride monohydrate (GS-0387-01, Form II) has been observed. MMB diHCl Form II is the most thermodynamically stable form of the dihydrochloride salts under all conditions relevant to drug product manufacturing and storage.

## 2.4.2.1. Manufacture, characterisation and process controls

MMB diHCl is synthesized in five main steps using well defined starting materials with acceptable specifications. In the sequential procedure narrative, quantities/ranges of materials (starting materials, intermediates, solvents, catalysts and reagents) are included. The intended commercial scale is defined.

Critical steps, critical process parameters (with their ranges), process controls and yields for each stage are defined. Tests and acceptance criteria performed at critical steps are described and justified. Isolated intermediates are characterized and controlled by suitable specifications. There is no alternative processing, non-routine reprocessing or reworking.

The starting materials comply with ICH Q11 requirements.  For each starting material, the following information was included: name and address of the manufacturer, flow chart of the synthetic process (including reagents, solvents and catalysts), discussion of carry-over of impurities from the starting material and specification. The parameters included in the specifications are sufficient for controlling the starting materials. The justification of the specification includes an evaluation of the risks and the ability of the subsequent steps to adequately control and/or purge impurities.

For each reagent, solvent or other material, a specification is also provided. In summary, the specifications for starting materials, solvents and reagents are deemed adequate.

<div style=\"page-break-after: always\"></div>

The development of the AS manufacturing process utilized 5 sites. Similar specifications and synthetic routes were used at all manufacturing sites, including the same regulatory starting materials and intermediates. The synthesis has progressed through different processes which used different reagents and solvents. For each of the five manufacturing steps, the process development activities were summarized.

A comparability study of AS manufactured at development sites vs. the proposed commercial site shows that there are no significant differences in quality.

The active substance is packaged in two low-density polyethylene (LDPE) bags secured with a plastic or wire tie. These LDPE bags are placed in a suitable high-density polyethylene drum sealed with a gasket line lid and fitted with a tamper-evident seal for shipment. The primary packaging material which complies with Commission Regulation (EU) 10/2011, as amended.

## 2.4.2.2. Specification

The active substance specification includes tests for: appearance, identification (IR, UPLC) identification of crystalline form (X-RPD), water content (KF), residual solvents (GC), assay (UPLC), related substances (UPLC),  hydrochloride content (titration), particle size (laser light scattering) residue on ignition/sulphated ash (Ph. Eur.) and microbial limits (Ph. Eur.).

Parameters included in the specification cover all the critical aspects for ensuring the quality of the AS. The proposed limits have been justified considering batch data and stability results and the relevant guidelines and Pharmacopoeia requirements. Impurity levels above the ICH Q3A thresholds have been toxicologically evaluated and qualified.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for testing has been presented.

Batch analysis data of 8 commercial scale batches manufactured by the proposed commercial site were provided. The results are within the specifications and consistent from batch to batch. In addition, batch data from 14 batches of varying batch sizes manufactured at the development sites were also presented. The results were generated according to analytical procedures in place at the time of product release and met the specification of the time.

## 2.4.2.3. Stability

Stability studies were conducted on multiple AS batches manufactured at development sites as well as by the proposed manufacturer.

Stability data from commercial scale batches of active substance stored in the intended commercial container closure system for up to 60 months under long term conditions (25ºC / 60% RH, 6 batches and 30°C/75% RH, 4 batches) and for up to 6 months under accelerated conditions (40ºC / 75% RH, 12 batches) according to the ICH guidelines were provided.

The following parameters were tested: appearance, water content, assay, related substances, HCl content, particle size, microbiological examination (annually) and XRPD (annually). The analytical methods used were the same as for release and were stability indicating. Although the batches were manufactured and tested at different times, all of them meet the currently proposed specification.

<div style=\"page-break-after: always\"></div>

Photostability testing following the ICH guideline Q1B was performed on a commercial scale batch. The active substance is photostable. Additional forced degradation studies were conducted under acid hydrolysis, alkaline hydrolysis, oxidation, elevated heat and humidity conditions.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 60 months with storage condition 'store below 30°C', in the proposed container.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

The finished product (FP) is presented as film-coated tablets containing 100, 150 or 200 mg of momelotinib (as dihydrochloride monohydrate salt).

The description of momelotinib film-coated tablets is presented Table 2.

Different tablet strengths are distinguishable by size, shape and debossing.

Table 1. Description of momelotinib, film-coated tablets

| Strength (units/dosageform)   | Description                                                                                                                                   |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| 100 mg, tablet                | Momelotinib Tablets, 100 mg, are brown, round, film-coated tablets, debossed with an underscored M on one side and 100 on the other side.     |
| 150 mg, tablet                | Momelotinib Tablets, 150 mg, are brown, triangle-shaped, film-coated tablets, debossedwithanunderscoredMononesideand150on theotherside.       |
| 200 mg, tablet                | Momelotinib Tablets, 200 mg, are brown, capsule-shaped, film-coated tablets, debossedwith anunderscored M on oneside and 200on the otherside. |

All strengths are manufactured from a common powder blend and differ only in the mass of powder compressed into tablets.

Key physicochemical characteristics of the solid-state form of the AS, such as particle size, solubility, and  stability  were  adequately  evaluated  and  the  potential  effect  on  the  relevant  properties  was considered according to the ICH Q8 Guideline.

The used crystalline Form II of momelotinib diHCl, is maintained under all conditions relevant to FP manufacturing and storage as demonstrated in stability studies by XRPD analysis of finished product.

Momelotinib diHCl.H2O is considered a BCS Class 2 compound. In aqueous solution, it undergoes hydrolytic and oxidative degradation and so exposure to moisture should be minimized during manufacture and storage.

An investigation on degradation products by hydrolysis and oxidative degeneration was carried out. To address the oxidative degradation of MMB, the impact of different antioxidants at different concentrations on the stability of the formulation was assessed in order to determine the antioxidant for the final formulation.

The choice, characteristics and function of the excipients have been discussed. Compatibility of the drug substance with the excipients has been demonstrated in formulation development studies and long-term stability studies. The levels of the different excipients were optimized in development studies.

<div style=\"page-break-after: always\"></div>

Several AS manufacturers have been used throughout development. A study has been carried out on the material from different manufacturers. No difference in the quality of the FP was observed for any tablet strength. The selected manufacturing process produces a powder blend with equivalent characteristics, irrespective of any minor differences in the incoming AS.

Different formulations have been used for different clinical trials phases. An overview of the formulations employed in clinical trials throughout the development of momelotinib was provided.

MMB diHCl Form II was selected to progress to the development of an immediate release tablet formulation to support Phase 3 studies.

The development of the manufacturing process has been adequately described and reflects the considerations in ICH Q8. The process is conventional for production of film coated tablets.

The applicant conducted risk assessments to identify steps and parameters that could impact the finished product critical quality attributes (CQAs). Design of Experiments (DoE) studies were conducted on these steps and the process optimized accordingly. However, no design space is claimed.

In order to select a suitable dissolution method for the finished product, medium pH, surfactant type and quantity, paddle speed and discriminatory power were studied. The low solubility of the AS necessitated the use of a surfactant. The chosen surfactant has been justified.

The selected dissolution method was demonstrated to be discriminatory with respect to tablet hardness and disintegrant levels and is adequately justified.

A bulk hold time study was conducted to assess the physiochemical and microbiological properties of the final powder blend, cores and coated tablets cumulatively during storage. Bulk hold times in defined containers were established for these intermediates.

The FP is packaged in HDPE bottles fitted with a child-resistant polypropylene screw cap with an aluminum-faced liner and induction sealed packed with one 3 g canister of silica gel desiccant and polyester coil. The primary components were selected based on their intended use in the packaging of commonly marketed products of dry solid oral dosage form in compliance with European Commission Regulation (EU) No. 10/2011.

The effectiveness of desiccant at reducing MMB degradation was assessed in a stability study performed under accelerated conditions (40 °C/75% RH for up to 6 months) in sealed bottles containing varying amounts of silica gel desiccant. Based on these results, cannisters of 3 g silica gel are used as a component of the primary packaging for momelotinib tablets.

## 2.4.3.2. Manufacture of the product and process controls

The applicant has provided sufficient information regarding all sites for the manufacturing site, including packing and batch release site and the relevant GMP certificates.

A clear narrative description of the manufacturing process was included as was a flow-chart which also shows the in-process controls. The process is considered a standard manufacturing process and includes blending, granulation, compression and film coating.

The commercial batch size for the manufacture of momelotinib common powder blend and of each strength was stated.

A table listing the process parameters and their target, NOR and PAR values was provided. It was also mentioned that if parameter changes are required during manufacturing, only one parameter per step may be varied within its PAR, the others being kept at their NOR values.

<div style=\"page-break-after: always\"></div>

For each stage of the FP manufacturing, the critical process parameters that impact the product characteristics were summarized. The proposed in-process controls are acceptable.

A holding time study has been carried out to support the proposed holding times for tablet cores and coated tablets; the proposed holding times are accepted. The applicant has confirmed that expiration period of a batch will be calculated in accordance with the Note for Guidance on Start of Shelf-Life of the Finished Dosage Form (CPMP/QWP/072/96).

Validation of Momelotinib Tablets, 100 mg, 150 mg and 200 mg, is being performed via a continuous process verification approach in accordance with the EMA Guideline on process validation for finished products - information and data to be provided in regulatory submissions (EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,Corr.1 - Nov 2016) .

Process qualification of Momelotinib Tablets, 100 mg, 150 mg and 200 mg followed a matrixed approach which included manufacture of 3 consecutive batches of common powder blend with subsequent manufacture of 2 lots each of the 100 mg and 150 mg tablets and 3 lots of 200 mg tablets for a total of 7 tablet lots. The validation plan was described in detail and tests results submitted.

Process qualification has been completed, and the results indicate that the manufacturing process is well-controlled, robust and is capable of routinely yielding product of consistent quality.

The commercial manufacturing process for momelotinib tablets is therefore considered sufficiently validated at the commercial site and scale.

## 2.4.3.3. Product specification

The finished product release and shelf life specifications include appropriate tests for this kind of dosage form: appearance, identification (UV, UPLC), water content (KF), assay (UPLC), degradation products (UPLC), uniformity of dosage units (Ph. Eur.), dissolution (Ph. Eur.), propyl gallate content (UPLC) and microbial limits (Ph. Eur.).

The FP specifications comprise of sufficient tests and appropriate limits to ensure the batch-to-batch quality of the product . The parameters and acceptance criteria for appearance, identification, assay, uniformity of dosage units, water content, dissolution and microbiological control are acceptable.

Regarding degradation products, impurities in the FP have been qualified at appropriate levels. Therefore, specifications for known impurities at release and at shelf-life can be considered justified.

The potential presence of elemental impurities (EIs) in the finished product has been assessed following a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. An overall risk assessment for elemental impurities has been presented, considering the sum of all contributions of relevant sources to elemental impurities in the FP. The assessment is based on actual maximum levels of EIs per component and show that none is likely to be present in the drug product above the control threshold (i.e. 30 % of the established PDE). The analytical method has been correctly described and suitably validated for its intended purpose. Based on the risk assessment and the presented batch data, it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk assessment to evaluate the potential for nitrosamine impurities in the drug product considering all suspected and actual root causes was performed in accordance with the latest guideline EMA Questions and Answers on Information on nitrosamines for marketing authorization holders ( EMA/409815/2020 ). In response to a major objection by the CHMP, the applicant documented the risks associated with nitrosamine formation in both AS and FP and provided it in a standard template.

<div style=\"page-break-after: always\"></div>

The major objection was thus resolved. No risk has been identified for the presence of potential nitrosamine impurities. Therefore, no specific control measures are deemed necessary.

The  analytical methods  used  have  been  adequately  described  and  appropriately  validated in accordance  with  the  ICH  guidelines.  Analytical  method  validation  studies  for  non-pharmacopoeial analytical methods have been conducted and, accordingly, the validation reports are provided, as per ICH Q2 .

Moreover, forced degradation studies for assay and related substances methods have been carried out. These methods are considered stability indicating.

Satisfactory information regarding the reference standards used for testing has been presented.

Batch analysis results are provided for three commercial scale batches of each strength confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification. In addition, batch data generated according to analytical procedures in place at the time from numerous batches used throughout the development program have been presented. Results met the specification of the time.

## 2.4.3.4. Stability of the product

Stability data from a total of 14 commercial scale batches of finished product covering all three strengths stored for up to 60 months under long term conditions (25ºC / 60% RH) and under intermediate conditions (30°C/75% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The batches of the medicinal product are representative to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for appearance, water content, assay, degradation products, dissolution, propyl gallate and microbial limits. The analytical procedures used are stability indicating. The results comply with the proposed specification limits. No significant changes have been observed.

The batches subject to stability studies include FP made using AS lots manufactured from the proposed commercial supplier using the formulation, process parameters, in-process controls, and equipment that is representative of commercial production. The registration stability package also includes FP data using AS batches from a previous manufacturer.

FP lots manufactured using AS from the previous manufacturer are considered equivalent to batches manufactured by the proposed commercial AS manufacturer and are thus appropriate for shelf-life determination.

A photostability study was conducted as per ICH Q1B. The results confirm that the tablets are not sensitive to light and the packaging does not need to be light protective.

An in-use stability study was performed at 30°C/75% RH and 40°C/75% RH with induction seals broken and tested at 7, 14, 21 and 30 days on two batches of 100 and 200 mg tablets and one batch of 150 mg tablets. The results met specifications. Tablets remain stable in conditions designed to mimic worst-case patient use and thus defining an in-use shelf life is not required.

Additional temperature excursion studies were conducted at 60°C/ambient RH for 1 and 2 weeks and at -20°C/ambient RH for 1 month for one batch each of 100 mg and 200 mg tablets. Results demonstrates the tablets remain stable in extreme conditions that mimic a worst-case shipping temperature excursion.

<div style=\"page-break-after: always\"></div>

Based on available stability data, the proposed shelf-life of 3 years with the storage conditions 'store in the original bottle in order to protect from moisture. Do not remove the desiccant. Do not swallow the desiccant. This medicinal product does not require any special temperature storage conditions' as stated in the SmPC (section 6.3 and 6.4) is acceptable.

## 2.4.3.5. Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. A MO raised during the procedure concerning the information regarding the risk assessment on the potential presence of nitrosamine impurities has been resolved by provision of additional data. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.4.6. Recommendations for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

The nonclinical development program was designed to support the use of MMB in the treatment of patients with myelofibrosis. The overall nonclinical program was conducted in accordance with the Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical trials and Marketing Authorisation for Pharmaceuticals [ICH M3(R2)] in addition to other relevant ICH guidances related to the development of a small molecule.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

The development of MMB has involved several companies, and therefore study reports from different companies for the potency and selectivity of MMB and metabolites on JAK family enzymes are available. The IC50 and Kd data from the different study reports are summarized in the Tables 1 and 2 below.

Table 2 . In vitro biochemical potency of MMB against JAK family enzymes

| System                                                 | Source                                        |     | IC50 Values (nM)       | IC50 Values (nM)        | IC50 Values (nM)   | IC50 Values (nM)         | IC50 Values (nM)   |
|--------------------------------------------------------|-----------------------------------------------|-----|------------------------|-------------------------|--------------------|--------------------------|--------------------|
|                                                        |                                               |     | JAK1                   | JAK2                    | JAK2V 617F         | JAK3                     | TYK2               |
| Alphascreen kinase assay                               | Pardanani et al. , 2009 & Tyner et al. , 2010 | MMB | 11 (ATP = 80 µM)       | 18 (ATP = 80 µM)        |                    | 155 (ATP = 80 µM)        | 17 (ATP = 80 µM)   |
| LanthaScreen TR-FRET enzymatic assay                   | PC-352- 2005                                  | MMB | 30 (ATP =70 μ M)       | 3.8 (ATP =25 μ M)       |                    |                          |                    |
| Alphascreen kinase assay                               | CRB09001                                      | MMB | 70 (ATP= 80 µM )       | 5.7 (ATP= 80 µM)        |                    | 270 (ATP = 80 µM)        | 260 (ATP = 635 µM) |
| Alphascreen kinase assay                               | CRB09001                                      | MMB |                        | 6.6 (ATP= 80 µM)        | 2.8 (ATP= 80 µM)   |                          |                    |
| Alphascreen kinase assay: batch to batch comparison #1 | CRB09001                                      | MMB |                        | 15.2 (n=8; ATP= 80 µM)  |                    | 77.7 (n=8; ATP= 80 µM)   |                    |
| Alphascreen kinase assay: batch to batch comparison #2 | CRB09001                                      | MMB | 21.5 (n=9; ATP= 80 µM) | 19.4 (n=20; ATP= 80 µM) |                    | 155.4 (n=19; ATP= 80 µM) |                    |
| Z'-LYTE FRET kinase assay: potency validation          | CRB09002                                      | MMB |                        | 22.3 (ATP = Km app)     |                    |                          |                    |
| Z'-LYTE FRET kinase assay                              | CRB09002                                      | MMB | 21 (ATP = 87 µM)       | 4.3 (ATP = 49 µM)       |                    | 17.1 (ATP = 14 µM)       | 5.0 (ATP = 23 µM)  |
| Millipore KinaseProfiler                               | CRB09003                                      | MMB |                        | 5.0 (ATP = 45 µM)       |                    |                          |                    |
| Commercial kinase potency screen                       | Asshoff et al, 2017                           | MMB | 26.9                   | 1.4                     |                    | 6.1                      | 19.9               |

The in vitro IC50 inhibition of MMB on JAK family enzymes were evaluated with different assays based on phosphorylation and in the presence of ATP. In general, at clinically relevant exposures, MMB appeared to have higher inhibitory activity on JAK2 with IC50 values ranging from 1.4 - 18 nM over the other JAK family members (JAK2 &gt; JAK1, 11-70 nM &gt;  TYK2, 5-260 nM &gt; JAK3, 6-270 nM). However IC50 values were highly variable for JAK3 and TYK2 depending of the ATP concentration (see

<div style=\"page-break-after: always\"></div>

table above). MMB has also potent activity at clinically relevant exposures on the MPN-associated JAK2V617F mutant (IC50=2.8 nM), almost equivalent to the activity on wild-type JAK2.

Table 3 . In vitro biophysical potency of MMB and metabolites against JAK family enzymes

| System     | Source            | K D (nM)   | K D (nM)   | K D (nM)   | K D (nM)   | K D (nM)   |
|------------|-------------------|------------|------------|------------|------------|------------|
|            |                   |            | JAK1       | JAK2       | JAK3       | TYK2       |
| KINOMEscan | WIQ002-01-s-00001 | MMB        | 28         | 0.13       |            |            |
|            |                   | M21        | 53         | 0.79       |            |            |
| KINOMEscan | PC-352-2006       | M21        | 150        | 1.1        | 8          | 1.2        |
|            |                   | M19        | > 10000    | 280        | 190        | 1200       |
| KINOMEscan | WIQ001-01-s-00001 | M19        | >30000     | 530        | 240        | 1700       |

The in vitro Kd potency of MMB and the metabolites M21 and 19 were also investigated in several studies with KINOMEscan assay which do not require the presence of ATP. MMB was more potent on JAK2 (0.13 nM) compared to JAK1 (28 nM), but no Kd values were available on JAK3 and TYK2, although this has been investigated for the metabolites M21 and M19. The applicant has been requested to clarify the selectivity of MMB and M21 for JAK 2 and JAK1 over other JAK family members (JAK 3, TYK2), as a post-approval commitment within two years after approval. The major metabolite M21 had inhibitory activities on JAK family members (JAK2 &gt; TYK2 &gt; JAK 3 &gt; JAK 1), but with lower inhibitory activity compared to the parent compound MMB. The metabolite M19 (minor in human and major in animal species) had low or no in vitro Kd potency on JAK family members, and is therefore not considered as an active metabolite.

In ATP-dependent kinase assays, MMB inhibited ACVR1 (ALK2) with IC50 values ranged from 6.8 to 8.4 nM. In ATP-independent competitive binding assays, MMB and metabolite M21 inhibited ACVR1 (ALK2) at clinically relevant exposures with low Kd values of 8.6-25 nM and 38-99 nM, respectively, compared to the metabolite M19 (1700-5300 nM).

Based on the binding mode, MMB and M21 are expected to be type 1, ATP-competitive kinase inhibitors.

The inhibitory activities of MMB, metabolites M21 and M19 on panel of kinases were investigated, and are summarized below in Table 4 (Reports PC-352-2006, CRB09001 CRB09002, and CRB09003).

<div style=\"page-break-after: always\"></div>

Table 4. Summary of biophysical and biochemical potency for MMB, M21, and M19 against various kinases

<!-- image -->

| DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP              | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | DiscoverXAssayswithnoATP   | EnzymaticAssaysContainingATP   | EnzymaticAssaysContainingATP   | EnzymaticAssaysContainingATP   | EnzymaticAssaysContainingATP   |
|----------------------------|---------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                            |                                       | MMB                        | MMB                        | M21                        | M21                        | M21                        | M19                        | M19                        | M19                        | MMB                            | MMB                            | MMB                            | [ATP]                          |
|                            | Value (units)                         | Kd (nM)                    | Fold- JAK2                 | Kd (nM)                    | M21/MMB                    | Fold- JAK2                 | Kd (nM)                    |                            | Fold- JAK2                 | Value (units)                  | IC50 (nM)                      | Fold- JAK2                     | (μM)                           |
| Merged enzyme list         | Enzyme name                           |                            |                            |                            |                            |                            |                            |                            |                            | Enzyme name                    |                                |                                |                                |
| JAK2                       | JAK2(JH1domain- catalytic)            | 0.13                       | 1.0                        | 0.95                       | 7.3                        | 1.0                        | 405                        | 3115.4                     | 1.0                        | JAK2                           | 17                             | 1.0                            | 80, Km app, 49 (Km)            |
| JAK2(h)                    |                                       |                            |                            |                            |                            |                            |                            |                            |                            | JAK2(h)                        | 5.0                            | 0.29                           | 45                             |
| IKK-β                      | IKK-beta                              | 1.9                        | 15                         | 1.7                        | -1.1                       | 1.8                        |                            |                            |                            | IKK-β(h)                       | 144                            | 8.2                            | 10                             |
| JAK1                       | JAK1(JH1domain- catalytic)            | 28                         | 220                        | 102                        | 3.6                        | 110                        | >10000                     |                            | >25                        | JAK1                           | 26                             | 1.5                            | 80, 87 (Km)                    |
| JNK3                       | JNK3                                  | 24                         | 190                        | 4.8                        | -5.0                       | 5.1                        | 55                         | 2.3                        | 0.14                       | MAPK10 (JNK3)                  | 1720                           | 98                             | 100                            |
| TBK1                       | TBK1                                  | 29                         | 220                        | 63                         | 2.2                        | 67                         | 1200                       | 41.4                       | 3.0                        | TBK1                           | 90                             | 5.1                            | Km app                         |
| JAK3                       | JAK3(JH1domain-                       |                            |                            | 8                          |                            | 8.5                        | 215                        |                            | 0.53                       | JAK3                           | 133                            | 7.6                            | 80, 14 (Km)                    |
| Tyk2                       | catalytic) TYK2(JH1domain- catalytic) |                            |                            | 1.2                        |                            | 1.3                        | 1450                       |                            | 3.6                        | Tyk2                           | 133                            | 7.6                            | 23 (Km), 625                   |
| ACVR1                      | ACVR1                                 | 16.8                       | 130                        | 68.5                       | 4.1                        | 72                         | 3500                       | 208.3                      | 8.6                        |                                |                                |                                |                                |
| ACVR1B                     | ACVR1B                                | 520                        | 4000                       | 540                        | 1.0                        | 570                        |                            |                            |                            |                                |                                |                                |                                |
| ALK                        | ALK                                   | >10000                     | >77000                     | >10000                     |                            | >11000                     | >10000                     |                            | >25                        |                                |                                |                                |                                |
| AURKA                      | AURKA                                 | 140                        | 1100                       | 300                        | 2.1                        | 320                        | 200                        | 1.4                        | 0.49                       |                                |                                |                                |                                |
| AURKC                      | AURKC                                 | 140                        | 1100                       | 430                        | 3.1                        | 460                        | 450                        | 3.2                        | 1.1                        |                                | Not Tested                     |                                |                                |
| BMPR1A                     | BMPR1A                                | 1000                       | 7700                       | 2400                       | 2.4                        | 2500                       | >10000                     |                            | >25                        |                                |                                |                                |                                |
| BMPR1B                     | BMPR1B                                | 19                         | 150                        | 8.7                        | -2.2                       | 9.2                        | 65                         | 3.4                        | 0.16                       |                                |                                |                                |                                |
| BMPR2                      | BMPR2                                 | 40000                      | >310000                    | 8000                       | -5.0                       | 8500                       | 2700                       | -14.8                      | 6.7                        |                                |                                |                                |                                |
| IKK-α                      | IKK-α                                 | 0.69                       | 5.3                        | 0.425                      | -1.6                       | 0.45                       |                            |                            |                            |                                |                                |                                |                                |
| IKK-e                      | IKK-e                                 | 26                         | 200                        | 33                         | 1.3                        | 35                         |                            |                            |                            |                                |                                |                                |                                |
| IRAK1                      | IRAK1                                 | 5.8                        | 45                         | 7.45                       | 1.3                        | 7.9                        |                            |                            |                            |                                |                                |                                |                                |
| IRAK4                      | IRAK4                                 | 930                        | 7200                       | 1400                       | 1.5                        | 1500                       |                            |                            |                            |                                |                                |                                |                                |
| JAK1                       | JAK1 (JH2 domain- pseudokinase)       |                            |                            |                            |                            |                            | 1800                       |                            | 4.4                        |                                |                                |                                |                                |
| JNK1                       | JNK1                                  | 35                         | 270                        | 11                         | -3.2                       | 12                         | 91                         | 2.6                        | 0.22                       |                                |                                |                                |                                |
| JNK2                       | JNK2                                  | 200                        | 1500                       | 67                         | -3.0                       | 71                         | 480                        | 2.4                        | 1.2                        |                                |                                |                                |                                |
| PDGFRB                     | PDGFRB                                | 47                         | 360                        | 92                         | 2.0                        | 97                         | >10000                     |                            | >25                        |                                |                                |                                |                                |
| TGFBR1                     | TGFBR1                                | 670                        | 5200                       | 650                        | -1.0                       | 690                        |                            |                            |                            |                                |                                |                                |                                |
| CDK1/cyclinB               |                                       |                            |                            |                            |                            |                            |                            |                            |                            | CDK1/cyclinB(h)                | 51                             | 2.9                            | 45                             |
| CDK2/cyclinA               |                                       |                            |                            |                            |                            |                            |                            |                            |                            | CDK2/cyclinA(h)                | 181 887                        | 10 51                          | 45 120                         |
| CDK9/cyclin T1             |                                       |                            |                            |                            |                            |                            |                            |                            |                            | CDK9/cyclin T1(h)              | 199                            | 11                             | 45                             |
| FLT3                       |                                       |                            |                            |                            |                            |                            |                            |                            |                            | FIt3                           | 180                            | 10                             | 80, Km app                     |
| JAK2 (JH1- JH2)            |                                       |                            |                            |                            |                            |                            |                            |                            |                            | JAK2 (JH1-JH2)                 | 6.6                            | 0.38                           | 80                             |
| JAK2 (JH1-  JH2) V617F     |                                       |                            |                            |                            |                            |                            |                            |                            |                            | JAK2 (JH1-JH2) V617F           | 2.8                            | 0.16                           | 80                             |
| JNK1a1                     |                                       |                            |                            |                            | Not Tested                 |                            |                            |                            |                            |                                | 802                            | 46                             |                                |
| MAPKAPK2                   |                                       |                            |                            |                            |                            |                            |                            |                            |                            | JNK1a1(h)                      | 2370                           | 140.0                          | 45                             |
| PDGFRA                     |                                       |                            |                            |                            |                            |                            |                            |                            |                            | MAPKAPK2 PDGFRA                | 160                            | 9.1                            | Km app Km app                  |
| PKCb1                      |                                       |                            |                            |                            |                            |                            |                            |                            |                            | PKCb1(h)                       | 1899                           | 110                            | 10                             |
| PKCg                       |                                       |                            |                            |                            |                            |                            |                            |                            |                            | PKCg(h)                        | 1823                           | 100                            | 15                             |
| PKCm                       |                                       |                            |                            |                            |                            |                            |                            |                            |                            | PKCm(h)                        | 113                            | 6.5                            | 45                             |
| PRKCN (PKD3)               |                                       |                            |                            |                            |                            |                            |                            |                            |                            | PRKCN (PKD3)                   | 109                            | 6.2                            | Km app                         |
| ROCK2                      |                                       |                            |                            |                            |                            |                            |                            |                            |                            | ROCK2                          | 179                            | 10                             | 100                            |

Key: h=human; Km=the concentration providing half of enzyme maximal activity; km app=Apparent Km.

Based on these in vitro data, MMB may inhibit IKK α and CDK1/cyclin B, and the metabolite M21 may inhibit IKK family members. However, additional biochemical (e.g. containing physiologically relevant levels of ATP), cell mechanistic, or potentially translational studies would be necessary to establish the clinical relevance of the inhibitory activity of MMB, M21, or M19 on other kinases. The applicant has been requested to clarify the selectivity of MMB and M21 over other targets as a post-approval

<div style=\"page-break-after: always\"></div>

commitment within two years after approval. Given the apparent loss of potency of M19 against JAK2 and the limited exposure of M19, the binding observed on other targets is unlikely to contribute to the clinical activity of MMB.

In primary human PBMCs, MMB had around 5-fold higher inhibitory activity on the JAK2-mediated phosphorylation of STAT5 with EC50 values of 59.6 nM, compared to JAK1/2-mediated phosphorylation of STAT3 (259 nM) and JAK1/3-mediated phosphorylation of STAT6 (235 nM). The metabolite M21 had lower inhibitory activities on these three pathways with EC50 ranged from 689 to 724 nM. In the U937 cell line, MMB inhibited IFN γ - or IFN α -mediated phosphorylation of STAT1 with IC50 values of 182 nM and 145 nM, respectively. Based on the biochemical IC50 values of JAK2 and TYK2 (5 and 133 nM, respectively) below the clinical free Cmax, inhibition of the IL-12-mediated phosphorylation of STAT4 is possible at clinically relevant doses. In conclusion, MMB demonstrated higher inhibitory activities on the signaling pathway involved for the targeted indication of myelofibrosis (myelopoiesis, erythropoiesis, thrombopoiesis, …), but inhibitory activities on other JAK signaling pathway are also possible at clinically relevant doses.

In cellular proliferation assays, MMB inhibited proliferation of JAK2-dependent BA/F3 murine myeloid cells (IC50=798 nM vs 1430 nM for parental cells and IC50 value of 2425 nM in JAK3-dependent cells), as well as JAK2V617F mutant HEL92.1.7 cells (IC50=1805 nM). In contrast, growth inhibition was minimal at an MMB concentration of 3 µM in a selection of 10 diverse tumor cell lines that were not dependent on the JAK pathway for proliferation. In Tyner et al. (2010), between 0.5 and 1.5 µM MMB caused growth suppression of JAK2-dependent hematopoietic cell lines with similar sensitivity between wild-type JAK2 and JAK2V617F, as well as in CMK cells which are dependent on both JAK1 and JAK3 due to an activating mutation of JAK3 (JAK3A572V). However, significant growth inhibition was observed in Molm14 cells which carry an internal tandem duplication of FLT3 and in cell lines engineered to express BCR-ABL. Overall, the data from panel of cell lines are consistent with growth inhibition of JAK2, but possibly on other JAK family-dependent cell lines and on other diverse tumor cell lines that do not depend on the JAK pathway for proliferation (e.g. FLT3, BCR-ABL) at clinically relevant doses.

MMB and M21 treatment resulted in a concentration-dependent reduction in BMP6-stimulated hepcidin RNA transcription in the HepG2 hepatoma cell line with EC50 values of 652 nM and 1420 nM, respectively. These data suggest that MMB and to a lesser degree, M21, may restore iron homeostasis via regulation of ACVR1-mediated hepcidin expression.

MMB and M21 were also shown to inhibit TNF α -induced NFκ B signaling with IC50 of 600 nM and 2900 nM, respectively. These data are in line with the observed binding to upstream NFκ B regulators IKKα, IKKβ, and/or IKKε with potency values ranging from well below to above the clinical free Cmax. This suggest that inhibition of this pathway could be expected to positively contribute to overall activity, however it is currently unknown whether these mechanisms contribute to the activity of MMB and/or M21 in myelofibrosis patients. MMB demonstrated similar potency against erythroid (IC50 range: 0.901.21 µM) and myeloid (IC50 range: 0.81-1.29 µM) progenitor proliferation, which is line with expected inhibition of JAK2-dependent signaling pathway.

The in vivo activities of MMB were evaluated in one mouse MPN model (myeloproliferative neoplasm) dependent on JAK2V617F, which is relevant for the proposed indications. MMB either partially or fully normalized white cell counts, hematocrit, spleen size, reduced extramedullary hematopoiesis and returned normal hematopoiesis to the bone marrow in a dose- and time-dependent manner, with higher efficacy observed at 50 mg/kg (= 240 mg Human Equivalent Dose for an adult of 60 kg). MMB also reduced the concentration of inflammatory cytokines IL-17, IL-3, and IP-10 relative to control animals. No change was observed in body weight. In this model, despite the hematologic responses and reduction of the JAK2V617F allele burden, JAK2V617F cells persisted and MPN recurred upon

<div style=\"page-break-after: always\"></div>

cessation of treatment. This suggest that inhibition of proliferation is observed, but there are no induction of apoptosis of the JAK2V617F-expressing cells. In this study, the overall impact of MMB on the homeostasis of blood cells in naive mice were also assessed, and doses up to 100 mg/kg had little to no effect on peripheral blood counts over a period of 8 weeks (= 480 mg Human Equivalent Dose for an adult of 60 kg).

In a rat ACD model, MMB-mediated inhibition of the JAK/STAT and ACVR1/SMAD pathways caused a reduction of pSTAT3 and pSMAD1/5/8 levels in the liver as well as a reduction of hepatic hepcidin gene (Hamp) transcription, which was not seen with ruxolitinib. There was an accompanying decrease in serum hepcidin, increase in serum iron, and RBC production in the bone marrow. However, erythropoietic precursors (I, II, and II) declined with increasing MMB doses, which could be related to JAK2 inhibition. In this rat ACD model, MMB also reduced IL-6 mRNA levels in the spleen, consistent with previous findings of its inhibitory effects on proinflammatory cytokines.

## 2.5.2.2. Secondary pharmacodynamic studies

The activity of MMB (10 μ M) was evaluated against a panel of 42 enzymes in the Adverse Reaction Enzymes assay. Only potential UGT1A1 inhibition was considered clinically relevant, with IC50 of 0.3 µM. Additional in vitro studies showed that MMB at 10 µM had no activity against a panel of enzymes and receptors (targets involved in drug dependence, vasoactive receptors, ion channels, …).

MMB did not inhibit thiamine transport in Caco-2 and THTR-overexpressing cells, and therefore is unlikely to contribute to encephalopathy similar to that reported with fedratinib.

## 2.5.2.3. Safety pharmacology programme

Safety pharmacology studies conducted showed no relevant effects on respiratory function or the central nervous system of rats at the highest dose tested with exposures at least 6-fold estimated MMB free drug Cmax in human with MF at the clinical dose of 200 mg. In the 26-week toxicity study in rats and 39-week toxicity study in dogs, functional observational battery testing showed no MMB-related adverse effects. In addition, in the 39-week study in dogs, no MMB-related adverse effects were observed in the peripheral nerves at the terminal necropsy. However, in the 26-week study in rats, the non-GLP neuro-electrophysiological evaluation done around Tmax showed at the highest dose of 50 mg/kg/day, reversible, mild slowing of caudal and digital nerve conduction velocity, but were not associated with any significant changes in the tibial motor responses or any changes in the amplitudes for either the caudal or digital nerves. These effects were observed at exposure margins of 6 and 11, based on MMB free Cmax and AUC, respectively, at the clinical dose of 200 mg. There were no safety margins for the metabolite M21. Additional non-GLP in vitro studies performed on ion channels associated with peripheral nerve function showed no inhibition at doses up to 3 µM (safety margin of 14 based on MMB free Cmax). Although there are sufficient safety margins based on free exposure for MMB, there were no safety margins for the major active metabolite M21 present at low levels in rats. In clinical trials, peripheral neuropathy was observed and therefore adverse effects observed on velocity in rats may be considered clinically relevant.

The cardiovascular in vitro studies showed that MMB was a weak inhibitor of hERG channel K+ current (IC50&gt;10 µM), with no clinical relevance. Although this study was not considered with GLP compliance, this is considered acceptable taking into account the available GLP in vivo cardiovascular in dogs and the clinical data in thorough QT study. Cardiovascular safety parameters evaluated in dogs indicated that MMB did not significantly affect cardiovascular parameters at doses up to 30 mg/kg in the safety pharmacology study. On day 1 MMB decreased arterial blood pressure and concurrently increased HR at 100 mg/kg, which is approximately 4-fold above the estimated free drug Cmax in humans with MF.

<div style=\"page-break-after: always\"></div>

The metabolite M21 was not detected in dog plasma, or at very low levels. In the 13-week study in dogs, dose-related increases in heart rate were observed at ≥ 8.5 mg/kg/day, correlated at 51 mg/kg/day with physiologic shortening of the PR interval (up to -13%) and QT intervals (up to -12 ms), but were not considered clinically significant.  In human, no MMB-related adverse effects were observed in the thorough QT study.

## 2.5.2.4. Pharmacodynamic drug interactions

MMB is intended to be administered as monotherapy in line with SmPC. The absence of pharmacodynamic drug interactions studies is considered acceptable.

## 2.5.3. Pharmacokinetics

The analytical methods are well described in the respective bioanalytical and validation reports. For some pivotal GLP toxicology studies, toxicokinetics analysis were not performed in compliance with GLP (8283319 4-week in mice; 8336287 4-week impurities in rats ; WIL-604183 Juvenile DRF in rats ; WIL-604256 Juvenile in rats and 8283320 26-week study carcinogenicity in mice), but validation was conducted following the principles of GLP. For the other pivotal GLP studies, SOP deviations were acknowledged and documented in the raw data, but none of the analytical method or SOP deviations were considered to have affected the quality or integrity of the study. The analysis of thiocyanate levels, thiamine and thiamine diphosphate were not performed with GLP compliance.

The in vitro permeability studies indicates that the intestinal absorption of MMB in humans is likely to be high.

In mice after oral administration, MMB was absorbed with Tmax of 0.5 hours to 8 hours. The increases in MMB and M19 exposure were supraproportional at lower doses (10 to 100 mg/kg), but subproportional at higher doses (from 100 to 300 mg/kg). The increases in M20 and M21 exposure were supraproportional at lower doses (10 to 30 mg/kg), but subproportional at higher doses (from 30 to 300 mg/kg). The metabolite M19 was present at higher levels with mean metabolite to parent exposure ratios up to 0.189, compared to metabolites M20 and M21 with mean metabolite to parent exposure ratios up to 0.007. The exposures of MMB and its metabolites in the 500 mg/kg group were similar to the 300 mg/kg, which may be indicative of saturated absorption.

The PK of MMB was evaluated in rats with different formulation (free base, solution or suspension, 3 MMB salt forms). The formulation of MMB as a dihydrochloride salt in solution was selected for further non-clinical and clinical development. Following IV administration as a dihydrochloride salt, the systemic CL of MMB was low (0.47 L/h/kg) and the volume of distribution was 0.8 L/kg. MMB is therefore well distributed into tissues. The absolute oral bioavailability of MMB dihydrochloride was moderate (50 to 70.1%). The absorption of MMB following oral administration of the dihydrochloride salt was 1.7 to 3 hours postdose. The half-life of MMB dihydrochloride was short (1.7 to 2.2 hours). In rats, following oral administration of MMB dihydrochloride, the metabolites M19 and M21 were present at lower levels with mean metabolite to parent exposure ratios of 0.04 and 0.008, respectively.

Following a single IV dose of MMB dihydrochloride in dogs, a short half-life of 0.7 hours, a clearance of 1.8 L/h/kg and a volume of distribution of 2.4 L/kg were observed. Following a single oral dose of MMB dihydrochloride in dogs, higher absolute oral bioavailability of MMB (38% fed vs &lt;21% fasted), delayed time to Cmax (3 hours fed vs 1 hour fasted) and higher AUC exposure (2-fold higher fed) were observed in fed status, compared to fasted status. The oral bioavailability of MMB in dogs was lower than in rats. No information about the metabolites are available for dogs in PK studies.

<div style=\"page-break-after: always\"></div>

In human, as indicated in the SmPC, MMB is rapidly absorbed after oral administration with the maximal plasma concentration (Cmax) achieved within 3 hours post-dose. Following an oral dose of MMB 200 mg, the mean terminal half-life (t½) of MMB was approximately 4 to 8 hours; the half-life of M21 was similar. In both rats and dogs, following single oral administration of MMB dihydrochloride, like in human, rapid absorption of MMB was observed (up to 3 hours ) with short half-life (up to 1.7 hours).

MMB, M8, M19, and M21 displayed moderate to high protein binding in plasma from all species, with higher protein binding in rat plasma compared with the other species. Unbound MMB was 11.8% in mouse, 2.5% in rat and 19.2% in dog and human. Unbound M8, M19 and M21 ranged from 0.9 to 66.6% across species. The plasma protein binding of MMB and metabolites has not been investigated in rabbits.

In vitro B/P concentration ratio for MMB was approximately 0.6-0.8 and 1.1 in rat and human blood, respectively, suggesting almost 2-fold higher distribution in the erythrocyte fraction in human. Because of the expected pharmacological activities of MMB on blood cells, in case of decreased in blood cells observed after administration of MMB, it will be difficult to determine whether this effect is due to the pharmacological activities or due to distribution in red blood cells.

Following a single oral dose (80 mg/kg; 100 μ Ci/kg) of  14 C-MMB to male SD (nonpigmented) and Long Evans (partially pigmented) rats, MMB was widely distributed in tissues with radioactivity in most tissues reaching a maximum concentration at 4 hours, with subsequent declining plasma concentrations through 120 hours post dose. MMB-associated radioactivity was similar in SD and Long Evans rats with wide tissue distribution and the highest concentrations of radioactivity in alimentary canals for both the nonpigmented and pigmented animals. Radioactivity was nonquantifiable in bone, brain, spinal cord, and testis at all sampling times suggesting low penetration of  14 C-MMB-derived radioactivity across the blood-brain and blood-testis barriers. Except for skin (pigmented) and eye uveal tract in Long Evans rats, where radioactivity was declining but still quantifiable at 168 hours post dose, radioactivity was cleared from tissues by 72 hours post dose, suggesting reversible binding. Consistent with low brain concentrations of  14 C-MMB in rats following oral dosing, brain uptake of MMB was low in Swiss mice following an IV injection at a 5 mg/kg dose level, with a brain:plasma ratio of approximately 0.215±0.036 at 60 minutes post dose.

In a prenatal and postnatal development study in SD rats, plasma MMB was not extensively converted to M19 or M21. Plasma AUC values of MMB in dams on Lactation Day 10 (LD10) were approximately 4to 8-fold greater than in pups, while plasma M19 exposure in dams was approximately 2- to 3-fold lower than that of pups. Although the presence of MMB has not been quantified in milk, the presence of MMB and metabolites in plasma of the pups suggest that MMB may be present in milk.

The rates of MMB metabolism in liver microsomes and in hepatocytes from human and various animal species were low to moderate and showed no major species differences in the relative rate of metabolism. The in vitro studies on metabolism had limited success to detect metabolic products, and therefore species comparison could not be made. The in vitro studies using human hepatocytes demonstrated that multiple CYP enzymes are largely responsible for the metabolism of MMB (CYP3A&gt; CYP2C8 ~ CYP2C19 ~ CYP2C9 &gt; CYP1A2).

The in vivo studies in animal species (mouse, rat and dog) showed that the three most abundant metabolites across the species were M19 (an amide hydrolysis product of MMB), M20 (a morpholino cleavage metabolite), and M21 (a morpholino lactam metabolite). Other metabolites in lower abundance included M8, M16, and M17. The amount of M19 was 3 to up to 33-fold greater in dog and rat, respectively, than in pooled human samples, and the amount of M20 was 5 to 11-fold greater in the rat than in the human pool. The major active metabolite M21 in human plasma was present in rat plasma but at 0.2-0.5-fold lower levels and was not detected in the dog. M8 was a minor metabolite in

<div style=\"page-break-after: always\"></div>

humans, detected at low abundance in one study in rat, and not detected in dog. There were no unique human metabolites. Rat is therefore a more relevant animal species than dog based on metabolism data, as the major active metabolite M21 is not present in dog.

The hydrolysis of MMB to M19 (major pathway in animal species but not in human) leads to the simultaneous formation of aminoacetonitrile, which can undergo further metabolism to form thiocyanate. The levels of thiocyanate in plasma were evaluated in rat and dog studies (see below in section 'Repeat-dose toxicity studies'). In human, levels of thiocyanate were not considered clinically significant.

Following a single oral dose of  14 C-MMB to intact mice, rats and dogs, total radioactivity derived from 14 C-MMB was eliminated into feces (&gt;70% in all nonclinical species), with minor clearance via urinary excretion (&lt;15% in all animal species). Since the biliary excreted radioactivity were up to 33% and 42% in bile-cannulated rats and dogs, respectively, almost half of the radioactivity excreted in feces was from biliary excretion rather than incomplete absorption. Biliary excretion is therefore the major route of elimination of  14 C-MMB-derived radioactivity. Based on the radioactivity excreted in urine and bile after oral administration, a minimum of approximately 49% and 44% of the orally administered dose was absorbed in rats and dogs, respectively. Most of the radioactivity derived from  14 C-MMB was excreted after oral administration, within 24 to 48 hours after dosing in animal species. The excretion data in animal species are consistent with data from a human mass balance study where after oral administration of 200 mg  14 C-MMB,  14 C-MMB was primarily eliminated in the feces (~69.3%) versus urine (~27.5%).

## 2.5.4. Toxicology

The toxicology program was performed in line with ICH M3(R2) guideline. Sprague Dawley rat, Beagle dog, rasH2 mouse and New Zealand White rabbit were selected for the pivotal nonclinical toxicity studies. Biochemical and biophysical potency data for MMB or its metabolites against non-human orthologs of JAK family enzymes are not available, but the kinase domains of JAK1, JAK2, JAK3, TYK2, and ACVR1 are well conserved between human and animal species. The main toxicity findings in the animal species used in the MMB toxicology program (mice, rats, rabbits and dogs) are consistent with effects reported for modulating JAK1, JAK2 and ACVR1 kinases and subsequent downstream sequelae, which support the relevance of animal species used in the toxicology studies. For the repeat-dose toxicity studies, rat is a more relevant animal species from PK point-of-view, compared to dog.

## 2.5.4.1. Single dose toxicity

Single dose toxicity studies were performed with MMB free base or MMB bis-bisulfate. In mice, MMB was well tolerated at doses up to 50 mg/kg BID. In rats, single oral maximum tolerated dose of MMB was 500 mg/kg. Reversible hematology changes observed at ≥ 250 mg/kg were consistent with the ontarget pharmacologic action of MMB on JAK family. In dogs, MMB was well tolerated at doses up to 500 mg/kg.

## 2.5.4.2. Repeat dose toxicity

In the repeat-dose toxicity studies in mice, rats and dogs, findings included reduced red cell mass (red blood cell count, hemoglobin, hematocrit), as well as lower white blood cell count correlated with doserelated cellular depletion in the bone marrow (femur and sternum) and with lymphoid depletion in the spleen, lymph node, thymus, and/or gut-associated lymphoid tissue. Recovery from the cellular and lymphoid depletion was noted but incomplete upon cessation of dosing. The leukopenia and

<div style=\"page-break-after: always\"></div>

lymphopenia did not result in opportunistic infections or neoplasms in the repeat-dose toxicity studies in both rats and dogs, as well as in the mouse and rat carcinogenicity or rat, although in the clinical trials with MMB, infection was a very common adverse reaction reported, in line with the class effect reported with other JAK inhibitors. These findings are consistent with the pharmacological activity of MMB on janus kinases involved for hematopoiesis and immune response, and are clinically relevant.

Decreased testes and epididymal weights were noted in 13- and 26-week toxicity studies in rats, correlating with degeneration/atrophy of germinal epithelium within seminiferous tubules of the testes, and oligospermia/germ cell debris in the epididymis. Similar microscopic findings in the testes and epididymides were also noted in a 4-week rat study. These effects were more severe at ≥ 50 mg/kg/day and irreversible, and occurred at exposure margins of 93 and 12 based on MMB total and free AUC, respectively, at the clinical dose of 200 mg. However, no radioactivity was detected in the testes of SD or Long Evans rats after a single dose of dose of 80 mg/kg 14C-MMB. In dogs, mild spermatid/spermatocyte degeneration in the testes and a mild increase in germ cell debris in the epididymides in males was observed in all groups including control group, and were considered related to the stage of sexual maturity (recently mature).

Histopathology findings in the female rat reproductive system included an increased incidence of corpora hemorrhagica, luteal cysts, and follicular cysts in the ovaries after administration of ≥ 30 mg/kg/day in the 4-week toxicity study. Epithelial degeneration was observed in the cervix at ≥ 10 mg/kg/day. There were no alterations to the female reproductive organs in the 13- or 26-week rat repeat-dose toxicity studies where the high dose was 68 mg/kg/day and 50 mg/kg/day, respectively.

Dose-limiting toxicities in the dog studies was inappetence and decreased body weight gain and/or body weight in the 4-week study at 100 mg/kg/day and the 39-week study at 50 mg/kg/day (exposure margin of at least 2.8 based on MMB total/free AUC).

In the 39-week study in dogs, an increase in posterior subcapsular cataracts was noted in 2 males and 3 females administered the high MMB dose of 50 mg/kg/day (exposure margin of 2.8 based on MMB total/free AUC). The cataracts were present after a 6-week recovery period in 1 male and 2 females that were retained. In the rat tissue distribution study, no radioactivity was detected in the eyes or lens of SD rats or in the lens of Long Evans rats. There were low levels of radioactivity detected in the eyes of Long Evans rats 8 and 24 hours after a single dose of 80 mg/kg 14C-MMB. The significance of this finding is unknown, but the incidence of cataracts was not increased in MMB-treated subjects in clinical studies.

In the 26-week study in rats and in the repeat-dose toxicity studies, effects on peripheral and central nervous systems and on cardiovascular system were observed and has been further discussed above in section 'Safety pharmacology'.

Histopathology findings in the 4-week rat toxicity study that were not observed in the longer duration studies or in dogs included hemorrhage in the gastrointestinal tract at ≥ 30 mg/kg/day, hemorrhage at the base of the heart in a few males administered 100 mg/kg/day, and a decreased incidence of minimal mononuclear infiltration in the liver at 100 mg/kg/day. The hemorrhage findings may be related to off-target effects toward VEGFR and/or FGFR family kinases and occurred at exposure margins of at least 58 and 7.6 based on MMB total and free AUC, respectively, at the clinical dose of 200 mg. In the clinical trials with MMB, haemorrhagic events were observed, but bleeding events are not uncommon in patients with myelofibrosis and may not be attributed to MMB.

Although the major active metabolite M21 is not considered qualified based on free exposure in animal species in line with the ICH M3(R2), it can be considered qualified based on pharmacodynamic activities similar to MMB. In addition, the adverse effects reported in the toxicology studies were consistent with those reported for other drugs in this class. Taking into account the clinical experience

<div style=\"page-break-after: always\"></div>

with MMB, additional toxicology studies with administration of the metabolite M21 were not considered necessary.

The hydrolysis of MMB to M19 leads to the simultaneous formation of aminoacetonitrile, which can undergo further metabolism to form cyanide and further formation of thiocyanate.  In animal species, MMB is mainly metabolized in M19, but not in human. In the 4-week study in rats and dogs, plasma thiocyanate analysis indicated dose-concordant increases in thiocyanate levels over the dosing period, but the levels were below than concentrations reported to cause toxicity. In human, levels of thiocyanate were not considered clinically significant.

Because inhibition of thiamine transporters has been proposed as a putative mechanism for the Wernicke encephalopathy reported during clinical development of the JAK inhibitor fedratinib, non-GLP additional studies were performed and showed no differences in mean plasma thiamine or thiamine diphosphate levels in the 39-week study in dogs. Such studies were not performed in rats.

## 2.5.4.3. Genotoxicity

The data from the standard battery of genotoxicity assessments, in line with ICH S2(R1), indicated that MMB does not present a genotoxic hazard to humans. No in vitro genotoxicity studies were performed with the major active metabolite M21. In the in vivo micronucleus test in rats, doses up to 1000 mg/kg of MMB were administered. Based on the TK data observed in the repeat-dose toxicity study in rats, the metabolite M21 should has been present at sufficient exposure levels to be considered as qualified.

## 2.5.4.4. Carcinogenicity

In the 104-week carcinogenicity study in rats, neoplastic findings were limited to an increased incidence of testicular interstitial (Leydig) cell adenomas in males at 15 mg/kg/day (18.33%), as well as at 5 mg/kg/day MMB plus 25 mg/kg/day M21 with lower incidence (10%). This finding was correlated with increased incidence of testicular enlargement and various testicular discolorations or foci observed macroscopically. This was considered most likely associated with JAK2-mediated inhibition of prolactin signaling pathways in the rat, while human health risk is considered unlikely as human Leydig cells lack similar prolactin dependence for normal function (Chapin, 2017). Except these findings with unlikely human relevance, no other tumorigenicity findings were observed at doses up to 15 mg/kg/day MMB, with exposure margins based on total and free AUC of 33 and 4.3 for MMB, respectively, at the clinical dose of 200 mg. There is no safety margin for the metabolite M21. In the 26-week carcinogenicity study in transgenic mice, there were no MMB-related neoplasms in animals administered up to 100 mg/kg/day, although there was a clear carcinogenic response in animals administered the positive control article. At the NOEL of 100 mg/kg/day, the safety margins are 26 and 16, based on MMB total and free AUC, respectively at the clinical dose of 200 mg. There is no safety margin for the active metabolite M21, as MMB was not converted extensively to M21.

## 2.5.4.5. Reproductive and developmental toxicity

Consistent with the MMB-related adverse effects observed on male reproductive system in the repeatdose toxicity studies, MMB had adverse effects on male reproductive system at ≥ 25 mg/kg/day (reduced seminal vesicle weight and reduced sperm concentration and motility) and reduced fertility at 100/68 mg/kg/day in the fertility and early embryonic development study. These effects are consistent with a combination of MMB-related inhibition of ACVR1 (ALK2) resulting in reduced activin signaling during spermatogenesis and reduced JAK/STAT signaling in different stages of the spermatogenic

<div style=\"page-break-after: always\"></div>

cycle.  The NOAEL for male fertility was considered to be 5 mg/kg/day, and corresponds to safety margins of 10 and 1 based on MMB total and free AUC, respectively, at the clinical recommended dose of 200 mg. The clinical translational relevance is unknown. In the GLP fertility and early embryonic development study in female rats, effects on female reproductive system were observed at 100/68 mg/kg/day (reduced numbers of corpora lutea and mean number of estrous cycles, reduced mean ovarian and vagina weight) and reduced fertility was observed at ≥ 25 mg/kg/day (increase in early resorptions, increased post-implantation loss and decreased number of live fetuses). ACVR1 signaling is important in ovarian development and function along with folliculogenesis, and MMB inhibition of ACVR1 signaling was the likely mechanism for the adverse female reproductive effects observed. The NOEL for maternal toxicity and fertility was 5 mg/kg/day and the NOEL for early embryonic development was 5 mg/kg/day, and corresponds to safety margins of 22 and 3 based on MMB total and free AUC, respectively, at the recommended clinical intended dose of 200 mg. In the SmPC, it has male and female fertilities in human have been included in the SmPC.

In an oral pre- and post-natal development study, rats received oral administration of MMB from gestation to end of lactation. Evidence of maternal toxicity, increases in embryonic and foetal death, and decreased birth weights were observed at doses of 6 mg/kg/day and higher. Pup survival was significantly reduced at 6 mg/kg/day or higher from birth to lactation and was therefore considered a direct effect of MMB via exposure through the milk. The free AUC exposure at the NOAEL for both 200 mg daily. Taking into account that exposure to momelotinib through the milk was observed at clinically relevant exposures and that potential toxic effects on fetal bone development have been observed with certain approved JAK inhibitors, contra-indication during breast-feeding has been included in the SmPC.

been highlighted that MMB impaired fertility in rats in section 4.6, and effects of MMB observed in male and female fertility studies have been described in section 5.3. No specific recommendations regarding MMB, when administered orally to pregnant rats and rabbits during organogenesis showed evidence of embryo-fetal toxicities, but no teratogenicity. In rats, maternal toxicity was observed at 68 mg/kg/day and was associated with embryonic death, soft tissue anomalies, and decreased foetal weights and skeletal variations at 6 mg/kg/day and higher (approximately 8-fold and 1-fold the recommended dose of 200 mg daily based on total and free AUC, respectively). One visceral malformation (absent aortic arch) was reported in two fetuses from two different litters in the high dose group only, and may be related to ACVR1 inhibition as this receptor has a role in outflow tract development in response to BMP signaling. The NOEL for embryo-fetal effects at 2 mg/kg was approximately 2 and 0.2 times higher than the total and free AUC, respectively, observed at the recommended dose of 200 mg. There are no safety margins for any metabolites, including the major active metabolite M21. In rabbits, severe maternal toxicity and evidence of embryo-foetal toxicity (abortions, embryonic deaths, decreased foetal weights and/or decreased foetal skeletal ossification) were observed at 60 mg/kg/day and higher (exposure equivalent to the recommended dose of 200 mg based on AUC). The NOAEL at 30 mg/kg/day was lower than the AUC observed at the recommended dose of 200 mg daily. In the SmPC, the embryo-fetal toxicities observed in animal species have been highlighted in section 4.6, and the effects of MMB observed in EFD studies have been described in section 5.3. Based on the low or absence of safety margins at clinical exposures, the role of JAK2 in development described in the literature and the known class effects of other marketed JAK inhibitors, contra-indication for pregnancy has been included in the SmPC. maternal and F1 litters at 2 mg/kg/day was lower than the AUC observed at the recommended dose of

In the pivotal juvenile toxicity study in rats, reversible lower mean body weights and body weight gains (with corresponding lower mean food consumption) that resulted in shorter mean tibial lengths and femur lengths, a delay in the age of attainment in balanopreputial separation, and decreased forelimb grip strength during the FOB assessment occurred at 10 mg/kg/day from PND 7 through 56. Reversible

<div style=\"page-break-after: always\"></div>

memory impairment was noted in males at 10 mg/kg/day during the Biel maze assessment during the dosing phase. There were no adverse MMB-related effects on reproductive endpoints or spermatogenic endpoints, but higher postimplantation loss resulting in lower mean number and litter proportion of viable embryos was noted at 10 mg/kg/day. The NOAEL for juvenile toxicity at 3 mg/kg was approximately 2.4 and 0.3 times higher than the total and free AUC, respectively, observed at the recommended dose of 200 mg.

## 2.5.4.6. Toxicokinetic data

In rats, the systemic MMB exposures (Cmax and AUC) increased generally in a greater than doseproportional manner at doses below 30 mg/kg/day, and in a less than dose-proportional manner at higher doses. Systemic MMB exposure (Cmax and AUC0-24) was in general slightly higher in females than males. Low accumulation of MMB has been observed with repeating dosing, but generally less than 2-fold. In rats, MMB was mainly metabolized in M19 and less to M21, M20 and M17. Systemic exposures to all metabolites were lower than to MMB. The metabolites M17 and M19 appeared to be generally higher in females than males while the metabolites M20 and M21 appeared to be sexindependent.

In dogs, the systemic MMB exposure (Cmax and AUC) increased generally in an approximate doseproportional manner or in a less than dose-proportional manner. Systemic MMB exposure (Cmax and AUC0-24) was in general similar between male and female dogs. Decreased systemic MMB exposure (Cmax and AUC) was observed overtime until week 13 (less than 2-fold in general), but MMB exposure at week 39 was in general similar than at day 1. In dogs, MMB was mainly metabolized in M19 but exposures were at lower levels than MMB. The metabolites M21, M20, M17 were barely or not present.

In mice, Systemic exposure to MMB, M19, M20, and M21 generally increased with the increasing MMB dose level with less than 2-fold differences in exposure between sexes and no accumulation. MMB was not converted extensively to M21, M20, or M8.

In rabbits, available AUC0-t metabolite to parent ratios indicated that MMB was not extensively converted to M21 but was extensively converted to M19. Systemic Cmax and AUC increases in MMB, M19 and M21 were generally greater than dose proportional, but no accumulation was observed.

## 2.5.4.7. Local Tolerance

In vitro studies showed that MMB is considered to be corrosive (UN Packing Group III category 1C) and to be a severe eye irritant (category 1).

## 2.5.4.8. Other toxicity studies

MMB did not show the potential to induce skin sensitization using the Local Lymph Node Assay in the Mouse. MMB is a chemical substance that will be administered orally, and there are no concerns for antigenicity.

In the toxicology studies in animal species, immunotoxicity was observed and is linked to the pharmacological activity of MMB (class effect of JAK inhibitors). In clinical trials with MMB, infections were very common adverse reactions. This has been highlighted in the SmPC. No additional nonclinical immunotoxicity studies are needed.

The absence of dependence studies for MMB is considered acceptable.

<div style=\"page-break-after: always\"></div>

Two 4-week oral toxicity studies were conducted in rats to qualify impurities and potential impurities in the Good Manufacturing Practice material. The impurities spiked into the drug substance did not alter the NOAEL in rats. The impurities have been tested with two QSAR methodologies (prediction with Leadscope model applier (statistical-based), Derek Nexus (expert rule-based) and/or CASE Ultra (expert rule-based)). All the impurities tested in the 4-week toxicology studies are categorized as class 5 (non-mutagenic). During the manufacturing process, genotoxic impurities are formed, but control strategies are applied (see quality report).

MMB has no phototoxic potential.

## 2.5.5. Ecotoxicity/environmental risk assessment

Table 1. Summary of main study results

| Substance (INN/Invented Name): momelotinib                          | Substance (INN/Invented Name): momelotinib   | Substance (INN/Invented Name): momelotinib   | Substance (INN/Invented Name): momelotinib         |
|---------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------------|
| CAS-number (if available):                                          | CAS-number (if available):                   | CAS-number (if available):                   | CAS-number (if available):                         |
| PBT screening                                                       |                                              | Result                                       | Conclusion                                         |
| Bioaccumulation potential- log K ow                                 | Unknown, additional data should be provided  | pH 7: 2.7                                    | Potential PBT (additional data should be provided) |
| Phase I                                                             | Phase I                                      | Phase I                                      | Phase I                                            |
| Calculation                                                         | Value                                        | Unit                                         | Conclusion                                         |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.009                                        | µ g/L                                        | > 0.01 threshold (N)                               |
| Other concerns (e.g. chemical class)                                |                                              |                                              | (N)                                                |

The Predicted Environmental Concentration in surface water (PECsurfacewater) has been calculated with a refined Fpen based on literature reference (Moulard, et al., 2012), which is considered acceptable taking into account that myelofibrosis is a rare disease. The Phase I assessment was completed based on a maximum daily dose of 200 mg active ingredient per inhabitant per day, daily consumption of 1 tablet for 365 days per year and a conservative prevalence of 9 cases of myelofibrosis per 100,000 individuals. Based on these input values, the conservative PECsurfacewater is calculated to be 0.009 µg/L, and is below the cut-off of 0.01 µg/L. MMB is not classified as endocrine active substances, parasitics or antibiotic. No Phase II assessment is required.

The applicant committed to conduct additional study for the calculation of the octanol/water partitioning coefficient (Kow) as a post-approval commitment (CHMP Recommendation), in line with guideline on the environmental risk assessment of medicinal products for human use (EMA/CHMP/SWP/44609/2010 Rev. 1). If the Kow value at any pH value between pH 5 and pH 9 meets the trigger values for PBT assessment (log Kow &gt; 4.5), further PBT assessment is required. The updated ERA and the study reports should be provided within 2 years following approval.

## 2.5.6. Discussion on non-clinical aspects

Overall, the pharmacological studies provide evidence for inhibition of JAK family kinases and ACVR1 that support efficacy in humans. The applicant has committed to clarify the selectivity of MMB and M21 on JAK family kinases compared to other targets, as well as to discuss the clinical relevance, as a postapproval commitment ( CHMP Recommendation ) within two years after approval. The repeat-dose toxicological data showed adverse effects related to the pharmacological activity of MMB on JAK family kinases. The non-clinical findings are in line with adverse effects observed in the clinical program.

<div style=\"page-break-after: always\"></div>

Based on the low or absence of safety margins at clinical exposures in the reproductive and developmental toxicity studies, the role of JAK2 in development described in the literature and the known class effects of other marketed JAK inhibitors, contra-indication during pregnancy and breastfeeding has been included in the SmPC.

With regards to the environmental risk assessment, momelotinib PEC surfacewater value is below the action limit of 0.01 µ g/L and is not a PBT substance as log Kow does not exceed 4.5. Therefore momelotinib is not expected to pose a risk to the environment. As a post-approval commitment ( CHMP Recommendation ) within two years after approval, the applicant should conduct additional studies for the calculation of the octanol/water partitioning coefficient (Kow), and further PBT assessment if needed.

## 2.5.7. Conclusion on the non-clinical aspects

From a non-clinical perspective, the MAA for Omjjara is approvable.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 5: Clinical Studies Contributing to the Clinical Pharmacology of MMB

| Study Phase/Number                        | Key Clinical Pharmacology Objectives                                                                                                                                                                                                                |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase 1-2: Subjects With MF               | Phase 1-2: Subjects With MF                                                                                                                                                                                                                         |
| CCL09101                                  | To determine the PK of MMB in subjects with PMF or post-PV/ET MF.                                                                                                                                                                                   |
| YM387-II-02                               | To determine the PK of BID, orally administered MMB in subjects with PMF or post-PV/ET MF.                                                                                                                                                          |
| Phase 2: Subjects With MF                 | Phase 2: Subjects With MF                                                                                                                                                                                                                           |
| GS-US-352-1672                            | To evaluate MMB PK in transfusion-dependent subjects with MF. To assess biomarkers of inhibition of JAK1/2 and ACVR1 in transfusion-dependent subjects with MF treated with MMB.                                                                    |
| Phase 3: Subjects With MF                 | Phase 3: Subjects With MF                                                                                                                                                                                                                           |
| MOMENTUM (SRA-MMB-301)                    | Sparse blood samples were collected for PK evaluation at times corresponding to trough concentrations (predose and at the week 8, 16, and 24 visits).                                                                                               |
| SIMPLIFY-1 (GS-US-352-0101)               | Sparse blood samples were collected for PK evaluation at times corresponding to trough concentrations (predose). In addition, rich PK sampling was performed in a subset of subjects to provide a more thorough evaluation of PK parameters.        |
| SIMPLIFY-2 (GS-US-352-1214)               | Sparse blood samples were collected for PK evaluation at times corresponding to trough concentrations (predose). In addition, rich PK sampling was performed in a subset of subjects for noncompartmental analysis and evaluation of PK parameters. |
| Phase 1: Subjects With Renal Impairment   | Phase 1: Subjects With Renal Impairment                                                                                                                                                                                                             |
| GS-US-352-1152                            | To evaluate the PK of MMB and its metabolites (GS-644603 [M21] and GS-642112 [M19]) in subjects with impaired renal function compared with matched healthy controls.                                                                                |
| Phase 1: Subjects With Hepatic Impairment | Phase 1: Subjects With Hepatic Impairment                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Study Phase/Number                                                                                                                                                                                                                                                                                                                                                                                      | Key Clinical Pharmacology Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GS-US-352-1153                                                                                                                                                                                                                                                                                                                                                                                          | To evaluate the PK of MMB and its metabolites (GS-644603 [M21] and GS-642112 [M19]) in subjects with impaired hepatic function compared with matched healthy controls.                                                                                                                                                                                                                                                                                                                                 |
| Phase 1: Healthy Subjects                                                                                                                                                                                                                                                                                                                                                                               | Phase 1: Healthy Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| YM387-I-02 (Bioequivalence and food effect)                                                                                                                                                                                                                                                                                                                                                             | To evaluate relative bioavailability and bioequivalence of single oral doses of MMB tablet to capsule and food effect on MMB tablet.                                                                                                                                                                                                                                                                                                                                                                   |
| GS-US-352-0102 (Food effect, Dose proportionality, Relative bioavailability, and DDI potential)                                                                                                                                                                                                                                                                                                         | Primary objectives: To assess the relative bioavailability of a tablet formulation of MMB compared with the capsule To explore the effect of high-fat and low-fat meal types on the PK of MMB administered as a tablet formulation To evaluate the effect of omeprazole, a representative proton pump inhibitor, on the PK of MMB                                                                                                                                                                      |
| GS-US-352-1150 (Thorough QT study)                                                                                                                                                                                                                                                                                                                                                                      | To evaluate the effect of MMB at therapeutic (200 mg) and supratherapeutic (800 mg) doses on QTc interval and other cardiovascular parameters in a single-dose crossover design using a time matched, baseline-adjusted, and placebo-corrected approach                                                                                                                                                                                                                                                |
| GS-US-352-0108 (Race/ethnicity)                                                                                                                                                                                                                                                                                                                                                                         | To investigate the PK of MMB following single-dose administration in healthy Japanese and Caucasian subjects.                                                                                                                                                                                                                                                                                                                                                                                          |
| GS-US-352-1151 (DDI)                                                                                                                                                                                                                                                                                                                                                                                    | Primary objectives: To evaluate the effect of multiple doses of the strong CYP3A4 inhibitor ritonavir on the PK of MMB To evaluate the effect of multiple doses of the strong CYP3A4 inducer rifampin on MMB PK To evaluate the effect of a single dose of the OATP inhibitor rifampin on MMB PK To evaluate the effect of multiple doses of MMB on CYP3A enzyme activity using the probe substrate MDZ To evaluate the effect of multiple doses of MMB on BCRP using the probe substrate rosuvastatin |
| GS-US-352-1149 (Mass balance)                                                                                                                                                                                                                                                                                                                                                                           | The primary objective was to determine the major routes of MMB elimination using a mass balance analysis following administration of a single oral dose of radiolabeled [ 14 C]-MMB. Secondary objectives: To evaluate the PK of MMB and metabolite(s), where possible To determine the metabolite profile of MMB in humans                                                                                                                                                                            |
| ACVR1, activin A receptor type 1; BCRP, breast cancer resistance protein; BID, twice daily; CYP, cytochrome P450; DDI, drug drug interaction; ET, essential thrombocythemia; JAK, Janus kinase; MDZ, midazolam; MF, myelofibrosis; MMB, momelotinib; OATP, organic anion transporting polypeptide; PK, pharmacokinetics; PMF, primary myelofibrosis; PV, polycythemia vera; QTc, QT interval corrected. | ACVR1, activin A receptor type 1; BCRP, breast cancer resistance protein; BID, twice daily; CYP, cytochrome P450; DDI, drug drug interaction; ET, essential thrombocythemia; JAK, Janus kinase; MDZ, midazolam; MF, myelofibrosis; MMB, momelotinib; OATP, organic anion transporting polypeptide; PK, pharmacokinetics; PMF, primary myelofibrosis; PV, polycythemia vera; QTc, QT interval corrected.                                                                                                |

Table 6: Phase 2 and 3 Clinical Studies of MMB in Subjects With Myelofibrosis

| Study ID / Acronym [1] Status First Subject Screened/ LSLV Regions   | Patient population                                                                                                                       | Study Design                                                                                                     | Dosing Regimen (MMB Tablets)                                                                                            | Planned / Actual Enrollment, Treated, Completed                                                              | Duration of Treatment [2]                                                                | Primary Endpoint                                                                             |
|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| SRA-MMB-301 MOMENTUM [3] RT period completed; OL                     | Subjects with intermediate-1 intermediate-2 or high-risk (DIPSS or DIPSS-Plus) PMF, post-PV MF, or post-ET MF. Symptomatic ( MFSAF TSS ≥ | Phase 3, international, randomized, double-blind, active- controlled, followed by optional open-label MMB or DAN | RT period MMB or DAN (2:1) and matching placebo: MMB 200 mg QD and DAN-placebo BID or DAN 300 mg BID and MMB-placebo QD | Planned, ~180/ actual, 195 RT period Treated, 195 (130 MMB, 65 DAN) Completed 24 weeks, 132 (94 MMB, 38 DAN) | RT period 24.00 weeks MMB, 23.71 weeks DAN MMB overall (including DAN → MMB) 26.71 weeks | First MFSAF TSS response rate at week 24, assessed using the MFSAF v4.0 questionnaire Second |

<div style=\"page-break-after: always\"></div>

| Study ID / Acronym [1] Status First Subject Screened/ LSLV Regions                                                                                      | Patient population                                                                                                                                                                                                                                                                                                                   | Study Design                                                                                                      | Dosing Regimen (MMB Tablets)                                                                                                                                                                                                            | Planned / Actual Enrollment, Treated, Completed                                                                                                                                                                                   | Duration of Treatment [2]                                                                                                                                                                                  | Primary Endpoint                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| treatment period ongoing; data cutoff 03 Dec 2021 for week 24 analysis Feb 2020/ Dec 2021 for week 24 analysis Europe, North America, Asia, Australasia | 10) Splenomegaly (palpable spleen ≥ 5 cm below LCM or spleen volume ≥ 450 cm 3 ) Anemic (Hgb < 10 g/dL) Prior JAK inhibitor                                                                                                                                                                                                          |                                                                                                                   | OL treatment period MMB → MMB: dose received in RT period DAN → MMB: MMB 200 mg QD DAN → DAN: 400 mg (max total daily dose)                                                                                                             | OL treatment period Treated, 132 (92 MMB → MMB, 40 DAN → MMB, 0 DAN → DAN) MMB overall Treated, 170 MMB (130 MMB, 40 DAN → MMB)                                                                                                   | Planned maximum duration of participation was approximately 7 years, with possibility to continue in extension study                                                                                       | TI rate at week 24, defined as the proportion of subjects with TI in the terminal 12 weeks of the 24-week RT period                                  |
| GS-US-352-01 01 SIMPLIFY-1 Completed Study termination by sponsor [4] Dec 2013/ May 2019 Europe, North America, Australia, Asia                         | Subjects with intermediate-2 or high-risk (IPSS) PMF, post-PV MF, or post-ET MF. Intermediate- 1 (IPSS) MF patients are allowed if associated with symptomatic splenomegaly, hepatomegaly, anemia (Hgb < 10 g/dL), and/or unresponsiven ess to available therapy Splenomegaly (palpable spleen ≥ 5 cm below LCM) JAK inhibitor naive | Phase 3, international, randomized, double-blind, active- controlled, followed by optional open-label MMB         | RT period MMB or RUX (1:1) and matching placebo: MMB 200 mg QD and RUX-placebo BID or RUX BID [5] and MMB-placebo QD OL treatment period MMB → MMB: dose received in RT period RUX → MMB: dose matching the equivalent MMB-placebo dose | Planned, ~420/ actual, 432 RT period Treated, 430 (214 MMB, 216 RUX) Completed 24 weeks, 376 (175 MMB, 201 RUX) OL treatment period Treated, 368 (171 MMB → MMB, 197 RUX → MMB) MMB overall Treated, 411 (214 MMB, 197 RUX → MMB) | RT period 23.9 weeks MMB, 24.0 weeks RUX MMB overall (including RUX → MMB) 77.0 weeks Planned maximum duration of participation was approximately 5 years, with possibility to continue in extension study | SRR at week 24, defined as the proportion of subjects with a reduction in spleen volume ≥ 35% from baseline at week 24 as measured by MRI or CT scan |
| GU-US-352- 1214 SIMPLIFY-2 Completed Study termination by sponsor [4] Jun 2014/ Apr 2019 Europe, North America, Asia                                    | Subjects with intermediate-2 or high-risk (DIPSS) PMF, post-PV MF, or post-ET MF. Intermediate- 1 (DIPSS) MF patients are allowed if associated with symptomatic splenomegaly, and/or hepatomegaly Splenomegaly (palpable spleen ≥ 5 cm below LCM) Prior ruxolitinib                                                                 | Phase 3, international, randomized, open-label, BAT- controlled, followed by optional extended treatment with MMB | MMB or BAT (2:1) MMB 200 mg QD or BAT (including RUX)                                                                                                                                                                                   | Planned, ~150/ actual, 156 RT period Treated, 156 (104 MMB, 52 BAT [46 RUX]) MMB overall Treated, 144 (104 MMB, 40 BAT → MMB)                                                                                                     | Randomized to MMB 40.0 weeks Randomized to BAT 38.1 weeks MMB overall (including BAT → MMB) 40.0 weeks Planned maximum duration of participation was approximately 5 years, with                           | SRR at week 24, defined as the proportion of subjects with a reduction in spleen volume ≥ 35% from baseline at week 24 as measured by MRI or CT scan |

<div style=\"page-break-after: always\"></div>

| Study ID / Acronym [1] Status First Subject Screened/ LSLV                        | Patient population                                                                                                                                                                                 | Study Design                                                                                                               | Dosing Regimen (MMB Tablets)      | Planned / Actual Enrollment, Treated, Completed                                                                                                                                          | Duration of Treatment [2]                                                                                               | Primary Endpoint                                                                                                        |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Regions                                                                           |                                                                                                                                                                                                    |                                                                                                                            |                                   |                                                                                                                                                                                          |                                                                                                                         |                                                                                                                         |
| (Israel)                                                                          |                                                                                                                                                                                                    |                                                                                                                            |                                   |                                                                                                                                                                                          | possibility to continue in extension study                                                                              |                                                                                                                         |
| GU-US-352- 1672 Completed Study termination by sponsor Jan 2016/ Aug 2017         | Subjects with intermediate-2 or high-risk (DIPSS) PMF, post-PV MF, or post-ET MF. Intermediate- 1 (DIPSS) MF patients are allowed if associated with symptomatic splenomegaly, and/or hepatomegaly | Phase 2, multicenter, open-label, single-arm, translational biology study in transfusion- dependent subjects               | MMB 200 mg QD                     | Planned, ~40/ actual, 41 Treated, 41                                                                                                                                                     | 23.4 weeks                                                                                                              | TI rate at week 24, defined as the proportion of subjects with TI in 12 week period during the 24-week treatment period |
| SRA-MMB- 4365 XAP 03 May 2018 to ongoing Europe, North America, Asia, Australasia | Study eligibility defined in prior study                                                                                                                                                           | Phase 2, international, open-label, extension study for GS- US-352-0101, GS-US-352- 1154, GS-US- 352-1214, and SRA-MMB-301 | MMB dose received in prior study. | Planned, ~400/ Actual, 170 • GS-US-352- 0101, 96 • GS-US-352- 1154, 19 • GS-US-352- 1214, 22 • SRA-MMB-301, 33 Treated, 170 Ongoing, 110 Data cutoff date: 03 Dec 2021, study is ongoing | 31.69 months (Q1, 7.98; Q3, 35.91) (Until MMB is commercially available in their region or development is discontinued) | [6]                                                                                                                     |

[1] Protocol number and study acronym, as applicable.  [2]  Duration of treatment is provided as overall median exposure to study drug.  [3] MOMENTUM was conducted during the COVID-19 pandemic.  [4]  Termination was planned after eligible ongoing subjects transitioned to study SRA-MMB-4365 (XAP) for long-term MMB treatment.  [5] The starting dose (5-20 mg BID) was based on screening laboratory values outlined in the study protocol. [6]   Objectives of study SRA-MMB-4365 (XAP): Extended access, long-term safety, OS, LFS in subjects with MF BID, twice daily; CT, computed tomography; DAN, danazol; ID, identification; LSLV, last subject last visit; MFSAF v4.0, Myelofibrosis Symptom Assessment Form version 4.0; max, maximum; MMB, momelotinib; MRI, magnetic resonance imaging; OL, open-label; QD, once daily; RT, randomized treatment; RUX, ruxolitinib; SRR, splenic response rate; TI, transfusion independence; TSS, total symptom score.

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

Momelotinib (MMB) has been developed for the treatment of adult patients with MF. MMB inhibits the JAK1/JAK2 kinases and the activin A receptor type 1 (ACVR1)/activin receptor-like kinase 2 (ALK2). The recommended dose according to the SmPC is 200 mg once daily, taken with or without food.

MMB has one major circulating metabolite, M21. The major metabolite M21 is active but less potent compared with MMB with a pharmacologic activity index of 34% for JAK1/2 inhibition  and  40%  for ACVR1 inhibition.

<div style=\"page-break-after: always\"></div>

Fourteen  clinical  studies  conducted  in  healthy  volunteers  and  patients  with  myelofibrosis  (MF) contributed to the characterization of the clinical pharmacology of MMB. Other than three early Phase 1 and 2 clinical  studies  (CCL09101,  YM387-I-02,  YM387-II-02)  that  were  performed  using  powder-incapsule formulation or tablet formulation of MMB dihydrochloride salt form I, and the mass balance study (GS-US-352-1149) in which an oral solution was used, all later Phase 1 and 2 studies and all Phase  3  studies  were  performed  using  a  film-coated  tablet  formulation  of  MMB  dihydrochloride monohydrate salt Form II. The commercial tablet formulation is identical to that used in the Phase 3 clinical studies.

## Absorption

MMB is rapidly absorbed after oral administration with median Tmax ranging from 1.8 to 3 h following a single dose of MMB (100 to 800 mg) in healthy volunteers. In MF patients receiving 200 mg QD, the median Tmax was 1.75 h for MMB and slightly longer (i.e. 3 h) for the active metabolite M21.

MMB is a low-solubility drug and has pH-dependent solubility. MMB showed moderate to high in vitro permeability. Based on these characteristics, MMB is classified as a BCS class 2 compound. No absolute bioavailability study has been conducted.

MMB and M21 are substrates of P-gp and BCRP in vitro .

## Relative bioavailability

Two dihydrochloride salt forms of MMB were evaluated in MMB clinical studies: MMB dihydrochloride salt Form I and MMB dihydrochloride monohydrate salt Form II, the latter being used in all phase 3 studies.  The  relative  bioavailability  between  the  tablet  formulation  (MMB  Form  II)  and  the  capsule formulation (MMB Form I) was investigated under fasting conditions in part A of study GS-US-3520102. Fifty eligible subjects were randomized to 1 of the 4 treatment sequences in which tablet doses (100, 150, 200 or 300 mg) in period 1 were compared to the target 300 mg capsule dose in period 2, separated  by  a  3  day  wash-out.  The  MMB  tablet  formulation  at  200  mg  resulted  in  a  comparable exposure (AUC and Cmax) to the 300-mg capsule and was therefore selected as the starting dose for Phase 3 studies in MF patients.

Table  7: MMB PK parameters Following Single Doses of 200-mg MMB Tablet (Test) versus 300-mg MMB Capsule (Reference)

|                                              |                 | Mean (46CV)       | Mean (46CV)       |                         |
|----------------------------------------------|-----------------|-------------------|-------------------|-------------------------|
| Treatment Sequence                           | PK Parameter    | 11                | Reference         | 96GLSMI Ratio (9096 C1) |
| 200-mg Tablet (Iest, =12) vs. 300-mg Capsule | C. (ngmL)       | 323.7 (58.2)      | 356.1 (54.9)      | 91.99 (78.98. 107.15)   |
|                                              | AUC.r(h*ng/mL)  | 2549.7 (66.1)     | 2665.5 (74.9)     | 101.69 (87.45,118.26)   |
|                                              | AUCn- (h*ng/mL) | 2324.5 (65.3)     | 2443.9 (71.3)     | 100.35 (86.73, 116.10)  |
| (Reference, n=11)                            | T.. (h)         | 2.00 (1.75, 2.00) | 2.00 (2.00, 3.00) |                         |
| (Reference, n=11)                            | tn (h)*         | 5.91 (4.83, 7.52) | 5.80 (4.48, 7.10) |                         |

Cowparisons were mnde relative to the reference 3oo-mg capsule

- Median (Ql. Q3)

<div style=\"page-break-after: always\"></div>

Figure  2: Mean (SD) Plasma Concentration-Time Profiles of MMB Following Single Doses of 200-mg MMB Tablet (Test) versus 300-mg MMB Capsule (Reference)

<!-- image -->

No further  bioequivalence  study  was  conducted  since  the  commercial  formulation  is  identical  to  the tablet formulation used in phase 3 clinical studies.

## Food effect

Part C of study GS-US-352-0102 evaluated the effect of food (low-fat and high-fat meal) on the 200 mg MMB Form II tablet using a fixed-sequence, open-label, crossover design.

Table 8: MMB PK Parameters Following Single-Dose Administration with Various Meal Types

| Part C (Food Effect) PKParameter   | 200-mg Tablet Fasted (Reference) (N =12)   | 200-mg Tablet Low-Fat Meal (Iest) (N=12)   | 200-mg Tablet High-Fat Meal (Test) (N =12)   |
|------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------|
| Median (Q1, Q3)                    | Median (Q1, Q3)                            | Median (Q1, Q3)                            | Median (Q1, Q3)                              |
| T (h)                              | 2.50 (1.50,4.00)                           | 4.00 (4.00, 4.00)                          | 4.50 (3.00, 5.00)                            |
| tin (b)                            | 6.79 (4.67, 7.19)                          | 5.48 (5.10, 6.88)                          | 5.76 (4.69, 6.98)                            |
| %GLSMRatio (90%6 CI)               | %GLSMRatio (90%6 CI)                       | %GLSMRatio (90%6 CI)                       | %GLSMRatio (90%6 CI)                         |
| C (ng/mL)                          |                                            | 137.94 (119.21, 159.61)                    | 127.63 (101.81, 160.00)                      |
| AUCmr(hng/mL)                      |                                            | 116.25 (101.07, 133.72)                    | 127.71 (107.54, 151.66)                      |
| AUC. (hng/mL)                      |                                            | 116.44 (100.83, 134.46)                    | 127.80 (106.92, 152.76)                      |

Food intake delayed the absorption of MMB (increase of tmax from 2.5h to 4.5h), and resulted in a modest increase in MMB exposure (Cmax increase 28% [high-fat meal] to 38% [low-fat meal] and AUC increased 16% [low-fat meal] to 28% [high-fat meal]) with minimal change to M21 exposure. These changes were not considered clinically relevant. MMB was administered to patients in all Phase 3 studies without instructions on food intake.

## Distribution

In patients with MF receiving MMB 200 mg once daily, the mean apparent volume of distribution (Vz/F) of MMB at steady-state was 984 L, suggesting extensive tissue distribution (SIMPLIFY-1).

In  the  mass  balance  study,  the  blood  to  plasma  ratio  ranged  from  0.73  to  0.87  indicating  low association  of  MMB  and  its  circulating  metabolites  with  blood  cells.  The in  vitro blood  to  plasma concentration ratio for MMB was approximately 1.

<div style=\"page-break-after: always\"></div>

In  the  hepatic  and  renal  impairment  studies,  ex  vivo  plasma  protein  binding  for  MMB  and  M21  was determined by equilibrium dialysis using plasma samples around Tmax (± 1 µM) and 24h following a single 200 mg MMB dose (GS-US-352-1153; GS-US-352-1152). In healthy control subjects, the free fraction of MMB and M21 at tmax was ± 9% and 8%, respectively. The observed slight decrease in free fraction  for  MMB  (7%  at  24h  post-dose)  with  decreasing  concentrations  is  not  considered  clinically relevant.  Slight  differences  were  also  observed  in  plasma  protein  binding  dependent  on  organ impairment status.

The protein binding data for MMB determined ex vivo are in line with a previous in vitro study using ultracentrifugation at concentrations of 0.5 and 5 µM (CDCO\\_Cytopia\\_07\\_006) showing free fractions of 8.5% and 12.7%.  In an in vitro study using equilibrium dialysis (AD-352-2012), the free fraction at a  concentration  of  2  µM  was  19.2%  and  14.6%  for  MMB  and  M21,  respectively.  According  to  the applicant, the discrepancies between both studies were mostly caused by data variations as well as different methodologies applied.

## Elimination

Based on the MMB PK substudy results from the Phase 3 study SIMPLIFY-1, steady-state MMB CL/F was found to be 103 L/h. Based on the population PK model, the elimination clearance for an oral dose of 200 mg MMB once daily was estimated at 83.1 L/h. T1/2 of MMB ranged from approximately 4 to 8 hours across studies.

## Mass balance

Study GS-US-352-1149 was a single dose mass balance study conducted in 6 healthy subjects under fasting conditions. Subjects received 200 mg of unlabeled MMB and [ 14 C]labeled MMB (~100 μCi) as a 200-mL solution. The overall mean recovery of radioactivity in urine and feces was 96.7% (range 93.9 to 98.0%) over the 264-hour study, with 69.3% of the dose recovered in feces and 27.5% in urine.

Figure 3: Mean (±SD) cumulative percent of radioactive dose recovered in urine and faeces

<!-- image -->

<div style=\"page-break-after: always\"></div>

In total, 19 metabolites were characterized from plasma, urine, and faeces samples. In plasma, the major radioactivity peaks were the unchanged parent compound and M21, accounting for approximately  17.3  and  64.2  %  of  total  radioactivity  exposure  (AUC0-24h).  The  other  circulating metabolites (M5, M8, M19, M20, and M28) accounted for less than 6% of total radioactivity. The active metabolite M21 was the only major metabolite contributing to &gt; 10% of total radioactivity and &gt; 25% of parent exposure.

Approximately  all  radioactivity  (27.3%  and  74.2%  of  dose)  could  be  identified  in  urine  and  faeces, respectively.  Only  12.6%  and  0.6%  of  the  dose  was  retrieved  as  parent  drug  in  faeces  and  urine, respectively.  MMB  was  primarily  eliminated  as  metabolites.  M14  was  the  predominant  metabolite excreted in faeces (21.4% of dose). The active metabolite, M21, was found both in faeces and urine (12.7% and 11.5% of dose, respectively).

Table 9: Percent of Radioactive Dose Present as [14C]-MMB and [14C]-Metabolites in Pooled Urine and Feces Samples From All Sampling Intervals by HPLC (PK Analysis Set)

|            | Mean %of radioactive dose*   | Mean %of radioactive dose*   | Mean %of radioactive dose*   |
|------------|------------------------------|------------------------------|------------------------------|
| Metabolite | urine (U)                    | feces (F)                    | U+F                          |
| M22/M23**  | 1,7                          | 1,4                          | 3,1                          |
| M5         | 2,3                          | 3,8                          | 6,1                          |
| M26/27**   | 2,3                          | 3,1                          | 5,4                          |
| M8         | 0,7                          | 2,5                          | 3,2                          |
| M14        | 1,8                          | 21,4                         | 23,2                         |
| M29        | 1,3                          | 2,6                          | 3,9                          |
| M32        | /                            | 1,5                          | 1,5                          |
| M31        | /                            | 2,3                          | 2,3                          |
| M16        | 1,6                          | 1,5                          | 3,1                          |
| M19/M33    | /                            | 7,1                          | 7,1                          |
| M20        | /                            | 1,7                          | 1,7                          |
| M1/M3**    | 1,5                          | /                            | 1,5                          |
| M28        | 1                            | /                            | 1                            |
| M15        | 1                            | /                            | 1                            |
| M21        | 11,5                         | 12,7                         | 24,2                         |
| MMB        | 0,6                          | 12,6                         | 13,2                         |
| Total      | 27,3                         | 74,2                         | 101,5                        |

## Metabolism

In  vitro  metabolism  data  indicate  that  hepatic  MMB  metabolism  is  predominantly  mediated  by  CYP enzymes.  Based  on  the  effect  of  selective  enzyme  inhibitors  on  the  metabolism  of  MMB  in  human hepatocytes, CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP3A4 are involved in the metabolism of MMB and  formation  of  M21.  The  formation  of  M21  was  also  investigated  in  a  separate  experiment  and indicated  that  this  occurred  in  at  least  two  steps  with  involvement  of  aldehyde  oxidase  following metabolism by CYP enzymes.

<div style=\"page-break-after: always\"></div>

No  MMB  metabolism  by  flavin-containing  monooxygenase  (FMO)  and  monoamine  oxidase  (MAO) enzymes was detected using recombinant enzymes.

|         | NormalizedFractional Metabolism(%)   | NormalizedFractional Metabolism(%)   |
|---------|--------------------------------------|--------------------------------------|
| Enzyme  | MMBMetabolism                        | M21Formation                         |
| CYP1A2  | 8.8                                  | 22.5                                 |
| CYP2B6  | 0                                    | 0                                    |
| CYP2C8  | 19.3                                 | 22.2                                 |
| CYP2C9  | 16.7                                 | 8.4                                  |
| CYP2C19 | 19.0                                 | 22.9                                 |
| CYP2D6  | 0                                    | 0                                    |
| CYP3A   | 36.2                                 | 24.1                                 |

The metabolism scheme proposed by the applicant is presented in Figure . MMB metabolism involved oxidation  and  scission  of  the  morpholine  ring,  amide  hydrolysis,  N-dealkylation,  nitrile  hydrolysis, nitrile oxidation, and taurine conjugation of the cyanomethylamide. M14 likely arises from oxidation of M19, amide hydrolysis of M8, and/or amide hydrolysis of M21.

Figure 4. Proposed biotransformation pathways of MMB in humans

<!-- image -->

Pharmacokinetics of metabolites

<div style=\"page-break-after: always\"></div>

Following a single oral dose of MMB from 150 to 800 mg under fasted conditions (GS-US-352-0102, part B), M21 had a slightly longer Tmax (median of 3.5 hours) and similar t1/2 (median range, 4.9-7.3 hours) compared to the parent MMB. The metabolite to parent ratio was in a similar range from 150 to 800 mg, with a mean molar ratio of M21 to MMB for AUCinf ranging from 1.4 to 2.1.

In the PK sub-study of the phase 3 SIMPLIFY studies in MF patients, PK parameters for M21 and MMB were measured at week 2 (steady state) of 200 mg MMB QD administration.

Table 10: PK parameters of MMB and M21 following MMB 200 mg QD in subjects with MF (SIMPLIFY-1, week 2 visit)

| PK Parameter's   | Statistics      | MMB            |   N | M21            |   N |
|------------------|-----------------|----------------|-----|----------------|-----|
| AUCtau (ng·h/mL) | Mean (%CV)      | 3288.3 (60.4)  |  19 | 4068.9 (39.0)  |  19 |
| Cmax (ng/mL)     | Mean (%CV)      | 479.3 (61.4)   |  20 | 411.4 (53.1)   |  20 |
| Ctau (ng/mL)     | Mean (%CV)      | 27.4 (92.3)    |  16 | 55.8 (63.0)    |  16 |
| Tmax (h)         | Median (Q1, Q3) | 1.8 (1.0, 3.0) |  20 | 3.0 (2.0, 3.7) |  20 |
| t1/2 (h)         | Median (Q1, Q3) | 5.1 (4.5, 7.4) |  19 | 7.6 (5.8, 9.9) |  18 |

Table 11: PK parameters of MMB and M21 following MMB 200 mg QD in subjects with MF (SIMPLIFY-2, week 2 visit)

| PKParameter's    | Statistic         | MMB            |   N | M21            |   N |
|------------------|-------------------|----------------|-----|----------------|-----|
| AUCtau (ng:h/mL) | Mean (%CV)        | 2153.6 (55.1)  |   6 | 4113.1 (23.2)  |   6 |
| Cmax (ng/mL)     | Mean (%CV)        | 367.0 (33.2)   |   7 | 486.9 (29.5)   |   7 |
| Ctau (ng/mL)     | Mean (%CV)        | 11.1 (101.3)   |   5 | 35.3 (59.3)    |   5 |
| Tmax 5           | Median ( (Q1, Q3) | 1.5 (1.0, 4.0) |   7 | 3.0 (2.0, 6.0) |   7 |
| t12 (h)          | Median ( (Q1, Q3) | 4.3 (3.8, 4.6) |   6 | 5.5 (5.1, 6.8) |   6 |

Compared  to  MMB  and  M21,  the  minor  metabolite  M19  had  a  relatively  longer  Tmax  (5-8h)  and terminal half-life (10.5-22.9h) across MMB doses of 150 to 800 mg in healthy volunteers.

## Dose proportionality and time dependencies

Following a single oral dose of MMB from 100 to 800 mg (study GS-US-352-0102), MMB, M121 and M19 plasma exposures increased in a less than dose-proportional manner at doses above 200 mg. The metabolite to parent ratio is not dose-dependent for M21 and M19 (range of mean AUC ratio of M21 and M19 to MMB: 1.4-2.1 and 0.2 to 0.3, respectively).

Table 12: Dose proportionality of MMB

| PKParameter       | Cmax/Dose(ng/mL/mg)   | Cmax/Dose(ng/mL/mg)   | AUCinf/Dose (hong/mL/mg)   | AUCinf/Dose (hong/mL/mg)   |
|-------------------|-----------------------|-----------------------|----------------------------|----------------------------|
| Dose              | GLSM                  | GLSMRatio             | GLSM                       | GLSMRatio                  |
| 100 mg (N =12)    | 1.54                  |                       | 12.80                      |                            |
| 150 mg (N =21)    | 1.81                  | 118.13 (87.22,159.99) | 14.67                      | 114.67 (81.96, 160.45)     |
| 200 mg (N = 36)   | 1.70                  | 111.05 (83.98,146.84) | 14.47                      | 113.11 (83.01,154.12)      |
| 300 mg (N =12-13) | 1.28                  | 83.11 (59.42, 116.25) | 10.26                      | 80.16 (54.88, 117.09)      |
| 400 mg (N = 8)    | 0.82                  | 53.35(36.39,78.22)    | 6.49                       | 50.73 (33.21,77.48)        |
| 800 mg (N = 8)    | 0.70                  | 45.40 (30.97, 66.56)  | 5.95                       | 46.49 (30.44, 71.02)       |

GLSMratioswerecomparisonsmaderelativetothe100-mgtablet.

<div style=\"page-break-after: always\"></div>

There was no significant accumulation of MMB and M21 after repeated daily dosing of 200 mg MMB in patients based on trough concentrations measured from week 2 up to week 24 in SIMPLIFY studies. Steady  state  seems  to  be  reached  by  week  2  (no  earlier  measurements  of  trough  concentrations available).

Table 13: Plasma Trough Concentrations of MMB and M21 Following MMB 200 mg Once Daily in Subjects with Myelofibrosis (SIMPLIFY-1)

|                        | SamplingTime     | SamplingTime     | SamplingTime     | SamplingTime     | SamplingTime     | SamplingTime     | SamplingTime     | SamplingTime     | SamplingTime              |
|------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|---------------------------|
| Analyte                | Week2 Predose    | Week4 Predosed   | Week4 Switchb    | Week8 Predose    | Week12 Predose   | Week16 Predose   | Week20 Predose   | Week24 Predose   | Week28 (OL Week4) Predose |
| MMB                    |                  |                  |                  |                  |                  |                  |                  |                  |                           |
| N                      | 124              | 111              | 44               | 99               | 87               | 87               | 76               | 61               | 46                        |
| Median(Q1, Q3) (ng/mL) | 17.8 (5.6,42.8)  | 16.5 (6.7,41.2)  | 27.4 (11.2,52.2) | 21.7 (8.8,47.6)  | 15.8 (6.8,41.6)  | 15.7 (8.4,32.2)  | 18.6 (8.5,32.1)  | 17.9 (9.9,41.8)  | 18.3 (6.3,54.1)           |
| GS-644603 (M21)        | GS-644603 (M21)  |                  |                  |                  |                  |                  |                  |                  |                           |
| N                      | 124              | 112              | 44               | 99               | 88               | 87               | 77               | 61               | 47                        |
| Median(Q1, Q3) (ng/mL) | 49.2 (20.2,81.1) | 42.4 (21.7,81.9) | 63.2 (37.2,116)  | 49.9 (29.8,82.6) | 46.3 (25.5,87.8) | 46.8 (24.1,69.8) | 48.1 (26.1,68.9) | 54.3 (34.3,93.6) | 48.7 (22.9,100)           |

MMB =momelotinib;N=numberof subjects;OL =open-label; Q1,Q3=first andthird quartiles; RUX=ruxolitinib

aMMB

b \"Week 4 Switch\"is the Switch (ruxolitinib to MMB)atopen-labelphase Week4.

## Target population

Exposures  (Cmax  and  AUC)  of  MMB  in  healthy  volunteers  and  subjects  with  MF  were  similar,  as presented in the figure below:

<!-- image -->

OObseriedValues

Notes:Healthyvolunteersincludedintheplottook200mgsingle-doseMMBtabletinstudies CSRGS-US-352-0102,CSRGS-US-352-0108,CSRGS-US-352-1150,CSRGS-US-352-1151, CSRGS-US-352-1152,CSRGS-US-352-1153.

SubjectswithMFincludedintheplottook200mgQDMMBtabletinstudiesCSRGS-US-352-0101 andCSRGS-US-352-1214andparticipatedintheintensivePKsubstudy(data atWeck2)ortook 300mgQDMMBcapsulein studyCSRCCL09101(dataonDay1).

AUCis citherAUCinrfor single dose(HV 200mg tablctgroupand MF 300mgcapsulegroup)or AUCuau (MF 200 mg tablet group) for multiple dose at steady state.

AUC,areaundertheplasmaconcentration-timecurve;AUCinf,area undertheplasma concentration-time curvefromtimezeroextrapolatedtoinfinitetimc;AUCau,areaundertheplasmaconcentration-time curveoverthedosinginterval;Cmx,maximumplasmaconcentration;HV,healthyvolunteers;MF, myelofibrosis;MMB，momelotinib;PK,pharmacokinctics;QD,oncedaily.

<div style=\"page-break-after: always\"></div>

## Figure 5: Box Plots for MMB  Exposures  in Healthy Volunteers and Subjects With Myelofibrosis

Rapid absorption (Tmax reached within 3 hours) and a short half-life (4 to 8 hours) were observed in both healthy volunteers and subjects with MF. The inter-subject variability is relatively high.

## Population PK analysis

A  population  PK  analysis  was  performed  to  develop  a  model  to  characterize  the  PK  of  MMB  and  its major metabolite, M21, and to evaluate the covariates including intrinsic and extrinsic factors that may explain the variability in the PK of MMB and M21.

The final model was used to simulate concentration-time profiles and predict daily average exposures of  both  MMB  and  M21  in  patients  with  MF  at  200  mg  once  daily  with  the  consideration  of  dose adjustment and/or interruption during Phase 3 trials.

Data  from  the  5  clinical  studies  in  phases  1  through  3  were  included  (CCL09101,  YM387-II-02, SIMPLIFY-1, SIMPLIFY-2, MOMENTUM). A total of 3548 and 2223 observed concentrations of MMB and M21, respectively, were included from 616 subjects with MF.

<!-- image -->

Fioo=F(relativebioavailability)for 100mg,assumed tobe1;Ffac=maximumfractional change in F;EDso=the dose corresponding to half of Ffrac; K = Absorption transit rate constant; CL, = apparent clearance of parent; CLm = apparent clearance of metabolite; Fmet = Fraction of metabolite in plasma, 0.64; Q2 = apparent inter-compartment clearances for the central and peripheral compartment; V2, = apparent volume of distribution of the central compartment; V4, = apparent volume of distribution of the peripheral compartment; V3m = apparent volumeofdistributionofthemetabolitecompartment

Note: The assumption thatFmet=0.64 is based onfindingsfromZheng(2018).

Figure 6: MMB and M21 model structure schematic

After discovery of dosing errors, the initial popPK models for MMB and M21 (base model for MMB and final model for MMB and M21) were updated using the corrected dataset by re-estimating the model parameters in different steps. The structural models  were kept intact; no additional  model development or exploration was performed.

<div style=\"page-break-after: always\"></div>

Table 14: updated final population Pk model for MMB and Metabolite M21-Parameter Estimates

| Parameter                                 | Estimate    | RSE%   | 95% CI       | Shrinkage   |
|-------------------------------------------|-------------|--------|--------------|-------------|
| TypicalValues                             |             |        |              |             |
| CL/F (L/h) of MMB                         | 49.5Fixed   |        |              |             |
| Vc/F (L) of MMB                           | 286Fixed    |        |              |             |
| Vp/F (L) of MMB                           | 203 Fixed   |        |              |             |
| Q/F (L/h) of MMB                          | 30.6 Fixed  |        |              |             |
| CL/F of M21 (L/h)                         | 17.7        | 3.54   | 16.4-18.9    |             |
| Vc/F of M21 (L)                           | 41.7        | 13.2   | 31.0-52.5    |             |
| Ktr (1/h)                                 | 0.649 Fixed |        |              |             |
| Doseonbioavailability,Ffrac               | 0.429 Fixed |        |              |             |
| Dose on bioavailability, ED50 (mg)        | 6.02Fixed   |        |              |             |
| CovariateEffects                          |             |        |              |             |
| CapsuleformulaliononKtr                   | 4.93Fixed   |        |              |             |
| eGFRonCL/FofM21                           | 0.525       | 13.1   | 0.390-0.660  |             |
| ASTonCL/Fof M21                           | 0.216       | 22.1   | 0.123-0.310  |             |
| BetweenSubjectVariability                 |             |        |              |             |
| On CL/F of MMB                            | 0.763       | 3.25   | 0.715-0.812  | 6.89%       |
| On CL/F of M21                            | 0.484       | 4.61   | 0.440-0.527  | 22.2%       |
| ResidualError                             |             |        |              |             |
| Prop.Error-CCL09101                       | 0.638Fixed  |        |              |             |
| Prop.Error-YM-387-II-02                   | 0.532Fixed  |        |              |             |
| Prop.Error-GS-US-352-0101                 | 1.18 Fixed  |        |              |             |
| Prop.Error-GS-US-352-1214 and SRA-MMB-301 | 0.731 Fixed |        |              |             |
| Prop. Error -M21 (all studies)            | 0.697       | 2.25   | 0.666 -0.727 |             |

Estimation method:FOCEl; Objective function value:55955.78

CL/F=apparentclearance;Vc/F=apparentcentral volume of distribution;Q/F=apparentinter-compartmental clearance;Vp/F=apparentperipheralvolumeofdistribution;Ktr=absorptiontransitraleconstant;Ffrac=maximum eGFR=estimated glomerular fillrationrale;AST=aspartate aminotransferase;%RSE=percentrelative standard error of the estimate =100%x(SE/parameterestimate);95%Cl=95%confidence interval;SE=standard error of the estimate;Prop.=proportional.

However, systematic model misspecification (overprediction of the central tendency and the variability) was noted on the VPCs sparse concentration data from studies GS-US-352-1214 and GS-US-352-101, and per se for the tablet formulation. The model prediction for the disposition was highly questioned for this subset of data. In their responses, the applicant acknowledged that many dosing times were missing in  the  source  data  used  in  the  initial  submission,  and  needed  to  be  imputed.  The  applicant noted that many trough data, especially in Phase 3 studies (SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM) may have been subjected to such misclassification. A sensitivity analysis was conducted on the current popPK model (with Erlang absorption) with the suspect data excluded and additional data included (not pertaining to the PK-substudy). The sensitivity analysis dataset contained 2419  momelotinib concentrations from 459 subjects, whereas the model in Report Amendment 5382- PKPD001 included 2480 momelotinib concentrations from 359 subjects. In sensitivity analysis, a substantial improvement in  the  model  fit  for  the  tablet  data  was  observed.  The  prediction-corrected  visual  predictive  checks (pcVPC) for the sparse concentration data from studies SIMPLIFY-1 and SIMPLIFY-2 did not indicate the  presence  of  systematic  misspecification.  In  addition,  the  pcVPC  for  the  rich  data  from  studies SIMPLIFY-1 and SIMPLIFY-2 indicates that Erlang absorption structural model in sensitivity analysis #1 adequately capture the absorption of the tablet formulation without negative impact on the model fit for the capsule data.

<div style=\"page-break-after: always\"></div>

At  the  CHMP's  request,  the  comprehensive  results  using  the  new  model  were  submitted  and  the updated model with better predictive performances for MMB and M21 was used for subsequent E-R analysis (see Discussion on Clinical Pharmacology).

## Special populations

## Renal impairment

The applicant provided the results of a dedicated study (Study GS-US-352-1152) of momelotinib and its  main  metabolites  in  patients  with  moderate  and  severe  renal  impairment.  No  patients  with  mild renal impairment were included in the study. Three cohorts of subjects were enrolled with moderate (Cohort 1), severe (Cohort 2), and mild (Cohort 3) renal impairment in addition to matched healthy subjects in all 3 cohorts.

The  comparison  of  the  PK  parameters  in  subjects  with  moderate/severe  renal  impairment  is summarised in the tables below:

Table 15 :  Summary  Statistics  and  Statistical  Comparisons  of  Plasma  PK  Parameters  in Subjects with Moderate Renal Impairment and Matched Healthy Subjects (MMB PK Analysis Set)

|                 | Mean\" (%CV)                     | Mean\" (%CV)                |                       |
|-----------------|---------------------------------|----------------------------|-----------------------|
| PKParameter     | Moderate Renal Impairment(N=10) | NormalRenalFunction (6 =N) | %GL.SM Ratio (90% CI) |
| AUCinr(h*ng/mL) | 3731.4 (47.1)                   | 4279.7 (44.1)              | 86.68 (54.48, 137.90) |
| AUCa (h*ng/mL)  | 3651.8 (47.3)                   | 4178.3 (43.6)              | 86.44 (54.42, 137.32) |
| Cmax (ng/mL)    | 406.6 (56.9)                    | 443.4 (41.9)               | 83.87 (53.56, 131.34) |
| CL/F (L/h)      | 71.7 (65.1)                     | 63.3 (76.1)                | 一                     |
| V/F (L)         | 864.3 (85.8)                    | 723.1 (71.6)               |                       |
| Tmx(h)b         | 3.00 (3.00,4.00)                | 4.00 (4.00,4.00)           |                       |
| ti/2 (h)b       | 7.55 (5.67, 9.37)               | 7.52 (6.69,8.85)           |                       |

GLSM = gcometric least square mean

Means presented are unadjusted

b Median (Q1, Q3)

<div style=\"page-break-after: always\"></div>

Table  16:  Summary  Statistics  and  Statistical  Comparisons  of  Plasma  PK  Parameters  in Subjects  with  Severe  Renal  Impairment  and  Matched  Healthy  Subjects  (MMB  PK  Analysis Sets)

|                 | Mean\"(%CV)                     | Mean\"(%CV)                 |                        |
|-----------------|--------------------------------|----------------------------|------------------------|
| PKParameter     | Severe Renal Impairment (N=10) | NormalRenalFunction (N=10) | %GLSM Ratio (90% CI)   |
| AUCir (h*ng/mL) | 3502.9 (59.2)                  | 3905.3 (42.6)              | 83.91(53.34,132.00)    |
| AUCin (h*ng/mL) | 3416.1 (58.6)                  | 3784.3 (40.6)              | 84.07 ( 53.79, 131.39) |
| C mx (ng/mL)    | 280.2 (53.4)                   | 374.6 (36.0)               | 68.12 (45.62, 101.71)  |
| CL/F (L/h)      | 81.8 (69.5)                    | 65.5 (67.4)                |                        |
| VF (L)          | 871.5 (74.9)                   | 757.6 (60.4)               | 一                      |
| Tmx (h)b        | 6.00 (4.00,6.00)               | 4.00 (4.00,4.00)           |                        |
| ti/2 (h) b      | 7.18 (6.24,8.23)               | 7.49 (6.85, 11.59)         |                        |

GLSM=geometric least square mean

Means presented are unadjusted

b Median (Q1, Q3)

Table  17:  Plasma  PK  Parameters  of  MMB,  GS-644603,  and  GS-642112  Following  a  Single Dose of MMB 200 mg in Subjects with Moderate or Severe Renal Impairment and Healthy Subjects as Determined by CLCr (PK Analysis Set)

|           |                 | Mean (%CV)                             | Mean (%CV)                         | Mean (%CV)                         |
|-----------|-----------------|----------------------------------------|------------------------------------|------------------------------------|
| Analyte   | PKParameter     | ModerateRenal ImpairmentbyCLcr (N =11) | SevereRenal ImpairmentbyCLcr (N=6) | Normal Renal FunctionbyCLcr (N=10) |
| MMB       | AUCinr(h*ng/mL) | 4152.9 (48.8)                          | 2561.7 (51.2)                      | 4173.1 (42.8)                      |
| MMB       | Cmx (ng/mL)     | 381.6 (51.6)                           | 202.4 (48.5)                       | 362.0 (32.5)                       |
| GS-644603 | AUCinr(h*ng/mL) | 6776.1 (45.8)                          | 4714.1 (55.4)                      | 3852.8 (33.2)                      |
| GS-644603 | Cmx (ng/mL)     | 416.5 (57.6)                           | 263.0 (69.0)                       | 283.4 (42.9)                       |
| GS-642112 | AUCinr(h*ng/mL) | 1685.0 (78.8)                          | 1794.2 (93.5)                      | 1721.0 (75.5)                      |
| GS-642112 | Cmx (ng/mL)     | 43.5 (57.1)                            | 41.6 (62.2)                        | 45.6 (25.6)                        |

Agely])*Weight[kg]/(Creatinine[mg/dL]*72)

A  single  dose  study  (GS-US-352-1152,  200mg)  is  deemed  adequate  to  characterize  the  PK  of momelotinib and its metabolites in subjects with renal impairment and to inform dosing recommendations in this population.

In  the  human  mass  balance  study  (GS-US-352-1149),  renal  excretion  was  a  very  minor  route  of clearance for momelotinib at therapeutic relevant exposures levels suggesting there is a low probability that renal impairment would affect exposure of momelotinib.

Study GS-US-352-0102 assessed the proportionality of exposure across the dose range of 100mg to 800mg for the tablet formulation and momelotinib's exposure was dose proportional between doses of 100 and 300mg. The observed less than proportional increase in exposure in doses above 300mg is attributed to saturation in absorption rather than an increase in the elimination rate of momelotinib (the half-life was comparable across doses).

<div style=\"page-break-after: always\"></div>

## Hepatic impairment

The effect of hepatic impairment on the PK and safety of MMB was evaluated in Phase 1 study GS-US352-1153 following a single dose of 200 mg of MMB in a fed state. Cohort 1 enrolled subjects with moderate hepatic impairment and matched healthy controls, Cohort 2 enrolled subjects with severe hepatic impairment and matched healthy controls, and Cohort 3 enrolled subjects with mild hepatic impairment and matched healthy controls.

Table 18: GS-US-352-1153: MMB PK Parameters Following a Single Dose of MMB 200 mg in Subjects  With  Moderate  Hepatic  Impairment  and  Matched  Healthy  Subjects  (MMB  PK Analysis Set)

|                 | Mean”(%CV)                         | Mean”(%CV)                     |                                             |
|-----------------|------------------------------------|--------------------------------|---------------------------------------------|
| PKParameter     | Moderate Hepatic Impairment (N=10) | Normal Hepatic Function (N=10) | %GeometricLeast-Squares Mean Ratio (90% CI) |
| AUC(h-ng/mL)    | 6268.9 (56.2)                      | 5958.2 (57.0)                  | 108.02 (71.00, 164.35)                      |
| AUC...(h·ng/mL) | 5799.3 (47.9)                      | 5823.1 (55.4)                  | 104.50 (70.24, 155.46)                      |
| Cmx (ng/mL)     | 482.4 (46.1)                       | 623.4 (42.7)                   | 79.34 (52.00, 121.04)                       |
| CL/F (L/h)      | 40.0 (46.6)                        | 44.9 (56.2)                    |                                             |
| V/F (L)         | 422.2 (52.9)                       | 418.5 (41.6)                   |                                             |
| Tmax (h)b       | 4.00 (3.00,6.00)                   | 3.50 (3.00, 4.00)              |                                             |
| Lin (h)b        | 7.38 (4.84, 8.57)                  | 6.77 (5.82, 9.30)              |                                             |

Table  19:  MMB  PK  Parameters  Following  a  Single  Dose  of  MMB  200  mg  in  Subjects  With Severe Hepatic Impairment and Matched Healthy Subjects (MMB PK Analysis Set)

|                 | Mean\" (%CV)                      | Mean\" (%CV)                    |                                             |
|-----------------|----------------------------------|--------------------------------|---------------------------------------------|
| PKParameter     | Severe Hepatic Impairment (N=10) | Normal Hepatic Function (N=10) | %GeometrieLeast-Squares Mean Ratio (90% CI) |
| AUCimr(h*ng/mL) | 9807.1 (53.9)                    | 5346.3 (67.2)                  | 197.11 (128.87, 301.48)                     |
| AUCimg(h*ng/mL) | 8997.4 (47.3)                    | 5203.0 (65.8)                  | 189.04 (125.90, 283.84)                     |
| Cmx (ng/mL)     | 547.6 (36.7)                     | 528.5 (51.5)                   | 112.63 (75.10, 168.92)                      |
| CL/F (L/h)      | 24.8 (40.2)                      | 52.0 (50.9)                    |                                             |
| V/F (L)         | 318.5 (51.7)                     | 511.9 (52.3)                   |                                             |
| Tmax (h)b       | 4.00 (4.00, 4.00)                | 4.00 (2.00,4.00)               |                                             |
| tin (h)b        | 8.90 (5.50, 14.06)               | 7.45 (5.20, 9.61)              |                                             |

MMB AUC was comparable, whereas Cmax was decreased by 21% between patients with moderate hepatic  impairment  (Child-Pugh  B)  and  patients  with  normal  hepatic  function.  MMB  Cmax  was increased by 13% and AUC was increased by 97% in patients with severe hepatic impairment (ChildPugh C) compared with patients with normal hepatic function.

There is a decrease in M21 exposure (by 48% in AUCinf and 76% in Cmax) in subjects with severe hepatic  impairment.  Concerning  GS-642112,  the  increases  in  plasma  exposures  in  subjects  with

<div style=\"page-break-after: always\"></div>

moderate and severe hepatic impairment are not expected to impact MMB activity, as GS-642112 is an inactive metabolite.

The effect of race/ethnicity on the PK and safety of MMB (200 mg MMB, single dose) was evaluated in study GS-US-352-0108 and in the POPPK modelling:

Table 20 : PK parameters for MMB following a single oral dose of MMB 200 mg under fasted conditions

| Parameters                  | Japanese\" (N=14)   | Caucasian\" (N= 14)   | %GeometricLeast Squares Mean Ratio (90% CI)   |
|-----------------------------|--------------------|----------------------|-----------------------------------------------|
| C.. (ng/mL) Mean (%CV)      | 1006.0 (29.3)      | 729.4 (35.9)         | 144.11 (108.53, 191.37)                       |
| Tms (h) Median (Ql, Q3)     | 3.00 (1.50, 3.00)  | 3.00 (2.00,3.00)     |                                               |
| tiz (h) Median (Ql, Q3)     | 4.25 (3.87, 6.13)  | 6.76 (5.86, 9.65)    |                                               |
| AUCuhs (ng-h/mL) Mean (%CV) | 8023.9 (43.5)      | 5652.6 (57.5)        | 155.10 (105.51, 228.01)                       |
| AUCar(ng-h/mL) Mean (%CV)   | 8074.4 (44.0)      | 5788.4 (58.0)        | 152.79 (103.59, 225.36)                       |

ANOVA = analysis of variance; CV = coelficient of variation; Q1 = first quartile; Q3 = third quartile

Means presented are unadjusted means

Percentage gcometric least squares mean ratio used means from ANOVA model with cthnicity as a fixed effeet

A comparison of the pharmacokinetic data revealed that exposure (AUCinf) was approximately 53% higher in Japanese subjects compared to Caucasian subjects in this study GS US 352 0108. Despite the trend for this slight increase in mean exposures in Japanese subjects, there was a considerable overlap in  momelotinib  exposures  (Cmax  and  AUC)  between  the  two  populations  and  the  differences  in exposure between Japanese and Caucasian subjects are not considered to be clinically relevant based on the overall safety profile of momelotinib and lack of exposure-safety relationship for momelotinib in subjects with myelofibrosis.

Of  note,  the  evaluation  of  the  covariate  'race'  in  the  popPK  analysis  is  considered  exploratory  in nature, as supportive evidence to the dedicated clinical pharmacology study.

A  summary  of  older  subjects  with  myelofibrosis  enrolled  in  the  momelotinib  three  phase  3  studies (controlled) and in GS-US-352-1672 as the one uncontrolled supportive study is provided in the table below:

|                        | Age 65-74 (0lder subjects number / total number)   | Age 75-84 (0lder subjects number / total number)   | Age 85+(0lder subjects number / total number)   |
|------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Controlled Studies     |                                                    |                                                    |                                                 |
| MOMENTUM               | 94/195 (48.2%)                                     | 57/195 (29.2%)                                     | 4/195 (2.1%)                                    |
| SIMPLIFY-1             | 176/432 (40.7%)                                    | 69/432 (16.0%)                                     | 2/432 (<1%)                                     |
| SIMPLIFY-2             | 73/156 (46.8%)                                     | 27/156 (17.3%)                                     | 1/156 (<1%)                                     |
| Non-controlled Studies | Non-controlled Studies                             |                                                    |                                                 |
| GS-US-352-1672         | 19/41 (46.3%)                                      | 9/41 (22.0%)                                       | 2/41 (4.9%)                                     |

<div style=\"page-break-after: always\"></div>

The safety and efficacy of Omjjara in children and adolescents less than 18 years of age have not been established.

## Pharmacokinetic interaction studies

The  PK  interaction  potential  of  momelotinib  and  its  major  metabolite  M21  has  been  evaluated  in  a number in vitro studies and in two in vivo DDI studies.

## Momelotinib as victim of drug interactions

In vitro metabolism data indicate that CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP3A4 are involved in the metabolism of MMB and formation of M21. Aldehyde oxydase is also involved in the formation of M21 following metabolism by CYP enzymes.

In  vitro ,  MMB and M21 were identified as substrates for P-gp, BCRP and OATP1B1/1B3, but not for OCT1.

The effect of multiple dose ritonavir (100 mg daily for 7 days) as strong inhibitor of CYP3A4, P-gp, and BCRP on the PK of multiple dose of momelotinib (100 mg daily for safety issues) has been evaluated (study GS-US-352-1151, cohort 1). A mild inhibitory effect has been observed on momelotinib Cmax (23%  increase,  90%  CI:  96.4%,  157.7%).  Momelotinib  AUCtau  was  increased  by  13.5%  and  the associated 90% CI of the GLSM ratio remained within the protocol-defined no-effect boundary of 70% to 143%. No marked increase in exposure of the metabolite M21 has been observed: 29.8% increase in Cmax (90% CI: 109.8%, 153.5%) and 24% increase in AUCtau (90% CI: 110.1%, 139.62%).

The effect of rifampicin 600 mg single-dose and multiple doses (9 days) on the PK of a single dose of momelotinib 200 mg (recommended daily dose) has also been investigated (study GS-US-352-1151, cohort 3). The single dose of rifampicin was tested to determine the impact of OATP inhibition, while the  multiple  dose  evaluated  the  impact  of  a  strong  CYP3A4  induction  on  the  PK  of  momelotinib. Rifampicin also induced CYP2C8, CYP2C9 and CYP2C19 isoenzymes and transporters such as P-gP and BCRP, also involved in the metabolism and the transport of momelotinib and the transport of its major metabolite  M21.  A  slight  to  moderate  inhibitory  effect  of  OATP1B1  and  OATP1B3  on  the  PK  of momelotinib  has  been  shown  (increase  in  Cmax  by  40.4%  (90%CI:97.16;  202.87)  and  AUCinf  by 57.1%  (90%CI:  122.01;  202.34).  When  the  induction  effect  is  only  considered,  a  29.4%  decrease (90%CI:52.06;95.68)  in  Cmax  and  46.1%  decrease  (90%CI:44.43;65.50)  in  AUCinf  as  well  as  an increase  in  major  metabolite  M21  (31.1%  increase  in  Cmax;  90%CI  98.5,  174.5)  were  observed. Additionally, a 14.6% decrease in AUCinf of M21 has been shown (90%CI 71.39, 102.1). When the total  effect  of  rifampicin  multiple  doses  is  considered,  a  slight  decrease  in  AUCinf  (GMR  [90%  CI]: 84.75% [71.01, 101.16]), and no impact in Cmax (GMR [90% CI]: 99.08% [82.16, 119.50], included in the default no-effect boundary of 80 to 125%) were observed.

The effect of the gastric pH reducing agent omeprazole 20 mg was evaluated on single-dose 200 mg PK  of  momelotinib  under  fasting  conditions  (Study  GS-US-352-0102  -  part  D).  A  mild  decrease  in momelotinib exposure (decrease ~36% (90%CI: 55.12; 75.41) and ~33% (90%CI: 61.19; 72.60) in Cmax and AUCinf, respectively; similar effect on M21 exposure) has been observed.

## Momelotinib as perpetrator of drug interactions

The following cut-offs are used for momelotinib for evaluation of interaction potential in vivo :

## Table 21 : Cut-offs are used for momelotinib for evaluation of interaction potential in vivo 22

<div style=\"page-break-after: always\"></div>

<!-- image -->

The concentration cut-off of 50 x Cmax,ss,plasma,unbound for the metabolite is calculated = 4.56 µM . The arithmetic mean Cmax,ss of 486 ng/mL (= 1.14 µM; molecular mass = 428.4 g/mol; M21 fu = 0.08) has been observed for M21 in the clinical SIMPLIFY-2 after 2 weeks administration of once daily 200 mg tablet.

The in vitro results for momelotinib and M21 as perpetrators are shown in the tables below.

Table  22:  Summary  of in  vitro results  for  DDI  potential  of  momelotinib  and  M21  with enzymes (CYPs and UGTs)

| Enzyme   | Inducer in vitro   | Inducer in vitro   | IC50 (µM) a   | IC50 (µM) a   | TDI parameters : K i (µM); K inact (min -1 )   | TDI parameters : K i (µM); K inact (min -1 )   |
|----------|--------------------|--------------------|---------------|---------------|------------------------------------------------|------------------------------------------------|
|          | MMB                | M21                | MMB           | M21           | MMB                                            | M21                                            |
| CYP1A2   | Yes                | Yes                | 28.7          | > 25          |                                                |                                                |
| CYP2B6   | Yes                | ?                  | 9.6           | > 25          |                                                |                                                |
| CYP2C8   | N.D                | N.D                | >25           | > 25          |                                                |                                                |
| CYP2C9   | N.D                | N.D                | >30           | > 25          |                                                |                                                |
| CYP2C19  | N.D                | N.D                | >30           | > 25          |                                                |                                                |
| CYP2D6   | N.D                | N.D                | >30           | > 25          |                                                |                                                |
| CYP3A4   | ?                  | ?                  | >30           | > 25          |                                                |                                                |
| UGT1A1   | N.D                | N.D                | 0.9           | 15.9          | N.D                                            | N.D                                            |
| UGT1A3   | N.D                | N.D                | >25           | >25           | N.D                                            | N.D                                            |
| UGT1A4   | N.D                | N.D                | >25           | >25           | N.D                                            | N.D                                            |
| UGT1A6   | N.D                | N.D                | >25           | >25           | N.D                                            | N.D                                            |
| UGT1A9   | N.D                | N.D                | 4.2           | >25           | N.D                                            | N.D                                            |
| UGT2B7   | N.D                | N.D                | >25           | >25           | N.D                                            | N.D                                            |

MMB = momelotinib; M21 = major metabolite

Empty box: no; N.D: not determined

a  Assuming Ki = IC50/2

<div style=\"page-break-after: always\"></div>

Table  23:  Summary  of in  vitro results  for  DDI  potential  of  momelotinib  and  M21  with transporters

| Transporter inhibition in vitro   | Momelotinib              | M21                      |
|-----------------------------------|--------------------------|--------------------------|
| OAT1                              | < 5 %inhibition at 15 µM | < 5 %inhibition at 10 µM |
| OAT3                              | 5 %inhibition at 15 µM   | < 5 %inhibition at 10 µM |
| OCT1                              | 16 %inhibition at 15 µM  | 21 %inhibition at 10 µM  |
| OCT2                              | < 5 %inhibition at 15 µM | 15 %inhibition at 10 µM  |
| OATP1B1                           | 6 %inhibition at 15 µM   | IC50 = 8.4 µM            |
| OATP1B3                           | < 5 %inhibition at 15 µM | IC50 = 8.5 µM            |
| BCRP                              | IC50 = 2.9 µM            | 6 %inhibition at 10 µM   |
| P-gp                              | 12 %inhibition at 15 µM  | < 5 %inhibition at 10 µM |
| MATE1                             | 34 %inhibition at 15 µM  | IC 50 = 2.4 µM           |
| MATE2-K                           | n.d.                     | n.d.                     |
| BSEP                              | < 5 %inhibition at 15 µM | 19 %inhibition at 10 µM  |

N.d. : not determined.

# IC50 was converted to Ki based on Ki = IC50/2, that is Ki was substituted by worst case assumption.

In  vitro  evaluations  indicated  that  momelotinib  and  M21  have  no  potential  to  significantly  inhibit CYP1A2,  CYP2C8,  CYP2C9,  CYP2C19  and  CYP2D6  at  clinically  relevant  concentrations.  A  direct inhibition by momelotinib of CYP2B6 cannot be ruled out. With a calculated R-value of 1.023, the risk has been correctly addressed by the applicant and the SmPC has been updated to mention that the specific NTI CYP2B6 substrates should be co-administered with caution.

Momelotinib is an inhibitor of UGT1A1 and UGT1A9 at clinically relevant concentrations. Momelotinib and its major circulating metabolite are not inhibitors of the other isoforms (UGT1A3/4/6 and 2B7) at clinically  relevant  concentrations.  The  lack  of  effect  on  other  UGT  isoenzymes  has  been  added  to section 5.2.

Clear signs of concentration dependent induction are observed for CYP1A2 for momelotinib and M21 and CYP2B6 for momelotinib. No in vitro induction signal has been shown for CYP2B6 for M21 and for CYP3A4 for both momelotinib and M21.

The effect of multiple doses of momelotinib 200 mg (8 days) on CYP3A enzyme activity using the probe substrate  MDZ (potential momelotinib induction of CYP3A4) in healthy volunteers has shown a mild induction on the PK of midazolam with a 8 % (90% CI: 78.6; 107.1 %) decrease in Cmax and a 16% (90% CI: 73.4; 96.3%) decrease in AUC0-t. Whilst it is possible this potential inductive effect is offset by  gut-level  CYP3A4  inhibition  by  momelotinib,  this  inhibition  potential  seems  to  be  minimal  as corroborated by the observed decrease in midazolam's AUC when co-administrated with momelotinib and no changes in midazolam's half-life (5.33h for midazolam + momelotinib vs 5.82h for midazolam).

In  vitro data  for  momelotinib  or  its  major  metabolite  M21  suggest  a  clinically  relevant  inhibitory potential for BCRP, OATP1B1, OATP1B3 and MATE1. No or only minor inhibition has been observed in vitro for BSEP, OAT1, OAT3 and OCT2 at clinically relevant concentrations. It cannot be ruled out that momelotinib  is  a  clinically  relevant  inhibitor  of  P-gP  in  the  intestine.  Caution  is  advised  when administering momelotinib with P-gp substrates with a narrow therapeutic index.

The  effect  of  multiple  doses  of  momelotinib  200  mg  (5  days)  on  BCRP  using  the  probe  substrate rosuvastatin  single  dose  (also  OATP1B1/1B3  substrate)  has  shown  a  moderate  inhibitor  effect:

<div style=\"page-break-after: always\"></div>

rosuvastatin Cmax was increased by 223% (90% CI: 264.4; 394.3%) and rosuvastatin AUC0-last was increased by 180 % (90% CI: 234,5%; 334,2%).

No in vivo study has been performed with oral contraceptives.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

MMB is an orally bioavailable, small molecule inhibitor of the Janus kinases (JAK) JAK1 and JAK2 and the activin A receptor type 1 (ACVR1)/activin receptor like kinase 2 (ALK2).  It interferes with the JAK STAT (signal transducers and activators of transcription) signaling pathways, which are dysregulated in MF pathogenesis thus contributing to clinical manifestations of the disease.  MMB also inhibits the ACVR1 SMAD (mothers against decapentaplegic) signaling pathway resulting in reduced hepcidin expression in the liver, thereby increasing iron availability for erythropoiesis.  This confers an additional effect on anaemia and impacts the need for red blood cell (RBC) transfusions.

## Primary and Secondary pharmacology

A translational single arm, open label Phase 2 study (GS-US-352-1672) was performed in MF patients with 200 mg tablet formulation to investigate the effects in transfusion-dependent patients with primary and secondary myelofibrosis and the proposed mechanism of action:  the inhibition of the JAK STAT and the inhibition ACVR1 SMAD pathways. The inhibition of the latter was assumed to result in decreased production of hepcidin, improved iron availability and erythropoiesis.  Patients received MMB for up to 24 weeks in the study.

Inhibition of JAK1/JAK2 was assessed by analysis of the PD biomarker: change in phospho STAT3 (pSTAT3) in interleukin (IL) 6 stimulated CD3+ CD4+ T cell. Samples for analysis of pSTAT3 were collected predose and at 2, 4, and 6 hours postdose at enrollment (first dose) and weeks 4 and 24. MMB treatment reduced pSTAT3 in IL 6 stimulated T cells at 2 hours postdose at both first dose and steady state, consistent with potent inhibition of the JAK STAT pathway.  Data were reported as the percentage of T cells positive for pSTAT3.  At 2 hours after the first dose, pSTAT3 decreased by a median of 14.3%.  At Weeks 4 and 24, predose (trough) pSTAT3 was 2.0% and 2.8% lower, respectively, compared with Day 1 predose.  At Weeks 4 and 24, median percentage inhibition of pSTAT3 at 2 hours postdose was 20.0% and 22.7%, respectively, compared with Day 1 predose. Maximal inhibition of pSTAT3 was reached 2 hours after each dose and inhibition persisted for ≥ 6 hours.

tdose

<!-- image -->

Source:  CSR GS US 352 1672, Figure 15.12.9 Note:  Percentage pSTAT3 was reported as the percentage of T cells positive for pSTAT3.

<div style=\"page-break-after: always\"></div>

Figure 7: GS-US-352-1672:  Median (Q1, Q3) Percentage Change from Baseline in pSTAT3 by Visit (Biomarker Analysis Set)

In the same study, blood samples for analysis of hepcidin, a marker of iron metabolism, were collected.  As hepcidin blood concentration varies diurnally, and in order to determine a baseline for each subject, serum was obtained at the baseline visit (no MMB administered) in the morning and then 6 hours later to allow for baseline correction per time of day.  After treatment (enrollment, weeks 2, 4, 8, 12, 16, 20, and 24), serum hepcidin samples were collected at predose in the morning and 6 hours postdose.

<!-- image -->

Source:  CSR GS US 352 1672, Figure 15.12.5.1 MMB, momelotinib; Q1, Q3, first quartile, third quartile.

Figure 8: GS-US-352-1672:  Median (Q1, Q3) Hepcidin (nM) Levels by Visit (Biomarker Analysis Set)

At every time point, median blood hepcidin decreased 6 hours after dosing with MMB and exhibited a downward trend over time, consistent with the decreased hepcidin production with MMB. These data suggest that MMB inhibits hepcidin production, consistent with inhibition of ACVR1.  Increased circulating hepcidin resulting from systemic inflammation in MF is associated with reduced iron availability for erythropoiesis.  Among all subjects, daily inhibition of hepcidin did not lead to an increase from baseline in serum iron at week 24.

Increased circulating hepcidin is associated with reduced iron availability for erythropoiesis.  Among all subjects, daily inhibition of hepcidin did not lead to an increase from baseline in serum iron at Week 24, but a transient median increase in serum iron of 39.8% was observed in transfusion-independent responders at Week 4.  Transferrin, hemoglobin, reticulocytes, and hematocrit also increased at Week 2 in transfusion-independent responders.  After the peak at Week 4, serum iron decreased consistent with restoration of iron homeostasis, and hemoglobin and hematocrit increased through Week 24.  Platelet counts also increased.

Further, by Week 24, 34.1% of subjects were transfusion independent for ≥12 weeks at any time on study, 39.0% of subjects had no RBC transfusion for at least 8 weeks at any time. At Week 24, 12.2% of subjects had a ≥ 35% reduction in spleen volume, and 15.8% of subjects had a ≥ 50% reduction from baseline to Week 24 in TSS based on the modified MPN-SAF TSS.

The results of this study are consistent with an inhibition of the JAK-STAT pathway and show hepcidin decrease associated with improving iron metabolism and erythropoiesis consistent with inhibition of

<div style=\"page-break-after: always\"></div>

ACVR1/ALK2, providing a mechanistic explanation for the reduction in transfusion dependency in TD patients with MF treated with MMB.

These clinical data are consistent with those observed in nonclinical studies where MMB, administered orally for three days at 5, 10 and 25 mg/kg, led to a dose dependent reduction of pSTAT3 and pSMAD1/5/8 levels in the liver as well as a reduction in circulating hepcidin in an anaemia of inflammation rat model (Asshoff, 2017).

## Effect on corrected QT interval

GS-US-352-1150 study (Thorough QT) was Phase 1, Partially-Blinded, Randomized, Placebo- and Positive-Controlled Study to Evaluate the Effect of Momelotinib on the QT/QTc Interval in Healthy Subjects. It was designed to evaluate the effect of MMB at therapeutic (200 mg, 1 × 200 mg tablet) and supratherapeutic (800 mg, 4 × 200 mg tablets) exposures on the change from baseline in corrected QT interval (QTc) in 48 healthy adult subjects.

The PK of MMB, the relationship between the concentration of MMB and QT/QTc intervals, and the effect of MMB on other ECG parameters were explored along with the safety and tolerability of MMB. Each period consisted of single tablet dose (on days 1, 11, 21, and 31) with one of the following treatments:  therapeutic dose of MMB at 200 mg, supratherapeutic dose of MMB at 800 mg, placebo control, and moxifloxacin positive control (not blinded).  Intensive sampling for MMB PK assessments was performed on days 1, 11, 21, and 31 (at predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose).  On treatment days, time matched digital 12 lead ECGs were collected in triplicate at various time points over a 24 hour period.  In addition, a single ECG was collected at approximately 2 hours postdose for safety monitoring.  All ECG acquisitions were completed before blood sample collections.  Forty eight healthy adult subjects were enrolled and completed the study.

No subject had a QTcF interval change from predose baseline &gt; 30 or &gt; 60 msec at any time point during any treatment (including MMB 200 and 800 mg, placebo, and moxifloxacin 400 mg).  No treatment emergent absolute QTcF intervals &gt; 480 or &gt; 500 msec were observed for any subject following any treatment.  Three subjects had treatment emergent absolute QTcF intervals &gt; 450 msec following moxifloxacin treatment.

## Concentration QTc relationship.

A linear mixed effect model was used to quantify the relationship between plasma concentrations of MMB and M21 and time matched, baseline adjusted, placebo corrected QT corrected by Fridericia method (ΔΔQTcF) with sex as a fixed effect and subject as a random effect.  Although the effect of MMB concentration on ΔΔQTcF was statistically significant (p = 0.037), no clinically relevant relationship between MMB plasma concentration and ΔΔQTcF was concluded due to the small negative slope ( 0.002) in the plot of ΔΔQTcF versus MMB plasma concentration.  A linear mixed effect model showed no relevant relationships between M21 plasma concentration and ΔΔQTcF.

A linear mixed effect model was used to quantify the relationship between plasma concentrations of MMB and M21 and ∆∆QTcF (time matched, baseline adjusted, placebo corrected QTcF), with sex as a fixed effect and subject as a random effect.

Although the effect of MMB concentration was statistically significant (p = 0.037), the small, negative slope ( 0.002) suggested that there were no clinically relevant relationships between MMB plasma concentrations and ∆∆QTcF interval.  For M21, the linear mixed effect model showed that there were no relevant relationships between M21 plasma concentration and ∆∆QTcF interval.

## Exposure-response analyses

<div style=\"page-break-after: always\"></div>

E-R analyses were conducted following the completion of the population PK analyses with an updated model.

With the data from all 3 Phase 3 studies, E-R analyses were conducted by using population PK model estimates of daily average individual exposures and considering dose modifications.  The E-R analyses were conducted to investigate the relationship of MMB exposures versus efficacy endpoints at Week 24 (e.g., TSS percent change from baseline, TSS responders, SVR, splenic volume responder, anemia/transfusions) and safety endpoints (e.g., grade ≥ 3 adverse events, early discontinuation, new onset  grade  ≥3  anemia,  new  onset  grade  ≥3  thrombocytopenia,  incidence  of  diarrhea,  incidence  of peripheral neuropathy, incidence of indirect bilirubin 2 fold increase).

The E-R analyses were presented using the exposure metrics derived from the updated PopPK model. These analyses, while considering limitations and exploratory nature of the model in patients, suggest that (i) there is a statistically significant E-R relationship for the TI response at Week 24 with higher MMB exposure associated with higher odds of being TI at Week 24 in JAKi exposed patients, but there does not appear to be such a relationship in JAKi naïve patients; (ii) there is no statistically significant E-R relationship  for  Grade ≥ 3  anemia  and  MMB  exposure  using  an  unadjusted  analysis.  However,  a trend of higher MMB exposure associated with a decrease in the odds of Grade ≥ 3 anemia is observed, after  adjusting  for  RBC  count  at  baseline;  (iii)  there  is  a  statistically  significant  E-R  relationship  for spleen-related endpoints with greater splenic volume reduction at Week 24 and a higher probability of SVR ≥ 35% at higher MMB exposures, regardless of adjusting for different patient-specific or diseaserelated  covariates;  (iv)  there  is  a  flat  E-R  relationship  for  safety  endpoints  (Grade ≥ 3  AEs,  early discontinuation, Grade ≥ 3 thrombocytopenia, any Grade diarrhea) except a trend was observed for a higher incidence of any Grade peripheral neuropathy at higher MMB exposure.

## 2.6.3. Discussion on clinical pharmacology

## Absorption

MMB is a low-solubility drug and has pH-dependent solubility. MMB showed moderate to high in vitro permeability. No absolute bioavailability study has been conducted. Based on mass balance data and assuming all metabolites are formed after absorption, absorption would be &gt;85%. MMB is classified as a BCS class 2 compound.

In general, the design of the relative BA and food effect study is acceptable.

The 200 mg MMB form II tablet was shown to be bioequivalent to the 300 mg form I capsule in terms of  AUC,  and  was  just  outside  the  80-125%  boundary  for  Cmax.  This  is  acceptable  since  strict bioequivalence  is  not  required  between  phase  I/II  and  phase  III  formulations.  Given  that  the commercial  formulation  is  identical  to  the  phase  III  formulation  (i.e  200  mg  form  II  tablet),  no additional bioequivalence studies are needed.

The effect of food on MMB form II tablet was investigated with a low-fat and high-fat meal. Given the modest changes observed with food intake in this study and the administration of MMB to patients in all  Phase  3  studies  irrespective  of  food  intake,  the  SmPC  wording  that  MMB  can  be  taken  with  or without food is accepted.

## Distribution

Some  differences  in  protein  binding  results  were  observed  between  studies  using  different  assay methodologies. However, these differences do not impact the calculation of the pharmacologic activity index significantly.

Blood/plasma ratio from the mass balance study is consistent with the in vitro data.

<div style=\"page-break-after: always\"></div>

## Elimination

In the mass balance study, 69.3% of the dose was recovered in feces and 27.5% in urine. More than 85% of the radioactive dose was excreted as metabolites, while parent drug accounted only for 12.6% and  0.6%  of  the  dose  in  feces  and  urine,  respectively.  Metabolism  is  thus  the  major  elimination pathway, whereas urinary excretion and active secretion of parent drug in bile or intestine are minor elimination  pathways.  MMB  was  shown  to  be  a  substrate  of  P-gp  and  BCRP in  vitro .  MMB  was  not investigated  as  a  substrate  of  renal  transporters,  which  is  acceptable  given  the  very  limited  urinary excretion.

MMB is metabolized via multiple metabolism pathways, primarily mediated by CYP enzymes. Based on the  proposed  metabolism  scheme,  the  formation  of  M21  with  sequential  metabolism  to  M8,  M28  or potentially M5 and/or M14, is a major pathway contributing to more than 25% of drug elimination. In vitro experiments indicated that CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C19 are involved in the metabolism of MMB and the formation of M21. Polymorphic CYPs (CYP2C9 and CYP2C19) play however a minor role in MMB metabolism and hence it is unlikely that clinical consequences will arise from CYP polymorphism. Following metabolism by CYP enzymes, aldehyde oxidase was shown to be involved in M21 formation. Interaction studies with a CYP3A4 inhibitor and inducer were conducted (see DDI).

Since it is unclear if the major faecal metabolite M14 (21.4% of dose in faeces, 1.8% in urine) is a secondary metabolite formed by oxidation of M19 or via hydrolysis of M8/M21 (or both), the pathway to  M19  could  theoretically  also  contribute  to ≥ 25%  of  drug  elimination.  However,  given  that  MMB metabolism in vitro (hepatocytes and HLM) was greatly reduced by a general CYP inhibitor, and that M19 is a minor circulating metabolite formed by amide hydrolysis of MMB, the pathway to M19 seems not to be a major elimination pathway.

Overall,  the  elimination  of  MMB  is  considered  sufficiently  characterized.  For  the  pharmacologically active  metabolite  M21,  CYP3A4  seems  to  be  involved  in  its  clearance  based  on in  vivo studies conducted with  ritonavir  and  rifampicin.  Since  M21  has  approximately  34%  activity  of  MMB  against JAK1/2 and 40% versus ACVR1, no further identification of potential enzymes involved is required.

In plasma, M21 was the only major metabolite contributing to &gt; 10% of total radioactivity and &gt; 25% of parent exposure and its interaction potential has been investigated (see interactions). The PK of M21 has  been  characterised  in  studies  in  healthy  volunteers  as  well  as  in  MF  patients.  M21  consistently showed higher systemic exposure than MMB.

## Dose proportionality and time dependency

MMB and M21 exposure increased less than dose proportional with increasing single dose for doses above 200 mg. No clinical studies evaluated dose proportionality at steady state for the MMB tablet form II. This is acceptable considering that MMB should be taken as a single 200 mg tablet once daily in line with SmPC recommendations.

In  line  with  the  short  half-life  of  MMB  and  M21  and  the  once  daily  administration,  no  significant accumulation seems to occur based on comparison of trough concentrations from week 2 up to week 24. No direct comparison of PK parameters (AUC, Cmax) after single and multiple administrations of 200 mg MMB (tablet) in MF patients is available. Indirect comparison with PK parameters after a single MMB administration in healthy volunteers (200 mg tablet) or in MF patients (300 mg capsule) suggests the absence of significant accumulation.

## Pharmacokinetics in target population

Based  on  the  pooling  of  PK  parameters  from  different  clinical  studies,  it  can  be  concluded  that exposures (Cmax and AUC) of MMB in healthy volunteers and subjects with MF were similar.

<div style=\"page-break-after: always\"></div>

## Population PK analysis

The approach taken by the applicant for model evaluation is overall state of the art.

It was asked to the applicant to submit the results of the new model (previously referred as sensitivity #1)  with  improved  predictive  performances.  In  its  D120  response,  the  applicant  presented  the complete results  for  the  sensitivity  analysis  #1  model  for  both  parent  (MMB)  and  metabolite  (M21) (question 14). The updated model was used for subsequent E-R analysis and the results were reflected in the conclusions.

Otherwise,  the  applicant  acknowledged  that  they  didn't  have  enough  data  for  a  formal  covariate analysis for most of the covariates. However, it was considered that there was sufficient data to assess covariates effects for age, sex and body weight as part of the PopPK analysis performed using data (combination of sparse and intense PK sampling) from 5 myelofibrosis studies (CCL09101, YM387-II02,  SIMPLIFY-1,  SIMPLIFY-2,  MOMENTUM)  that  was  adequate  to  support  the  conclusion  that  these covariates  did  not  have  a  significant  or  clinically  relevant  effect  on  momelotinib  PK  exposure parameters.  The applicant acknowledged that there was limited frequency for covariates for race and concomitant medication. To further support the covariate assessment on PK exposure, the applicant performed an additional analysis to assess the influence of intrinsic factors (i.e., age, sex, bodyweight, and  race)  on  momelotinib  exposure  (AUCinf  and  Cmax  based  on  noncompartmental  PK  based  on intense PK sampling) using data from six clinical pharmacology studies in which healthy adult subjects received  a  single  dose  of  200  mg  of  momelotinib  in  fasted  state.  A  total  of  150  individuals  were included in this analysis.  The totality of evidence (clinical PK and PopPK) supports the conclusions that age, gender, race (White, Black, Asian) and weight do not have a clinically relevant effect on the PK of momelotinib.

Modelling  and  simulation  results  are  not  robust  enough  to  support  a  statement  of  covariate (bodyweight, age, gender and race) effects on the PK of momelotinib.

Additional  analyses  results  using  data  from  six  clinical  pharmacology  studies  in  scatterplots  were provided and the applicant clarified on which metrics exactly the covariate effects are precluded.

Gender and race (White vs Asian) do not have a clinically relevant effect on the pharmacokinetics of momelotinib  based  on  exposure  (AUC)  data  in  healthy  subjects.  Exploratory  results  of  population pharmacokinetics  analysis  in  patients  did  not  show  any  effects  of  age,  weight,  or  gender  on momelotinib pharmacokinetics, as reflected in the section 5.2 of the SmPC.

## Special populations

Overall, the pharmacokinetics in special populations are well described.

The  applicant  was  asked  to  further  discuss  the  adequacy  of  the  single  dose  study  design  to appropriately  characterise  the  PK  of  momelotinib  in  subjects  with  renal  impairment  (given  the  nonlinear PK) and whether conclusions on dosing recommendations can be drawn from single-dose data. Based  on  the  justification  provided  by  the  applicant,  it  was  considered  that  the  single  dose  design employed in study GS-US-352-1152 was appropriate to characterize and compare exposures in renally impaired subjects.

As hepatic elimination is a major route of excretion for momelotinib, hepatic impairment may result in increased plasma momelotinib concentrations. In this context, the applicant provided the results of a dedicated study of momelotinib and its main metabolites in patients with moderate and severe hepatic impairment.

<div style=\"page-break-after: always\"></div>

The  applicant  considered  the  reduced  exposure  of  the  pharmacologically  active  metabolite,  M21,  to guide  the  dose  adjustment  recommendation.  The  overall  37%  (based  on  geometric  mean  ratio) increase of AUC for the combined exposure justifies the recommended dose reduction of 25% of the starting  dose  from  200mg  to  150mg  once  daily  to  account  for  the  increase  in  plasma  exposures  of momelotinib and the decrease in plasma exposures of M21 in subjects with severe hepatic impairment.

Given  that  momelotinib  exhibits  high  extent  of  plasma  protein  binding  (&gt;90%),  the  unbound concentrations  of  the  drug  and  active  metabolites  should  have  been  analysed  in  renal  and  hepatic impaired patients, in addition to total concentrations.  The percentage of free fractions of momelotinib and M21 is presented at 4h and 24h in all subjects in renal impairment study GS-US-352-1152 and in hepatic impairment study GS-US-352-1153. Given the similarities in free fractions between impaired and non-impaired populations both in the renal and hepatic impairment studies, the conclusions using total exposure are judged acceptable.

Apparent differences in exposure between Japanese and Caucasian subjects (53% increase) are not considered  to  be  clinically  relevant  based  on  the  overall  safety  profile  of  momelotinib  and  lack  of exposure-safety relationship for momelotinib in subjects with myelofibrosis. This is further corroborated by no differences in exposure-response relationships observed for all efficacy measures (in terms of both Spleen Volume Reduction (SVR) and Total Symptom Score (TSS) endpoints) between Japanese, Asian and non-Asian subjects with MF in the Phase 3 studies.

Based on the results obtained, dose adjustment is not considered necessary for patients with different racial or ethnic backgrounds.

Based on POP PK analysis, dose modifications are not considered necessary for patients based on age, body weight and gender.

## Pharmacokinetic interaction studies

## Momelotinib as victim of drug interactions

In vitro , MMB and M21 were not a substrate of the OCT1 receptor.

CYP3A4 showed the highest contribution to the metabolism of momelotinib and the formation of M21. Furthermore, MMB as well as M21 were shown to be substrates of Pgp and BCRP in vitro . While a mild inhibitory effect on momelotinib PK has been observed with ritonavir administrated concomitantly as strong inhibitor of CYP3A4, P-gP and BCRP, the applicant has considered that the ritonavir effect is not clinically relevant.

Ritonavir (a strong CYP3A4 inhibitor) increased momelotinib Cmax by 23.3% and AUC by 13.5%. Tmax and t1/2 of momelotinib remained unchanged. These changes are not considered clinically relevant and a  dose  adjustment  is  not  warranted  when  Omjjara  is  co-administered  with  a  CYP3A4  inhibitor. However, the  argumentation  provided  by  the  applicant  on  PgP  and  BCRP  inhibition  is  not  followed  as  the applicant did not provide any supporting data on the clinical impact of the co-regulation he is referring to. The absence of characterization of the effect of strong P-gp and BCRP inhibitors should be described in the SmPC and appropriate recommendation should be provided ( pending issue ).

An in  vitro signal  has  been  observed  for  OATP1B1  and  OATP1B3  for  MMB  and  M21  as  substrate.  A slight to moderate increase in momelotinib exposure has been observed with rifampicin single-dose in healthy volunteers.

The  applicant  agreed  to  revise  the  text  in  section  4.5  relating  to  inhibitors  of  OATP1B1/1B  and  to mention that coadministration with a single dose of rifampicin (inhibitor of OATP1B1/1B3) moderately

<div style=\"page-break-after: always\"></div>

increased momelotinib exposure (Cmax by 40.4% and AUCinf by 57.1%). In addition, it is stated that caution and monitoring for adverse reactions is advised in case of concomitant use with inhibitors of OATP1B1/1B3.

When the impact of the strong CYP3A inducer rifampicin on the PK of momelotinib is considered solely, a  moderate  induction  effect  has  been  observed.  Consequently,  the  applicant  has  recommended additional monitoring in case of concomitant use of strong CYP3A4 inducer or the use of an alternative drug to the strong CYP3A4 inducer.

The applicant clarified text to provide comparison of single-dose rifampicin + momelotinib and multiple dose  rifampicin  +  momelotinib  in  the  SmPC.  The  applicant  considers  that  reduction  in  momelotinib exposure due to induction by multiple dose rifampicin would not lead to a clinically significant reduction in efficacy.

Coadministration  of  strong  CYP3A4  inducers  may  lead  to  decreased  momelotinib  exposure  and consequently a risk for reduced efficacy. Additional monitoring is recommended with concomitant use of momelotinib and strong CYP3A4 inducers or an alternative medicinal product to the strong CYP3A4 inducer should be considered.

Coadministration of omeprazole, a representative PPI, slightly decreased momelotinib exposure. The applicant does not consider the changes clinically relevant.

Even if not optimal and even if 40 mg has had the greatest potential for interaction, it is agreed that the  20mg  dose  allows  an  adequate  characterisation  of  the  effect  of  omeprazole  dosing  with momelotinib.

The DDI risk as victim and perpetrator through aldehyde oxidase has been sufficiently discussed.

The  results  of  the in  vitro phenotyping  study  (AD-352-2021)  indicated  that  momelotinib  (MMB) metabolism  was  through  multiple  enzymes  including  CYP3A  (fm  ~0.36),  CYP2C8,  CYP2C19  and CYP2C9 (fm ~0.15 - 0.2 each) and CYP1A2 (fm ~0.1). Aldehyde oxidase (AO) was involved in M21 (active metabolite) formation in the sequential step after the primary CYP pathway. Since AO is a highcapacity enzyme and based on the profiles of known AO substrates, clinically significant DDIs with M21 (due  to  the  clinical  inhibition  of  AO)  are  unlikely  to  occur  [Dalvie,  2019;  Zaleplon  and  Ziprasidon Labels].

## Momelotinib as perpetrator of drug interactions

In accordance with the EMA Guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2**), only the potential perpetrator profile of the parent drug and the major metabolite M21 (AUC both larger than one fourth of the AUC of parent drug and larger than 10% of the drug-related exposure) is discussed below.

First  of  all,  regarding  the  experimental  conditions  of  the in  vitro perpetrator  studies,  a  number  of uncertainties were identified during the first round. Especially, was not clear whether stability and nonspecific binding of momelotinib and M21 have been adequately handled in all in vitro systems used. Further justifications were awaited to support that the actual unbound concentrations of momelotinib and M21 in the in vitro system are representative of the nominal concentrations.

Non-specific binding to human liver microsomes were conducted for both MMB and M21 in an in vitro study AD-352-2031. Therefore, the in vitro inhibitory potency of MMB and M21 towards CYP450 and UGT enzymes in human liver microsomes were corrected for free fraction for the DDI risk assessment. The applicant acknowledges the gaps in the in  vitro study  design  (i.e.,  the  media  concentrations  of MMB and M21 were not measured in the in vitro systems using cellular assays for transporter inhibition or CYP hepatocyte induction) which could impact the in vitro DDI risk assessment for MMB and M21.

<div style=\"page-break-after: always\"></div>

However, a clinical DDI study with rosuvastatin and single dose rifampin was conducted to address the in  vivo BCRP  and  OATP1B1/1B3  inhibition  DDI,  respectively  (GS-US-352-1151).  In  addition,  any potential in vivo DDI risk via P-gp inhibition by MMB or M21 at the gut level was already recognized and  is  reflected  in  updated  SmPC  wording  following  the  worst-case  scenario  analysis  (refer  to Response of Q98). Also worth noting is that MMB and M21 did not inhibit OAT1/3 and OCT2 (&lt;5% inhibition)  at  the  highest  assay  concentrations  (OPT-2012-066,  OPT-2012-086,  OPT-2012-126, AD3522019,  AD3522030).  Therefore,  additional  non-specific  binding  would  not  make  a  significant impact to the overall outcome of in vitro DDI risk assessment.

For CYP and UGT inhibition studies using human liver microsomes, the incubations were done up to 60 min. In vitro metabolic stability in human hepatic microsomes indicated that MMB concentrations were relatively stable for 60 minute incubations. Less than 20% parent turn-over was detected in NADPHdependent metabolism samples, while no measurable non-NADPH dependent degradation of MMB was detected over the 60 min incubation (CDCO-Cytopia\\_07\\_025, CDCO-Cytopia\\_08\\_004). In addition, all the assays were designed so that conditions were linear with respect to time and protein concentration while substrates were present at concentrations lower than their respective Km values. Therefore, the performance of the in vitro perpetrator DDI studies is judged acceptable.

## CYP enzymes and UGT

In vitro inhibition of all mandatory CYP enzymes has been studied for both momelotinib and the major metabolite M21.

Based on  vitro results,  the  risk  of  a  clinically  relevant  direct  inhibition  of  CYP2B6  by  momelotinib cannot be ruled out (IC50/2 &lt; 5.2 µM) but at clinically relevant concentrations neither momelotinib nor the major circulating metabolite M21 represent a risk of inhibition of CYP1A2, 2C8, 2C9, 2C19 and 2D6 enzymes. With a calculated R-value of 1.023, the risk by CYP2Bhas been correctly addressed by the applicant and the SmPC has been updated to mention that the specific NTI CYP2B6 substrates should be co-administered with caution.

In  addition,  UGT  inhibition  has  been  studied.  Momelotinib  is  an  inhibitor  of  UGT1A1  and  UGT1A9  at clinically relevant concentrations, but the clinical relevance is unknown. The applicant agrees to add in section 5.2. that momelotinib is an inhibitor of UGT1A1  and  UGT1A9  at  clinically relevant concentrations  but  that  the  clinical  relevance  is  unknown  and  that  momelotinib  and  its  major circulating  metabolite  are  not  inhibitors  of  the  other  isoforms  (UGT1A3/4/6  and  2B7)  at  clinically relevant concentrations.

The use of two UGT substrates and the positive controls has been justified. Both sulindac sulfone and naloxone were used as UGT1A3 and UGT2B7 substrates in various literature references [Brunell, 2011; Gall, 1999]. In addition, the validation for these substrates and positive controls were also conducted and established at the test facility.

Because cellular stress has been observed for all 3 donors for both momelotinib and M21, is cannot be ruled out that the in vitro induction results are masked by the cell toxicity. Rising levels of mRNA to more than 100% increase (2-fold) with rising momelotinib concentrations were observed up to 1 µM for CYP1A2 and 2B6 for momelotinib in at least one donor and then began to drop at 3 µM and after. The same observation was done for M21 up to 3 µM (and then a drop at 10 µM) in one donor for CYP1A2. As a consequence a potential induction by momelotinib and M21 of CYP1A2 and CYP2B6 at clinically relevant drug concentrations cannot be ruled out.  The applicant recognizes the limitation of the in vitro hepatocyte induction assay due to cellular stress observed at higher concentrations tested, which hindered generating in vitro enzyme induction kinetic parameters for DDI risk assessment. Dose dependent  weak  CYP1A2  mRNA  induction  was  indicated in  vitro (60N-1687)  for  MMB  at  clinically relevant  concentration  in  2  donors  tested,  but  with  &lt;  20%  response  of  the  positive  control,  50  µM omeprazole. Only a small CYP2B6 mRNA increase (&lt;3-fold) was observed in 1 of 3 donors tested (60N-

<div style=\"page-break-after: always\"></div>

1687),  suggesting  very  weak  induction  potential  by  MMB.  For  M21,  there  were  no  notable  dose dependent increase on CYP1A2 and CYP2B6 mRNA levels at clinically relevant concentrations tested in vitro .  Although  only  very  weak  induction  for  CYP1A2  and  CYP2B6  was  observed in  vitro ,  a  clinically relevant DDI cannot be ruled out completely. The SmPC section 4.5 wording for CYP450 substrates has been  updated  accordingly,  stating  that  narrow  therapeutic  index  or  sensitive  substrate  drugs  of CYP1A2 (e.g., theophylline, tizanidine) or CYP2B6 (e.g., cyclophosphamide) should be co-administered with caution.

Regarding a potential CYP3A4 induction, no fold-change result of CYP3A4 mRNA was ≥ 2-fold for both momelotinib  and  M21  but  the  results  were  dropping  progressively  in  all  3  donors  across  rising momelotinib and M21 concentrations, while cytotoxicity has been observed for both momelotinib and M21. In addition, the concentrations of momelotinib used for CYP3A4 are too low to exclude an in vivo DDI in the enterocytes. Therefore, a potentially clinically relevant in vivo induction of CYP3A4 cannot be ruled out based on these in vitro results.

However, an in vivo DDI study has been carried out investigating the effect of multiple doses of MMB on midazolam, a sensitive CYP3A4 substrate. A mild induction effect has been observed.

Study  GS-US-352-1151  Cohort  4  assessed  the  potential  effect  of  momelotinib  to  alter  midazolam exposure via induction of CYP3A4. In this study, momelotinib was dosed at the therapeutic clinical dose of 200mg QD for 7 days prior to the assessment of midazolam + momelotinib.

Despite the predefined no-effect boundaries in the study, the applicant considers that study GS-US352-1151  demonstrates  a  very  weak  (if  any)  induction  of  CYP3A4  by  momelotinib  as  assessed  via interaction with the sensitive CYP3A4 substrate midazolam. Whilst it is possible this potential inductive effect  is  offset  by  gut-level  CYP3A4  inhibition  by  momelotinib,  this  inhibition  potential  seems  to  be minimal as corroborated by the observed decrease in midazolam's AUC when co-administrated with momelotinib and no changes in midazolam's half-life (5.33h for midazolam + momelotinib vs 5.82h for midazolam). The overall net effect on midazolam's exposure remains minimal and supports guidance for coadministration of momelotinib with sensitive CYP3A4 substrates.

Based  on  the  total  evidence  provided  by  the  applicant  and  even  if  the  design  of  the  study  is  not optimal  to  cover  a  maximal  induction,  the  midazolam  study  informs  sufficiently  on  the  potential  of CYP3A induction which is judged minimal. No change in midazolam's half-life is observed.

The proposed indication may include women of childbearing potential. A clinically relevant induction of CYP1A2, CYP2B6 and CYP3A cannot be ruled out based on in vitro results. Furthermore, there may still be mechanisms of induction which presently are unknown.

Without an in vivo dedicated DDI study studying the impact of momelotinib on oral contraceptives, a risk  of  induction  of  other  non-CYP3A  enzymes  cannot  be  completely  excluded.  The  effectiveness  of concomitant  administration  of  oral  contraceptives  may  be  reduced  and  given  that  embryo-foetal toxicity  has  been  shown  with  momelotinib  in  studies  in  animals,  female  patients  of  child-bearing potential receiving momelotinib must use highly effective contraceptive methods during treatment. In this context, the applicant agreed to update sections 4.4, 4.6, and 5.2 to reflect that women using oral hormonal contraceptives should add an additional barrier method during OMJJARA treatment and for at least one week after the last dose.

## Transporters

The effect of momelotinib and M21 on all mandatory transporters has been investigated. In addition, the potential inhibition on optional transporters OCT1, MATE1 and BSEP has been investigated for both momelotinib and M21.

<div style=\"page-break-after: always\"></div>

Positive  inhibitory  signals for  momelotinib  or  its  major  metabolite  M21  have  been  found in  vitro at clinically relevant concentrations for BCRP, OATP1B1, OATP1B3 and MATE1.

For the effect of momelotinib on OATP1B1/1B3, the applicant acknowledged the gaps in the in  vitro assay  such  as  the  upper  concentration  was  only  up  to  15  µM  and  the  preincubation  step  was  not performed  in  OATP1B  inhibition  experiments  to  better  investigate  the in  vitro inhibitory  potency  of MMB. Given that MMB has low solubility, it is unlikely to achieve the targeted concentrations in vitro to cover the calculated clinically relevant hepatic exposure, therefore further in  vitro investigations  will not cover clinically relevant concentrations. Further, it was noted that M21 was an in vitro inhibitor for OATP1B1 and 1B3, but the static DDI model predicted no clinically relevant risk based on regulatory DDI guidance.

A clinical DDI study with rosuvastatin (BCRP substrate, OATP1B1, OATP1B3 substrate) was conducted to assess the DDI potential of BCRP inhibition and OATP1B1/1B3 inhibition in human subjects (GS-US352-1151). Overall, the rosuvastatin Cmax was increased 3.2-fold and AUCinf was increased 2.7-fold upon co-administration of MMB, but T1/2 remained unchanged, indicating that the rosuvastatin DDI was caused by BCRP inhibition by MMB at the gut level and unlikely through inhibition of OATP1B1 and 1B3  in  liver.  Based  on  the  DDI  study  with  rosuvastatin,  the  applicant  accepted  to  add  appropriate statement  in  Section  4.5  of  the  SmPC  saying  that  momelotinib  is  an  inhibitor  of  breast  cancer resistance  protein  (BCRP) in  vitro . Upon CHMP's request, the statement has been extended to the other BCRP substrates.

Regarding  MATE1,  no in  vivo studies  have  been  conducted  using  MATE1  substrates.  In  vitro,  the MATE1 inhibition  assay  determined  an  IC50  of  2.4 µ M for  M21  and  further  static  analysis  indicated potential clinically relevant DDI with R value of 1.93 calculated using EMA DDI guidance. Upon EMA's request,  the  SmPC  is  adequately  updated  to  use  caution  when  co-administrating  sensitive  MATE1 substrates (e.g., metformin).

For OCT1, the applicant acknowledged the upper concentration of 15 µM in the in vitro assay is not sufficient  to  cover  the  calculated  hepatic  inlet  concentration.  Due  to  the  solubility  limitation  of  MMB (&lt;3µg/mL  at  pH  7,  m2.7.1),  it  is  unlikely  to  achieve  the  targeted  clinically  relevant  concentration therefore, an additional in vitro study will not cover clinically relevant concentrations. Therefore, the applicant  updated  the  SmPC  Section  4.5  to  use  caution  when  co-administrating  sensitive  OCT1 substrates (e.g., metformin).

No or only minor inhibition has been observed in vitro for  BSEP, OAT1, OAT3 and OCT2 at clinically relevant concentrations. The negative in vitro signals have been added in the section 5.2 of the SmPC.

The  potential  inhibitory  effect  on  MATE2  has  not  been  evaluated.  However,  due  to  the  solubility limitations  of  MMB  and  M21,  an in  vitro assay  will  not  likely  provide  an  adequate  assessment. Therefore, the applicant revised the SmPC for caution with coadministration with metformin and other sensitive MATE1 and MATE2 substrates.

## Pharmacodynamics

MMB treatment reduced pSTAT3 and hepcidin after dosing is in line with the proposed mechanism of action. An acute and sustained reduction of circulating hepcidin was observed for the duration of the 24 week study, associated with increased iron levels and haemoglobin, following administration of momelotinib to patients with myelofibrosis.

Study GS US 352 1150 (QT) was designed to evaluate the effect of MMB at therapeutic (200 mg, 1 x 200  mg  MMB  tablet)  and  supratherapeutic  (800  mg,  4  ×  200  mg  MMB  tablets)  exposures  on  the change from baseline in QTc interval in a single dose crossover design. As the result of GS-US-3521150 study, no subject had a QTcF interval change from predose baseline &gt; 30 or &gt; 60 msec at any

<div style=\"page-break-after: always\"></div>

time point during any treatment (including MMB 200 and 800 mg, placebo, and moxifloxacin 400 mg). No treatment emergent absolute QTcF intervals &gt; 480 or &gt; 500 msec were observed for any subject following any treatment. The results of the TQT study were negative as defined by ICH E14 guidance.

One of the exploratory objectives of MOMENTUM trial was to explore potential correlates with response including  but  not  limited  to  mutational  analysis.  As  regards  potential  predictive  biomarkers,  some exploratory  analyses  were  conducted  using  samples  from  SIMPLIFY-1  and  -2  studies,  while  such analyses  are  still  ongoing  for  MOMENTUM  trial.  Therefore,  the  results  for  baseline  ferritin  levels potentially differentially enriched for the week 24 TI response for momelotinib compared to the control arms are not yet available for the latter.

Data currently available on the inflammatory cytokine responses to momelotinib treatment are limited and inconclusive, and further data are awaited, e.g., from the SIMPLIFY-1 study.

## E-R analyses

There  were  no  clinically  relevant  relationships  between  time  matched,  baseline  adjusted,  placebo corrected QTcF and plasma concentrations of MMB or its metabolites based on a linear mixed effect model that was used to quantify the relationship between plasma concentrations of MMB and M21 and ∆∆ QTcF  (time  matched,  baseline  adjusted,  placebo  corrected  QTcF),  with  sex  as  a  fixed  effect  and subject as a random effect.

With the data from all 3 Phase 3 studies, E-R analyses were conducted by using population PK model estimates of daily average individual exposures and considering dose modifications.  The E-R analyses were conducted to investigate the relationship of MMB exposures versus efficacy endpoints at Week 24 (e.g., TSS percent change from baseline, TSS responders, SVR, splenic volume responder, anemia/transfusions) and safety endpoints (e.g., grade ≥ 3 adverse events, early discontinuation, new onset  grade  ≥3  anemia,  new  onset  grade  ≥3  thrombocytopenia,  incidence  of  diarrhea,  incidence  of peripheral neuropathy, incidence of indirect bilirubin 2 fold increase).

The E-R analyses were presented using the exposure metrics derived from the updated PopPK model. These analyses, while considering limitations and exploratory nature of the model in patients, suggest that (i) there is a statistically significant E-R relationship for the TI response at Week 24 with higher MMB exposure associated with higher odds of being TI at Week 24 in JAKi exposed patients, but there does not appear to be such a relationship in JAKi naïve patients; (ii) there is no statistically significant E-R relationship  for  Grade ≥ 3  anemia  and  MMB  exposure  using  an  unadjusted  analysis.  However,  a trend of higher MMB exposure associated with a decrease in the odds of Grade ≥ 3 anemia is observed, after  adjusting  for  RBC  count  at  baseline;  (iii)  there  is  a  statistically  significant  E-R  relationship  for spleen-related endpoints with greater splenic volume reduction at Week 24 and a higher probability of SVR ≥ 35% at higher MMB exposures, regardless of adjusting for different patient-specific or diseaserelated  covariates;  (iv)  there  is  a  flat  E-R  relationship  for  safety  endpoints  (Grade ≥ 3  AEs,  early discontinuation, Grade ≥ 3 thrombocytopenia, any Grade diarrhea) except a trend was observed for a higher incidence of any Grade peripheral neuropathy at higher MMB exposure.

## 2.6.4. Conclusions on clinical pharmacology

In conclusion, the pharmacokinetics of momelotinib has been adequately studied.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Clinical efficacy

## 2.6.5.1. Dose response studies

Four main studies contributed to the selection of dose for pivotal studies, the first three conducted in patients in subjects with PMF or post PV/ET MF and the last one - in healthy volunteers:

- CCL09101 - phase I/II study to safety, tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and PK of the MMB capsule Form I
- YM387 II 02 - phase I/II study to determine the PK of capsule administered BID
- GS US 352 0102 - phase I to assess the relative bioavailability of a tablet formulation of MMB compared with the capsule
- GS US 352 1672 - phase II study with tablet formulation to evaluate MMB PK in transfusion dependent subjects with MF and to assess biomarkers of inhibition of JAK1/2 and ACVR1 in transfusion dependent subjects with MF treated with MMB

## CCL09101 study

In  the  Phase  1  dose  escalation  phase,  the  MMB  dose  was  escalated  from  100  mg  to  400  mg  daily through 5 successive cohorts of subjects in a 3 + 3 design.  Escalation to the next dose group occurred if  none  of  the  first  3  subjects  experienced  a  dose  limiting  toxicity  (DLT)  or  if  ≤  2  of  6  subjects experienced a DLT. In the 400 mg once daily (QD) cohort, 2 of 6 subjects experienced a total of 2 DLTs with no other DLTs observed at other doses.  In the Phase 2 portion of the study, the 150 mg and 300 mg QD cohorts were selected for cohort expansion in addition to a 150 mg BID cohort. The recommended daily dose of the MMB capsule (Form I) was determined to be 300 mg QD.

## YM387 II 02 study

The  study  evaluated  dose  levels  of  200  mg  BID  and  250  mg  BID  in  the  dose  escalation  and  dose confirmation phases to investigate whether additional therapeutic benefit could be achieved with higher daily doses administered in this regimen. No events met the protocol defined criteria for DLT in the dose escalation phase, though the MMB 250 mg BID dose was not well tolerated.  Of the 7 subjects who initially received 250 mg BID, only one subject received this dose for over 30 days.  All 6 others either  had  dose  decreases,  dose  interruptions,  or  discontinued  from  the  study  within  30  days. Therefore, only 200 mg BID dose group was expanded in the dose-confirmation phase.

Table below presents PK parameters at steady state following once daily or BID dosing regimen from studies CCL09101 and YM387-II-02.

Table  24:  Comparison  Between  Studies  CCL09101  and  YM387-II-02:  PK  Parameters Following QD or BID Dosing of MMB Form I Capsule at Steady State

| Study                   | CCL09101                  | CCL09101                  | CCL09101                   | YM387-II-02                |
|-------------------------|---------------------------|---------------------------|----------------------------|----------------------------|
| PK Parameter            | 150 mg QD (N = 17-18) [1] | 300 mg QD (N = 25-27) [1] | 150 mg BID (N = 13-14) [1] | 200 mg BID (N = 13-21) [1] |
| C max (ng/mL)           | 338.5 (59.2)              | 658.3 (53.8)              | 320.8 (94.0)               | 505.0 (61.3)               |
| T max (h) [2]           | 2.00 (1.00, 2.13)         | 2.00 (1.58, 2.93)         | 1.99 (1.50, 2.00)          | 2.00 (1.00, 2.08)          |
| t 1/2 (h) [2]           | 4.67 (3.77, 5.53)         | 4.60 (2.98, 5.45)         | 3.02 (2.54, 4.37)          | 4.87 (3.70, 5.31)          |
| AUC tau (ng · h/mL) [3] | 2349.9 (82.9)             | 4281.3 (54.7)             | 1744.8 (101.8)             | 3095.6 (56.3)              |

Source:  CSR CCL09101; YM387-II-02 [1] Number of subjects was different for different PK parameters.   [2] All data are presented as mean (CV%) except Tmax and t1/2 are presented as median (Q1, Q3). [3] AUCtau = AUC0-24 for QD; AUCtau = AUC0-12 for BID. AUCtau, area under the plasma concentration time curve over the dosing interval; BID, twice daily; Cmax, maximum plasma concentration; Q1, Q3, first quartile, third quartile; QD, once daily; t1/2, terminal elimination half life; Tmax, time to Cmax.

<div style=\"page-break-after: always\"></div>

Table 25:   Comparison Between Studies CCL09101 and YM387-II-02:  Responses (mITT Population) And Discontinuation (Safety Population) by Initial Dose

| Study                                                                    | CCL09101           | CCL09101         | CCL09101          | YM387-II-02     | YM387-II-02   |
|--------------------------------------------------------------------------|--------------------|------------------|-------------------|-----------------|---------------|
| Response/Safety Category: (%)                                            | n 150 mg QD (N=52) | 300 mg QD (N=59) | 150 mg BID (N=42) | 200 mg (N = 53) | BID           |
| Clinical Improvement                                                     | 23 (44.2%)         | 34 (57.6%)       | 23 (54.8%)        | 31 (58.5)       |               |
| Splenomegaly > 5 cm at baseline                                          | 48                 | 52               | 37                | 44              |               |
| Spleen Responders                                                        | 15 (31.3%)         | 17 (32.7%)       | 12 (32.4%)        | 33 (75.0)       |               |
| Transfusion Dependent Subjects at Baseline                               | 24                 | 30               | 15                | 25              |               |
| Transfusion Responders                                                   | 12 (50.0%)         | 20 (66.7%)       | 8 (53.3%)         | 9 (36.0)        |               |
| Anemic Subjects at Baseline                                              | 33                 | 42               | 29                | 35              |               |
| Anemia Responders                                                        | 13 (39.4%)         | 20 (47.6%)       | 9 (31.0%)         | 10 (28.6)       |               |
| Average Daily Dose (mg) [3]                                              | 217.43             | 297.71 [1]       | 296.76            | 293.7 [2]       |               |
| Decrease in Dose due to AE                                               | 12 (23.1%)         | 24 (40.0%) [1]   | 12 (28.6%)        | 26 (48.1%)      |               |
| Number of Patients with at Least 1 TEAE Leading to Study Discontinuation | 5 (9.6)            | 8 (13.3) [1]     | 7 (16.7)          | 17 (31.5)       |               |

Source:  CCL09101 Tables 9-1, 9-2, 9-4, 11-1, 11-9; YM387-II-02 Tables 9-1, 9-2, 9-7, 11-1, 11-10.

Note:  mITT (modified intent-to-treat) Population consisted of all enrolled subjects who received at least 1 dose of MMB and had at least 1 postbaseline IWG-MRT evaluation. [1] n = 60 [2] n = 54 [3] Median is reported

Taking both studies CCL09101 and YM387 II 02 study into consideration, the therapeutic activity of MMB 300 mg once daily was similar regarding spleen size reduction, transfusion and anemia response, and decreased symptoms when compared to 200 mg BID.

However,  the  200  mg  BID  had  a  higher  discontinuation  rate,  more  pronounced  side  effects  (e.g., thrombocytopenia, peripheral neuropathy), and similar average daily doses when compared to 300 mg once daily regimen.  The higher daily dose given as 200 mg BID or 250 mg BID regimen led to more dose adjustment during treatment due to AEs without having more benefit.  Given the similar benefitrisk  across  the  range  of  exposures  in  the  150  mg  once  daily,  300  mg  once  daily,  and  200  mg  BID doses, benefit-risk data were in support of the 300 mg once daily dose which was taken forward in subsequent development studies.

Therefore, the 300 mg capsule formulation was identified as the optimal dose with a favourable benefit risk  profile  in  the  phase  1  2  dose  escalation/dose  confirmation  studies  CCL09101  and  YM387  II  02 based on overall PK, safety, and therapeutic activity profiles of once daily and BID doses in subjects with MF.

## GS US 352 0102

A  bridging  PK  study  was  conducted  to  evaluate  the  relative  bioavailability  between  a  new  tablet formulation  and  the  capsule  formulation . The  study  evaluated  the  relative  bioavailability  of  several MMB doses in tablets (dihydrochloride monohydrate salt Form II; 100, 150, 200, or 300 mg) compared with  the  capsule  formulation  used  in  studies  CCL09101  and  YM387  II  02.    Data  from  this  study indicated that the 200 mg tablet (Form II) dose provided similar exposure to the 300 mg capsule dose used in earlier studies (please refer to the PK part of the report) leading to selection of the 200 mg tablet (Form II) dose for the subsequent Phase 3 program.

<div style=\"page-break-after: always\"></div>

## GS-US-352-1672 study

This translational Phase 2 study was performed in transfusion-dependent MF patients at MMB 200 mg starting dose of the tablet formulation QD for all subjects to demonstrate the mechanism of action of MMB (please  refer  to  the  PD  part  of  the  report).  Biomarker,  phosphorylated  signal  transducer  and activator  of  transcription  3  (pSTAT3)  in  interleukin  (IL)  6  stimulated  T  cells  sampled  from  study subjects  were  also  collected  on  the  same  schedule  as  PK  samples.  Peripheral  hepcidin  decreased  6 hours after dosing with MMB and exhibited a downward trend over time, consistent with the decreased hepcidin production with MMB.  This study confirmed that the 200 mg once daily tablet was associated with evidence of desired pharmacology and demonstrated efficacy with an acceptable safety profile.

Overall, the safety, efficacy, and PK data from earlier Phase 1-2 studies CCL09101 and YM387-II-02, a bioequivalence Phase 1 study GS-US-352-0102, and data from the translational Phase 2 study GS-US352-1672 justify the selection of MMB 200 mg tablet Form II once daily for pivotal studies in patients with myelofibrosis.

The dose of MMB 200 mg tablet once daily was used in all of the Phase 3 conducted in MF.

Further,  the E-R  analyses were  conducted  based  on  results  from  phase  3  studies  MOMENTUM, SYMPLIFY-1 and SYMPLIFY-2 (please refer to the PK/PD part of the report).

## 2.6.5.2. Main studies

The applicant submitted 2 main studies (one in JAKi-treated patients and one in Jaki-naïve patients).

Main study for JAKitreated patients: Study SRA-MMB-301 (MOMENTUM), a Phase 3, Randomized, Double-blind Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Postpolycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

Main study for JAKi-naive patients: Study GU-US-352-0101 (SIMPLIFY-1), a Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

## Methods

MOMENTUM is an international, randomized, double blind, active controlled, pivotal phase 3 study of the efficacy and safety of MMB versus DAN in subjects with intermediate or high risk primary MF (PMF) or post polycythemia vera or post essential thrombocythemia (post PV/ET) MF who previously received JAK inhibitor therapy and were symptomatic and anemic.  The 24 week double blind, randomized treatment period was completed and open label treatment with MMB is ongoing.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations: DAN, Danazol; Hgb, hemoglobin; JAKi, Janus kinase inhibitor; TSS, total symptom score

Figure 9 : MOMENTUM trial design schema

SIMPLIFY 1 was an international, randomized, double blind, active controlled, pivotal phase 3 study of the efficacy and safety of MMB versus RUX in JAK inhibitor naïve subjects with intermediate or high risk PMF or post PV/ET MF.  The primary objective was to determine the efficacy of MMB compared with RUX as measured by SRR at week 24.

<!-- image -->

Abbreviations: BID, twice daily; JAKi, Janus kinase inhibitor; LTFU, long-term follow-up; QD, once daily.

## · Study Participants

Table 26:   Key eligibility criteria in MOMENTUM and SIMPLIFY-1 studies

| Inclusion Criteria               | MOMENTUM                                                                                                                                                                                                                                                                            | SIMPLIFY-1                                                                                                                                                                |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Age                              | ≥ 18 years                                                                                                                                                                                                                                                                          | Same as MOMENTUM                                                                                                                                                          |
| MF diagnosis                     | Confirmed diagnosis of PMF per the WHO 2016 criteria, or post-PV/ET MF per the IWG-MRT criteria                                                                                                                                                                                     | Same as MOMENTUM                                                                                                                                                          |
| History of JAK inhibitor therapy | Previously treated with an approved JAK inhibitor • for ≥ 90 days, • or for ≥ 28 days if therapy was complicated by RBC transfusion requirement of ≥ 4 units in an 8-week period or grade 3 or 4 adverse events of thrombocytopenia, anemia, or hematoma No additional nontreatment | No history of JAK inhibitor therapy . MF therapy required in the opinion of the investigator. Exclusion: Eligible for allogeneic bone marrow or stem cell transplantation |

<div style=\"page-break-after: always\"></div>

| Inclusion Criteria             | MOMENTUM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | SIMPLIFY-1                                                                                                                                                |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                | interval required if JAK inhibitor was discontinued before screening. Ongoing JAK inhibitor taper required over at least 1 week. If low dose (eg, RUX 5 mg once daily), taper could be reduced or not required with sponsor approval. A nontreatment interval began ≥ 7 days before day BL1.                                                                                                                                                                                                                                                        |                                                                                                                                                           |
| Symptoms                       | Symptomatic, defined as an MFSAF TSS ≥ 10 assessed by a single MFSAF v4.0 assessment at screening before the first day of baseline assessments (day BL1)                                                                                                                                                                                                                                                                                                                                                                                            | Not specified                                                                                                                                             |
| Anemia                         | Anemic, defined as any of the following: • For any subject: received a transfusion within 28 days before day BL1, with pretransfusion Hgb < 10 g/dL • For subject not receiving JAK inhibitor at screening, Hgb < 10 g/dL during the baseline period (days BL1-BL7) • For subject receiving JAK inhibitor at screening, Hgb < 10 g/dL during screening, before day BL7 Exclusion: Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding, | Not specified                                                                                                                                             |
| Splenomegaly                   | or thalassemia Palpable splenomegaly ≥ 5 cm below the left costal margin or spleen volume ≥ 450 cm 3 on imaging, ), assessed during Screening, at any point prior to Randomization                                                                                                                                                                                                                                                                                                                                                                  | Palpable splenomegaly ≥ 5 cm below the left costal margin Exclusion: Prior splenectomy and splenic irradiation within 3 months prior to the first dose of |
| Concomitant or prior treatment | Exclusion of: • Active anti-MF therapy within 1 week prior to Day BL1. Supportive care including steroids for non-MF indications may be used • Erythropoiesis                                                                                                                                                                                                                                                                                                                                                                                       | study drug Exclusion Prior use of a JAK1 or JAK2 inhibitor Use of strong cytochrome P450 (CYP)3A4 inhibitors or strong CYP3A4 inducers or dual            |

<div style=\"page-break-after: always\"></div>

| Inclusion Criteria                | MOMENTUM                                                                                                                                                                                                                                                   | SIMPLIFY-1                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | stimulating agent (ESA) within 4 weeks prior to Randomization • Danazol within 3 months prior to Randomization • Splenic irradiation within 3 months prior to Randomization • Current treatment with simvastatin, atorvastatin, lovastatin or rosuvastatin | inhibitors of CYP3A4 and CYP2C9 within 1 week prior to the first dose of study drug Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or investigational therapy within 4 weeks of the first dose of study drug Changes to dose of iron chelator therapy within 14 days of the first dose of study drug |
| Prognostic risk category          | High risk, intermediate-2 risk, or intermediate-1 risk MF defined by the DIPSS or DIPSS-plus                                                                                                                                                               | High risk or intermediate-2 risk defined by the IPSS for PMF, or intermediate-1 risk defined by the IPSS and associated with symptomatic splenomegaly, hepatomegaly, anemia (Hgb < 10 g/dL), and/or unresponsiveness to available therapy                                                                                                 |
| ECOG                              | 0, 1, or 2                                                                                                                                                                                                                                                 | Same as MOMENTUM                                                                                                                                                                                                                                                                                                                          |
| Acceptable laboratory assessments | ANC ≥ 0.75 × 10 9 /L                                                                                                                                                                                                                                       | ANC ≥ 0.75 × 10 9 /L in the absence of growth factor in the prior 7 days                                                                                                                                                                                                                                                                  |
| Acceptable laboratory assessments | Platelet count ≥ 25 × 10 9 /L (without requirement for platelet transfusion)                                                                                                                                                                               | Platelet count ≥ 50 × 10 9 /L (≥ 100 × 10 9 /L if AST or ALT ≥ 2 × ULN) in the absence of platelet transfusion or thrombopoietin mimetics in the prior 7 days                                                                                                                                                                             |
| Acceptable laboratory assessments | Peripheral blood blast count < 10%                                                                                                                                                                                                                         | Same as MOMENTUM                                                                                                                                                                                                                                                                                                                          |
| Acceptable laboratory assessments | AST and ALT ≤ 3 × ULN (≤ 5 × ULN if liver was involved by extramedullary hematopoiesis per investigator opinion or if related to iron chelator therapy that was started within the prior 60 days)                                                          | Same as MOMENTUM                                                                                                                                                                                                                                                                                                                          |
| Acceptable laboratory assessments | Calculated CrCl of ≥ 30 mL/min, calculated according to Cockcroft-Gault                                                                                                                                                                                    | Calculated CrCl of ≥ 45 mL/min                                                                                                                                                                                                                                                                                                            |
| Acceptable laboratory assessments | Direct bilirubin ≤ 2.0 × ULN                                                                                                                                                                                                                               | Same as MOMENTUM                                                                                                                                                                                                                                                                                                                          |
| Safety-                           | Active uncontrolled infection                                                                                                                                                                                                                              | Ongoing active                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Inclusion Criteria             | MOMENTUM                                                                                                                                                                                                                                                                                                                               | SIMPLIFY-1                                                                                                                                                       |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| related exclusion criteria     | (subjects receiving outpatient antibacterial and/or antiviral treatments for infection that is under control or as infection prophylaxis may be included in the trial)                                                                                                                                                                 | infection (subjects receiving outpatient antimicrobial treatment for infections that are under control may be included)                                          |
| related exclusion criteria     | Significant active or chronic bleeding event ≥ Grade 2 per CTCAE v5.0, within 4 weeks prior to randomization                                                                                                                                                                                                                           | Active or chronic bleeding within 4 weeks prior to the first dose of study drug;                                                                                 |
| related exclusion criteria     | Unstable angina pectoris within 6 months prior to randomization Symptomatic congestive heart failure within 6 months prior to randomization Uncontrolled cardiac arrhythmia within 6 months prior to randomization QTcF interval > 500 msec, unless attributed to bundle branch block Current progressive thrombosis despite treatment | Symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; QTc interval > 450 msec, unless attributed to bundle branch block            |
| related exclusion criteria     | Presence of peripheral neuropathy ≥ Grade 2 per CTCAE v5.0                                                                                                                                                                                                                                                                             | Presence of peripheral neuropathy ≥ CTCAE Grade 2                                                                                                                |
| related exclusion criteria     | Unresolved non-hematologic toxicities from prior therapies that are > Grade 1 per CTCAE v5.0 Child- Pugh score ≥ 10                                                                                                                                                                                                                    | Unresolved non- hematologic toxicities from prior therapies that are > CTCAE Grade 1                                                                             |
| related exclusion criteria     | Known positive status for HIV Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier (testing required for hepatitis B and C)                                                                                                                                                                       | Known positive status for HIV Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier |
| Exclusion for other malignancy | Prior or concurrent malignancy, whose natural history or treatment has a significant potential to interfere with the safety or efficacy assessment of the investigational regimen                                                                                                                                                      | History of a concurrent or second malignancy with exceptions                                                                                                     |

## · Treatments

## Study SRA-MMB-301 (MOMENTUM)

- MMB starting dose was 200 mg once daily .  Blinded MMB treatment continued through week 24 of the randomized treatment period, then in open label treatment for up to an additional 180  weeks .    After ≥ 24  weeks  of  open  label  treatment,  subjects  could  continue  long  term treatment with MMB in the ongoing single arm extended access study SRA MMB 4365 (XAP).

<div style=\"page-break-after: always\"></div>

- DAN starting total daily dose was 600 mg , administered in two divided doses .  DAN treated subjects continue open label treatment with DAN from week 24 through the end of week 48 or could cross over to open label MMB:  1) after completing 24 weeks of randomized treatment, 2)  at  the  end  of  week  24  if  treatment  was  discontinued  early  but  study  assessments  were continued and no prohibited medication was administered (unless approved by the sponsor), or 3)  any  time  before  the  end  of  week  24  if  the  protocol  defined  criteria  were  met  for  splenic progression.  After ≥ 24 weeks of open label treatment with MMB, subjects could continue long term MMB treatment in study XAP.

## Study GU-US-352-0101 (SIMPLIFY-1)

- MMB was administered at a starting dose of 200 mg once daily.
- RUX starting dose of RUX was between 5 and 20 mg twice daily (BID), inclusive, based on platelet  count,  creatinine  clearance,  and  transaminase  levels  (aspartate  aminotransferase [AST] or alanine aminotransferase [ALT]) at screening.

The duration of blinded study treatment was 24 weeks.  After the double blind treatment period, all subjects remaining on therapy in the study were to continue or begin open label treatment with MMB for up  to  an  additional  216  weeks to  obtain  data  on  long  term  treatment.  The  maximum participation in the treatment period for any subject was 4 years (208 weeks). Following treatment, subjects will be followed for safety and disease status for a period of 3 months (12 weeks) and for survival approximately every 6 months for 5 years (260 weeks). Treatment with RUX was not allowed during the open label period.  After study termination by the sponsor, eligible subjects could continue long term treatment with MMB in study XAP.

## · Objectives

## Study SRA-MMB-301 (MOMENTUM)

## Primary objectives

- To determine the efficacy of MMB versus DAN assessed by improvement in Myelofibrosis Symptom Assessment Form (MFSAF) TSS in subjects with PMF, post-PV MF, or post-ET MF who were previously treated with approved JAK inhibitor therapy
- To compare the effect of MMB versus DAN on TI status at week 24

## Secondary objectives

- To compare SRR for subjects treated with MMB versus DAN
- To compare change from baseline MFSAF TSS for subjects treated with MMB versus DAN
- To compare RBC transfusion requirements in subjects treated with MMB versus DAN
- To assess the duration of MFSAF TSS response
- To assess duration of TI status at week 24
- To compare the benefit of MMB versus DAN on anaemia response and transfusion requirements, and to estimate the duration of response
- To compare the effect of MMB versus DAN on TI status at week 24
- To characterize the safety of MMB
- To compare the OS and leukemia-free survival (LFS) of subjects treated with MMB versus DAN

<div style=\"page-break-after: always\"></div>

- To compare patient-reported fatigue and physical function for MMB versus DAN
- To compare patient-reported health status and health-related QoL for MMB versus DAN
- To assess association of MMB exposure (PK) with outcome

## Study GU-US-352-0101 (SIMPLIFY-1)

## Primary objectives

- To determine the efficacy of MMB compared with RUX as measured by splenic response rate at Week 24 (SRR24)

## Secondary objectives

- To determine the effect of MMB compared with RUX on the improvement of total symptom score (TSS) at Week 24
- To determine the effect of MMB compared with RUX on rate of RBC transfusions through Week 24
- To determine the effect of MMB compared with RUX on rate of RBC transfusions through Week 24

To determine the effect of MMB compared with RUX on RBC TD rate at Week 24

<div style=\"page-break-after: always\"></div>

## · Outcomes/endpoints

Table 27:   Primary and Key Secondary/Secondary Endpoints in the Hierarchical Testing for MOMENTUM and SIMPLIFY-1

| MOMENTUM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | SIMPLIFY-1                                                                                                                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary 1 st Difference in MFSAF TSS response rate at wk 24 defined as the proportion of subjects who achieve a ≥ 50% reduction in TSS over the 28 days immediately prior to the end of wk 24 compared to baseline, as measured by MFSAF v4.0 diary 2 nd TI rate at wk 24 proportion of patients with TI at the end of wk 24 TI is defined as not requiring RBC transfusion (except in the case of clinically overt bleeding) for ≥ 12 weeks, with all and Hgb levels during the ≥ 12 weeks interval of ≥ 8g/dL (except in the case of clinically overt bleeding) | Primary SRR (reduction in spleen volume ≥ 35% from baseline) at wk 24                                                                                                                                                                                                              |
| Key secondary SRR (reduction in spleen volume ≥ 25% from baseline) at wk 24 Change from baseline in MFSAF TSS at wk 24 SRR (reduction in spleen volume ≥ 35% from baseline) at wk 24 Proportion with zero RBC units transfused during the RT period                                                                                                                                                                                                                                                                                                               | Secondary TSS response rate at wk 24 (the proportion of subjects who achieves a ≥ 50% reduction from baseline in TSS to wk 24, as measured by the modified MPN-SAF TSS v2.0 diary) RBC transfusion rate during the double-blind treatment period TI rate at wk 24 TD rate at wk 24 |

For MOMENTUM, multiplicity between the 2 primary endpoints was adjusted by hierarchical testing.  If superiority for TSS response rate at week 24 was statistically significant (p ≤ 0.05) in favor of MMB, the study was to be considered positive and a superiority test performed for TI rate at week 24.  If the result of the superiority test for TI rate at week 24 was not significant, a noninferiority test was to be performed; at least 80% of the DAN response rate had to be preserved for MMB to demonstrate noninferiority. For SIMPLIFY-1, SRR and TSS response rate were tested for noninferiority; at least 60% (for SRR) and 67% (for TSS) of the RUX response rates had to be preserved for MMB to demonstrate noninferiority.  MFSAF, Myelofibrosis Symptom Assessment Form; RBC, red blood cell; RT, randomized treatment; SRR, splenic response rate; TD, transfusion dependence; TI, transfusion independence; TSS, total symptom score; wk, week

<div style=\"page-break-after: always\"></div>

## · Sample size

## Study SRA-MMB-301 (MOMENTUM)

A sample size of 180 subjects was determined based on power considerations to detect a statistically significant treatment difference in the proportion of subjects with TSS response (primary endpoint), as well as in the proportion of subjects with TI status and in Splenic Response Rate (SRR, secondary endpoint). With a sample size of 180 subjects to be randomized to MMB or DAN in a 2:1 ratio, using a 2-sided significance level of 0.05, the study has

- a 98.8% power to detect a true difference of 21% in TSS (23% with MMB versus 2% with DAN), or
- a 90% power to detect a true difference of 15% in TSS (17% with MMB versus 2% with DAN) based on the method in Fleiss et al (1980)
- a 90% power to detect a true difference of 24% in the proportion of subjects with TI status (45% versus 21%) and a true difference of 14% in SRR (15% versus 1%).

All power computations were made with East software, version 6.5 (Cytel), or SAS, Version 9.4. No formal interim analyses were performed (An interim analysis for sample size reassessment was removed at protocol amendment 2.0).

## Study GU-US-352-0101 (SIMPLIFY-1)

With a sample size of 420 subjects to be randomized to MMB or RUX in a 1:1 ratio, the study was planned to provide &gt; 90% power for testing the noninferiority hypothesis on SRR24, assuming a SRR for MMB of 34% [lower bound of the 95% CI on the ruxolitinib effect on splenic response rate observed in ruxolitinib Study 351 Comfort I (Verstovsek et al 2012)]. The sample size of 420 subjects provides

- 90% power for testing the noninferiority hypothesis on RR-TSS24, assuming a RR-TSS24 for MMB of 38% (lower bound of the 95% CI on the ruxolitinib effect on response rate observed in ruxolitinib Study 351 Comfort I),
- at least 85% power for testing a ≥ 15% difference between the two treatment groups on RRTI24 and RR-TD24, using a chi-square test.

provide ~80% power at the 2-sided 0.05 level using a negative binomial model., assuming 1) MMB improves the rate of RBC transfusion by 20% compared with placebo (ie, with an expected transfusion rate of 0.62 units/subject-month), and 2) a dispersion parameter of 2.5.

## · Randomisation and Blinding (masking)

## Study SRA-MMB-301 (MOMENTUM)

Subjects were randomized in a 2:1 ratio via the interactive response technology/system (IRT/IXRS) to receive MMB plus DAN placebo (MMB arm) or DAN plus MMB placebo (DAN arm). A non-deterministic biased-coin minimization method (Pocock, 1975; Han, 2009) was used to reduce imbalance between treatment arms for the following baseline potential prognostic factors:

- -MFSAF TSS baseline score (≥ 22 versus &lt; 22)
- -Baseline palpable spleen length below the LCM (≥ 12 cm versus &lt; 12 cm)
- -Baseline RBC or whole blood units transfused in the 8-week period prior to randomization (0, 1-4, and 5+)
- -Investigational site.

<div style=\"page-break-after: always\"></div>

Allocation probabilities of 0.9 and 0.8 were used in randomizing a patient to MMB arm and DAN arm, respectively, when it is the preferred treatment arm per the imbalance score. If the imbalance scores of the two treatment arms are identical, then a weighted coin was flipped with probability of 2/3 for selecting  MMB as the preferred treatment and probability of 1/3 for selecting DAN as the preferred treatment. The unbiased randomization ratio under these allocation probabilities was 2:1 (Han, 2009). The weighted sum of the marginal imbalance was used as the imbalance score to minimize marginal imbalance across the 4 factors.

A re-randomization test was conducted as a sensitivity analysis of the first primary efficacy endpoint of MFSAF TSS response rate at week 24. Ten thousand simulated trials were generated so that subjects randomized in the study were rerandomized into 2 arms under the same study randomization method, producing an empirical distribution of the CMH test statistic under the null hypothesis. Subjects were rerandomized  in  the  same  order  they  were  originally  randomized,  taking  into  account  stratification factors based on baseline TSS, spleen size, number of transfusion units, and study site. The empirical p-value (i.e. the rerandomization p-value) was the frequency, calculated as total number of times out of 10,000, that a simulated test statistic was strictly larger than the test statistic on the observed data using the original randomization allocation.

Study  SRA-MMB-301  has  a  double-blinded  randomized  treatment  period  of  24  weeks  for  subjects, investigators, study site personnel, and sponsor personnel involved in the conduct of the study blinded to the identity of the treatment assignments. The DMC included at least one unblinded independent biostatistician who was involved in charter development, SAP analysis, data monitoring and analysis.

For  subjects  discontinuing  study  drug  before  the  week  24  visit,  every  attempt  was  to  be  made  to maintain blinding of treatment assignment and to continue all study assessments through the end of week 24. Unless required for safety reasons, treatment assignments remained blinded. Requests for unblinding were  directed to the medical  monitor.  If  immediate  unblinding  was  required,  the investigator could obtain the treatment assignment from the IRT, and the activity was logged by the system and the sponsor automatically notified.

Following completion of Week 24 assessments, subjects were given the option to receive momelotinib in the open label extended treatment period.

Subjects  who  completed  week  24  and  elected  to  receive  momelotinib  in  the  open-label  extended treatment period remained blinded.

Subjects who elected to receive danazol in the open-label treatment period after blinded randomised period  were  unblinded  to  their  treatment  assignment  after  completing  week  24.  Subjects  with confirmed  symptomatic  splenic  progression  before  week  24  were  also  unblinded  before  receiving momelotinib in the open-label treatment period to confirm they received danazol in the randomized treatment period.

The management of blinding for this study, including protection of data and maintaining the blind to minimize the potential  bias  on  study  conduct,  is  described  in  the  SRA-MMB-301  Blinding/Unblinding Plan (v3.0, 17 Jun 2021).

## Study GU-US-352-0101 (SIMPLIFY-1)

Subjects were randomized via interactive web response system (IXRS) on a 1:1 basis to receive MMB QD plus RUX placebo BID (MMB arm) or RUX BID plus MMB QD placebo (RUX arm). Treatment assignment was stratified by:

- -TD (yes or no); TD was defined as having received at least 4 units of RBC transfusions or had a hemoglobin level &lt; 8 g/dL in the 8 weeks prior to randomization, excluding cases associated with clinically overt bleeding.

<div style=\"page-break-after: always\"></div>

- -Platelet count (&lt; 100 × 10 9 /L, ≥ 100 × 10 9 /L and ≤ 200 × 10 9 /L, or &gt; 200 × 10 9 /L).

The SIMPLIFY-1 study is a double-blind study. The blinded randomized treatment period had a duration of 24 weeks. During this period subjects, investigators, study site personnel, and sponsor personnel involved in the conduct of the study were blinded to the identity of the treatment assignments. Only a sponsor-independent statistician designated to provide statistical support for the DMC was unblinded. Double-blind treatment assignments remained blinded until all subjects had completed Week 24 and the study was unblinded for the purpose of the final efficacy analysis.

Treatment assignment was to remain blinded. Breaking the blind was allowed in the following events:

- -In the event of a medical emergency to determine subject emergency medical care.

-For expedited reporting of suspected unexpected serious adverse reactions (SUSARs), the sponsor's Drug Safety and Public Health (DSPH) department was allowed to independently unblind cases.

-In the double-blind phase, subjects with symptomatic spleen growth were discontinued from blinded study drug and unblinded by the investigator.

Unblinding was recorded in the IXRS.

## · Statistical methods

## Study SRA-MMB-301 (MOMENTUM)

The primary analyses of the primary and key secondary efficacy endpoints was planned when each subject has completed the randomized treatment period, crossed over early or dropped out from the randomized treatment.

Analysis Populations:

- ITT population: all randomized subjects. Subjects were evaluated based on randomized treatment. The ITT analysis set was used as the primary analysis set for efficacy analyses.
- Safety population: all subjects in the ITT population who received ≥ 1 dose of study drug.
- Per  protocol  population:  randomized  subjects  who  received  ≥  1  dose  of  study  drug  and  had  no important protocol deviation.

## Multiple comparisons / Multiplicity:

A hierarchical  method  was  used  for  the  analysis  of  both  primary  as  well  as  key  secondary  efficacy endpoints to control the study-wide type I error at 5% (2-sided).

<div style=\"page-break-after: always\"></div>

Table 28: Hierarchical test order of primary and key secondary endpoints

<!-- image -->

| HierarchicalTesting   | HierarchicalTesting                      | HierarchicalTesting   | HierarchicalTesting       |                   |                                                                                              |
|-----------------------|------------------------------------------|-----------------------|---------------------------|-------------------|----------------------------------------------------------------------------------------------|
| Test Order            | Endpoint                                 | Testing               | Criterionfor significance | Testing*          | Criterion for significance                                                                   |
|                       | MFSAFTSS24 response (primary)            | Superiority           | P≤0.05                    |                   |                                                                                              |
| 2                     | TI24 status (primary)                    | Superiority           | P≤0.05                    | Non- inferiority* | lower limit of 95%confidence interval on (MMB TI proportion) -- 0.80*(DAN TI proportion) > 0 |
| 3                     | SRR 24(based on 25% reduction criterion) | Superiority           | P≤0.05                    |                   |                                                                                              |
| 4                     | MFSAF TSS24 change from baseline         | Superiority           | P≤0.05                    |                   |                                                                                              |
| 5                     | SRR 24(based on 35% reduction criterion) | Superiority           | P≤0.05                    |                   |                                                                                              |
| 6                     | Rate of no transfusion at Week 24        | Superiority           | P≤0.05                    |                   |                                                                                              |

*Ifsuperiorityisnot metforTI 24status,thenthelowerlimitof the95%confidence intervalofthenon-inferiority difference will be compared to O.

The primary endpoint TSS response rate at week 24 (TSS24) was planned to be tested for superiority at 2-sided level 0.05 first. If superiority for TSS response rate at week 24 was statistically significant (p ≤ 0.05) in favour of momelotinib, the study was to be considered positive and a superiority test of the second primary endpoint TI rate at week 24 was performed at 2- sided level 0.05. If the result of the superiority test for TI at week 24 was not significant, a noninferiority test was to be performed for TI  rate  at  week  24  at  2-sided  level  0.05  under  pre-specified  percentage  of  control  arm  treatment effect to preserve (80% of the danazol response rate).

If  the  second  primary  efficacy  endpoint  of  TI  rate  at  week  24  demonstrated  at  least  statistically significant noninferiority between treatments, the first key secondary endpoint (SRR at Week 24) was evaluated  for  statistical  significance  (2-sided  p ≤ 0.05).  Each  next  key  secondary  endpoint  was evaluated  for  statistical  significance  only  if  all  preceding  tests  in  the  hierarchy  were  statistically significant in favour of momelotinib.

Analyses of all other secondary and related endpoints were descriptive with nominal p-values.

The  study  meets  both  primary  endpoints  if  superiority  of  TSS  24  is  significant  and  at  least  noninferiority of TI 24 is significant regardless of the significance of TI 24 superiority.

Methods:

- -First primary endpoint MFSAF TSS 24 response ( ≥ 50% reduction in mean TSS over the 28 days before the end of Week 24):
- The  PRO  measure  used  to  determine  the  primary  endpoint  is  the  Myelofibrosis  Symptom Assessment  Form  version  4.0  Diary  (MFSAF  v4.0).  The  MFSAF  v4.0  is  publicly  available, maintained and licensed by the Critical Path (C-PATH) Institute on behalf of the Mayo Clinic for use in clinical trials. The questionnaire includes 7 items to assess important symptoms of MF:  fatigue,  night  sweats,  pruritus,  abdominal  discomfort,  pain  under  ribs  on  left  side  of body, early satiety, and bone pain (see Table below). MFSAF v4.0 measures the severity of

<div style=\"page-break-after: always\"></div>

these  symptoms,  by  scoring  each  item  on  a  11-point  numeric  rating  scale  (NRS)  with  0 corresponding to 'absent' and 10 corresponding to 'worst imaginable'. The item scores were summed for a Total Symptom Score (TSS) that can range from 0 to 70, where a higher score represents  more  severe  disease-related  symptoms.  The  MFSAF  v4.0  was  completed  by patients daily using the SF550 Bluebird ePRO device, distributed by eResearch Technologies (ERT),  during  the  baseline  assessment  period  (7  days),  daily  throughout  the  24-week Randomized  Treatment  Period  and  further  each  4  weeks  (7  days  during  the  Open-label Extended Treatment Period.

- TSS scores obtained after receiving prohibited anti-MF therapy or steroids for the treatment of MF or who exceeded the permitted use of steroids for non-MF conditions, were considered missing. If more than one TSS was reported on a given day, the last TSS on the day was used  for  analysis.  If  no  consecutive  28day  period  with  ≥  20  available  daily  TSS  was available or the last randomized treatment participation day was before day 161, the week 24  TSS  was  considered  missing.  In  case  of  missing  the  week  24  TSS,  subjects  were considered non-responders.
- The superiority  test  of  MFSAF  TSS  response  has  been  performed  using  a  Cochran-MantelHaenzel test ( CMH), stratified by: MFSAF TSS baseline score (≥ 22 versus &lt; 22), baseline palpable spleen length below the LCM (≥ 12 cm versus &lt; 12 cm), and baseline RBC or whole blood  units  transfused  in  the  8-week  period  prior  to  randomization  (0,  1-4,  and  5+),  as recorded for randomization. Primary inference will be based on the asymptotic p-value based on the Wald statistic from this CMH test.
- -Second primary endpoint TI 24 status:
- Subjects  receiving  other  active  MF  therapy  during  the  randomized  treatment  period  and subjects without TI at week 24 (including missing TI data) were classified as 'Not TI' (ie, non-responder) at week 24.
- The superiority test of Week 24 TI status has been performed using a CMH test, stratified by baseline  MFSAF  TSS,  baseline  spleen  length,  and  baseline  RBC  or  whole  blood  units transfused. Primary inference is based on the asymptotic p-value based on the Wald statistic from this CMH test.
- If the result of the superiority test was not statistically significant, a noninferiority test was to be performed. Noninferiority was based on synthesis approach where the treatment effect of the active control is not pre-specified, but the percentage of the active control effect to be preserved is specified. As such, noninferiority was to be declared if 80% of the response rate in  the  DAN  arm  was  preserved  in  the  MMB  arm.  The  80%  of  DAN  response  threshold represents approximately 4 percentage points under the expected DAN response proportion of  21%.  The  expected  response  proportion  for  DAN  of  21%  is  based  on  available  clinical literature for DAN treatment in MF with consideration of the patient population to be enrolled in this study.
- A stratum-adjusted 2-sided 95% CI was calculated for the difference between the proportion of subjects with TI in the MMB arm and 80% of the proportion of subjects with TI in the DAN arm. If the lower bound of the CI was greater than 0, MMB was to be declared noninferior to DAN.
- -First  and  third  key  secondary  endpoints  SRR  24  based  on ≥ 25%  and ≥ 35%  spleen  volume reduction criterion, respectively:
- Scans (MRI or CT if subject unable to have an MRI) were performed at local imaging centers and sent to a central imaging laboratory for assessment of spleen volume. When feasible, the same imaging modality was used throughout the study.
- Scans performed ≤ 10 days after the beginning of open -label treatment could be considered valid for assessment. Subjects with scans performed &gt; 10 days after the beginning of open-

<div style=\"page-break-after: always\"></div>

label treatment, subjects receiving other active MF therapy during the randomized treatment period, subjects with a missing evaluation at baseline or week 24, and subjects with differing spleen scanning modalities at baseline and week 24 were set to non-responder for SRR at week 24.

- The superiority test has been performed using a CMH test, stratified by baseline MFSAF TSS, baseline spleen length, and baseline RBC or whole blood units transfused.
- -Second key secondary endpoint MFSAF TSS 24 change from baseline:
- Changes  from  baseline  in  TSS  at  weeks  4,  8,  12,  16,  20,  and  24  were  analyzed  using  a mixed model for repeated measurements (MMRM), i.e. missing data are handled by directlikelihood  approach  under  the  missing  at  random  (MAR)  assumption,  using  all  available subject-level  derived  scores  (daily  data  summarized  for  each  4-week  period).  The  model included terms for treatment, time point (week) as the categorical variable, and treatmentby-week interaction,  as  well  as  baseline  MFSAF  TSS,  baseline  palpable  spleen  length,  and baseline RBC or whole blood units transfused as fixed effects. Least squares (LS) mean, SE, and 95% CI were presented by treatment at each time point. The p-value for the LS mean difference  between  the  2  treatments  at  week  24  was  calculated  and  used  as  the  primary inference for this endpoint.
- Individual symptom scores, mean TSS, and their change and percent change from baseline were summarized using descriptive statistics by treatment at each evaluation time point. For calculation of mean TSS at Weeks 4, 8, 12, 16, 20, 24, if fewer than 20 daily measurements out of 28 are available, TSS will be set to missing for the time point considered.
- The superiority test has been performed using a CMH test, stratified by baseline MFSAF TSS, baseline spleen length, and baseline RBC or whole blood units transfused.
- -Fourth key secondary endpoint Rate of no transfusion at Week 24:
- The superiority test for change in MFSAF TSS from baseline at week 24 in the momelotinib arm  compared  to  the  danazol  arm,  has  been  performed  using  a  CMH  test,  stratified  by baseline  MFSAF  TSS,  baseline  spleen  length,  and  baseline  RBC  or  whole  blood  units transfused.
- -Overall survival (OS), Leukemia-Free Survival (LFS):
- Subjects without a documented event were handled by censoring (on the last date known to be alive or at the date of last disease assessment for OS and LFS, respectively).
- Summary statistics were provided by treatment with number of events, median and 95% CI, and survival probabilities at specific time points presented.
- The survival functions were estimated by the Kaplan-Meier method. The survival curves of the 2 treatment groups was compared using a log-rank test stratified by baseline MFSAF TSS, baseline spleen length, and baseline RBC or whole blood units transfused as recorded in the IRT was used. A stratified Cox regression model was used to estimate the hazard ratio and its 95% CI.

## Subgroups

The dual primary and all key secondary endpoints were summarized by treatment (including forest plots) in the following subgroups:

- -Transfusion status (TI / TR / TD) at baseline
- -Transfusion status (TI / non-TI) at baseline
- -Sex (male, female)
- -Age (&lt; 65, ≥ 65 years)

<div style=\"page-break-after: always\"></div>

- -Race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White, other)
- -Baseline platelet count (&lt; 50, ≥ 50 but ≤ 150, &gt; 150 but ≤ 300, &gt; 300 × 10 9  /L)
- -Baseline platelet count (≤ 150, &gt; 150 × 10 9  /L)
- -Baseline platelet count (≤ 200, &gt; 200 × 10 9  /L)
- -Baseline MFSAF TSS (&lt; 22, ≥ 22)
- -Baseline median spleen volume (less than the median, greater than or equal to the median)
- -RBC or whole blood units transfused in the 8-week period before randomization (0, 14, ≥ 5 units)
- -Baseline Hgb (&lt; 8, ≥ 8 g/dL)
- -Baseline glomerular filtration rate (3060, ≥ 60 mL/min)
- -Baseline DIPSS prognostic category (low, intermediate-1, intermediate-2, high risk)
- -MF diagnosis (PMF, post-PV MF, post-ET MF)
- -JAK2 mutation status (positive, negative, unknown)
- -Prior JAK inhibitor total daily dose received immediately before enrollment (3 groups: 0; &lt; 20 mg twice a day of RUX or ≤ 200 mg of fedratinib; ≥ 20 mg twice a day of RUX or &gt; 200 mg of fedratinib)
- -Geographic region (Asia, Australasia, Europe, North America)
- -Duration of JAK inhibitor treatment received before randomization (&lt; 12, ≥ 12 weeks)
- -Receiving ongoing JAK inhibitor at screening (yes, no)

Selected other secondary endpoints were analysed in subgroups based on TI or TD as applicable.

## Sensitivity and supportive analyses:

Selected sensitivity analyses and supportive analyses of the primary efficacy endpoints, key secondary endpoints, and other secondary endpoints were to be conducted, in particular the following:

- -Primary endpoint MFSAF TSS 24 response:
- Sensitivity analysis in the population of subjects excluding those with major violations in PRO data.
- Sensitivity analysis by constructing an exact (unstratified) CI for the treatment effect (using Pearson  chi-square  test)  to  evaluate  the  impact  of  stratification  on  results  and  more specifically the impact of empty strata on the power of the test.
- If &gt; 10% of subjects crossed over from DAN to MMB treatment before the end of week 24, sensitivity  analysis  on  data  collected  before  the  treatment  switch  by  carrying  forward  the MFSAF TSS value from latest time point under DAN treatment for subjects who crossed over.
- Sensitivity analysis to assess the robustness of the results to the method of handling missing data  (NRI  approach  in  primary  analysis):  Observed  case  (OC)  approach  (i.e.  without imputation  for  missing  values),  Last  observation  carried  forward  (LOCF)  approach  (i.e. carrying  forward  the  latest  non-missing  MFSAF  TSS  value)  and  Multiple  imputation  (MI) procedure (i.e.  imputing  plausible  values  for  missing  scores;  multiple  imputation  step  was performed  by  treatment  and  strata  used  at  randomization;  logistic  regression  model  was applied to the derived response status, including fixed categorical effects for baseline MFSAF TSS, baseline spleen length, and baseline RBC or whole blood units transfused

<div style=\"page-break-after: always\"></div>

- A re-randomization test, calculating a rerandomization p-value, on the first primary efficacy endpoint of MFSAF TSS response rate at week 24, to assess the impact of the used allocation procedure.
- -Primary endpoint TI 24 status:
- A supplemental analysis of TI status was performed considering subjects who crossover from DAN to MMB before Week 24 TI status evaluation as non-responders ('Not TI') at Week 24.
- -Key secondary endpoint MFSAF TSS 24 change from baseline
- Validity of missing at random assumption: A control-based multiple imputation under a missing not at random assumption was investigated to assess the extent to which the missing at random assumption in the MMRM was robust.
- Validity of the multivariate normality assumption was also investigated.
- -OS:
- An analysis of OS up to week 24.
- Comparison of cumulative incidences of non-COVID-19 and COVID-19 deaths up to week 24 between treatment groups using a competing risk approach. The cumulative incidences of non-COVID-19  and  COVID-19  deaths  over  time  were  estimated  using  a  nonparametric Aalen-Johansen estimator in which subjects with competing events due to the other cause were  not  censored  at  the  time  of  the  event.  The  nonparametric  cumulative  incidence estimates  between  treatment  arms  were  compared  using  Gray's  method.  The  treatment effect  was  estimated  by  the  Fine  and  Gray  model  for  subdistribution  hazards  under  a proportional hazard assumption.

## Missing data

The following approaches were default methods for handling of missing data:

- For response binary efficacy outcomes (primary and key secondary efficacy endpoints): Missing data were handled in the primary analysis using the non-responder imputation (NRI) approach, considering  subjects  with  a  missing  evaluation  as  a  non-responder.  For  sensitivity  purpose, alternative  endpoint-specific  methods  were  considered  (multiple  imputation,  observed  case approach, censoring).
- For time-to-event variables: Missing data were handled by censoring subjects with unobserved events.
- For  continuous  outcomes  collected  at  several  post-baseline  timepoints,  missing  data  will  be handled through direct-likelihood approach by using a mixed model for repeated measurements (MMRM). When the data are examined via MMRM (repeated measures mixed model), the missing data  are  handled  by  ML  (machine  learning)  approach  under  the  missing  at  random  (MAR) assumption. The parameter of interest is estimated such that it maximizes the overall likelihood including both subjects with missing and non-missing outcome.

For sensitivity purpose, alternative endpoint-specific methods were considered (multiple imputation, observed case approach, censoring).

## Study GU-US-352-0101 (SIMPLIFY-1)

Per SAP, a final (primary) analysis was planned when all subjects had reached the Week 24 time point, at  the  end  of  the  double  blind  phase.  Optionally  follow-up  analyses  for  regulatory  requirements  for long-term efficacy, safety, and overall survival follow-up were also prespecified by the SAP. No formal

<div style=\"page-break-after: always\"></div>

interim efficacy analyses were planned. The CSR (report date 30 MAR 2021) is reporting the results of a  follow-up  analysis  with  data  cut-off  date  01  JUL  2019.  The  results  of  the  final  (primary)  analysis (data cut-off date of 12 SEP 2016), referred to by the CRS as the 'Week 24 Interim Analysis', were reported in the Interim Week 24 CSR, dated 16 MAR 2017. An additional follow-up analysis from the open-label treatment phase (Week 48 interim analysis) had been conducted with data cut-off date of 12 SEP 2017 and was reported in the Interim 2 CSR (report date 11 APR 2018).

## Analysis Populations:

- ITT population: all randomized subjects. Subjects were evaluated based on randomized treatment. The  ITT  analysis  set  was  used  as  the  primary  analysis  set  for  efficacy  analyses,  except  for  the secondary  efficacy  endpoint  of  TSS  response  rate  at  Week  24,  for  which  the  analysis  was performed on subjects in the ITT Analysis Set who had a baseline TSS &gt; 0 or who had a baseline TSS = 0 but a nonzero or missing TSS at Week 24.
- Safety population: all subjects in the ITT population who received ≥ 1 dose of study drug.
- Per protocol population: randomized subjects who received ≥ 1 dose of study drug, had a baseline TSS, was diagnosed with MF, had a baseline spleen volume measurement within 30 days prior to randomization, had exposure to study drug ≥ 80% of the planned exposure duration in the double -blind phase, ie, duration of exposure to study drug ≥ 135 days.

## Multiple comparisons / Multiplicity:

A hierarchical method was used for the analysis of primary and secondary efficacy endpoints to control the study-wide type I error at 5% (2-sided). The following testing order was followed:

- 1) Noninferiority of MMB to RUX on splenic response rate at Week 24
- 2) Noninferiority of MMB to RUX on TSS response rate at Week24
- 3) Superiority of MMB to RUX on TI response rate at Week 24
- 4) Superiority of MMB to RUX on TD response rate at Week 24
- 5) Superiority of MMB to RUX on rate of RBC transfusion in the double-blind phase
- 6) Superiority of MMB to RUX on splenic response rate at Week 24
- 7) Superiority of MMB to RUX on TSS response rate at Week 24

If  a  null  hypothesis  was  not  rejected,  formal  sequential  testing  was  stopped,  and  only  nominal significance was cited for the subsequent hypotheses and considered exploratory.

## Methods:

- -Primary endpoint SRR 24 based on ≥ 35% spleen volume reduction criterion:
- Scans (MRI or CT if subject unable to have an MRI) were performed at local imaging centers and sent to a central imaging laboratory for assessment of spleen volume. Only assessments with the same imaging modality as the baseline assessment were used for the analysis.
- Subjects with missing baseline spleen volume or with unavailable Week 24 spleen volume due to early discontinuation from the double-blind phase or a missing scan were considered nonresponders.
- Noninferiority  was  to  be  declared  if  60%  of  the  MMB/RUX  splenic  response  rate  was preserved,  corresponding  to  preservation  of  77%  of  the  RUX/placebo  response  ratio, applying the fixed margin method. Non-inferiority of MMB will be evaluated using the CMH approach  to  adjust  for  the  stratification  factors.  If  the  lower  bound  of  the  2-sided  95% confidence interval for the difference in splenic response rates pa - 0.6pc is greater than 0, then MMB was be declared non-inferior to ruxolitinib.
- If  non-inferiority  is  established,  the  2-sided  95%  CI  for  the  difference  in  splenic  response rate (pa - pc) was obtained to test the superiority of MMB vs. RUX. If the lower bound of this 2-sided 95% CI was greater than 0, MMB was be declared superior to ruxolitinib in splenic

<div style=\"page-break-after: always\"></div>

response rate.

- -Secondary endpoint modified MPN-SAF TSS 24:
- The PRO measure used to determine the primary endpoint is the modified Myeloproliferative Neoplasm Symptom Assessment Form v2.0 (MPN-SAF). The modified MPN-SAF is an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPNs, including  patients  with  MF  (fatigue,  tiredness,  early  satiety,  abdominal  discomfort,  night sweats,  pruritus,  bone  pain,  pain  under  ribs  on  the  left  side,  and  inactivity).  The  TSS  is calculated using seven items from the modified MPN-SAF TSS (inactivity item is excluded as it  is  not  considered  a  symptom  but  rather  an  impact  of  MF).  The  modified  MPN-SAF  v2.0 measures the severity of these symptoms, by scoring each item on a 11-point numeric rating scale (NRS) with 0 corresponding to 'absent' and 10 corresponding to 'worst imaginable'. The item scores were summed for a TSS that can range from 0 to 70. The modified MPN-SAF v2.0  was  completed  by  patients  daily  on  an  electronic  diary  (eDiary)  device  during  the baseline assessment period (7 days) and throughout the 24-week Randomized Treatment. No PRO data were collected after Week 24.
- The primary analysis was based on subjects in the ITT Analysis Set who had a baseline TSS &gt; 0 or who had a baseline TSS = 0 but a nonzero or missing TSS at Week 24. The daily TSS was  considered  missing  if  any  individual  scores  were  missing.  If  multiple  records  were available on the same day, the last record was used. If no consecutive 28day period with ≥ 20 available daily TSS was available or the last randomized treatment participation day was before day 162, the week 24 TSS was considered missing. Subjects with missing Week 24 TSS but non-missing baseline TSS were considered non-responders.
- Non-inferiority was to be declared if 67% of the response rate in the RUX arm was preserved in the MMB arm. The CMH approach was to be to adjust for the stratification factors. If the lower bound of the 2-sided 95% confidence interval for the difference in TSS pa - 0.67pc was greater than 0, then MMB was be declared non-inferior to RUX.
- If non-inferiority was established, the 2-sided 95% CI for the difference in TSS (pa - pc) was obtained to test the superiority of MMB vs. RUX. If the lower bound of this 2-sided 95% CI is greater than 0, MMB was be declared superior to ruxolitinib in TSS.
- -Secondary endpoints RBC TI 24 and TD 24:
- Superiority of MMB compared to RUX was tested for these endpoints using a CMH testing approach adjusted for stratification factors.
- For the primary analysis of RBC TI response status at Week 24, subjects with a last doubleblind phase participation date prior to Day 162 were considered TD (not TI).
- Cases associated with clinically overt bleeding were excluded.
- -Secondary endpoint Rate of TBV transfusion in the DB phase:
- Calculated by dividing the total number of RBC units transfused in the double-blind phase by duration of the double-blind phase (in months)
- Transfusions due to clinically overt bleeding will be excluded from this analysis.
- Analysis used a negative binomial regression method with an offset parameter to account for follow-up time. To account for multiple units within a transfusion, identical recurrence times were perturbed so that they appeared non-identical.

## Subgroups

The primary and secondary endpoints were summarized by treatment (including forest plots) in the following subgroups: age (&lt; 65 years or ≥ 65 years), gender (male or female), race (white or all other races), baseline spleen volume (&lt; median or ≥ median), baseline TSS (quartiles: &lt; Q1, ≥ Q1

<div style=\"page-break-after: always\"></div>

and &lt; median, ≥ median and &lt; Q3, ≥ Q3), baseline transfusion dependence (defined as requiring at least 4 units of transfusion or a hemoglobin &lt; 8 g/dL in the 8 weeks prior to randomization), baseline hemoglobin (&lt; 8 g/dL or ≥ 8 g/dL), baseline platelet count (&lt; 100, ≥100 and ≤ 200, &gt; 200 [x 10 9 /L]), IPSS prognostic category (intermediate or high-risk), MF disease status (PMF, post-PV MF, or post-ET MF), JAK2V617F mutation (positive or negative, based on medical history), Region (Western Europe, Eastern Europe, or Asia)

## Sensitivity and supportive analyses:

Selected sensitivity analyses and supportive analyses of the primary efficacy endpoint and key secondary endpoints were to be conducted, in particular the following:

- -Primary endpoint SRR 24:
- 1. Analysis based on the Per Protocol Analysis Set.
- 2. Unstratified exact and CMH methods for both noninferiority and superiority were performed on the ITT Analysis Set without adjusting for the stratification factor.

· 3. Last observation carried forward (LOCF): For subjects with missing spleen volume at Week 24, the last prior available spleen volume was used to impute missing spleen volume at Week 24. A missing spleen volume due to splenectomy or early discontinuation of study drug in the doubleblind phase due to symptomatic spleen growth, disease progression, or death were not carried forward and were treated as nonresponders.

· 4. The noninferiority analysis of MMB versus RUX was also performed using the fixed-margin approach  (or  95%  CI  lower  limit  method)  with  a  margin  of  16%  in  MMB-RUX  response  rate difference. Based on the historical data (Verstovsek, 2012), the lower bound of the 95% CI on the difference in response rates was ~32%. Given the range of response rates, an NI margin of 16% would correspond to a ~50% preservation of the treatment effect of the ruxolitinib control (compared to placebo).

- -Secondary endpoint modified MPN-SAF TSS 24:
- In  addition  to  the  same  4  sensitivity  analyses  as  performed  for  SRR  24,  also  the  following sensitivity analyses were performed:

· 5.  ITT  Analysis  Set  with  a  nonmissing  baseline  TSS  &gt;  0  or  with  a  baseline  TSS  =  0  but  a nonzero or missing TSS at Week 24, applying relaxed rule of available daily TSS in the analysis window (baseline TSS: average of ≥ 1 available daily TSS in the 7 -day baseline period; baseline TSS was missing if no daily TSS was available in the 7-day baseline period)

· 6. Week 24 TSS: average of ≥ 4 available daily TSS in the consecutive 28 -day period. If no consecutive  28day  period  with  ≥  4  available  daily  TSS  was  available  or  the  last  randomized treatment participation day was before day 162, the week 24 TSS was considered missing.

- -Secondary endpoints RBC TI 24 and TD 24:

Similar  sensitivity  analyses  as  the  first  2  sensitivity  analyses  for  the  primary  endpoint  SRR  24 were also  performed  for  RBC  TI24  and  TD  24  consisted  of  all  subjects  who  were  randomized, regardless  of  study  drug,  with  study  treatment  assignment  designated  according  to  initial randomization.

<div style=\"page-break-after: always\"></div>

## Missing data

All available data were included in data listings and tabulations. Models for repeated measures will be valid under the 'missingness at random' (MAR) assumption, in case a general linear model (GLM) is used.  In  case  a  GEE  is  used,  the  model  will  be  valid  under  'missingness  completely  at  random' (MCAR). If confidence intervals are to be calculated for proportions, missing data will be considered as failure,  corresponding  with  a  'Non-responder  imputation'  (NRI)  approach.  For  sensitivity  purpose, alternative endpoint-specific methods were considered (LOCF).

## Results

## · Participant flow

## Study SRA-MMB-301 (MOMENTUM)

In MOMENTUM  study, data cutoff date of primary analysis at Week 24 was 03 DEC 2021. Updated data of Week 48 Analysis were provided with data cutoff date of 17 Jan 2023.

195 subjects were randomized 2:1, 130 subjects to the MMB group and 65 subjects to the DAN group. 94 of the 130 subjects (72.3%) in the MMB group and 38 of the 65 subjects (58.5%) in the DAN group completed treatment in the blinded RT phase. In the OL phase, 93 of the 130 subjects (71.5%) MMBtreated subjects continued to receive MMB (MMB to MMB) and 41 of the 65 subjects (63.1%) DANtreated subjects crossed over to MMB (DAN to MMB). No subject who completed randomized treatment with DAN chose to continue open-label treatment with DAN. Overall, most subjects in the OL phase completed Week 48 (Week 24 in OL Phase) visit (67 of 93 MMB to MMB [72.0%] subjects and 32 of 41 DAN to MMB [78.0%] subjects).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: Table 14.1.1.2

- [1]Twelve subjects who discontinued study drug during the study planned to enroll in XAP for long-term survival follow-up only: 9 MMB (5 prematurely disco1 4 discontinued OL treatment) and3DAN (1RT,2 OL treatment)(Listing 16.2.1.2).
- [2] Onesubjecthadconfirmedsplenicprogression attheendoftheRTperiod.
- [3] Onesubjecthadconfirmed splenicprogression attheend oftheRTperiod and entered theOLperiod.

DAN, danazol; MMB,momelotinib; OL,open-label; prog,progression;RT,randomized treatment; transform., transformation;XAP,MMB extension study SRA-1

Figure 10: Subject disposition flow chart (MOMENTUM)

## Study GU-US-352-0101 (SIMPLIFY-1)

In SIMPLIFY-1  study, as of data cutoff date of 01 JUL 2019 , 432 subjects were 1:1 randomized, from which 215 subjects were assigned to the MMB group and 217 subjects to the RUX group. As 1 subject in each treatment group was randomized but not treated, a total of 214 subjects in the MMB group and 216 subjects in the RUX group received treatment. Most subjects in the MMB arm who completed randomized treatment (171/175 subjects, 79.5%) started open-label MMB treatment. In the RUX arm, most subjects who completed randomized treatment period (197/201 subjects, 90.8%) crossed-over to MMB. All but 1 subject (who crossed over from RUX arm) in the continuing MMB open-label treatment prematurely discontinued study drug during the open-label phase.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:Table15.8.1.3

Figure 11: Subject disposition flow chart (SIMPLIFY-1)

## · Recruitment

## Study SRA-MMB-301 (MOMENTUM)

The MOMENTUM study was conducted at 107 active study sites (78 Europe, 14 North America, 10 Asia, 5 Australasia). The number of subjects randomized at each study site ranged from 1 to 7.

Table 29: Key dates defining recruitment, unblinding, analyses ad follow-up (MOMENTUM)

| Event                                                                | Date        |
|----------------------------------------------------------------------|-------------|
| First subject screened                                               | 07 Feb 2020 |
| First subject dosed                                                  | 24 Apr 2020 |
| Lastsubject randomized                                               | 17 Jum 2021 |
| Last subject last visit for double-blind randomized treatment period | 03 Dec 2021 |
| Data cutoff for ongoing data for clinical study report               | 03 Dec 2021 |
| Databasc lock for analysis for this report                           | 13Jan2022   |
| Treatment unblinding                                                 | 13Jan2022   |

## Study GU-US-352-0101 (SIMPLIFY-1)

The double-blind phase of the SIMPLIFY-1 study was conducted at 131 active study sites (82 Europe, 16  North  America,  22  Asia,  11  Australasia).  No  individual  study  site  enrolled  &gt;  3.0%  of  the  total subjects.

<div style=\"page-break-after: always\"></div>

Table 30: Key dates defining recruitment, unblinding, analyses ad follow-up (SIMPLIFY-1)

| Event                                                   | Date             |
|---------------------------------------------------------|------------------|
| FirstSubjectScreened                                    | 06December2013   |
| FirstSubjectEnrolled(orRandomized)                      | 17January2014    |
| LastSubjectEnrolled(orRandomized)                       | 28March2016      |
| LastDataCollectionforthePrimaryEndpoint (LastWeek24MRl) | 08September2016  |
| LastSubjectLastVisitforDouble-BlindPhase                | 12September2016  |
| DataCutoffforInterimWeek24InterimAnalysis               | 12 September2016 |
| TreatmentUnblinding                                     | 21October2016    |
| DataCutoffforInterimWeek48InterimAnalysis               | 12September2017  |
| LastSubjectLastObservationforFinalReport                | 02May2019        |
| DatabaseFinalizationforFinalReport                      | 01July2019       |

## · Conduct of the studies

## Study SRA-MMB-301 (MOMENTUM)

## Changes in the planned analysis

The  statistical  analysis  plan  was  finalized  on  30  DEC  2021  (V2.0),  which  is  before  the  date  of treatment unblinding for statistical analyses (13 JAN 2022). No changes to SAP were provided. The clinical SAP was finalized after the latest protocol Amendment 2.0 (18 DEC 2018).

## Protocol amendments

The original protocol v1.0 (dated 27 Jun 2019) was globally amended twice.

In addition, 1 minor administrative amendment (Amendment v1.2: 28 Aug 2019; addition of a sponsor approval page) and 12 country-specific amendments were required. Subjects were first enrolled in the study under protocol amendment v1.2. The main changes and additions are listed below:

## Protocol Amendment v1.1 (Global) - 16 Aug 2019:

- Clarified criteria for dose reduction due to thrombocytopenia, neutropenia, and nonhematologic or other toxicities; and subsequent dose re-escalation.
- Modified thresholds for platelet count recovery required to resume treatment based on baseline value.
- Updated procedures for managing transition from randomized treatment to open-label treatment so treatment assignment would only be unblinded when required to determine eligibility for openlabel treatment with MMB or DAN.

## Protocol Amendment v2.0 (Global) - 18 Dec 2020:

- Removed interim analysis for sample size reassessment from the study design.
- Modified the planned statistical analysis: moved the MMRM analysis of the MFSAF TSS secondary endpoint to the fourth position in the overall statistical testing hierarchy; revised description of the hierarchal statistical testing of secondary endpoints, updated descriptions of the secondary endpoints.
- Changed timing of first dose after randomization, JAK inhibitor nontreatment period, exclusion of active anti-MF medication, and baseline spleen volume assessment to allow flexibility for scheduling randomization and day 1.
- Inclusion criteria were modified:

<div style=\"page-break-after: always\"></div>

- -Criterion 3: an MFSAF TSS of ≥ 10 units was required during screening prior to baseline day 1
- -Criteria 4a and 4c: clarified the definition of anemic.
- -Criterion 5b: added that subjects receiving a low dose of a JAK inhibitor could have a reduced taper period, or no taper, with sponsor approval.
- -Criterion 9: platelet count must be met without requirement for platelet transfusion.
- Exclusion criteria were modified:
- -Criterion 1b: clarified that approved JAK inhibitors were prohibited and reduced the study period and window for use.
- -Criterion 1c: reduced the study period and window for use of anti-MF therapy.
- -Criterion 1e: investigational JAK inhibitors were prohibited within 4 weeks prior to randomization.
- -Criterion 7: added thalassemia as a cause of clinically significant anemia.
- Updated criteria for adjusting or stopping doses to provide guidance that investigator clinical discretion should be used and that in the event of grade 3 or 4 toxicity, relevant laboratory tests should be closely monitored per investigator clinical discretion.
- Clarified the anticipated risks of DAN to emphasize that the provided safety information references the approved indications for DAN and should be interpreted by the investigator for guidance when assessing subjects in this study.
- Updated criteria for crossing over to open-label MMB to add sponsor approval for short-term use of restricted anti-MF medication to treat severe splenic progression, revise criteria for splenic progression, and add sponsor approval for spleen volume measurements read locally.
- Updated restricted treatment use for consistency with exclusion criterion 1 and to clearly define the beginning and end of the study period.
- Added that alternative methods, including paper forms, could be used to record PRO responses in exceptional circumstances, with sponsor approval.
- Updated adverse event and serious adverse event reporting criteria and procedures.
- Clarified requirements for hepatitis testing.
- Added that local laboratory assessments could be used to determine eligibility, with sponsor approval, if central laboratory assessments were not available prior to day 1.
- Clarified the window (± 7 days) for MFSAF assessments and PRO responses during the open-label extended treatment period.
- Added that subjects requiring antihypertensive medication should be closely monitored on the day of the first study drug dose and that medication could be administered if clinically necessary.
- Added that investigators were to advise subjects on the conservation of gametes prior to receiving study drug due to the possibility of infertility.
- Added a protocol addendum for guidance on modified study procedures that could be followed during the COVID-19 pandemic.

## Protocol deviations

Important (major) protocol deviations were defined by the applicant as deviations from the protocol that  could  significantly  affect  the  rights,  safety,  or  well-being  of  subjects  or  the  completeness, accuracy, and reliability of the study data. These reported for 5 subjects (2.6%) overall in the study, including 1 subject (0.8%) in the MMB group and 4 subjects (6.2%) in the DAN group. One deviation in  each  group  involved  a  subject  receiving  a  restricted  medication  (ESA  in  the  MMB  group  and rosuvastatin  in  the  DAN  group).  Two  deviations  in  the  DAN  group  involved  accidental  unblinding (described  next),  and  1  involved  informed  consent  (spouse  signed  for  subject).  One  accidental unblinding involved the investigator entering the treatment assignment of 1 subject who was unblinded

<div style=\"page-break-after: always\"></div>

for safety reasons into the electronic data capture system, thereby unblinding a sponsor staff member. The  other  accidental  unblinding  involved  a  clinical  research  associate  forwarding  an  email  with unblinding  information  for  1  subject  to  the  sponsor  and  contract  research  organization  teams.  Both unblinding events occurred after the subjects discontinued treatment. Corrective actions were taken in both cases.

Additional violations in PRO data collection:

The  vendor  supplying  the  ePRO  device  and  software  experienced  a  cyberattack  on  20  Sep  2020, causing  the  vendor  to  proactively  disconnect  servers  from  the  internet.  The  resulting  12-day interruption of new screening of subjects led to a notification of the temporary recruitment stop and submission of the resumption of study screening where required by local regulations. All data entered in  ePRO  devices  by  subjects  during  this  period  were  successfully  uploaded  when  the  servers  were reconnected to the internet. A small amount of data were lost due to errors with ePRO devices during the outage. Study site activities prevented or limited by the outage included data entry, triggering of visit-based questionnaires on the devices by sites, viewing subject data, and monitoring compliance. Thirty-three minor protocol deviations were associated with this event. In addition, at one study site in South  Korea,  more  than  1  MFSAF  questionnaire  a  day  was  completed  for  some  subjects.  An investigation of these violations in PRO data collection showed that the events were isolated to 4 of 5 subjects enrolled at this single study site.

## Study GU-US-352-0101 (SIMPLIFY-1)

## Protocol amendments

The original protocol (dated 26 Jun 2013) was amended 3 times during the study. In addition, 1 minor amendment (Amendment 1.1: 12 Feb2014) and 3 country-specific amendments (2 for Japan only and 1 for South Korea only) were required. Subjects were first enrolled in the study under the original study protocol. The main changes and additions are listed below:

## Protocol Amendment 1 (Global) - 13 Dec 2013:

- Updated study objectives per regulatory agency guidance
- Updated inclusion criteria based on newly available nonclinical data
- Updated exclusion criteria based on regulatory agency guidance, newly available nonclinical data, and requirements for radiology review
- Clarified follow-up procedures and duration
- Clarified that the PK profile of the MMB metabolites GS-642112 and GS 644603 was to be evaluated
- Updated study assessments based on evolving data for MF and JAK inhibitors and requirements for radiology review
- Updated planned statistical analysis of secondary endpoints per regulatory agency guidance
- Updated safety endpoints to include assessment of OS per regulatory agency guidance
- Updated clinical and nonclinical background information, and the study rationale based on newly available nonclinical data, as well as newly evolving clinical data for MF and JAK inhibitors
- Updated relative bioavailability data for MMB tablets versus capsules based on the most recent Gilead Sciences (Gilead) internal data
- Updated MMB administration based on newly available internal data
- Clarified requirements for MMB dose increases during the open-label phase
- Clarified procedure and requirements for restarting study drug after dose interruption or tapering
- Updated requirements for increasing study drug dose in the event of insufficient efficacy

<div style=\"page-break-after: always\"></div>

- Removed requirement that ECG may only be collected after subject has been supine for at least 3 minutes
- Updated table of analytes to be measured based on newly evolving data for MF and JAK inhibitors
- Updated IWG-MRT/ELN assessments to reflect June 2013 guidelines
- Updated screening requirement to not require bone marrow aspirate/biopsy if performed within 90 days prior to the first dose of study drug
- Added certain subgroup analyses from the SAP
- Updated exploratory endpoints based on newly evolving data for MF and JAK inhibitors

## Amendment 1.1 (Global): 12 February 2014:

- Updated text to address the Grounds for Non-acceptance (GNA) from the European Voluntary Harmonization Procedure (VHP)
- Updated exclusion criteria to include the use of dual inhibitors of CYP3A4 and CYP2C9
- Updated dose increase instructions for insufficient efficacy of study drug
- Added information regarding metabolism of MMB by CYP3A4

## Amendment 2: 18 July 2014

- Updated text to address the GNA from the European VHP. These updates were made in Amendment 1.1 and were reconciled into Amendment 2.
- Added ophthalmic examinations to assess for cataracts and visual acuity based on MMB Investigator's Brochure, version 7
- Clarified methods for managing missing data in the primary analysis
- Updated language regarding concomitant medications based on newly available drug-drug interaction data
- Clarified maximum duration of study
- Updated MMB clinical trials list as of June 2014
- Clarified duration of blinding of treatment assignments per Italian Central Ethics Committee request
- Clarified conditions for permanent discontinuation, dose interruption, and restarting of study drug
- Updated table of analytes and assessment schedule to reflect deletion of C-reactive protein (CRP), deletion of thiocyanate, and addition of ferritin
- Updated exploratory endpoints as follows:
- -Removed progression-free survival
- -Removed response rates for ANC and platelets, as well as rate of new onset of anemia
- Added rate of new RBC TD by Week 24 among those who were not TD at baseline
- Clarified the primary analysis in terms of missing data

## Amendment 3: 20 July 2017

- Protocol study visits extended to allow continued treatment with MMB through Week 216.
- To align with Investigator's Brochure Edition 11, dated 14 Jul 2017.
- Updated MMB formulation to allow for contingency to use plain-faced or debossed, round or triangle-shaped tablet presentation, should the clinical drug supply be depleted or expire prior to the end of the study.

<div style=\"page-break-after: always\"></div>

- Updated to reflect the actual exploratory endpoints analyzed and clarify definitions.

Amendment 3.1 (South Korea only): 23 October 2017

- To correct footnote sequence error in the Double-Blind and Open- Label Study Procedures Tables.

## Protocol deviations

The occurrence of important protocol deviations during the double-blind phase was higher in the MMB group (20.5%, 44 subjects) than in the RUX group (14.7%, 32 subjects). The majority of important protocol  deviations  during  the  combined  screening  and  double-blind  treatment  phase  were  GCP violations related to the consenting process (the majority due to delayed reconsenting; 9.8% in the MMB group and 5.5% in the RUX group) and missing data related to key endpoints (5.6% in the MMB group and 5.1% in the RUX group).

The occurrence of important protocol deviations in the open-label phase was comparable for the group of  subjects  who  received  MMB  during  the  double-blind  phase  and  remained  on  MMB  (8.8%,  15 subjects) and those who were randomized to RUX during the double-blind phase and switched to MMB (8.1%, 16 subjects). Similar to the double-blind phase, the majority of important protocol deviations during the open-label phase were GCP violations related to the consenting process (the majority due to delayed  reconsenting;  5.8%  in  the  MMB  to  MMB  group  and  5.6%  in  the  RUX  to  MMB  group)  and missing data related to key endpoints (1.8% and 2.5%, respectively). For the overall exposed to MMB group, 18.9% of subjects had at least 1 important protocol violation, primarily GCP violations (10.9%) and missing data related to key endpoints (6.1%).

Table 31: Important protocol deviations (Screening and double-blind phase, ITT population, SIMPLIFY-1)

| ProtocolDevlation, n(96)                                        | MMB (N-215)   | RUX (N=217)   | Total (N= 432)   |
|-----------------------------------------------------------------|---------------|---------------|------------------|
| Numberof Subjects with at Lest 1ImporantProtocolDeviation       | 44 (20.596)   | 32 (14.796)   | 76(17.696)       |
| GCP Vioation                                                    | 21(9.896)     | 12 (5.596)    | 33 (7.69%6)      |
| MissingData Rehtedto Key Endpoint                               | 12 (5.69%6)   | 11(5.196)     | 23(5.3%6)        |
| Eligibility Violation                                           | 6(2.896)      | 5(2.3%)       | 11(2.5%)         |
| Received Excluded Concomilanl MedicationDuringthe TrcamentPhase | 3 (1.49%)     | 4(1.8%)       | 7(1.69%6)        |
| Wrong Treatment'Ineorrect Dose                                  | 2 (0.9%6)     | 4(1.89%6)     | 6(1.496)         |
| Other Trea tment Compliance                                     | 3 (1.49%6)    | 0             | 3 (0.796)        |

GCP-Good ClinienlPraclice:MMBmomclotinib;RUXruxoliinib

A description ofthe devintions is prescnted in Listing I 6.2. 2.2.

Souruc: Table 15.8.2.3

<div style=\"page-break-after: always\"></div>

Table 32: Important protocol deviations (Open-label phase and overall exposed to MMB, ITT population, SIMPLIFY-1)

<!-- image -->

|                                                                     | Open-label Phase(Weck 24 Onward)   | Open-label Phase(Weck 24 Onward)   | Open-label Phase(Weck 24 Onward)   | OverallExposed to MMB   | OverallExposed to MMB   |
|---------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|-------------------------|-------------------------|
| Protocol Devlatlon Category                                         | Condnulng (MMB to MMB) (N-171)     | Switeh (RUX to MMB) (N-197)        | Total (N-368)                      | MMBIn DB phase (N-215)  | Total (N-412)           |
| Subjects withatleast I important protocoldeviation                  | 15(8.896)                          | 16(8.196)                          | 31(8.4%6)                          | 62 (28.896)             | 78 (18.9%6)             |
| Protocoldevialioncodedtemm                                          |                                    |                                    |                                    |                         |                         |
| GCPviolation                                                        | 10(5.896)                          | 11(5.6%6)                          | 21(5.796)                          | 34(15.896)              | 45 (10.996)             |
| Missingdatareatedto key endpoints                                   | 3(1.896)                           | 5(2.5%)                            | 8(2.296)                           | 20 (9.396)              | 25 (6.1%6)              |
| Eligibility viohtion                                                | 0                                  | 0                                  | 0                                  | 6(2.896)                | (9651)9                 |
| Received excluded concomitant medication duringthe trealment period | 1(0.696)                           | 0                                  | 1(0.396)                           | 4(1.9%)                 | 4(1.096)                |
| Wrongtreatment/incorect dose                                        | 1(0.6%)                            | 1(0.5%6)                           | 2(0.5%)                            | 3 (1.4%)                | 4(1.096)                |
| Othertreatment compliance                                           | 0                                  | 0                                  | 0                                  | 3 (1.4%)                | 3 (0.7%6)               |

DB=double-blind:GCP-GoodClinicnlPrclice:MMB=momclotinib:RuX-ruxolitinib

A descriplion ofihedeviilions is presenied in Listing I6.2.2.2.

Source: Tabk 15.8.2.4

## Changes in the planned analysis

The statistical analysis plan was amended several times with the last amendment 2.1 dating from 19 SEP 2014, which is before the date of treatment unblinding for statistical analyses (21 OCT 2016). The clinical  SAP  was  finalized  prior  to  protocol  Amendment  3  (20  JUL  2017);  however,  changes  in Amendment  3  described  above  did  not  affect  the  planned  statistical  analyses  and  thereby  did  not warrant an additional update of the clinical SAP. The following changes were made in the SAP prior to the Week 24 unblinded analysis:

- For transfusion related secondary endpoints, the sequential testing order was changed to test the rate  of  RBC  transfusion  in  the  DB  phase  after  the  testing  of  TI  24  response  rate  and  TD  24 response rate, based on experiences in the SIMPLIFY-2 study (TI 24 and TD 24 were expected to have larger power). Testing of superiority of MMB to RUX on SRR 24 and TSS 24 was added to the sequential testing procedure.
- Some exploratory endpoints, including PFS and duration of TSS were removed.
- Definition of exploratory endpoint 'Time to TI' was changed to be defined on subjects who are not TI at baseline and achieved TI at any postbaseline in the double-blind phase.
- Definition of exploratory endpoint 'duration of TI' was changed to the interval from the first onset date of TI response to the earliest onset date of loss of TI response among those subjects who are not TI at baseline but achieved TI at any post baseline in the double-blind phase.
- For secondary endpoints of rate of transfusion, TD and TI, the transfusion and Hgb level used for derivation will exclude cases associated with clinically overt bleeding.

## Post-hoc analyses

Supportive  exploratory  post  hoc  analyses  aimed  to  better  understand  the  magnitude  of  MMB's symptomatic  benefit  and  the  mechanistically-based  anaemia  benefit.  A  separate  post-hoc  statistical analysis plan was written (11 MAR 2021). The following post-hoc exploratory analyses were conducted:

<div style=\"page-break-after: always\"></div>

- Post-hoc analyses related to splenic response: Duration of splenic response
- Post-hoc analyses related to symptom response:
- -Assessment  of  non-inferiority  using  an  alternative  non-inferiority  margin,  applying  the  2-sided 95%-95% fixed-margin method to the COMFORT-I result. Based on TSS response rates at week 24 in COMFORT-I of 45.9% in the RUX group and 5.3% in the placebo group, the modified Wald response ratio of RUX/placebo was estimated as 8.2759 (95% CI: 4.2096, 16.2702). Under the 95%-95% approach, the entire treatment effect of RUX over placebo was estimated by the lower bound of the 95% CI of 4.2096. Applying the requirement of 50% of the RUX active treatment effect over placebo to be retained in the MMB group of SIMPLIFY-1 in log scale, the noninferiority margin for the MMB/RUX ratio was derived as 0.4874.
- -An  assessment  of  change  and  percent  change  in  TSS  compared  to  baseline  as  described  for symptomatic subjects (subjects with baseline TSS of at least 10)
- -An  assessment  of  the  difference  in  the  adjusted  treatment  group  means  using  a  longitudinal mixed-effects model (Mixed-effect Model Repeated Measure [MMRM]) to estimate the treatment effect using TSS as a continuous variable
- -An examination of the individual item scores at baseline and their changes over time
- -An evaluation of combined symptom score 6 (CSS6), TSS without the inclusion of the fatigue
- Post-hoc analyses related to anemic response: transfusion independence by Week 48; duration of TI  at  any  time;  proportion  of  subjects  receiving  an  RBC  transfusion;  zero-inflated  negative binomial (ZINB) model for total RBC transfusion rate; recurrent event model for RBC transfusion; time to first, third, and fifth units of RBC transfusions; Hbg increases at Week 24 in ITT and TI subgroups.

Post hoc subgroup analyses: baseline TI, nonTI, TSS (≥ 10,  Hbg (&lt; 10 g/dL, &lt; 12 g/dL and ≥ 12 g/dL), TSS ≥ 10 AND Hbg &lt; 10 g/dL, platelet count (≤150, &gt; 150 and ≤ 300, &gt; 300 [x 10 9 /L]).

## · Baseline data

## Table 33:  Clinically Important Demographic and Baseline Characteristics by Study (ITT)

| Characteristic, Mean (Min, Max or %)         | MOMENTUM (N = 195)      | SIMPLIFY-2 (N = 156)   | SIMPLIFY-1 (N = 432)   |
|----------------------------------------------|-------------------------|------------------------|------------------------|
| Age, years, Mean (SD)                        | 70.38 (7.86)            | 67.4 (8.00)            | 64.7 (10.62)           |
| Male, n (%)                                  | 123 (63.1)              | 93 (59.6)              | 244 (56.5)             |
| PMF/Post-PV MF/Post-ET MF (%)                | 63.6/19.5/16.9          | 60.3/19.2/20.5         | 56.5/22.7/20.8         |
| Int-1/Int-2/High risk (%)                    | 5.1/57.4/35.4           | 25.0/57.7/17.3         | 20.6/33.1/46.3         |
| Prior JAK inhibitor exposure in weeks, range | 133.96 (4, 617.6)       | 66.48 (3.7, 257.6)     | 0                      |
| Mean total symptom score, range              | 27.21 (4.9, 67.7)       | 19.2 (0, 57)           | 18.7 (0, 56)           |
| Transfusion independent, n (%)               | 27 (13.8)               | 51 (32.7)              | 299 (69.2)             |
| Transfusion dependent, n (%)                 | 97 (49.7)               | 85 (54.5)              | 105 (24.3)             |
| Transfusion requiring, n (%)                 | 71 (36.4)               | 20 (12.8)              | 28 (6.5)               |
| Mean Hgb g/dL, range                         | 7.99 (3.8, 10.7)        | 9.4 (6, 16)            | 10.6 (6, 19)           |
| Mean platelet count × 10 9 /L, range         | 144.68 (24, 733)        | 155.9 (9, 777)         | 301.2 (50, 2865)       |
| Hgb < 10 g/dL, n (%)                         | 195 (100)               | 105 (67.3)             | 180 (41.7)             |
| Platelet count ≤ 200 × 10 9 /L, n (%)        | 150 (76.9)              | 118 (75.6)             | 170 (39.4)             |
| Mean spleen volume cm 3 , range              | 2341.13 (609.5, 9717.2) | 2457.2 (241, 7433)     | 2185.1 (206, 9022)     |

Source:  CSR SRA MMB 301 Table 14.1.3.1, Table 14.1.3.2, Table 14.1.4.4, Table 14.2.1.2, Table 14.2.1.5; CSR GS US 352 0101 Table 15.8.3.1.1, Table 15.8.3.2.1, Table 15.8.3.5; CSR GS US 352 1214 Table 15.8.3.1.1, Table

<div style=\"page-break-after: always\"></div>

15.8.3.2.1, Table 15.8.3.5; Table 2.7.3.3.1 ET, essential thrombocythemia; Hgb, hemoglobin; Int, intermediate; JAK, Janus kinase; Min, Max, minimum, maximum; PMF, primary myelofibrosis; PV, polycythemia vera.

Table 34:  Clinically Important Demographic and Baseline Characteristics in overall ITT population (MOMENTUM) and the post-hoc defined anaemic subpopulations with Hgb &lt; 10 g/dL (SIMPLIFY-2/SIMPLIFY-1)

| Characteristic, Mean (Min, Max or %)         | MOMENTUM (N = 195)      | SIMPLIFY-2 (N = 105)   | SIMPLIFY-1 (N = 180)   |
|----------------------------------------------|-------------------------|------------------------|------------------------|
| Age, years, Mean (SD)                        | 70.38 (7.86)            | 68.7 (7.26)            | 67.1 (9.11)            |
| Male, n (%)                                  | 123 (63.1)              | 70 (66.7)              | 106 (58.9)             |
| PMF/Post-PV MF/Post-ET MF (%)                | 63.6/19.5/16.9          | 64.8/15.2/20.0         | 62.8/12.8/24.4         |
| Int-1/Int-2/High risk (%)                    | 5.1/57.4/35.4           | 11.4/64.8/23.8         | 3.3/25.6/71.1          |
| Prior JAK inhibitor exposure in weeks, range | 133.96 (4, 617.6)       | 63.74 (3.7, 257.6)     | 0                      |
| Mean total symptom score, range              | 27.21 (4.9, 67.7)       | 18.2 (0, 56)           | 18.5 (0, 50)           |
| Transfusion independent, n (%)               | 27 (13.8)               | 14 (13.3)              | 66 (36.7)              |
| Transfusion dependent, n (%)                 | 97 (49.7)               | 77 (73.3)              | 92 (51.1)              |
| Transfusion requiring, n (%)                 | 71 (36.4)               | 14 (13.3)              | 22 (12.2)              |
| Mean Hgb g/dL, range                         | 7.99 (3.8, 10.7)        | 8.4 (6, 10)            | 8.6 (6, 10)            |
| Mean platelet count × 10 9 /L, range         | 144.68 (24, 733)        | 162.6 (28, 777)        | 262.2 (54, 2865)       |
| Hgb < 10 g/dL, n (%)                         | 195 (100)               | 105 (100)              | 180 (100)              |
| Platelet count ≤ 200 × 10 9 /L, n (%)        | 150 (76.9)              | 79 (75.2)              | 96 (53.3)              |
| Mean spleen volume cm 3 , range              | 2341.13 (609.5, 9717.2) | 2504.4 (392, 6740)     | 2140.1 (352, 9022)     |

Source:  CSR SRA MMB 301 Table 14.1.3.1, Table 14.1.3.2, Table 14.1.4.4, Table 14.2.1.2, Table 14.2.1.5; Appendix 2 GS US 352 0101 Table 15.8.3.1.1a, Table 15.8.3.2.1a, Table 15.8.3.5a; Appendix 2 GS US 352 1214 Table 15.8.3.1.1a, Table 15.8.3.2.1a, Table 15.8.3.5a, Table 2.7.3.3.1a

<div style=\"page-break-after: always\"></div>

Table  35:  Key  demographic  and  baseline  characteristics  in  MOMENTUM,  SIMPLIFY-1  and SIMPLIFY-2 (ITT and post-hoc defined Hgb &lt; 10 g/dL subgroup)

|                                    | MOMENTUM    | MOMENTUM   | SIMPLIFY-1            | SIMPLIFY-1            | SIMPLIFY-1     | SIMPLIFY-1     | SIMPLIFY-2            | SIMPLIFY-2            | SIMPLIFY-2     | SIMPLIFY-2     |
|------------------------------------|-------------|------------|-----------------------|-----------------------|----------------|----------------|-----------------------|-----------------------|----------------|----------------|
|                                    |             |            | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population | ITT population | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population | ITT population |
| Characteristic                     | MMB N = 130 | DAN N = 65 | MMB N = 86            | RUX N = 94            | MMB N = 215    | RUX N = 217    | MMB N = 66            | BAT N = 39            | MMB N = 104    | BAT N = 52     |
| Age at baseline (years)            |             |            |                       |                       |                |                |                       |                       |                |                |
| Median                             | 71.00       | 72.00      | 70                    | 68                    | 67.0           | 66.0           | 67.0                  | 70.0                  | 67.0           | 69.5           |
| Min, max                           | 38.0, 86.0  | 54.0, 86.0 | 41, 85                | 25, 86                | 28, 85         | 25, 86         | 51, 92                | 52, 82                | 41, 92         | 52, 82         |
| Age group, n (%)                   |             |            |                       |                       |                |                |                       |                       |                |                |
| < 65 years                         | 29 (22.3)   | 11 (16.9)  | 24 (27.9)             | 36 (38.3)             | 90 (41.9)      | 95 (43.8)      | 24 (36.4)             | 9 (23.1)              | 41 (39.4)      | 14 (26.9)      |
| ≥ 65 years                         | 101 (77.7)  | 54 (83.1)  | 62 (72.1)             | 58 (61.7)             | 125 (58.1)     | 122 (56.2)     | 42 (63.6)             | 30 (76.9)             | 63 (60.6)      | 38 (73.1)      |
| Sex at birth, n (%)                |             |            |                       |                       |                |                |                       |                       |                |                |
| Male                               | 79 (60.8)   | 44 (67.7)  | 50 (58.1)             | 56 (59.6)             | 124 (57.7)     | 120 (55.3)     | 52 (78.8)             | 18 (46.2)             | 69 (66.3)      | 24 (46.2)      |
| Female                             | 51 (39.2)   | 21 (32.3)  | 36 (41.9)             | 38 (40.4)             | 91 (42.3)      | 97 (44.7)      | 14 (21.2)             | 21 (53.8)             | 35 (33.7)      | 28 (53.8)      |
| Race, n (%)                        |             |            |                       |                       |                |                |                       |                       |                |                |
| White                              | 107 (82.3)  | 50 (76.9)  | 69 (80.2)             | 76 (80.9)             | 179 (83.3)     | 178 (82.0)     | 54 (81.8)             | 34 (87.2)             | 83 (79.8)      | 44 (84.6)      |
| Black or African American          | 2 (1.5)     | 2 (3.1)    | 2 (2.3)               | 0                     | 2 (0.9%)       | 2 (0.9%)       | 5 (7.6)               | 0                     | 6 (5.8)        | 0              |
| Asian                              | 12 (9.2)    | 6 (9.2)    | 7 (8.1)               | 8 (8.5)               | 17 (7.9)       | 20 (9.2)       | 0                     | 0                     | 0              | 0              |
| Not permitted                      | na          | na         | 6 (7.0)               | 10 (10.6)             | 15 (7.0)       | 16 (7.4)       | 7 (10.6)              | 5 (12.8)              | 15 (14.4)      | 8 (15.4)       |
| Other                              | 7 (5.4)     | 5 (7.7)    | 2 (2.3)               | 0                     | 2 (0.9)        | 1 (0.5)        | na                    | na                    | na             | na             |
| Ethnicity, n (%)                   |             |            |                       |                       |                |                |                       |                       |                |                |
| Hispanic or Latino                 | 5 (3.8)     | 6 (9.2)    | 1 (1.2)               | 2 (2.1)               | 6 (2.8)        | 4 (1.8)        | 3 (4.5)               | 4 (10.3)              | 5 (4.8)        | 4 (7.7)        |
| Not Hispanic or Latino             | 115 (88.5)  | 54 (83.1)  | 78 (90.7)             | 80 (85.1)             | 191 (88.8)     | 194 (89.4)     | 53 (80.3)             | 30 (76.9)             | 81 (77.9)      | 40 (76.9)      |
| Not permitted                      | na          | na         | 7 (8.1)               | 12 (12.8)             | 18 (8.4)       | 19 (8.8)       | 10 (15.2)             | 5 (12.8)              | 18 (17.3)      | 8 (15.4)       |
| Not reported                       | 9 (6.9)     | 3 (4.6)    | na                    | na                    | na             | na             | na                    | na                    | na             | na             |
| Geographic region, n (%)           |             |            |                       |                       |                |                |                       |                       |                |                |
| Asia                               | 11 (8.5)    | 6 (9.2)    | 8 (9.3)               | 7 (7.4)               | 17 (7.9)       | 18 (8.3)       | na                    | na                    | na             | na             |
| Australasia                        | 4 (3.1)     | 3 (4.6)    | na                    | na                    | na             | na             | na                    | na                    | na             | na             |
| Europe                             | 98 (75.4)   | 44 (67.7)  | na                    | na                    | na             | na             | 37 (56.1)             | 32 (82.1)             | 70 (67.3)      | 43 (82.7)      |
| Eastern Europe                     | na          | na         | 25 (29.1)             | 36 (38.3)             | 70 (32.6)      | 86 (39.6)      | na                    | na                    | na             | na             |
| Western Europe [1]                 | na          | na         | 53 (61.6)             | 51 (54.3)             | 128 (59.5)     | 113 (52.1)     | na                    | na                    | na             | na             |
| North America [1]                  | 17 (13.1)   | 12 (18.5)  | na                    | na                    | na             | na             | 29 (43.9)             | 7 (17.9)              | 34 (32.7)      | 9 (17.3)       |
| MF disease type, n (%)             |             |            |                       |                       |                |                |                       |                       |                |                |
| PMF                                | 78 (60.0)   | 46 (70.8)  | 59 (68.6)             | 54 (57.4)             | 128 (59.5)     | 116 (53.5)     | 45 (68.2)             | 23 (59)               | 64 (61.5)      | 30 (57.7)      |
| Post-PV MF                         | 27 (20.8)   | 11 (16.9)  | 11 (12.8)             | 12 (12.8)             | 48 (22.3)      | 50 (23.0)      | 8 (12.1)              | 8 (20.5)              | 18 (17.3)      | 12 (23.1)      |
| Post-ET MF                         | 25 (19.2)   | 8 (12.3)   | 16 (18.6)             | 28 (29.8)             | 39 (18.1)      | 51 (23.5)      | 13 (19.7)             | 8 (20.5)              | 22 (21.2)      | 10 (19.2)      |
| Time since MF diagnosis (years), n | na          | na         | 86                    | 94                    | 213            | 217            | 65                    | 39                    | 103            | 52             |
| Mean (SD)                          | na          | na         | 3.2 (3.86)            | 3.1 (4.41)            | 3.6 (4.75)     | 3.1 (4.45)     | 6.0 (6.59)            | 5.1 (4.75)            | 5.8 (6.02)     | 5.3 (4.56)     |
| Median                             | na          | na         | 1.7                   | 1.6                   | 1.6            | 1.5            | 3.2                   | 3.9                   | 3.7            | 4.0            |

<div style=\"page-break-after: always\"></div>

|                                              | MOMENTUM         | MOMENTUM         | SIMPLIFY-1            | SIMPLIFY-1            | SIMPLIFY-1     | SIMPLIFY-1     | SIMPLIFY-2            | SIMPLIFY-2            | SIMPLIFY-2     | SIMPLIFY-2     |
|----------------------------------------------|------------------|------------------|-----------------------|-----------------------|----------------|----------------|-----------------------|-----------------------|----------------|----------------|
|                                              |                  |                  | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population | ITT population | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population | ITT population |
| Characteristic                               | MMB N = 130      | DAN N = 65       | MMB N = 86            | RUX N = 94            | MMB N = 215    | RUX N = 217    | MMB N = 66            | BAT N = 39            | MMB N = 104    | BAT N = 52     |
| Q1, Q3                                       | na               | na               | 0.6, 4.0              | 0.3, 2.7              | 0.5, 4.4       | 0.3, 3.0       | 2.2, 8.0              | 2.1, 6.8              | 2.2, 7.5       | 2.2, 7.2       |
| Min, max                                     | na               | na               | 0.1, 22.5             | 0.1, 22.0             | 0, 28.0        | 0, 24.2        | 0.3, 33.5             | 0.2, 24.9             | 0.3, 33.5      | 0.2, 24.9      |
| Prior JAK inhibitor therapy duration (weeks) |                  |                  |                       |                       |                |                |                       |                       |                |                |
| Mean (SD)                                    | 138.52 (123.02 ) | 124.83 (120.03 ) | na                    | na                    | na             | na             | 63.98 (68.37)         | 63.30 (56.66)         | 68.90 (66.98)  | 61.36 (52.93)  |
| Median                                       | 98.71            | 95.86            | na                    | na                    | na             | na             | 39.64                 | 42.86                 | 47.43          | 46.71          |
| Q1, Q3                                       | 39.86, 194.14    | 36.00, 151.14    | na                    | na                    | na             | na             | 13.07, 86.14          | 10.79, 115.07         | 15.43, 104.43  | 13.43, 105.29  |
| Min, max                                     | 4.1, 477.0       | 4.0, 617.6       | na                    | na                    | na             | na             | 5.9, 257.6            | 3.7, 175.7            | 5.9, 257.6     | 3.7, 175.7     |
| Prior JAK inhibitor therapy duration, n (%)  |                  |                  |                       |                       |                |                |                       |                       |                |                |
| < 12 weeks                                   | 3 (2.3)          | 2 (3.1)          | na                    | na                    | na             | na             | 6 (9.1)               | 7 (17.9)              | 13 (12.5)      | 9 (17.3)       |
| ≥ 12 weeks                                   | 127 (97.7)       | 63 (96.9)        | na                    | na                    | na             | na             | 13 (19.7)             | 8 (20.5)              | 16 (15.4)      | 10 (19.2)      |
| Ongoing JAK inhibitor at screening           | 58 (44.6)        | 32 (49.2)        | na                    | na                    | na             | na             | 47 (71.2)             | 24 (61.5)             | 75 (72.1)      | 33 (63.5)      |
| Missing                                      | na               | na               | na                    | na                    | na             | na             | 50 (75.8)             | 29 (74.4)             | 77 (74.0)      | 39 (75.0)      |
| Prognostic risk                              | DIPSS            | DIPSS            |                       | IPSS                  | IPSS           | IPSS           | DIPSS                 | DIPSS                 | DIPSS          | DIPSS          |
| Intermediate-1                               | 7 (5.4)          | 3 (4.6)          | 2 (2.3)               | 4 (4.3)               | 46 (21.4)      | 43 (19.8)      | 5 (7.6)               | 7 (17.9)              | 23 (22.1)      | 16 (30.8)      |
| Intermediate-2                               | 72 (55.4)        | 40 (61.5)        | 26 (30.2)             | 20 (21.3)             | 76 (35.3)      | 67 (30.9)      | 44 (66.7)             | 24 (61.5)             | 62 (59.6)      | 28 (53.8)      |
| High                                         | 50 (38.5)        | 19 (29.2)        | 58 (67.4)             | 70 (74.5)             | 93 (43.3)      | 107 (49.3)     | 17 (25.8)             | 8 (20.5)              | 19 (18.3)      | 8 (15.4)       |
| ECOG performance status, n (%)               |                  |                  |                       |                       |                |                |                       |                       |                |                |
| 0                                            | 16 (12.3)        | 15 (23.1)        | 30 (34.9)             | 24 (25.5)             | 76 (35.3)      | 72 (33.2)      | 19 (28.8)             | 15 (38.5)             | 36 (34.6)      | 19 (36.5)      |
| 1                                            | 83 (63.8)        | 34 (52.3)        | 48 (55.8)             | 56 (59.6)             | 122 (56.7)     | 120 (55.3)     | 44 (66.7)             | 18 (46.2)             | 61 (58.7)      | 26 (50.0)      |
| 2                                            | 31 (23.8)        | 16 (24.6)        | 8 (9.3)               | 14 (14.9)             | 17 (7.9)       | 25 (11.5)      | 3 (4.5)               | 6 (15.4)              | 7 (6.7)        | 7 (13.5)       |
| TSS at baseline, n [2]                       | 130              | 65               | 85                    | 93                    | 213            | 214            | 45                    | 28                    | 104            | 52             |
| Mean (SD)                                    | 27.96 (13.84)    | 25.70 (12.79)    | 19.0                  | 18.1                  | 19.4           | 17.9 (11.47)   | 21.82 (9.95)          | 27.39 (13.34)         | 18.5 (12.97)   | 20.5           |
| Median                                       | 26.43            | 23.57            | (13.72)               | (11.90)               | (13.18)        | 16.4           | 21.14                 | 24.29                 | 15.6           | (16.03)        |
| Q1, Q3                                       | 16.71,           | 15.33,           | 17.6                  | 16.3                  | 17.4 8.4,      | 8.6,           |                       |                       | 8.7,           | 15.9 7.1,      |
|                                              | 38.00            | 36.14            | 6.3, 29.3             | 8.9, 24.9             | 27.6           | 25.0           | 13.86, 27.17          | 15.93, 37.00          | 25.8           | 29.9           |
| TSS category, n (%) [3]                      | 67.7             |                  |                       |                       |                |                |                       |                       |                |                |
| < 22                                         | 53 (40.8)        | 26 (40.0)        | na                    | na                    | 126 (59.2)     | 141 (65.9)     | 45 (68.2)             | 23 (59.0)             | 66 (63.5)      | 31 (59.6)      |
| ≥ 22                                         | 77 (59.2)        | 39 (60.0)        | na                    | na                    | 87 (40.8)      | 73 (34.1)      | 21 (31.8)             | 16 (41.0)             | 38 (36.5)      | 21 (40.4)      |
| < 10                                         | 8 (6.2)          | 5 (7.7)          | na                    | na                    | 61 (28.6)      | 65 (30.4)      | 21 (31.8)             | 11 (28.2)             | 29 (27.9)      | 17 (32.7)      |
| ≥ 10                                         | 122 (93.8)       | 60 (92.3)        | na                    | na                    | 152 (71.4)     | 149 (69.6)     | 45 (68.2)             | 28 (71.8)             | 75 (72.1)      | 35 (67.3)      |

<div style=\"page-break-after: always\"></div>

|                                                                | MOMENTUM          | MOMENTUM            | SIMPLIFY-1            | SIMPLIFY-1            | SIMPLIFY-1        | SIMPLIFY-1        | SIMPLIFY-2            | SIMPLIFY-2            | SIMPLIFY-2        | SIMPLIFY-2        |
|----------------------------------------------------------------|-------------------|---------------------|-----------------------|-----------------------|-------------------|-------------------|-----------------------|-----------------------|-------------------|-------------------|
|                                                                |                   |                     | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population    | ITT population    | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population    | ITT population    |
| Characteristic                                                 | MMB N = 130       | DAN N = 65          | MMB N = 86            | RUX N = 94            | MMB N = 215       | RUX N = 217       | MMB N = 66            | BAT N = 39            | MMB N = 104       | BAT N = 52        |
| Palpable spleen length below the left costal margin, n (%) [3] |                   |                     |                       |                       |                   |                   |                       |                       |                   |                   |
| < 12 cm                                                        | 66 (50.8)         | 32 (49.2)           | na                    | na                    | na                | na                | 22 (33.3)             | 15 (38.5)             | 37 (35.6)         | 18 (34.6)         |
| ≥ 12 cm                                                        | 55 (42.3)         | 28 (43.1)           | na                    | na                    | na                | na                | 44 (66.7)             | 24 (61.5)             | 66 (63.5)         | 34 (65.4)         |
| Central lab spleen volume (cm 3 ), n                           | 129               | 63                  | 86                    | 94                    | 214               | 217               | 66                    | 39                    | 104               | 52                |
| Mean (SD)                                                      | 2367.10 (1302.27) | 2287.95 (1154.83 )  | 1981.4 (776.14 )      | 2285.2 (1286.9 0)     | 2186.9 (1201.6 3) | 2183.3 (1243.8 4) | 2625.5 (1467.2 7)     | 2299.6 (1157.2 0)     | 2512.0 (1541.3 5) | 2347.7 (1133.3 2) |
| Median                                                         | 2112.02           | 2059.27             | 1788.1                | 1958.5                | 2009.6            | 1910.8            | 2576.8                | 2049.3                | 2201.9            | 2062.9            |
| Q1, Q3                                                         | 1445.5,           | 1446.4,             | 1429.9,               | 1367.7,               | 1347.9,           | 1361.5,           | 1340.9,               | 1369.2,               | 1327.2,           | 1537.7,           |
| Min, max                                                       | 609.5, 9717.2     | 627.7, 6016.1       | 352, 4027             | 686, 9022             | 324, 6862         | 206, 9022         | 392, 6740             | 458, 5299             | 241, 7433         | 458, 5299         |
| Transfusion independent, n (%)                                 | 17 (13.1)         | 10 (15.4)           | 25 (29.1)             | 41 (43.6)             | 147 (68.4)        | 152 (70.0)        | 5 (7.6)               | 9 (23.1)              | 32 (30.8)         | 19 (36.5)         |
| Transfusion dependent, n (%)                                   | 63 (48.5)         | 34 (52.3)           | 49 (57.0)             | 43 (45.7)             | 53 (24.7)         | 52 (24.0)         | 52 (78.8)             | 25 (64.1)             | 58 (55.8)         | 27 (51.9)         |
| RBC units transfused ≤ 8 weeks before randomization, n (%) [3] |                   |                     |                       |                       |                   |                   |                       |                       |                   |                   |
| 0                                                              | 28 (21.5)         | 13 (20.0)           | na                    | na                    | na                | na                | na                    | na                    | na                | na                |
| 1-4                                                            | 58 (44.6)         | 27 (41.5)           | na                    | na                    | na                | na                | na                    | na                    | na                | na                |
| ≥ 5                                                            | 44 (33.8)         | 25 (38.5)           | na                    | na                    | na                | na                | na                    | na                    | na                | na                |
| RBC units transfused ≤ 8 weeks before randomization, n         | na                | na                  | 86                    | 94                    | 215               | 217               | 66                    | 39                    | 104               | 52                |
| Mean (SD)                                                      | na                | na                  | 2.5 (3.31)            | 2.2 (3.30)            | 1.1 (2.66)        | 1.1 (2.52)        | 4.4 (3.64)            | 3.8 (3.63)            | 3.1 (3.59)        | 3.1 (3.51)        |
| Median                                                         | na                | na                  | 2.0                   | 0                     | 0                 | 0                 | 4.0                   | 3.0                   | 2.0               | 2.0               |
| Q1, Q3                                                         | na                | na                  | 0, 4.0                | 0, 3.0                | 0, 2.0            | 0, 0              | 1.0, 8.0              | 1.0, 6.0              | 0.0, 6.0          | 0.0, 5.0          |
| Min, max                                                       | na                | na                  | 0, 17                 | 0, 13                 | 0, 17             | 0, 13             | 0, 12                 | 0, 15                 | 0, 12             | 0, 15             |
| Hemoglobin (g/dL), n                                           | 129               | 65                  | 86                    | 94                    | 215               | 216               | 66                    | 39                    | 104               | 52                |
| Mean (SD)                                                      | 8.06              | 7.86                | 8.6                   | 8.7                   | 10.6              | 10.7              | 8.2 (0.89)            | 8.8                   | 9.4               | 9.5 (1.59)        |
|                                                                | (1.14)            | (0.83)              | (0.95)                | (1.00)                | (2.09)            | (2.37)            | 8.1                   | (0.75)                | (1.92)            | 9.2               |
| Median                                                         | 8.00              | 8.00                | 8.6                   | 9.0                   | 10.5              | 10.3              |                       | 8.7                   | 9.0               |                   |
| Q1, Q3 Min, max                                                | 7.50, 8.80 3.8,   | 7.30, 8.40 5.7, 9.7 | 7.9, 9.4 6, 10        | 8.1, 9,6 6, 10        | 9.1, 12.0 6, 16   | 9.2, 11.9 6, 19   | 7.6, 8.8 6, 10        | 8.3, 9.5 7, 10        | 7.9, 10.7 6, 16   | 8.5, 10.1 7, 14   |
| Hemoglobin category, n (%)                                     |                   |                     |                       |                       |                   |                   |                       |                       |                   |                   |
| < 8 g/dL                                                       | 62 (47.7)         | 32 (49.2)           | 28 (32.6)             | 21 (22.3)             | 28 (13.0)         | 21 (9.7)          | 27 (40.9)             | 6 (15.4)              | 27 (26.0)         | 6 (11.5)          |
| ≥ 8 g/dL                                                       | 67 (51.5)         | 33 (50.8)           | 58 (67.4)             | 73 (77.7)             | 187 (87.0)        | 195 (89.9)        | 39 (59.1)             | 33 (84.6)             | 77 (74.0)         | 46 (88.5)         |
| < 10 g/dL                                                      | 126 (96.9)        | 65 (100)            | 86 (100)              | 94 (100)              | 86 (40.0)         | 94 (43.3)         | 66 (100)              | 39 (100)              | 66 (63.5)         | 39 (75.0)         |
| ≥ 10 g/dL                                                      | 3 (2.3) [4]       | 0                   | 0                     | 0                     | 129 (60.0)        | 122 (56.2)        | 0                     | 0                     | 38 (36.5)         | 13 (25.0)         |

<div style=\"page-break-after: always\"></div>

|                                   | MOMENTUM         | MOMENTUM         | SIMPLIFY-1            | SIMPLIFY-1            | SIMPLIFY-1      | SIMPLIFY-1      | SIMPLIFY-2            | SIMPLIFY-2            | SIMPLIFY-2      | SIMPLIFY-2     |
|-----------------------------------|------------------|------------------|-----------------------|-----------------------|-----------------|-----------------|-----------------------|-----------------------|-----------------|----------------|
|                                   |                  |                  | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population  | ITT population  | Hgb <10 g/dL Subgroup | Hgb <10 g/dL Subgroup | ITT population  | ITT population |
| Characteristic                    | MMB N = 130      | DAN N = 65       | MMB N = 86            | RUX N = 94            | MMB N = 215     | RUX N = 217     | MMB N = 66            | BAT N = 39            | MMB N = 104     | BAT N = 52     |
| < 12 g/dL                         | 129 (99.2)       | 65 (100)         | 86 (100)              | 94 (100)              | 159 (74.0)      | 164 (75.6)      | 66 (100)              | 39 (100)              | na              | na             |
| ≥ 12 g/dL                         | 0                | 0                | 0                     | 0                     | 56 (26.0)       | 53 (24.4)       | 0                     | 0                     | na              | na             |
| Platelet count (× 10 9 /L), n     | 128              | 64               | 86                    | 94                    | 215             | 217             | 64                    | 39                    | 102             | 52             |
| Mean (SD)                         | 151.68 (130.90 ) | 130.69 (100.97 ) | 229.3 (155.88 )       | 292.3 (323.20 )       | 300.9 (206.86 ) | 301.5 (255.85 ) | 186.4 (161.60 )       | 123.5 (95.39)         | 170.8 (148.01 ) | 126.5 (95.92)  |
| Median                            | 97.00            | 94.00            | 186.5                 | 205.0                 | 240.5           | 249.0           | 125.5                 | 91.0                  | 118.5           | 90.5           |
| Q1, Q3                            | 60.00, 195.50    | 53.50, 175.00    | 126.0, 290.0          | 135.0, 373.0          | 155.0, 384.0    | 146.0, 396.0    | 75.5, 273.5           | 64.0, 151.0           | 70.0, 223.0     | 64.0, 166.5    |
| Min, max                          | 24.0, 733.0      | 26.0, 459.0      | 62, 884               | 54, 2865              | 50, 1165        | 52, 2865        | 32, 777               | 28, 509               | 9, 777          | 27, 509        |
| Platelet count (× 10 9 /L), n (%) |                  |                  |                       |                       |                 |                 |                       |                       |                 |                |
| < 50                              | 18 (13.8)        | 13 (20.0)        | na                    | na                    | na              | na              | 6 (9.1)               | 5 (12.8)              | 9 (8.7)         | 7 (13.5)       |
| ≥ 50 and ≤ 150                    | 63 (48.5)        | 30 (46.2)        | na                    | na                    | 47 (21.9)       | 57 (26.3)       | 33 (50.0)             | 24 (61.5)             | 57 (54.8)       | 30 (57.7)      |
| > 150 and ≤ 300                   | 33 (25.4)        | 15 (23.1)        | na                    | na                    | 89 (41.4)       | 71 (32.7)       | 12 (18.2)             | 8 (20.5)              | 18 (17.3)       | 12 (23.1)      |
| > 300                             | 14 (10.8)        | 6 (9.2)          | na                    | na                    | 79 (36.7)       | 89 (41.0)       | 13 (19.7)             | 2 (5.1)               | 18 (17.3)       | 3 (5.8)        |
| ≤ 150                             | 81 (62.3)        | 43 (66.2)        | na                    | na                    | 47 (21.9)       | 57 (26.3)       | 39 (59.1)             | 29 (74.4)             | 66 (63.5)       | 37 (71.2)      |
| > 150                             | 47 (36.2)        | 21 (32.3)        | na                    | na                    | 168 (78.1)      | 160 (73.7)      | 25 (37.9)             | 10 (25.6)             | 36 (34.6)       | 15 (28.8)      |
| < 100                             | 66 (50.8)        | 34 (52.3)        | 13 (15.1)             | 13 (13.8)             | 18 (8.4)        | 23 (10.6)       | 25 (37.9)             | 20 (51.3)             | 42 (40.4)       | 27 (51.9)      |
| ≥ 100 and ≤ 200                   | 31 (23.8)        | 19 (29.2)        | 36 (41.9)             | 34 (36.2)             | 66 (30.7)       | 63 (29.0)       | 21 (31.8)             | 13 (33.3)             | 33 (31.7)       | 16 (30.8)      |
| ≤ 200                             | 97 (74.6)        | 53 (81.5)        | na                    | na                    | 84 (39.1)       | 86 (39.6)       | na                    | na                    | na              | na             |
| > 200                             | 31 (23.8)        | 11 (16.9)        | 37 (43.0)             | 47 (50.0)             | 131 (60.9)      | 131 (60.4)      | 18 (27.3)             | 6 (15.4)              | 27 (26.0)       | 9 (17.3)       |

[1]  Western Europe includes North America for SIMPLIFY-1.

[2] TSS was assessed using MFSAF v4.0 in MOMENTUM and the modified MPN-SAF v2.0 in SIMPLIFY-1.

[3] Data were from the case report form.

[4] Baseline Hgb levels were 10.0, 10.6, and 10.7 g/dL.

## Prior and concomitant MF therapies Study SRA-MMB-301 (MOMENTUM)

## JAK inhibitor therapy:

All 195 subjects received prior JAK inhibitor therapy as required by the protocol. All subjects (100%) received  RUX  and  9  subjects  (4.6%)  also  received  fedratinib.  The  mean  (SD)  duration  of  prior treatment  with  JAK  inhibitors  was  138.52  (123.02)  weeks  in  the  MMB  group  and  124.83  (120.03) weeks in the DAN group. The overall median duration of prior treatment with JAK inhibitors was 98.57 weeks (1.9 years).

<div style=\"page-break-after: always\"></div>

Table 36: Summary of prior JAK inhibitor therapy (ITT population, MOMENTUM)

|                                        | MMB (N=130)     | DAN （N=65)      | Total （N=195)   |
|----------------------------------------|-----------------|-----------------|-----------------|
| Prior JAKitherapy                      |                 |                 |                 |
| Ruxolitinib                            | 130 (100.0%)    | 65（100.0%)      | 195 (100.0%)    |
| Fedratinib                             | 7 (5.48)        | 2 (3.18)        | 9 (4.6%)        |
| Duration of prior JAKi therapy （weeks) |                 |                 |                 |
| N                                      | 130             | 65              | 195             |
| Mean (SD)                              | 138.52 (123.02) | 124.83 (120.03) | 133.96 (121.89) |
| Median                                 | 98.71           | 95.86           | 98.57           |
| Q1，Q3                                  | 39.86,194.14    | 36.00,151.14    | 39.57,191.14    |
| Min, Max                               | 4.1,477.0       | 4.0,617.6       | 4.0,617.6       |
| Duration of prior Ruxolitinib (weeks)  |                 |                 |                 |
| N                                      | 130             | 65              | 195             |
| Mean (SD)                              | 135.96(120.94)  | 123.69(117.09)  | 131.87(119.51)  |
| Median                                 | 96.14           | 95.86           | 95.86           |
| Q1，Q3                                  | 39.86,193.00    | 36.00,151.14    | 39.57,185.57    |
| Min,Max                                | 4.1,477.0       | 4.0，583.6       | 4.0,583.6       |
| Duration of prior Fedratinib (weeks)   |                 |                 |                 |
| N                                      | 7               | 2               | 9               |
| Mean (SD)                              | 47.55(40.16)    | 36.93(4.14)     | 45.19(35.13)    |
| Median                                 | 31.71           | 36.93           | 34.00           |
| Q1，Q3                                  | 15.86,92.43     | 34.00,39.86     | 22.00,42.71     |
| Min, Max                               | 13.1,115.0      | 34.0,39.9       | 13.1,115.0      |

## Study GU-US-352-0101 (SIMPLIFY-1)

Patients with prior use of a JAK-inhibitor were excluded from the SIMPLIFY-1 study. From the patients enrolled in the double-blind treatment phase, 33.0% of patients in the MMB arm and 32.7% of patients in the RUX arm received prior MF therapy. In both treatment arms, hydroxycarbamide was the most frequent used prior MF therapy (around 20 - 25% of patients).

## Treatment Compliance

## MOMENTUM

Table 37: Treatment Compliance During 24 Weeks of Randomized Treatment and the Entire Treatment Period (Safety Population, MOMENTUM)

|                                 | RandomizedTreatment   | RandomizedTreatment   | EntireTreatmentPeriod[1]   | EntireTreatmentPeriod[1]   | EntireTreatmentPeriod[1]   | EntireTreatmentPeriod[1]   |
|---------------------------------|-----------------------|-----------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Parameter                       | MMB (N = 130)         | DAN (N = 65)          | MMB (N=38)                 | MMB->MMB (N=92)            | DAN-→MMB (N=40)            | MMBOverall (N=170)         |
| Dose intensity (mg/day) [2]     |                       |                       |                            |                            |                            |                            |
| n                               | 130                   | 65                    | 38                         | 92                         | 40                         | 170                        |
| Mean (SD)                       | 188.84 (18.41)        | 576.47 (65.28)        | 186.51 (18.05)             | 187.19 (21.52)             | 181.28 (34.08)             | 185.65 (24.39)             |
| Median                          | 200.00                | 600.00                | 195.83                     | 200.00                     | 200.00                     | 200.00                     |
| Q1, Q3                          | 181.82,200.00         | 600.00,600.00         | 174.48,200.00              | 180.31,200.00              | 168.21,200.00              | 174.71,200.00              |
| Min, max                        | 128.3,200.0           | 241.8, 600.0          | 138.7,200.0                | 105.1,200.0                | 50.0,200.0                 | 50.0,200.0                 |
| Relative dose intensity (%) [3] |                       |                       |                            |                            |                            |                            |
| n                               | 130                   | 65                    | 38                         | 92                         | 40                         | 170                        |
| Mean (SD)                       | 94.42 (9.20)          | 96.08 (10.88)         | 93.26 (9.02)               | 93.59 (10.76)              | 90.64 (17.04)              | 92.82 (12.19)              |
| Median                          | 100.00                | 100.00                | 97.92                      | 100.00                     | 100.00                     | 100.00                     |
| Q1, Q3                          | 90.91,100.00          | 100.00,100.00         | 87.24,100.00               | 90.16,100.00               | 84.11,100.00               | 87.35,100.00               |
| Min, max                        | 64.1, 100.0           | 40.3,100.0            | 69.4,100.0                 | 52.6,100.0                 | 25.0,100.0                 | 25.0,100.0                 |

Source: Table 14.3.0.1, Table 14.3.0.3

[1]TheMMBgroup includes subjects treatedwithMMBin the randomized treatment periodwhodid not continue in the open-label treatment period. MMB-→MMBincludessubjectstreatedwithMMBintherandomizedtreatmentperiodwhocontinuedtoreceiveMMBintheopen-labeltreatment period.DAN→MMB includes subjects treated with DAN in therandomized treatment period who crossed over to receive MMBin the open-label treatment period.

- [2]Doseintensity= actual cumulativedose/actual durationof the treatment(days).

[3]Relative dose intensity = actual dose intensity/planned dose intensity.

DAN, danazol; Min, max,Minimum, maximum; MMB,momelotinib; Q1, Q3,first quartile, third quartile.

<div style=\"page-break-after: always\"></div>

## SIMPLIFY-1

Table 38: Treatment Compliance During Double Blind Treatment Phase (Safety Population, SIMPLIFY-1)

<!-- image -->

|                                                                         | MMB (N=214)   | RUX (N=216)   |
|-------------------------------------------------------------------------|---------------|---------------|
| NumberofSubjectswhoReturnedatLeast1Bottleandhad calculabledrugadherence | 214 (100.0%)  | 216 (100.0%)  |
| On-treatmentAdherenceRate(&)                                            |               |               |
| N                                                                       | 214           | 216           |
| Mean (SD)                                                               | 98.5 (5.24)   | 97.8 (10.66)  |
| Median                                                                  | 100.0         | 99.2          |
| Q1，Q3                                                                   | 98.2,100.6    | 96.9，100.0    |
|                                                                         | 67,111        | 41，182        |
| Subjectswithon-treatmentAdherenceRatebyCategory                         |               |               |
| <75%                                                                    | 2 0.9%)       | 5（ 2.3%)      |
| >=75%to<90%                                                             | 8 （ 3.7%)     | 8 3.7%)       |
| >=90%                                                                   | 204(95.3%)    | 203(94.0%)    |

- Numbers analysed

Study SRA-MMB-301 (MOMENTUM)

Table 39: Analysis sets for the double-blind treatment phase (MOMENTUM)

| Population          | MMB (N =130)   | DAN (N =65)   | Total (N =195)   |
|---------------------|----------------|---------------|------------------|
| Intent-to-treat [1] | 130 (100%)     | 65 (100%)     | 195 (100%)       |
| Safety [2]          | 130 (100%)     | 65 (100%)     | 195 (100%)       |
| Per protocol [3,4]  | 129 (99.2%)    | 61 (93.8%)    | 190 (97.4%)      |

Study GU-US-352-0101 (SIMPLIFY-1)

Table 40: Analysis sets for the double-blind treatment phase (SIMPLIFY-1)

|                                                             | MMB (N=215)   | RUX (N=217)   |
|-------------------------------------------------------------|---------------|---------------|
| ITTAnalysisSet                                              | 215(100.0%)   | 217(100.0%)   |
| SafetyAnalysisSet                                           | 214 (99.5%)   | 216 (99.5%)   |
| Per-ProtocolAnalysisSet                                     | 179(83.3%)    | 203 (93.5%)   |
| ReasonsforExclusion                                         | 36(16.7%)     | 14 (6.5%)     |
| Durationonanystudydrugis<80%ofplanned168days,ie<135days     | 32(14.9%)     | 10 (4.6%)     |
| MissingBaselineTotalSymptomScore                            | 2 (0.9%)      | 3 (1.4%)      |
| Nottreatedwithanystudydrug                                  | 1(0.5%)       | 1(0.5%)       |
| MissingBaselinespleenvolumewithin30dayspriortorandomization | 1(0.5%)       | 0             |

Table  41:  Analysis  sets  for  the  open-blind  treatment  phase  and  overall  exposure  to momelotinib period (SIMPLIFY-1)

|                   | Open-labelPhase               | Open-labelPhase           | OverallExposedtoMMB   | OverallExposedtoMMB   |
|-------------------|-------------------------------|---------------------------|-----------------------|-----------------------|
|                   | Continuing (MMBtoMMB) (N=171) | Switch (RUXtoMMB) (N=197) | MMBinDB (N=215)       | Total (N=412)         |
| ITTAnalysisSet    | 171(100.0%)                   | 197(100.0%)               | 215 (100.0%)          | 412(100.0%)           |
| SafetyAnalysisSet | 171(100.0%）                   | 197(100.0%)               | 214 (99.5%)           | 411 (99.8%)           |
| PKAnalysisSet     |                               | 82 (41.6%)                | 206(95.8%)            | 288(69.9%)            |

<div style=\"page-break-after: always\"></div>

## · Outcomes and estimation

## Study SRA-MMB-301 (MOMENTUM)

Following  initial  submission  of  the  application,  the  applicant  identified  a  vendor  error  related  to  the MOMENTUM anti-myelofibrosis  prohibited  medication  dataset  which  resulted  in  a  misclassification  of one patient for the endpoints of transfusion independence status at Week 24 and splenic response rate at Week 24 (subject should be considered non-responder instead of responder). Below, the analysis data  cutoff  date  of  03  Dec  2021  was  used  for  all  efficacy  analyses  of  the  24-week  randomized treatment period (reported in the originally submitted clinical study report dated 15 Aug 2022), except for the analyses of endpoints that included TI rate and SRR at week 24, for which the database lock date of 17 Jan 2023 was used (provided in response to first LoQ), due to correction of the subjects who received a prohibited anti-MF medication. For secondary and exploratory analyses that included data collected through the end of study (including OS and LFS), the updated database lock date of 17 Jan 2023 was used.

## Primary Efficacy Endpoints in MOMENTUM

First primary endpoint: MFSAF TSS 24

Table 42: MFSAF TSS Response Rate at Week 24 (ITT population, MOMENTUM)

|                                                                              | MOMENTUM            | MOMENTUM            |
|------------------------------------------------------------------------------|---------------------|---------------------|
| TSS Response Rate at Week 24                                                 | MMB (N = 130)       | DAN (N = 65)        |
| Evaluable at week 24, n                                                      | 130                 | 65                  |
| Responder, n (%)                                                             | 32 ( 24.6% )        | 6 ( 9.2% )          |
| Exact 95% CI [1]                                                             | 17.49, 32.94        | 3.46, 19.02         |
| Superiority proportion difference, %(95% CI)                                 | 15.67 (5.54, 25.81) | 15.67 (5.54, 25.81) |
| p-value                                                                      | 0.0095              | 0.0095              |
| Nonresponder, n (%)                                                          | 98 (75.4%)          | 59 (90.8%)          |
| Last TSS date before day 161                                                 | 38 (29.2%)          | 28 (43.1%)          |
| Last participation date on day 161 or later but TSS at week 24 not available | 0                   | 0                   |
| Increase from baseline > 0% at week 24                                       | 17 (13.1%)          | 10 (15.4%)          |
| Reduction from baseline < 50% at week 24                                     | 43 (33.1%)          | 21 (32.3%)          |

Proportion differences were analyzed using the stratified CMH method. [1] Exact binomial CI for MOMENTUM. CMH, Cochran-Mantel-Haenszel; DAN, danazol; ITT, intent-to-treat; MMB, momelotinib; na, not applicable; RUX, ruxolitinib; TSS, total symptom score.

<div style=\"page-break-after: always\"></div>

<!-- image -->

The number of subjects without week 24 data is represented as blank space for each treatment group.  N, number of subjects with percent change in TSS at week 24 available.  N*, number of subjects without a week 24 TSS.  DAN, danazol; ITT, intent-to-treat; MFSAF, Myelofibrosis Symptom Assessment Form; MMB, momelotinib; TSS, total symptom score.

Figure  13:  Percent  Change  From  Baseline  in  MFSAF  TSS  at  Week 24  for  Each  Subject (ITT Population, MOMENTUM)

Table 44: Summary of MFSAF TSS response rate at Week 48 (ITT population, MOMENTUM)

|                                    | MMB->MMB                   | MMB->MMB                      | DAN->MMB                  | DAN->MMB                      |
|------------------------------------|----------------------------|-------------------------------|---------------------------|-------------------------------|
|                                    | Week 24 Responder (N = 32) | Week 24 Nonresponder (N = 61) | Week 24 Responder (N = 6) | Week 24 Nonresponder (N = 35) |
| MFSAF TSS response rate at week 48 |                            |                               |                           |                               |
| Evaluable at week 48, n            | 25                         | 43                            | 5                         | 25                            |
| Responders, n (%) [1]              | 18 (72.0%)                 | 12 (27.9%)                    | 5 (100%)                  | 10 (40.0%)                    |
| Nonresponders, n (%) [2]           | 7 (28.0%)                  | 31 (72.1%)                    | 0                         | 15 (60.0%)                    |

Percentages were calculated based on the number of subjects who crossed over to open-label treatment with MMB and had sufficient TSS data available for response evaluation. [1] Had a ≥ 50% reduction from baseline mean MFSAF TSS during the 28-day period immediately before the end of week 48. [2] Completed the week 48 visit and did not meet responder criteria defined in [1].

## Second primary endpoint: TI rate at Week 24

The  superiority  test  did  not  demonstrate  a  statistically  significant  between-group  difference  (p  = 0.1265). The response rate was 30.00% (95% CI: 22.28, 38.66) for the MMB group and 20.00% (95% CI: 11.10, 31.77) for the DAN group, with a treatment difference of 9.80% (95% CI: -2.03, 21.62).

A noninferiority test demonstrated statistically significant noninferiority of MMB compared with DAN, with a delta for noninferiority (defined as p[MMB] - 0.8 × p[DAN]) of 13.58% (95% CI: 1.86, 25.30).

MMB could be declared noninferior to DAN because the lower bound of the 95% CI was greater than 0. One subject  in  the  MMB  group  with  TI  at  week  24  received  several  transfusions  for  overt  bleeding within 12 weeks before week 24.

<div style=\"page-break-after: always\"></div>

The  proportion  of  subjects  with  TI  at  baseline  was  low  in  both  groups  (13.1% MMB,  15.4% DAN). Overall, the proportion of subjects with TI at week 24 increased from baseline by 16.9% in the MMB group and 4.6% in the DAN group.

Table 45: TI rate at Week 24 (ITT population, MOMENTUM)

| Endpoint                                                                         | MMB (N = 130)        | DAN (N = 65)         |
|----------------------------------------------------------------------------------|----------------------|----------------------|
| Second: Transfusion independence rate at week 24                                 |                      |                      |
| Responder, n (%)                                                                 | 39 ( 30.0% )         | 13 ( 20.0% )         |
| Response rate (95% CI) [1]                                                       | 30.00 (22.28, 38.66) | 20.00 (11.10, 31.77) |
| Superiority test: Treatment arm difference by stratified CMH (95% CI)            | 9.80 (-2.03, 21.62)  | 9.80 (-2.03, 21.62)  |
| p-value [2]                                                                      | 0.1265               | 0.1265               |
| Noninferiority test: Treatment arm difference for noninferiority (95% CI) [2, 3] | 13.58 (1.86, 25.30)  | 13.58 (1.86, 25.30)  |
| 1-sided p-value                                                                  | 0.0116               | 0.0116               |
| Nonresponder, n (%)                                                              | 91 (70.0%)           | 52 (80.0%)           |
| Missing week 24 evaluation                                                       | 34 (26.2%)           | 27 (41.5%)           |
| ≥ 1 RBC or whole blood transfusion in the 12 - week period                       | 63 (48.5%)           | 36 (55.4%)           |
| ≥ 1 central or local Hgb laboratory level < 8 g/dL in the 12-week period         | 45 (34.6%)           | 22 (33.8%)           |
| No more than 1 Hgb assessment in the 12- week period                             | 5 (3.8%)             | 4 (6.2%)             |
| Time between Hgb assessments ≥ 42 days in the 12-week period                     | 13 (10.0%)           | 10 (15.4%)           |
| Week 24 visit out of window (161-176 days)                                       | 2 (1.5%)             | 1 (1.5%)             |
| Prohibited anti-MF medication during randomized treatment period                 | 5 (3.8%)             | 1 (1.5%)             |

Proportion differences were analyzed using the stratified CMH method except where noted.

'(nominal)' is used to clarify a nominal p-value for a descriptive result of a hypothesis test that was included only after a hypothesis test was not rejected in a hierarchical test sequence.

[1] Exact binomial CI for MOMENTUM.

[2] For MOMENTUM, delta = p(MMB) - 0.80 × p(DAN), where p(MMB) was the proportion of subjects with TI in the MMB group and p(DAN) was the proportion of subjects with TI in the DAN group.  The 95% CI was stratum adjusted.

CMH, Cochran-Mantel-Haenszel; DAN, danazol; ITT, intent-to-treat; MMB, momelotinib; na, not applicable; RUX, ruxolitinib; TI, transfusion independence.

Table 46: Summary of TI rate at Week 48 (ITT population, MOMENTUM)

|                          | MMB--MMB                  | MMB--MMB                      | DAN-*MMB                   | DAN-*MMB                     |
|--------------------------|---------------------------|-------------------------------|----------------------------|------------------------------|
|                          | Week 24 Responder (N =39) | Week 24 Nonresponder (N = 54) | Week 24 Responder (N = 13) | Week 24 Nonresponder (N =28) |
| TI rate at week 48       |                           |                               |                            |                              |
| Evaluable at week 48, n  | 34                        | 33                            | 10                         | 20                           |
| Responders, n (%) [1]    | 30 (88.2%)                | 8 (24.2%)                     | 8 (80.0%)                  | 10 (50.0%)                   |
| Nonresponders, n (%) [2] | 4 (11.8%)                 | 25 (75.8%)                    | 2 (20.0%)                  | 10 (50.0%)                   |

Percentages were calculated based on the number of subjects who crossed over to open-label treatment with MMB and had sufficient transfusion  and  Hgb  data  available  for  response  evaluation.  [1]  Completed  the  week  48  visit  and  had  no  RBC  or  whole  blood transfusion, no Hgb level &lt; 8 g/dL, and provided Hgb assessments during the 12 weeks immediately before the week 48 visit. [2] Completed the week 48 visit and did not meet the TI criteria defined in [1].

<div style=\"page-break-after: always\"></div>

## Secondary Efficacy Endpoints in MOMENTUM

First and third key secondary endpoint: SRR at Week 24 based on ≥ 25% and ≥ 35% reduction in spleen volume from baseline, respectively

The  first  and  third  key  secondary  efficacy  endpoints  were  met  as  demonstrated  by  statistically significant superiority of MMB over DAN.

Table 47 : SRR at Week 24, ≥25% reduction in spleen volume (ITT population, MOMENTUM)

| Endpoint                                                         | MMB (N = 130)        | DAN (N = 65)         |
|------------------------------------------------------------------|----------------------|----------------------|
| Key Secondary                                                    |                      |                      |
| First: SRR at week 24 based on ≥ 25% reduction in spleen volume  |                      |                      |
| Responder, n (%)                                                 | 51 ( 39.2% )         | 4 ( 6.2% )           |
| Response rate (95% CI) [1]                                       | 39.23 (30.79, 48.18) | 6.15 (1.70, 15.01)   |
| Treatment arm difference by stratified CMH (95% CI)              | 33.05 (22.59, 43.51) | 33.05 (22.59, 43.51) |
| p-value                                                          | < 0.0001             | < 0.0001             |
| Nonresponder, n (%)                                              | 79 (60.8%)           | 61 (93.8%)           |
| Missing baseline evaluation                                      | 0                    | 0                    |
| Missing week 24 evaluation                                       | 38 (29.2%)           | 28 (43.1%)           |
| Scan taken > 10 days after start of open-label treatment         | 2 (1.5%)             | 0                    |
| Different modalities of spleen scan at baseline and week 24      | 2 (1.5%)             | 0                    |
| < 25% reduction or increased spleen volume                       | 36 (27.7%)           | 33 (50.8%)           |
| Prohibited anti-MF medication during randomized treatment period | 5 (3.8%)             | 1 (1.5%)             |

All p-values were 2-sided.  [1]  Exact binomial CI.

Table 48 : SRR at Week 24, ≥35% reduction in spleen volume (ITT population, MOMENTUM)

| Endpoint                                                         | MMB (N = 130)        | DAN (N = 65)        |
|------------------------------------------------------------------|----------------------|---------------------|
| Key Secondary                                                    |                      |                     |
| Third: SRR at week 24 based on ≥ 35% reduction in spleen volume  |                      |                     |
| Responder, n (%)                                                 | 29 ( 22.3% )         | 2 ( 3.1% )          |
| Response rate (95% CI) [1]                                       | 22.31 (15.48, 30.44) | 3.08 (0.37, 10.68)  |
| Treatment arm difference by stratified CMH (95% CI)              | 18.18 (9.77, 26.59)  | 18.18 (9.77, 26.59) |
| p-value                                                          | 0.0011               | 0.0011              |
| Nonresponder, n (%)                                              | 101 (77.7%)          | 63 (96.9%)          |
| Missing baseline evaluation                                      | 0                    | 0                   |
| Missing week 24 evaluation                                       | 38 (29.2%)           | 28 (43.1%)          |
| Scan taken > 10 days after start of open-label treatment         | 2 (1.5%)             | 0                   |
| Different modalities of spleen scan at baseline and week 24      | 2 (1.5%)             | 0                   |
| < 35% reduction or increased spleen volume                       | 59 (45.4%)           | 35 (53.8%)          |
| Prohibited anti-MF medication during randomized treatment period | 5 (3.8%)             | 1 (1.5%)            |

All p-values were 2-sided.  [1]  Exact binomial CI

<div style=\"page-break-after: always\"></div>

Table  49 :  Summary of SRR (≥25% and ≥35% reduction from baseline spleen volume at Week 48 (ITT population, MOMENTUM)

|                                                           | MMB->MMB         | MMB->MMB                                                               | DAN-→MMB       | DAN-→MMB                                                                  |
|-----------------------------------------------------------|------------------|------------------------------------------------------------------------|----------------|---------------------------------------------------------------------------|
| SRR (25%Reduction FromBaselineSpleen Volume)at Week 48    | Week 24 (N = 51) | Week 24 (N = 42)                                                       | Week 24 (N=4)  | Week 24 25%Responder25% Nonresponder25% Responder25% Nonresponder (N =37) |
| Evaluable at week 48, n                                   | 43               | 24                                                                     | 3              | 27                                                                        |
| Responder, n (%)                                          | 35 (81.4%)       | 8 (33.3%)                                                              | 3 (100%)       | 8 (29.6%)                                                                 |
| Nonresponder, n (%)                                       | 8 (18.6%)        | 16 (66.7%)                                                             | 0              | 19 (70.4%)                                                                |
|                                                           | MMB->MMB         | MMB->MMB                                                               | DAN->MMB       | DAN->MMB                                                                  |
| SRR (≥ 35% Reduction FromBaselineSpleen Volume)at Week 48 | Week 24 (N = 29) | Week 24 35%Responder35%Nonresponder35%Responder35%Nonresponder (N =64) | Week 24 (N =2) | Week 24 (N =39)                                                           |
| Evaluableatweek48,n                                       | 24               | 43                                                                     | 2              | 28                                                                        |
| Responder, n (%)                                          | 19 (79.2%)       | 10 (23.3%)                                                             | 1 (50.0%)      | 3 (10.7%)                                                                 |
| Nonresponder, n (%)                                       | 5 (20.8%)        | 33 (76.7%)                                                             | 1 (50.0%)      | 25 (89.3%)                                                                |

SRR at week 48 was assessed in subjects who crossed over to open-label treatment with MMB and had a week 48 spleen scan. The imaging modality was required to match at baseline and week 48. 25% responder at week 24 was defined as a subject with ≥ 25% reduction from baseline spleen volume at week 24. 35% responder at week 48 was defined as a subject with ≥ 35% reduction from baseline spleen volume at week 24.

Second key secondary endpoint: Change in MFSAF Total Symptom Score From Baseline at Week 24 The second key secondary endpoint was met, as demonstrated by statistically significant superiority of MMB over DAN in change from baseline in MFSAF TSS at week 24.

Table 50: Change in MFSAF TSS from baseline at Week 24 (ITT population, MOMENTUM)

|                                     | MOMENTUM ITT   | MOMENTUM ITT   |
|-------------------------------------|----------------|----------------|
| TSS Change From Baseline at Week 24 | MMB (N = 130)  | DAN (N = 65)   |
| Baseline                            |                |                |
| Mean (SD)                           | 27.96 (13.84)  | 25.70 (12.79)  |
| LS mean (SE)                        | na             | na             |
| Week 24                             |                |                |
| LS mean (SE)                        | -9.36 (1.08)   | -3.13 (1.62)   |
| LS mean difference (SE)             | -6.22 (1.92)   | -6.22 (1.92)   |
| 95% CI                              | -10.0, -2.43   | -10.0, -2.43   |
| p-value [1]                         | 0.0014         | 0.0014         |

The MMRM model was adjusted for baseline MFSAF TSS (&lt; 22 vs ≥ 22), baseline palpable spleen length below the left costal margin (&lt; 12 cm vs ≥ 12 cm), and baseline RBC or whole blood units transfused in the 8-week period before randomization (0, 14, ≥ 5 units) [1] p-value for the LS mean difference between 2 groups from the MMRM

Fourth key secondary endpoint: Rate of no transfusion at Week 24

This endpoint was met, as demonstrated by statistically significant superiority of MMB over DAN.

<div style=\"page-break-after: always\"></div>

Table 51: Rate of no transfusion at Week 24 (ITT population, MOMENTUM)

| Endpoint                                            | MMB (N = 130)        | DAN (N = 65)        |
|-----------------------------------------------------|----------------------|---------------------|
| Key Secondary                                       |                      |                     |
| Fourth: Rate of no transfusion at week 24           |                      |                     |
| Responder, n (%)                                    | 46 ( 35.4% )         | 11 ( 16.9% )        |
| Response rate (95% CI) [1]                          | 35.38 (27.20, 44.25) | 16.92 (8.76, 28.27) |
| Treatment arm difference by stratified CMH (95% CI) | 17.20 (7.99, 26.40)  | 17.20 (7.99, 26.40) |
| p-value                                             | 0.0012               | 0.0012              |
| Nonresponder, n (%)                                 | 84 (64.4%)           | 54 (83.1%)          |

All p-values were 2-sided, [1]  Exact binomial CI.

## Other secondary endpoints

- Proportion of subjects with ≤ 4 RBC or whole blood units transfused during the 24 -week RT Period was 55.4% for MMB and 44.6% for DAN, with a proportion difference by stratified CMH method of 10.62% (95% CI: -2.40, 23.64), p = 0.1133.
- Cumulative Transfusion Risk at Week 24: the overall mean number of units transfused during the RT  period  was  estimated  from  a  ZINB  model  as  7.24 units  (95% CI: 5.49,  8.98)  for  the  MMB group  and  13.99 units  (95% CI: 9.99,  17.99)  for  the  DAN  group,  with  a  treatment  difference of -6.75 units (95% CI: -11.11, -2.39), p = 0.0024.  The estimated mean cumulative transfusion risk at week 24 from a proportional hazards recurrent events model was lower for MMB compared with DAN (6.55 vs 10.86).  The hazard ratio for an RBC unit transfused for MMB compared with DAN was 0.556 (95% CI: 0.397, 0.778), p = 0.0006.

## Study GU-US-352-0101 (SIMPLIFY-1)

## Primary Efficacy Endpoints

SRR at Week 24 based on ≥ 35% reduction in spleen volume from baseline

Table 52 :  SRR at Week 24, ≥ 35% reduction in spleen volume (ITT, SIMPLIFY -1)

| Endpoint                                                                | MMB (N = 215)   | RUX (N = 217)   |
|-------------------------------------------------------------------------|-----------------|-----------------|
| Primary                                                                 |                 |                 |
| SRR at week 24 based on ≥ 35% reduction in spleen volume                |                 |                 |
| Responder, n (%)                                                        | 57 ( 26.5% )    | 64 ( 29.5% )    |
| Exact 95% CI (95% CI) [1]                                               | 20.74, 32.94    | 23.51, 36.04    |
| Noninferiority proportion difference - stratified CMH method, %(95% CI) | 9 (2, 16)       | 9 (2, 16)       |
| p-value                                                                 | 0.014           | 0.014           |
| Nonresponder, n (%)                                                     | 158 (73.5%)     | 153 (70.5%)     |
| Missing baseline evaluation                                             | 1 (0.5%)        | 0               |
| Missing week 24 evaluation                                              | 31 (14.4%)      | 13 (6.0%)       |
| Last participation date < Day 141 in double- blind phase                | 24 (11.2%)      | 7 (3.2%)        |
| < 35% reduction or increased spleen volume                              | 127 (59.1%)     | 140 (64.5%)     |
| > 0% spleen volume increase at Week 24                                  | 26 (12.1%)      | 28 (12.9%)      |

All p-values were 2-sided.  [1] Exact binomial CI.

<div style=\"page-break-after: always\"></div>

## Secondary Efficacy Endpoints in SIMPLIFY-1

## 1. MPN-SAF TSS response rate at Week 24

In the SIMPLIFY-1 study, the first secondary endpoint of noninferiority of MMB to RUX in TSS response rate at week 24 was not met and formal sequential testing was stopped.

Table 53:   MPN-SAF TSS Response Rate at Week 24 (ITT population, SIMPLIFY-1)

|                                                                                  | SIMPLIFY-1    | SIMPLIFY-1    |
|----------------------------------------------------------------------------------|---------------|---------------|
| TSS Response Rate at Week 24                                                     | MMB (N = 215) | RUX (N = 217) |
| Evaluable at week 24, n                                                          | 211           | 211           |
| Responder, n (%)                                                                 | 60 (28.4%)    | 89 (42.2%)    |
| Exact 95% CI [1]                                                                 | 22.45, 35.03  | 35.43, 49.15  |
| Noninferiority proportion difference, % (95% CI)                                 | 0 (-8, 8) [2] | 0 (-8, 8) [2] |
| p-value                                                                          | 0.98          | 0.98          |
| Nonresponder, n (%)                                                              | 151 (71.6%)   | 122 (57.8%)   |
| Last TSS date before day 162 [2]                                                 | 31 (14.7%)    | 12 (5.7%)     |
| Last participation date on day 162 or later but TSS at week 24 not available [3] | 5 (2.4%)      | 9 (4.3%)      |
| Increase from baseline > 0% at week 24                                           | 47 (22.3%)    | 32 (15.2%)    |
| Reduction from baseline < 50% at week 24                                         | 114 (54.0%)   | 101 (47.9%)   |

SIMPLIFY-1 evaluable subjects included subjects with baseline TSS &gt; 0 and subjects with baseline TSS of 0 but nonzero or missing TSS at week 24.   Proportion differences were analyzed using the stratified CMH method.  [1] Exact binomial CI for MOMENTUM and based on Clopper-Pearson method without stratification for SIMPLIFY-1.  [2]  Delta = p(MMB) - 0.67 × p(RUX), where p(MMB) was the proportion with TSS response in the MMB group and p(RUX) was the proportion with TSS response in the RUX group.   [3] Day 162 for SIMPLIFY-1.

## 2. TI response rate at Week 24

In the SIMPLIFY-1 trial, given the null hypotheses for the previous secondary endpoint was not rejected, formal sequential testing was stopped and this endpoint was not formally tested for superiority. Only nominal significance was cited and considered exploratory.

Table 54:  TI rate at Week 24 (ITT population, SIMPLIFY-1)

|                                                         | SIMPLIFY-1        | SIMPLIFY-1        |
|---------------------------------------------------------|-------------------|-------------------|
| TI Rate at Week 24                                      | MMB (N = 215)     | RUX (N = 217)     |
| Responder, n (%)                                        | 143 (66.5%)       | 107 (49.3%)       |
| Exact 95% CI [1]                                        | 59.78, 72.79      | 42.48, 56.16      |
| Proportion difference - Stratified CMH method (95% CI)  | 18 (9, 26)        | 18 (9, 26)        |
| p-value                                                 | < 0.001 (nominal) | < 0.001 (nominal) |
| Nonresponder, n (%)                                     | 72 (33.5%)        | 110 (50.7%)       |
| Transfusion (except bleeding) in the last 12 weeks      | 32 (14.9%)        | 87 (40.1%)        |
| Any hemoglobin assessment < 8 g/dL in the last 12 weeks | 27 (12.6%)        | 68 (31.3%)        |
| Last participation date prior to Day 162 in DB phase    | 32 (14.9%)        | 12 (5.5%)         |
| Other                                                   | 17 (7.9%)         | 34 (15.7%)        |

The TI rate at week 24 was higher for MMB compared with RUX (66.5% vs 49.3%), p &lt; 0.001.  The proportion of subjects with TI at baseline was high in both groups (68.4% MMB, 70.0% RUX).  Overall,

<div style=\"page-break-after: always\"></div>

the proportion of subjects with TI at week 24 decreased from baseline by 1.9% in the MMB group and by 20.7% in the RUX group.

## 3. TD rate at Week 24

Table 55:  TD rate at Week 24 (ITT population, SIMPLIFY-1)

|                                  | SIMPLIFY-1    | SIMPLIFY-1    |
|----------------------------------|---------------|---------------|
| TD Rate at Week 24               | MMB (N = 215) | RUX (N = 217) |
| TD at week 24, n (%)             | 65 (30.2%)    | 87 (40.1%)    |
| Exact 95% CI [1]                 | 24.17, 36.85  | 33.52, 46.94  |
| Proportion difference, %(95% CI) | -10 (-19, -2) | -10 (-19, -2) |
| p-value                          | 0.019         | 0.019         |

A  smaller  proportion  of  subjects  in  the  MMB  group  were  TD  at  Week  24  (30.2%,  65  subjects) compared with the RUX group (40.1%, 87 subjects). The proportion difference was -10% (nominal pvalue: 0.019)

## 4. Rate of RBC transfusion in the double-blind phase

In SIMPLIFY-1 trial, the median RBC transfusion rate was lower for MMB (0 units/month; range, 0.0-9.1) compared with RUX (0.4 units/month; range, 0.0-8.2), with a transfusion rate ratio of 0.28 (95% CI: 0.19, 0.43), nominal p &lt; 0.001, per the negative binomial model adjusted for strata.

## · Ancillary analyses

Subgroup analysis in subgroups by anaemia severity for SIMPLIFY-1 and SIMPLIFY-2, including posthoc defined subgroup with Hgb &lt; 10 g/dL

## SIMPLIFY-1 study

Table 56 : SRR at Week 24, ≥ 35% reduction in spleen volume (ITT population and Hgb &lt; 10 g/dL subgroup, SIMPLIFY-1)

|                                                  | Hemoglobin <10 g/dL Subgroup   | Hemoglobin <10 g/dL Subgroup   | Overall ITTPopulation   | Overall ITTPopulation   |
|--------------------------------------------------|--------------------------------|--------------------------------|-------------------------|-------------------------|
| SRR at Week 24                                   | MMB (N = 86)                   | RUX (S6 = N)                   | MMB (N = 215)           | RUX (N = 217)           |
| Responder, n (%)                                 | 27 (31.4)                      | 31 (32.6)                      | 57 (26.5)               | 64 (29.5)               |
| Exact 95% CI [1]                                 | 21.81, 42.30                   | 23.36, 43.02                   | 20.74, 32.94            | 23.51, 36.04            |
| Superiority proportion difference, % (95% CI)    | 0 (-13, 14)                    | 0 (-13, 14)                    | -3 (-12, 5)             | -3 (-12, 5)             |
| p-value                                          | na                             | na                             | 0.45                    | 0.45                    |
| Noninferiority proportion difference, % (95% CI) | 13 (2, 25)                     | 13 (2, 25)                     | 9 (2, 16)               | 9 (2, 16)               |
| p-value                                          | na                             | na                             | 0.014                   | 0.014                   |

<div style=\"page-break-after: always\"></div>

## SIMPLIFY-2 study

Table 57 : SRR at Week 24, ≥ 35% reduction in spleen volume (ITT population and anemia subgroups, SIMPLIFY-2)

<!-- image -->

|                                                                 | ITT Population   | ITT Population   | Hgb < 10 g/dL   | Hgb < 10 g/dL   | Hgb ≥ 10 and <12 g/dL   | Hgb ≥ 10 and <12 g/dL   |
|-----------------------------------------------------------------|------------------|------------------|-----------------|-----------------|-------------------------|-------------------------|
| Endpoint                                                        | MMB (N = 104)    | BAT (N = 52)     | MMB (N = 66)    | BAT (N =39)     | MMB (N = 27)            | BAT (N = 7)             |
| Primaryefficacyendpoint                                         |                  |                  |                 |                 |                         |                         |
| SRR (reduction in spleen volume ≥ 35% from baseline) at week 24 |                  |                  |                 |                 |                         |                         |
| Responder, n (%)                                                | 7 (6.7%)         | 3 (5.8%)         | 6 (9.1%)        | 2 (5.1%)        | 1 (3.7%)                | 0                       |
| Exact 95% CI [1]                                                | 2.75, 13.38      | 1.21, 15.95      | 3.41, 18.74     | 0.63, 17.32     | 0.09, 18.97             | 0.00, 40.96             |
| Superiority proportion difference, % (95% CI) [2]               | 1 (-9, 10)       | 1 (-9, 10)       | 4 (-16, 23)     | 4 (-16, 23)     | 4 (-38,44)              | 4 (-38,44)              |
| p-value                                                         | 0.90             | 0.90             |                 |                 |                         |                         |

1. Secondary endpoint of MPN-SAF TSS response rate at Week 24

SIMPLIFY-1 study

<div style=\"page-break-after: always\"></div>

Table  58:  MPN-SAF  TSS  Response  Rate  and  Change  from  baseline  at  Week  24  (ITT population and Hgb &lt; 10 g/dL subgroup, SIMPLIFY-1)

|                                                                 | Hgb<10g/dLSubgroup   | Hgb<10g/dLSubgroup   | ITT Population   | ITT Population   |
|-----------------------------------------------------------------|----------------------|----------------------|------------------|------------------|
|                                                                 | MMB (N = 86)         | RUX (S6 =N)          | MMB (N = 215)    | RUX (N = 217)    |
| TSSResponseRateatWeek24                                         |                      |                      |                  |                  |
| Evaluable atweek24,n                                            | 84                   | 94                   | 211              | 211              |
| Responder, n (%)                                                | 21 (25.0)            | 34 (36.2)            | 60 (28.4)        | 89 (42.2)        |
| Exact 95% CI [1]                                                | 16.19,35.64          | 26.51, 46.73         | 22.45, 35.03     | 35.43, 49.15     |
| Superiority proportion difference, % (95% CI)                   | -12 (-26, 2)         | -12 (-26, 2)         | -14 (-23, -5)    | -14 (-23, -5)    |
| p-value                                                         | na                   | na                   | 0.9985 [2]       | 0.9985 [2]       |
| Noninferiorityproportiondifference, % (95% CI)                  | 0 (-12, 12) [3]      | 0 (-12, 12) [3]      | 0 (-8, 8) [3]    | 0 (-8, 8) [3]    |
| p-value                                                         | na                   | na                   | 0.98             | 0.98             |
| Non-responders                                                  | 63 (75.0)            | 60 (63.8)            | 151 (71.6)       | 122 (57.8)       |
| LastTSSdatebeforeday162                                         | 16 (19.0)            | 8 (8.5)              | 31 (14.7)        | 12 (5.7)         |
| Lastparticipationdateonday162or laterbutTSSatweek24notavailable | 3 (3.6)              | 6 (6.4)              | 5 (2.4)          | 9 (4.3)          |
| Increasefrombaseline>0%at week24                                | 17 (20.2)            | 13 (13.8)            | 47 (22.3)        | 32 (15.2)        |
| Reductionfrombaseline<50%at week24                              | 43 (51.2)            | 46 (48.9)            | 114 (54.0)       | 101 (47.9)       |
| TSSChangeFromBaseline at Week 24 [4]                            |                      |                      |                  |                  |
| Baseline                                                        |                      |                      |                  |                  |
| n                                                               | 85                   | 94                   | 213              | 214              |
| Mean (SD)                                                       | 19.0 (13.72)         | 18.1 (11.84)         | 19.4 (13.18)     | 17.9 (11.47)     |
| Week24                                                          |                      |                      |                  |                  |
| LS mean (SE)                                                    | -5.06 (0.94)         | -6.68 (0.82)         | -5.87 (0.93)     | -7.11 (0.91)     |
| LS mean difference(SE)                                          | 1.62 (1.25)          | 1.62 (1.25)          | 1.24 (0.83)      | 1.24 (0.83)      |
| 95% CI                                                          | -0.85, 4.09          | -0.85, 4.09          | -0.40,2.88       | -0.40,2.88       |
| p-value                                                         | na                   | na                   | 0.1380           | 0.1380           |

<div style=\"page-break-after: always\"></div>

## SIMPLIFY-2 study

Table 59: MPN-SAF TSS Response Rate at Week 24 (ITT population and anemia subgroups, SIMPLIFY-2)

|                                                                              | ITT Population   | ITT Population   | Hgb < 10 g/dL   | Hgb < 10 g/dL   | Hgb ≥ 10 and <12 g/dL   | Hgb ≥ 10 and <12 g/dL   |
|------------------------------------------------------------------------------|------------------|------------------|-----------------|-----------------|-------------------------|-------------------------|
| TSS Response Rate at Week 24                                                 | MMB (N= 104)     | BAT (N=52)       | MMB (N= 66)     | BAT (N=39)      | MMB (N = 27)            | BAT (N = 7)             |
| Evaluable at week 24, n                                                      | 103              | 51               | 65              | 38              | 27                      | 7                       |
| Responder, n (%)                                                             | 27 (26.2%)       | 3 (5.9%)         | 21 (32.3%)      | 1 (2.6%)        | 5 (18.5%)               | 1 (14.3%)               |
| Exact 95% CI [1]                                                             | 18.04, 35.80     | 1.23. 16.24      | 21.23, 45.05    | 0.07, 13.81     | 6.30, 38.08             | 0.36, 57.87             |
| Proportion difference, % (95% CI) [2]                                        | 20 (9,32)        | 20 (9,32)        | 30 (10,48)      | 30 (10,48)      | 4 (-38,44)              | 4 (-38,44)              |
| p-value                                                                      | ≤0.001           | ≤0.001           |                 |                 |                         |                         |
| Nonresponder, n (%)                                                          | 76 (73.8%)       | 48 (94.1%)       | 44 (67.7%)      | 37 (97.4%)      |                         |                         |
| Last TSS date before day 162                                                 | 28 (27.2%)       | 10 (19.6%)       | 18 (27.7%)      | 7 (18.4%)       |                         |                         |
| Last participation date on day 162 or later but TSS at Week 24 not available | 3 (2.9%)         | 3 (5.9%)         | 1 (1.5%)        | 3 (7.9%)        |                         |                         |
| Increase from baseline >0% at week 24                                        | 25 (24.3%)       | 23 (45.1%)       | 15 (23.1%)      | 17 (44.7%)      |                         |                         |
| Reduction from baseline < 50% at Week 24                                     | 45 (43.7%)       | 34 (66.7%)       | 25 (38.5%)      | 26 (68.4%)      |                         |                         |

2. Secondary endpoint of transfusion independence (TI) rate and transfusion dependence rate (TD) rate at Week 24

## SIMPLIFY-1 study

Table 60: TI rate and TD rate at Week 24 (ITT population and Hgb &lt; 10 g/dL subgroup, SIMPLIFY-1)

|                                                                      | Hemoglobin <10 g/dL Subgroup   | Hemoglobin <10 g/dL Subgroup   | Overall ITT Population SIMPLIFY-1   | Overall ITT Population SIMPLIFY-1   |
|----------------------------------------------------------------------|--------------------------------|--------------------------------|-------------------------------------|-------------------------------------|
|                                                                      | MMB (N = 86)                   | RUX (S6 = N)                   | MMB (N = 215)                       | RUX (N = 217)                       |
| TI Rate atWeek 24                                                    |                                |                                |                                     |                                     |
| Responder, n (%)                                                     | 40 (46.5)                      | 26 (27.4)                      | 143 (66.5)                          | 107 (49.3)                          |
| Exact 95% CI [1]                                                     | 35.68, 57.59                   | 18.72, 37.48                   | 59.78, 72.79                        | 42.48, 56.16                        |
| Superiority proportion difference, % (95% CI)                        | 22.00 (9.0, 36.0)              | 22.00 (9.0, 36.0)              | 18 (9, 26)                          | 18 (9, 26)                          |
| p-value                                                              | na                             | na                             | < 0.001 (nominal)                   | < 0.001 (nominal)                   |
| TDRateatWeek24                                                       |                                |                                |                                     |                                     |
| Responder, n (%)                                                     | 41 (47.7)                      | 58 (61.1)                      | 65 (30.2)                           | 87 (40.1)                           |
| Exact 95% CI [1]                                                     | 36.79, 58.73                   | 50.50, 70.89                   | 24.17, 36.85                        | 33.52, 46.94                        |
| Superiority proportion difference, % 95% (Cl), stratified CMH method | -16 (-30, -2)                  | -16 (-30, -2)                  | -10 (-19, -2)                       | -10 (-19, -2)                       |
| p-value                                                              | na                             | na                             | 0.019 (nominal)                     | 0.019 (nominal)                     |

<div style=\"page-break-after: always\"></div>

## SIMPLIFY-2 study

Table 61: TI rate at Week 24 (ITT population and anemia subgroups, SIMPLIFY-2)

|                                       | ITTPopulation   | ITTPopulation   | Hgb<10g/dL   | Hgb<10g/dL   | Hgb≥10and <12g/dL   | Hgb≥10and <12g/dL   |
|---------------------------------------|-----------------|-----------------|--------------|--------------|---------------------|---------------------|
| Endpoint                              | MMB (N =104)    | BAT (N=52)      | MMB (N =66)  | BAT (N =39)  | MMB (N=27)          | BAT (N= 7)          |
| Transfusionindependencerateat week24  |                 |                 |              |              |                     |                     |
| Responder, n (%)                      | 45 (43.3%)      | 11 (21.2%)      | 22 (33.3%)   | 5 (12.8%)    | 16 (59.3%)          | 2 (28.6%)           |
| Exact 95% CI [1]                      | 33.59, 53.35    | 11.06. 34.70    | 22.20, 46.01 | 4.30, 27.43  | 38.80, 77.61        | 3.67, 70.96         |
| Proportion difference, % (95% Cl) [2] | 20 (9, 32)      | 20 (9, 32)      | 21 (1, 39)   | 21 (1, 39)   | 31 (-12,71)         | 31 (-12,71)         |
| p-value                               | 100'0           | 100'0           |              |              |                     |                     |

Table 62: TD rate at Week 24 (ITT population and anemia subgroups, SIMPLIFY-2)

|                                    | ITTPopulation     | ITTPopulation   | Hgb<10g/dL   | Hgb<10g/dL   | Hgb≥10and <12g/dL   | Hgb≥10and <12g/dL   |
|------------------------------------|-------------------|-----------------|--------------|--------------|---------------------|---------------------|
| Endpoint                           | MMB (N=104)(N-52) | BAT             | MMB (N =66)  | BAT (N =39)  | MMB (N =27)         | BAT (N- 7)          |
| Transfusiondependencerateat week24 |                   |                 |              |              |                     |                     |
| Dependent,n (%)                    | 52 (50.0%)        | 33 (63.5%)      | 39 (59.1%)   | 28 (71.8%)   | 9 (33.3%)           | 4 (57.1%)           |
| Exact 95%CI[1]                     | 40.03, 59.97      | 48.96, 76.38    | 46.29, 71.05 | 55.13, 85.00 | 16.52. 53.96        | 18.41, 90.10        |
| Proportion difference(95%C1)[2]    | -13 (-29,3)       | -13 (-29,3)     | -13 (-32,7)  | -13 (-32,7)  | -24 (-61,17)        | -24 (-61,17)        |
| p-value                            | 0.10              | 0.10            |              |              |                     |                     |

The proportion of subjects with Hgb responses (ie, increases of ≥ 1, ≥ 1.5, or ≥ 2 g/dL from baseline) MOMENTUM

Table 63: Rates of Hemoglobin Response Defined as ≥ 1, ≥ 1.5, or ≥ 2 g/dL Increases From Baseline During the 24-Week Randomized Treatment Period (ITT population, MOMENTUM)

|                                  | MOMENTUM            | MOMENTUM            |
|----------------------------------|---------------------|---------------------|
| Hgb Response Rate                | MMB                 | DAN                 |
| Entire 24-week RT period         |                     |                     |
| ITT population, N                | 130                 | 65                  |
| Increase of ≥ 1 g/dL             | 69 (53.1%)          | 22 (33.8%)          |
| Exact 95% CI [1]                 | 44.13, 61.88        | 22.57, 46.65        |
| Proportion difference, %(95% CI) | 19.00 (4.68, 33.32) | 19.00 (4.68, 33.32) |
| p-value                          | 0.0124              | 0.0124              |
| Increase of ≥ 1.5 g/dL           | 52 (40.0%)          | 15 (23.1%)          |
| Exact 95% CI [1]                 | 31.51, 48.95        | 13.53, 35.19        |
| Proportion difference, %(95% CI) | 15.68 (2.47, 28.90) | 15.68 (2.47, 28.90) |
| p-value                          | 0.0282              | 0.0282              |
| Increase of ≥ 2 g/dL             | 38 (29.2%)          | 13 (20.0%)          |
| Exact 95% CI [1]                 | 21.59, 37.85        | 11.10, 31.77        |
| Proportion difference, %(95% CI) | 6.97 (-5.41, 19.35) | 6.97 (-5.41, 19.35) |
| p-value                          | 0.2844              | 0.2844              |

<div style=\"page-break-after: always\"></div>

|                            | MOMENTUM   | MOMENTUM   |
|----------------------------|------------|------------|
| Hgb Response Rate          | MMB        | DAN        |
| Last 12 weeks of RT period |            |            |
| ITT population, N          | 130        | 65         |
| Increase of ≥ 1 g/dL       | 50 (38.5%) | 17 (26.2%) |
| Increase of ≥ 1.5 g/dL     | 38 (29.2%) | 12 (18.5%) |
| Increase of ≥ 2 g/dL       | 28 (21.5%) | 8 (12.3%)  |

Hemoglobin values within 4 weeks post-transfusion were excluded.  Proportion differences were analyzed using the stratified CMH method.  [1]Exact binomial CI for MOMENTUM.

<!-- image -->

Subjects treated with DAN during the 24-week randomized treatment period crossed over to MMB for open-label treatment.

Figure 14: Mean (±SE) Hemoglobin Levels Over Time (ITT Population, MOMENTUM)

<div style=\"page-break-after: always\"></div>

SIMPLIFY-2

## Table 64: Hemoglobin Increases at Week 24 (ITT Population, SIMPLIFY-2)

<!-- image -->

|                                                                    | Intent-to-Trent Analysis Set                                       | Intent-to-Trent Analysis Set                                       |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                    | MMB (N=104)                                                        | (N=52)                                                             |
| Inerease of≥ 0.5 g/dL at Week 24 excluding 4 week post-transfuslon | Inerease of≥ 0.5 g/dL at Week 24 excluding 4 week post-transfuslon | Inerease of≥ 0.5 g/dL at Week 24 excluding 4 week post-transfuslon |
| Including mising response, n                                       | 104                                                                | 52                                                                 |
| Yes                                                                | 49 (47.196)                                                        | 13 (25.096)                                                        |
| No                                                                 | 26 (25.096)                                                        | 27 (51.9.96)                                                       |
| Missing                                                            | 29 (27.996)                                                        | 12 (23.196)                                                        |
| Exeluding Missing Response.n                                       | 75                                                                 | 40                                                                 |
| Yes                                                                | 49 (63.3.96)                                                       | 13 (32.5%6)                                                        |
| No                                                                 | 26 (34.796)                                                        | 27 (67.5.96)                                                       |
| Increase of≥ 1 g/dL at Week 24 excluding 4 week post-transfusion   | Increase of≥ 1 g/dL at Week 24 excluding 4 week post-transfusion   | Increase of≥ 1 g/dL at Week 24 excluding 4 week post-transfusion   |
| Including missing response, n                                      | 104                                                                | 32                                                                 |
| Yes                                                                | 36 (34.696)                                                        | 10 (19.2%)                                                         |
| No                                                                 | 39 (37.596)                                                        | 30 (57.7%)                                                         |
| Missing                                                            | 29 (27.996)                                                        | 12 (23.1%6)                                                        |
| Excluding missing response, n                                      | 75                                                                 | 40                                                                 |
| Yes                                                                | 36 (48.096)                                                        | 10 (25.0%6)                                                        |
| No                                                                 | 39 (52.096)                                                        | 30 (75.0%)                                                         |
| Increase of≥ 1.5 g/dL at Weck 24 excluding 4 week post-transfusion | Increase of≥ 1.5 g/dL at Weck 24 excluding 4 week post-transfusion | Increase of≥ 1.5 g/dL at Weck 24 excluding 4 week post-transfusion |
| Including missing response, n                                      | 104                                                                | 52                                                                 |
| Yes                                                                | 27 (26.0%6)                                                        | 4 (7.7%6)                                                          |
| No                                                                 | 48 (46.296)                                                        | 36 (69.2%%)                                                        |
| Missing                                                            | 29 (27.994)                                                        | 12 (23.196)                                                        |
| Exchuding missing response. n                                      | 75                                                                 |                                                                    |
|                                                                    | 27 (36.096)                                                        | 4 (10.0%)                                                          |
| ON                                                                 | 48 (64.096)                                                        | 36 (90.096)                                                        |
| Incrense of≥ 2 g/dL at Week 24 excluding 4 week post-transfuslon   | Incrense of≥ 2 g/dL at Week 24 excluding 4 week post-transfuslon   | Incrense of≥ 2 g/dL at Week 24 excluding 4 week post-transfuslon   |
| Including missing response, n                                      | 101                                                                | 52                                                                 |
| Yes                                                                | 17 (16.396)                                                        | 0                                                                  |
| No                                                                 | 58 (55.896)                                                        | 40 (76.996)                                                        |
| Missing                                                            | 29 (27.996)                                                        | 12 (23.196)                                                        |
| Excluding missing response. n                                      | 75                                                                 | 40                                                                 |
| Yes                                                                | 17 (22.746)                                                        | 0                                                                  |
| ON                                                                 | 58 (77.396)                                                        | (%6001)0                                                           |

Haemoglobin increase: at least 1 increase versus baseline, in the 12 weeks before Week 24 excluding all hemoglobin values 4 weeks post-transfusion Abbreviations: BAT = best available therapy; MMB = momelotinib; RT = Randomized

Haemoglobin increases at Week 24 versus baseline was a post hoc exploratory analysis in which haemoglobin increases were categorized into ≥ 0.5, ≥ 1, ≥ 1.5, and ≥ 2 g/dL. Haemoglobin values within 4 weeks post-transfusion were removed to avoid confounding transfusion-induced increases in haemoglobin.

Mean percent changes in haemoglobin over time are depicted for both treatment phases in Figure below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Forefficacy analyses of Hgb.assessments from bothcentral and local labs areincluded. Source:Table15.12.6.14.1,15.12.6.14.2,Listing162.8.1.1

SE=StandardEmor.

DataExtracted:CRFdata:25JUN2019

Source:version3progg-adhoc-line-comb.sasvB.4Outoutfle:adhoc-g-se-hgb-db-dl.ou17JUL2020:00:54

Figure 15: Mean (± SE) Plot of Hemoglobin, Change and Percent Change from Baseline Over Time in the RT and ET Phases (Intent-to-Treat Analysis Set, SIMPLIFY-2)

## SIMPLIFY-1

<!-- image -->

DataExtracted:CRFdataOtJUL2019

Source:wersion3progg-achoc-ine-comb.sasv9.4Outputfle:achoc-g-se-hgb-o-olout21SEP2020:12:19

Figure 16: Mean (±SE) Hemoglobin Levels Over Time (ITT Population, SIMPLIFY-1)

<div style=\"page-break-after: always\"></div>

At baseline, the mean (median) hemoglobin level was 10.6 g/dL (10.5 g/dL) in the MMB group and 10.7  g/dL  (10.3  g/dL)  in  the  RUX  group.  MMB  induced  a  rapid  increase  in  Hgb  levels  that  was maintained over time. In the RUX group, mean hemoglobin level decreased, reaching a nadir at week 8 -  12,  after  which  mean  hemoglobin  level  showed  a  recovering  trend,  however  did  not  completely recover by Week 24. Beyond week 24, with the majority of patients crossed over to MMB treatment, hemoglobin levels reached and exceeded the mean baseline level.

The proportion of subjects with Hgb responses (ie, increases of ≥ 1, ≥ 1.5, or ≥ 2 g/dL from baseline) (exploratory and post-hoc analysis)

Table 65: Rates of Hemoglobin Response Defined as ≥0.5, ≥ 1, ≥ 1.5, or ≥ 2 g/dL Increases From Baseline During the 24-Week Randomized Treatment Period (ITT  population  and  TI population, SIMPLIFY-1)

|                            | SIMPLIFY-1   | SIMPLIFY-1   |
|----------------------------|--------------|--------------|
| Hgb Response Rate          | MMB          | RUX          |
| Last 12 weeks of RT period |              |              |
| ITT population, N          | 215          | 217          |
| Missing                    | 34 (15.8%)   | 14 (6.5%)    |
| Increase of ≥ 0.5 g/dL     | 111 (51.6%)  | 45 (20.7%)   |
| Increase of ≥ 1 g/dL       | 80 (37.2%)   | 36 (16.6%)   |
| Increase of ≥ 1.5 g/dL     | 51 (23.7%)   | 25 (11.5%)   |
| Increase of ≥ 2 g/dL       | 36 (16.7%)   | 13 (6.0%)    |
| TI at baseline, n          | 147          | 152          |
| Missing                    | 20 (13.6%)   | 6 (3.9%)     |
| Increase of ≥ 0.5 g/dL     | 74 (50.3%)   | 24 (15.8%)   |
| Increase of ≥ 1 g/dL       | 49 (33.3%)   | 18 (11.8%)   |
| Increase of ≥ 1.5 g/dL     | 29 (19.7%)   | 12 (7.9%)    |
| Increase of ≥ 2 g/dL       | 18 (12.2%)   | 3 (2.0%)     |

Hemoglobin values within 4 weeks post-transfusion were excluded.

Proportion differences were analyzed using the stratified CMH method.

The proportion of subjects with increased Hgb from baseline during the 12 weeks before week 24 was consistently higher in each incremental category in the MMB group versus the RUX group for the ITT population and the subgroup of subjects with TI at baseline.

- Proportion of TI at Week 24 in subjects with baseline TD (subgroup analysis):

Around a quarter of subjects [24.7% MMB (n = 53), 24.0% RUX (n = 52)] were TD at baseline (requiring  ≥  4  RBC  or  whole  blood  transfusion  units  or  a  hemoglobin  &lt;  8  g/dL  in  the  8  weeks before  randomization,  excluding  cases  associated  with  clinically  overt  bleeding).  A  greater proportion of subjects with baseline TD in the MMB group converted to TI at week 24 compared with the RUX group: 30.2% (n = 16) vs 17.3% (n = 9). The treatment difference was 13% (95% CI: -3, 30).

- Proportion of patients with zero RBC transfusions during the randomized treatment period (posthoc analysis): a greater proportion of the MMB group had zero transfusions through week 24 compared with RUX (73% vs 46%)
- Proportion of patients with ≤4 RBC transfusions during the randomized treatment period (post -hoc analysis): the proportion of subject with 4 or fewer units transfused up to Week 24 were 83% (MMB) and 62% (RUX).

<div style=\"page-break-after: always\"></div>

In the Hgb &lt;10 g/dL subgroup, the Hgb levels were consistently higher in the MMB group compared to the RUX group throughout the entire randomized treatment period. Treatment with MMB resulted in a &gt;0.5 g/dL increase in mean Hgb levels by Week 2 that remained stable and above baseline levels over the 24-week treatment period. In the RUX Hgb &lt;10 g/dL subgroup in SIMPLIFY-1, there was a modest increase in Hgb levels by Week 2 (&lt;0.5 g/dL). Following this, Hgb levels decreased to a new nadir around Week 4 that remained stable with a characteristic recovery that returned Hgb to baseline levels by Week 24. Recall however that 61.1% of the RUX group were transfusion dependent by week 24. The RUX effect on Hgb levels in the Hgb &lt;10 g/dL subgroup were not consistent with the overall ITT population, in which Hgb levels remained below baseline, possibly due to the confounding factor of transfusions and/or RUX dose adjustments.

Figure 17: Mean (±SE) Hemoglobin Levels Over Time during the double-blind phase (Hgb &lt; 10 g/dL subpopulation, SIMPLIFY-1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Post-hoc subgroup analysis in function of baseline hemoglobin &lt; 10 g/dL, ≥ 10 g/dL and &lt; 12 g/dL, &lt; 12 g/dL, ≥ 12 g/dL; TSS ≥ 10; TSS ≥ 10 AND hemoglobin &lt; 10 g/dL; platelet count ≤ 150,&gt; 150 and ≤ 300, &gt; 300 x 10 9 /L

Table 66: Post-hoc subgroup analyses of SRR, MPN-SAF TSS and TI rate at Week 24 (ITTpopulation, SIMPLIFY-1)

|                                   | SIMPLIFY-1                   | SIMPLIFY-1                   |
|-----------------------------------|------------------------------|------------------------------|
| Subgroup                          | MMB (N = 215)                | RUX (N = 217)                |
| SRR at Week 24                    | SRR at Week 24               | SRR at Week 24               |
| Overall splenic responders        | 57 (26.5%)                   | 64 (29.5%)                   |
| BL Hgb category                   |                              |                              |
| < 10 g/dL                         | 27/86 (31.4%)                | 31/95 (32.6%)                |
| ≥ 10 and < 12 g/dL                | 19/73 (26.0%)                | 17/69 (24.6%)                |
| < 12 g/dL                         | 46/159 (28.9%)               | 48/164 (29.3%)               |
| ≥ 12 g/dL                         | 11/56 (19.6%)                | 16/53 (30.2%)                |
| BL TSS Category                   |                              |                              |
| TSS ≥ 10                          | 38/152 (25.0%)               | 43/149 (28.9%)               |
| TSS ≥ 10 AND hemoglobin < 10 g/dL | 17/59 (28.8%)                | 22/65 (33.8%)                |
| BL transfusion status             |                              |                              |
| TI                                | 41/147 (27.9%)               | 46/152 (30.3%)               |
| Non-TI                            | 16/68 (23.5%)                | 18/65 (27.7%)                |
| TD                                | 12/53 (22.6%)                | 15/52 (28.8%)                |
| BL platelet count (× 10 9 /L)     |                              |                              |
| ≥ 50 and ≤ 150                    | 11/47 (23.4%)                | 2/57 (3.5%)                  |
| > 150 and ≤ 300                   | 31/89 (34.8%)                | 23/71 (32.4%)                |
| > 300                             | 15/79 (19.0%)                | 39/89 (43.8%)                |
| TSS Response Rate at Week 24      | TSS Response Rate at Week 24 | TSS Response Rate at Week 24 |
| Overall evaluable TSS responders  | 60/211 (28.4%)               | 89/211 (42.2%)               |
| BL Hgb category                   |                              |                              |
| < 10 g/dL                         | 21/84 (25.0%)                | 34/94 (36.2%)                |
| ≥ 10 and < 12 g/dL                | 25/71 (35.2%)                | 29/64 (45.3%)                |
| < 12 g/dL                         | 46/155 (29.7%)               | 63/158 (39.9%)               |
| ≥ 12 g/dL                         | 14/56 (25.0%)                | 26/53 (49.1%)                |
| BL TSS Category                   |                              |                              |
| TSS ≥ 10                          | 50/152 (32.9%)               | 64/149 (43.0%)               |
| TSS ≥ 10 AND hemoglobin < 10 g/dL | 15/59 (25.4%)                | 21/65 (32.3%)                |
| BL transfusion status             |                              |                              |
| TI                                | 45/146 (30.8%)               | 66/148 (44.6%)               |
| Non-TI                            | 15/65 (23.1%)                | 23/63 (36.5%)                |
| TD                                | 12/51 (23.5%)                | 20/50 (40.0%)                |
| BL platelet count (× 10 9 /L)     |                              |                              |
| ≥ 50 and ≤ 150                    | 13/45 (28.9%)                | 19/57 (33.3%)                |
| > 150 and ≤ 300                   | 29/88 (33.0%)                | 29/69 (42.0%)                |
| > 300                             | 18/78 (23.1%)                | 41/85 (48.2%)                |
| TI Rate at Week 24                | TI Rate at Week 24           | TI Rate at Week 24           |
| Overall TI responders             | 143 (66.5%)                  | 107 (49.3%)                  |
| BL Hgb category                   |                              |                              |
| < 10 g/dL                         | 40/86 (46.5%)                | 26/95 (27.4%)                |
| ≥ 10 and < 12 g/dL                | 59/73 (80.8%)                | 35/69 (50.7%)                |
| < 12 g/dL                         | 99/159 (62.3%)               | 61/164 (37.2%)               |
| ≥ 12 g/dL                         | 44/56 (78.6%)                | 46/53 (86.8%)                |
| BL TSS Category                   |                              |                              |
| TSS ≥ 10                          | 100/152 (65.8%)              | 76/149 (51.0%)               |
| TSS ≥ 10 AND hemoglobin < 10 g/dL | 25/59 (42.4%)                | 18/65 (27.7%)                |
| BL transfusion status             |                              |                              |
| TI                                | 119/147 (81.0%)              | 94/152 (61.8%)               |
| Non-TI                            | 24/68 (35.3%)                | 13/65 (20.0%)                |
| TD                                | 16/53 (30.2%)                | 9/52 (17.3%)                 |
| BL platelet count (× 10 9 /L)     |                              |                              |
| ≥ 50 and ≤ 150                    | 29/47 (61.7%)                | 24/57 (42.1%)                |
| > 150 and ≤ 300                   | 64/89 (71.9%)                | 38/71 (53.5%)                |
| > 300                             | 50/79 (63.3%)                | 45/89 (50.6%)                |

<div style=\"page-break-after: always\"></div>

Analyses of changes in individual symptom item scores from baseline at Week 24

- MOMENTUM study : analysis of change in MFSAF individual symptom item scores from baseline at Week 24:

Table 67: Treatment Differences in Change in MFSAF Individual Item Scores From Baseline at Week 24 (ITT population, MOMENTUM)

| MFSAF Individual Item Score   | LS Mean Difference (95%6 CI) []   |   p-value [2] |
|-------------------------------|-----------------------------------|---------------|
| Disease-related fatigue       | -0.71 (-1.42, 0.00)               |        0.0513 |
| Night sweats                  | 1.27 (-2.00, -0.53)               |        0.0009 |
| Itching                       | -0.31 (-1.14, 0.51)               |        0.4546 |
| Abdominal discomfort          | -1.11 (-1.91, -0.31)              |        0.0068 |
| Rib pain                      | -0.80 (-1.54, -0.05)              |        0.0363 |
| Fullness                      | -0.78 (-1.58, 0.01)               |        0.053  |
| Bone pain                     | 1.19 (-1.92, -0.46)               |        0.0016 |

Figure 18: Median Individual MFSAF Symptom Scores at Baseline and Week 24 (ITT Population, MOMENTUM)

<!-- image -->

Reductions (improvements) in MFSAF individual item scores from baseline at week 24 were greater in the MMB than in the DAN group based on the MMRM analysis, with the greatest treatment differences noted in night sweats, abdominal discomfort, bone pain, and rib pain, favouring MMB (p ˂ 0.05).

<div style=\"page-break-after: always\"></div>

Table 68: Change From Baseline at Week 24 in Disease-Related Fatigue, Cancer-Related Fatigue, and Subject-Reported Physical Function (ITT population, MOMENTUM)

| Change From Baseline at Week 24                      | MMB (N = 130)   | DAN (N = 65)   |
|------------------------------------------------------|-----------------|----------------|
| Disease-Related Fatigue by MFSAF                     |                 |                |
| Baseline MFSAF fatigue item score, mean (SD)         | 6.20 (2.14)     | 5.77 (2.08)    |
| Change from baseline at week 24                      |                 |                |
| Least squares mean (SE) [1]                          | -1.53 (0.20)    | -0.82 (0.31)   |
| Least squares mean difference (SE) [1]               | -0.71 (0.36)    | -0.71 (0.36)   |
| 95% CI [1]                                           | -1.42, 0.00     | -1.42, 0.00    |
| p-value [2]                                          | 0.0513          | 0.0513         |
| Cancer-related fatigue by EORTC QLQ-C30              |                 |                |
| Baseline EORTC QLQ-C30 fatigue item score, mean (SD) | 63.82 (24.07)   | 55.38 (24.81)  |
| Change from baseline at week 24                      |                 |                |
| Least squares mean (SE) [1]                          | -14.34 (2.35)   | -3.52 (3.65)   |
| Least squares mean difference (SE) [1]               | -10.82 (4.21)   | -10.82 (4.21)  |
| 95% CI [1]                                           | -19.15, -2.48   | -19.15, -2.48  |
| p-value [2]                                          | 0.0113          | 0.0113         |
| Subject-reported physical function by PROMIS         |                 |                |
| Baseline PROMIS physical function score, mean (SD)   | 32.49 (9.55)    | 34.38 (10.45)  |
| Change from baseline at week 24                      |                 |                |
| Least squares mean (SE) [1]                          | 1.19 (0.77)     | -0.11 (1.21)   |
| Least squares mean difference (SE) [1]               | 1.31 (1.42)     | 1.31 (1.42)    |
| 95% CI [1]                                           | -1.49, 4.11     | -1.49, 4.11    |
| p-value [2]                                          | 0.3570          | 0.3570         |

[1] Based on MMRM adjusted for baseline MFSAF TSS (&lt; 22 vs ≥ 22), baseline palpable spleen length below the left costal margin (&lt; 12 cm vs ≥ 12 cm), and baseline RBC or whole blood units transfused in the 8-week period before randomization (0, 1-4, ≥ 5 units).  [2] p-value for the least squares mean difference between the 2 groups from the MMRM

- SIMPLIFY-1 study : analysis of change in MFSAF individual symptom item scores from baseline at Week 24 from the modified MPN SAF TSS v2.0 (post-hoc analysis):

Figure  19:  Median  Individual  MPN-SAF  Symptom  Scores  at  Baseline  and  Week  24 (ITT Population, SIMPLIFY-1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Overall survival

In  MOMENTUM trial, OS was a prespecified secondary endpoint. As of database lock date of 17 Jan 2023,  during  the  entire  study  period  (randomized  and  open-label  treatment  period),  a  total  of 58 events  (deaths)  occurred  in  38 subjects  (29.2%)  from  the  former  randomized  MMB  group  and 20 subjects (30.8%) from the former DAN group.

Table 69: Overall survival (ITT population, MOMENTUM)

|                                | MOMENTUM (ITT Population)   | MOMENTUM (ITT Population)   |
|--------------------------------|-----------------------------|-----------------------------|
| Overall Survival               | MMB (N = 130)               | DAN (N = 65)                |
| Median follow-up [1]           | 393.00 days (1.1 y)         | 377.00 days (1.0 y)         |
| Event (death), n (%)           | 38 (29.2%)                  | 20 (30.8%)                  |
| Censored, n (%)                | 92 (70.8%)                  | 45 (69.2%)                  |
| Kaplan-Meier estimate overall  |                             |                             |
| Median (95% CI)                | 624.0 (582.0 [1.6 y, NC)    | NC (471.0 days [1.3 y], NC) |
| Min, max                       | 41, 629+ days (0.11, 1.7 y) | 26, 729+ days (0.07, 2.0 y) |
| Hazard ratio (95% CI) [2]      | 0.890 (0.504, 1.572)        | 0.890 (0.504, 1.572)        |
| p-value [3]                    | 0.6879                      | 0.6879                      |
| Overall survival up to week 24 |                             |                             |
| Hazard ratio (95% CI) [3]      | 0.506 (0.238, 1.076)        | 0.506 (0.238, 1.076)        |
| p-value [3]                    | 0.0719                      | 0.0719                      |

- [1] By reverse Kaplan-Meier method for MOMENTUM.  Based on the safety population for SIMPLIFY-1.
- [2] From a stratified Cox proportional hazards model.  [3] From a stratified log-rank test.

<!-- image -->

Vertical line at week 24 indicates when ongoing subjects received MMB as open-label treatment.+ indicates a censored observation. [1] From a stratified log-rank test. [2] Hazard ratio (MMB vs DAN) was from a stratified Cox proportional hazards model with a single factor of treatment group and baseline MFSAF total symptom score (&lt; 22 vs ≥ 22), baseline palpable spleen length below the left costal margin (&lt; 12 vs ≥ 12 cm), and baseline red blood cell or whole blood units transfused in the 8 -week period before randomization (0, 14, ≥ 5 units) as strata

Figure 20: Kaplan-Meier Plot of Overall Survival (ITT Population, MOMENTUM)

<div style=\"page-break-after: always\"></div>

In SIMPLIFY-2 trial, Overall Survival was a prespecified exploratory endpoint.

Table 70: Overall Survival for the Combined RT and ET Phases (Safety Analysis Set, SIMPLIFY-2)

<!-- image -->

|                                                | Week24Interim Analysis                         | Week24Interim Analysis                         | Week48Interim Analysis                         | Week48Interim Analysis                         | Final Analysis                                 | Final Analysis                                 |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                                | MMB ( =104)                                    | BAT (N = 52)                                   | MMB (N =104)                                   | BAT (N =52)                                    | MMB ( =104)                                    | BAT (N = 52)                                   |
| Subjects with events                           | Subjects with events                           | Subjects with events                           | Subjects with events                           | Subjects with events                           | Subjects with events                           | Subjects with events                           |
| Death, n (%)                                   | 14 (13.5%)                                     | 11 (21.2%)                                     | 34 (32.7%)                                     | 19 (36.5%)                                     | 46 (44.2%)                                     | 23 (44.2%)                                     |
| Subjects died in the RT Phase                  | 6 (42.9%)                                      | 5 (45.5%)                                      | 6 (17.6%)                                      | 5 (26.3%)                                      | 6 (13.0%)                                      | 5 (21.7%)                                      |
| Subjects died in ET Phase                      | 5 (35.7%)                                      | 2 (18.2%)                                      | 11 (32.4%)                                     | 4 (21.1%)                                      | 14 (30.4%)                                     | 4 (17.4%)                                      |
| Subjects died in follow-up                     | 3 (21.4%)                                      | 4 (36.4%)                                      | 17 (50.0%)                                     | 10 (52.6%)                                     | 26 (56.5%)                                     | 14 (60.9%)                                     |
| Subjects censored, n (%)                       | 90 (86.5%)                                     | 41 (78.8%)                                     | 70 (67.3%)                                     | 33 (63.5%)                                     | 58 (55.8%)                                     | 29 (55.8%)                                     |
| Kaplan-lfeierestimateofoverallsurvival(months) | Kaplan-lfeierestimateofoverallsurvival(months) | Kaplan-lfeierestimateofoverallsurvival(months) | Kaplan-lfeierestimateofoverallsurvival(months) | Kaplan-lfeierestimateofoverallsurvival(months) | Kaplan-lfeierestimateofoverallsurvival(months) | Kaplan-lfeierestimateofoverallsurvival(months) |
| 25-percentile (95% CI)                         | NR (11.47, NR)                                 | 15.77 (5.91, 16.39)                            | 18.69 (11.47, 23.82)                           | 12.19 (5.91, 21.29)                            | 18.69 (11.47, 23.82)                           | 12.19 (5.91, 22.34)                            |
| Median (95% CI)                                | NR                                             | 15.77 (15.77, 16.39)                           | 27.70 (24.28, NR)                              | NR (20.27, NR)                                 | 34.33 (27.33, NR)                              | 37.52 (21.29, NR)                              |
| 75-percentile (95%CI)                          | NR                                             | 16.39 (15.77, 16.39)                           | NR                                             | NR                                             | NR                                             | NR                                             |
| Min, Max                                       | 0.30, 24.15                                    | 0.43, 16.39                                    | 0.30, 37.65                                    | 0.43, 29.01                                    | 0.30, 50.40                                    | 0.43, 44.32                                    |
| Stratifiedlog-rank testp-value                 | 0.24                                           | 0.24                                           | 0.47                                           | 0.47                                           | 0.86                                           | 0.86                                           |
| StratifiedHazardRatio (95% CI)                 | 0.62 (0.28, 1.38)                              | 0.62 (0.28, 1.38)                              | 0.81 (0.45, 1.44)                              | 0.81 (0.45, 1.44)                              | 0.96 (0.58, 1.59)                              | 0.96 (0.58, 1.59)                              |

Death in RT Phase is death occurring on or after the first RT dose up to the earliest of the last RT dose + 30 days, or the first ET dose -1 day. Death in the ET Phase is death occurring on or after the first ET dose up to the last ET MBB dose + 30 days. Death in the Follow-up Phase is death occurring after 30 days of the last dose in RT or ET Phases, whichever was latest. Overall survival (months) = (date of death or censoring - date of first dose in the RT Phase + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 21: Kaplan-Meier Plot of Overall Survival (Safety Analysis Set, SIMPLIFY-2)

<!-- image -->

In SIMPLIFY 1 trial, overall survival analysis (exploratory endpoint) is based on safety population (1 subject  in  each  treatment  group  was  randomized  but  not  treated,  and  therefore  included  in  ITT analysis set but not in Safety analysis set).  OS data presented below are derived from follow-up data from XAP as of the data cutoff date of 03 Dec 2021.

During  the  entire  period,  a  total  of  140 events  (deaths)  occurred  in  67 subjects  (31.3%)  from  the former randomized MMB group and 73 subjects (33.8%) from the former RUX group as of the data cutoff date of 03 Dec 2021. The hazard ratio was estimated as 1.03 (95% CI: 0.74, 1.44; log-rank test p = 0.8646).  The median Kaplan-Meier estimate of OS was not reached in either group. As less than 7 subjects  were  followed  when  the  median  was  estimated  for  the  RUX  group,  the  result  should  be interpreted with caution. The 1-, 2-, and 3-year survival rates in the MMB group were approximately 93%, 82% and 71%.

Table 71: Overall survival (Safety Analysis Set, SIMPLIFY-1, DCO of 03 Dec 2021)

|                               | Week 24 Analysis (data cut- off date of 12 Sep 2016)   | Week 24 Analysis (data cut- off date of 12 Sep 2016)   | Follow-up data from XAP as of the data cutoff date of 03 Dec 2021   | Follow-up data from XAP as of the data cutoff date of 03 Dec 2021   |
|-------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Overall Survival              | MMB (N = 214)                                          | RUX (N = 216)                                          | MMB (N = 214)                                                       | RUX (N = 216)                                                       |
| Median follow-up [1]          |                                                        |                                                        | 3.43 y                                                              | 3.47 y                                                              |
| Event (death), n (%)          | 14 (6.5%)                                              | 19 (8.8%)                                              | 67 (31.3%)                                                          | 73 (33.8%)                                                          |
| Censored, n (%)               | 200 (93.5%)                                            | 197 (91.2%)                                            | 147 (68.7%)                                                         | 143 (66.2%)                                                         |
| Kaplan-Meier estimate overall |                                                        |                                                        |                                                                     |                                                                     |
| Median (95% CI)               | NR                                                     | NR                                                     | NR (4.73 y, NR)                                                     | NR (4.94 y, NR)                                                     |
| Min, max                      | 0.72, 29.63 mo                                         | 0.36, 29.83 mo                                         | 0.06, 7.53 y                                                        | 0.03, 7.35 y                                                        |
| Hazard ratio (95% CI) [2]     | 0.80 (0.40, 1.59)                                      | 0.80 (0.40, 1.59)                                      | 1.03 (0.74, 1.44)                                                   | 1.03 (0.74, 1.44)                                                   |
| p-value [3]                   | 0.52                                                   | 0.52                                                   | 0.8646                                                              | 0.8646                                                              |

<div style=\"page-break-after: always\"></div>

Figure 22: Kaplan-Meier Plot of Overall Survival (Safety Analysis Set, SIMPLIFY-1, data cutoff date of 03 Dec 2021)

<!-- image -->

## Leukemia-free survival (LFS)

In MOMENTUM trial, LFS  was as OS a secondary endpoints not included in the prespecified hierarchical testing. Provided data are as of database lock date of 17 Jan 2023.

Table 72: Leukemia-free survival (ITT population, MOMENTUM)

|                           | MOMENTUM (ITT Population)     | MOMENTUM (ITT Population)     |
|---------------------------|-------------------------------|-------------------------------|
| Leukemia-Free Survival    | MMB (N = 130)                 | DAN (N = 65)                  |
| Median follow-up [1]      | 361.00 days (1.0 y)           | 372.00 days (1.0 y)           |
| Event, n (%)              | 40 (30.8%)                    | 22 (33.8%)                    |
| Leukemic transformation   | 5 (3.8%)                      | 5 (7.7%)                      |
| Death                     | 35 (26.9%)                    | 17 (26.2%)                    |
| Censored, n (%)           | 90 (69.2%)                    | 43 (66.2%)                    |
| Kaplan-Meier estimate     |                               |                               |
| Median (95% CI)           | 624.0 (582.0 [1.7 y], NC)     | NC (471.0 [1.3 y], NC)        |
| Min, max                  | 41, 629+ days (1.3 mo, 1.7 y) | 26, 677+ days (0.9 mo, 1.9 y) |
| Hazard ratio (95% CI) [2] | 0.804 (0.466, 1.386)          | 0.804 (0.466, 1.386)          |
| p-value [3]               | 0.4320                        | 0.4320                        |

- [1]  By reverse Kaplan-Meier method for MOMENTUM.  Based on the safety population for SIMPLIFY-1.
- [2]  From a stratified Cox proportional hazards model.
- [3]  From a stratified log-rank test.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Vertical line at week 24 indicates when ongoing subjects received MMB as open-label treatment.+ indicates a censored observation.

Figure 23: Kaplan-Meier Plot of Leukemia-Free Survival (ITT Population, MOMENTUM)

<div style=\"page-break-after: always\"></div>

In SIMPLIFY-2 trial, LFS was a prespecified exploratory endpoint.

Table 73: Analysis of Leukemia-free Survival for the Combined RT and ET Phases (Safety Analysis Set,SIMPLIFY-2)

|                                                     | InterimWeek24 Analysis                              | InterimWeek24 Analysis                              | Interim 2Analysis                                   | Interim 2Analysis                                   | Final Analysis                                      | Final Analysis                                      |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                     | MMB (N =104)                                        | BAT ( = 52)                                         | MMB (N = 104)                                       | BAT ( = 52)                                         | MMB (N = 104)                                       | BAT (N = 52)                                        |
| Subjectswith events                                 | 15 (14.4%)                                          | 12 (23.1%)                                          | 36 (34.6%)                                          | 20 (38.5%)                                          | 48 (46.2%)                                          | 24 (46.2%)                                          |
| Leukemic transformation, n (%%)                     | 4 (3.8%)                                            | 1 (1.9%)                                            | 7 (6.7%)                                            | 1 (1.9%)                                            | 7 (6.7%)                                            | 1 (1.9%)                                            |
| Death                                               | 11 (10.6%)                                          | 11 (21.2%)                                          | 29 (27.9%)                                          | 19 (36.5%)                                          | 41 (39.4%)                                          | 23 (44.2%)                                          |
| Subjects censored                                   | 89 (85.6%)                                          | 40 (76.9%)                                          | 68 (65.4%)                                          | 32 (61.5%)                                          | 56 (53.8%)                                          | 28 (53.8%)                                          |
| Kaplan-leierestimateofleukemia-freesurvival(months) | Kaplan-leierestimateofleukemia-freesurvival(months) | Kaplan-leierestimateofleukemia-freesurvival(months) | Kaplan-leierestimateofleukemia-freesurvival(months) | Kaplan-leierestimateofleukemia-freesurvival(months) | Kaplan-leierestimateofleukemia-freesurvival(months) | Kaplan-leierestimateofleukemia-freesurvival(months) |
| 25-percentile (95% Cl)                              | NR (11.50, NR)                                      | 15.77 (5.68, 16.39)                                 | 16.26 (10.94, 21.29)                                | 12.12 (5.68, 21.29)                                 | 16.43 (10.94, 21.29)                                | 12.19 (5.68, 21.29)                                 |
| Median (95% CI)                                     | NR                                                  | 15.77 (15.77, 16.39)                                | 27.73 (24.28, NR)                                   | 25.13 (20.27, NR)                                   | 33.97 (27.33, NR)                                   | 37.52 (20.27, NR)                                   |
| 75-percentile (95% Cl)                              | NR                                                  | 16.39 (15.77, 16.39)                                | NR                                                  | NR                                                  | NR                                                  | NR                                                  |
| Min, Max                                            | 0.23, 24.21                                         | 0.43, 16.39                                         | 0.23, 37.72                                         | 0.43, 29.01                                         | 0,23, 50.40                                         | 0.43, 44.32                                         |
| Stratifiedlog-rank test p-value                     | 0.19                                                | 0.19                                                | 0.52                                                | 0.52                                                | 0.85                                                | 0.85                                                |
| Stratified hazard ratio (95% CI)                    | 0.60 (0.28, 1.29)                                   | 0.60 (0.28, 1.29)                                   | 0.83 (0.47, 1.46)                                   | 0.83 (0.47, 1.46)                                   | 0.95 (0.58, 1.57)                                   | 0.95 (0.58, 1.57)                                   |

Abbreviations: BAT = best available therapy; ET = extended treatment; MMB = momelotinib; NR = not reached; RT = randomized treatment Leukemia-free survival (months) = (date of leukemic transformation, death or censoring date of randomization+ 1) / 30.4375.

DataExtracted:CRFdata:25JUN2019

Figure 24: Kaplan-Meier Plot of Leukemia-Free Survival (Safety population, SIMPLIFY-2)

<!-- image -->

<div style=\"page-break-after: always\"></div>

In  the  SIMPLIFY-1  trial,  in  the  MMB  group,  67 subjects  (31.2%)  had  events,  including  12 subjects (5.6%)  with  leukemic  transformation  and  55 subjects  (25.6%)  who  died.    In  the  RUX  group, 68 subjects  (31.3%)  had  events,  including  9 subjects  (4.1%)  with  leukemic  transformation  and 59 subjects  (27.2%)  who  died.    The  median  Kaplan-Meier  estimate  of  LFS  was  not  reached  for  the MMB group and was 53.06 months for the RUX group in the final analysis.  The hazard ratio was 1.07 (95% CI: 0.76, 1.50), p = 0.70.

Table 74:  Leukemia-free survival (ITT population, SIMPLIFY-1)

|                           | Week 24 Analysis (data cut- off date of 12 Sep 2016)   | Week 24 Analysis (data cut- off date of 12 Sep 2016)   | Final analysis (data cut-off date 01 Jul 2019)   | Final analysis (data cut-off date 01 Jul 2019)   |
|---------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Leukemia-Free Survival    | MMB (N = 215)                                          | RUX (N = 217)                                          | MMB (N = 215)                                    | RUX (N = 217)                                    |
| Median follow-up [1]      |                                                        |                                                        | 35.4 mo                                          | 35.2 mo                                          |
| Event, n (%)              | 15 (7.0%)                                              | 20 (9.2%)                                              | 67 (31.2%)                                       | 68 (31.3%)                                       |
| Leukemic transformation   | 1 (0.5%)                                               | 2 (0.9%)                                               | 12 (5.6%)                                        | 9 (4.1%)                                         |
| Death                     | 14 (6.5%)                                              | 18 (8.3%)                                              | 55 (25.6%)                                       | 59 (27.2%)                                       |
| Censored, n (%)           | 200 (93.0%)                                            | 197 (90.8%)                                            | 148 (68.8%)                                      | 149 (68.7%)                                      |
| Kaplan-Meier estimate     |                                                        |                                                        |                                                  |                                                  |
| Median (95% CI)           | NR                                                     | NR                                                     | NR (44.09, NR)                                   | 53.06 mo (48.72, NR)                             |
| Min, max                  |                                                        |                                                        | 0.03, 59.30 mo                                   | 0.36, 56.34 mo                                   |
| Hazard ratio (95% CI) [2] | 0.81 (0.42, 1.59)                                      | 0.81 (0.42, 1.59)                                      | 1.07 (0.76, 1.50)                                | 1.07 (0.76, 1.50)                                |
| p-value [3]               | 0.54                                                   | 0.54                                                   | 0.70                                             | 0.70                                             |

- [1] By reverse Kaplan-Meier method for MOMENTUM.  Based on the safety population for SIMPLIFY-1.

[2] From a stratified Cox proportional hazards model.

[3] From a stratified log-rank test.

Figure 25: Kaplan-Meier Plot of Leukemia-Free Survival (ITT Population, SIMPLIFY-1, data cut-of date 01 Jul 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Missing data sensitivity analyses

[Note:  worst-case  analyses:  imputing  non-response  for  MMB  subjects  and  response  for  control  arm subjects;  modified  worst-case  analysis:  subjects  in  the  MMB  arm  with  missing  data  due  to  reasons other than disease progression were analyzed as non-responders, control arm subjects with missing data  due  to  reasons  other  than  insufficient  efficacy  or  disease  progression,  the  more  favorable treatment arm was used to impute missing data for the control arm (MMB arm for MOMENTUM and SIMPLIFY-2  for  all  3  endpoints  and  TI  rate  in  SIMPLIFY-1;  RUX  arm  for  TSS  response  and  SRR  in SIMPLIFY-1)]

MOMENTUM [Discontinuation  during  RT  due  to  reasons  indicating  insufficient  efficacy  or  disease progression: MMB: 11/130 (8.5%), DAN: 11/65 (16.9%)]

- MFSAF TSS response rate at W24 [ Missing data at W24: MMB: 39/130 (30%), DAN: 28/65 (43.1%); Primary analysis: 24.6% (95% CI: 17.5%, 32.9%) vs 9.2% (95% CI: 3.5%, 19.0%), superiority proportion difference: 15.7 % (95% CI : 5.5%, 25.8%), p-value : 0.0095]
- -Complete case analysis under MCAR : 35.2% (95% CI: 25.4%, 45.9%) vs 16.2% (95% CI: 6.2%, 32.0%), superiority proportion difference: 20.7 % (95% CI : 6.0%, 35.5%), p-value : 0.0210
- -Multiple imputation under MAR : 31.1% (95% CI: 22.7%, 39.4%) vs 13.4% (95% CI: 4.0%, 22.9%),  superiority  proportion  difference: 17.5 %  (95%  CI :  4.8%,  30.2%),  p-value : 0.0071
- -Observed case analysis: 35.2% (95% CI: 25.4%, 45.9%) vs 16.2% (95% CI: 6.2%, 32.0%), superiority proportion difference: 20.7 % (95% CI : 6.0%, 35.5%), p-value : 0.0210
- -Last observation carried forward analysis: 29.2% (95% CI: 21.6%, 37.9%) vs 10.8% (95% CI:  4.4%,  20.9%),  superiority  proportion  difference: 18.3 % (95% CI :  7.6%,  29.1%),  pvalue : 0.0043
- -Modified worst-case analysis : 24.6% (95% CI: 17.5%, 32.9%) vs 15.4% (95% CI: 5.4%, 25.4%), superiority proportion difference: 9.2 % (95% CI : -3.2%, 21.7%), p-value : 0.1460
- -Worst-case analysis : 24.6% (95% CI: 17.5%, 32.9%) vs 52.3% (95% CI: 39.5%, 64.9%), superiority proportion difference: -27.7 % (95% CI : -42.2, -13.3%), p-value : 0.9999
- -Tipping point analysis: An average shift of at least 13 points in the patients with missing TSS on  Week  24  compared  to  those  with  non-missing  TSS  (on  a  scale  of  70  points)  would  be needed to change statistical significance.
- SRR  at  W24  [ Missing  data  at  W24:  MMB:  43/130  (33.1%),  DAN:  28/65  (43.1%);  Primary analysis:  22.3%  (95%  CI:  15.5%,  30.4%)  vs  3.1%  (95%  CI:  0.4%,  10.7%),  superiority proportion difference: 18.2 % (95% CI : 9.8%, 26.6%), p-value : 0.0011]
- -Complete case analysis under MCAR : 33.3% (95% CI: 23.6%, 44.3%) vs 5.4% (95% CI: 0.7%, 18.2%), superiority proportion difference: 26.8 % (95% CI : 13.6%, 39.9%), p-value : 0.0022
- -Multiple  imputation  under  MAR :  31.2%  (95%  CI:  21.9%,  40.5%)  vs  6.5%  (95%  CI:  0%, 13.9%),  superiority  proportion  difference: 24.0 %  (95%  CI :  12.1%,  35.8%),  p-value : 0.0001
- -Modified worst-case analysis : 22.3% (95% CI: 15.5%, 30.4%) vs 11.1% (95% CI: 1.9%, 20.4%), superiority proportion difference: 10.3 % (95% CI : -1.4, 22.1%), p-value : 0.0854

<div style=\"page-break-after: always\"></div>

- -Worst-case analysis : 22.3% (95% CI: 15.5%, 30.4%) vs 46.2% (95% CI: 33.7%, 59.0%), superiority proportion difference: -25.3 % (95% CI : -39.8, -0.8%), p-value : 0.9997
- -Tipping  point  analysis: No  tipping  point  could  be  identified to change  the  statistical significance
- TI  rate  at  W2  [ Missing  data  at  W24:  MMB:  34/130  (26.2%),  DAN:  27/65  (41.5%);  primary analysis:  30.0%  (95%  CI:  22.3%,  38.7%)  vs  20.0%  (95%  CI:  11.1%,  31.8%),  non-inferiority proportion difference: 13.6 % (95% CI : 1.9%, 25.3%), p-value : 0.0116]
- -Complete case analysis under MCAR : 36.1% (95% CI: 27.1%, 45.9%) vs 26.0% (95% CI: 14.6%, 40.3%), non-inferiority proportion  difference: 16.2 % (95% CI : 2.5%, 29.9%), pvalue : 0.0101
- -Multiple  imputation  under  MAR :  35.0%  (95%  CI:  26.3%,  43.8%)  vs  22.8%  (95%  CI: 12.0%, 33.7%), non-inferiority proportion  difference: 16.8 % (95% CI : 4.1%, 29.4%), pvalue : 0.0048
- -Modified worst-case analysis : 30.0% (95% CI: 22.3%, 38.7%) vs 24.7% (95% CI: 13.4%, 36.0%),  non-inferiority  proportion  difference: 10.1 % (95% CI :  -2.3%,  22.6%),  p-value : 0.0551
- -Worst-case analysis : 30.0% (95% CI: 22.3%, 38.7%) vs 43.1% (95% CI: 30.8%, 56.0%), non-inferiority proportion difference: -4.6 % (95% CI : -17.2%, 8.0%), p-value : 0.7642
- -Tipping  point  analysis:  Reversing  the  result  of  NI  from  statistical  significance  to  nonsignificance  would  require  the  odds  of  being  a  TI  responder  at  week  24  in  the  22  MMB subjects with missing data to be ~0.09 times the odds of being a TI responder at week 24 in the  subjects  with  complete  data.  In  other  words,  the  MMB  response  rate  in  the  missing subjects would need to be more than 10 times lower than that for subjects in the MMB arm with  non-missing  week  24  TI  status  (ie,  response  rate  reduced  from  the  observed  35% response rate in the completers to approximately 5%) to reverse the statistical significance in the non-inferiority test.

SIMPLIFY-2 [33.7%  vs  21.2%  of  subjects  in  the  MMB  arm  and  the  BAT  arm  (88%  of  subjects received ruxolitinib as best available therapy, mostly lower dose) discontinued randomized treatment early, respectively. However, there are confounders (discontinuation data of BAT were inconsistently collected and reported because changes in therapy or no therapy were permissible options for the BAT arm, open-label study, variable treatment comparator) making this difference not clinically meaningful; Discontinuation during RT due to reasons indicating insufficient efficacy or disease progression: MMB: 8/104 (7.7%), BAT: 2/52 (3.8%)]

- MFSAF TSS response rate at W24 [Primary analysis: 26.2% (95% CI: 18.0%, 35.8%) vs 5.9% (95% CI: 1.2%, 16.2%), superiority proportion difference: 20 % (95% CI : 9%, 32%), p-value : &lt; 0.001 ]
- -Last  observation carried forward analysis: 27.2% (95% CI: 18.9%, 36.8%) vs 7.8% (95% CI: 2.2%, 18.9%), superiority proportion difference: 19% (95% CI : 8%, 31%), p-value : 0.002
- -Modified worst-case analysis : 26.2% (95% CI: 18.0%, 35.8%) vs 11.1% (95% CI: 1.7%, 20.4%), superiority proportion difference: 14.8% (95% CI : 1.4, 28.2%), p-value : 0.03

<div style=\"page-break-after: always\"></div>

- -Other less conservative sensitivity analyses were not performed as the statistical significance was held despite the imbalance in missing data between the MMB and BAT arms
- SRR at W24 [Primary analysis: 6.7% (95% CI: 2.8%, 13.4%) vs 5.8% (95% CI: 1.2%, 16.0%), superiority proportion difference: 1 % (95% CI : -9%, 10%), p-value : 0.90 ]
- -Last observation carried forward analysis: 6.7% (95% CI: 2.8%, 13.4%) vs 5.8% (95% CI: 1.2%, 16.0%), superiority proportion difference: 1 % (95% CI : -9%, 10%), p-value : 0.90
- -Worst-case  analysis:  6.7%  (95%  CI:  2.8%,  13.4%)  vs  30.8%  (95%  CI:  18.7%,  45.1%), superiority proportion difference: -24.4 % (95% CI : -38.6%, -10.2%), p-value : 0.9996
- -Additional missing data analysis for SRR ( ≥ 35% reduction from baseline spleen volume) was not performed due to the lack of statistical significance and a small number of responders in the original analysis.
- TI rate at W24 [Missing data at W24: MMB: 21 (20.2%), BAT: 9 (17.3%) who discontinued early from  the  randomized  treatment  period  (for  reasons  other than  lack of efficacy,  disease progression,  leukemic  transformation,  or  adverse  event  of  MF)  without  a  documented  RBC transfusion or Hgb &lt; 8 g/dL during the terminal 12 weeks prior to week 24 and were therefore considered missing for TI status at week 24; Primary analysis: 43.3% (95% CI: 33.6%, 53.3%) vs 21.2% (95% CI: 11.2%, 34.7%), superiority proportion difference: 22.9 % (95% CI : 9.1%, 36.6%), p-value : 0.001 ]
- -Modified worst-case analysis : 43.3% (95% CI: 33.6%, 53.3%) vs 28.7% (95% CI: 15.8%, 41.5%),  superiority  proportion  difference: 15.3 %  (95%  CI :  0.1%,  30.5%),  p-value : 0.0487
- -Worst-case analysis : 43.3% (95% CI: 33.6%, 53.3%) vs 42.3% (95% CI: 28.7%, 56.8%), superiority proportion difference: 1.6 % (95% CI : -14.7%, 17.8%), p-value : 0.8499
- -Other less conservative sensitivity analyses were not performed as the statistical significance was held in the modified worst-case sensitivity analysis despite the imbalance in missing data between the MMB and BAT arms

SIMPLIFY-1 [Discontinuation during RT due to reasons indicating insufficient efficacy or disease progression: MMB: 9/215 (4.2%), RUX: 4/217 (1.8%)]

- MFSAF TSS response rate at W24 [Missing data at W24: MMB: 36/211 (17.1%), RUX: 21/211 (10.0%); Primary analysis: 28.4% (95% CI: 22.5%, 35.0%) vs 42.2% (95% CI: 35.4%, 49.1%), non-inferiority proportion difference: 0% (95% CI : -8%, 8%), p-value : 0.98 ]
- -Complete case analysis under MCAR : 34.3% (95% CI: 27.3%, 41.8%) vs 46.8% (95% CI: 39.6%, 54.2%), non-inferiority proportion difference: 3.0 % (95% CI : -5.6%, 11.6%), pvalue : 0.2501
- -Multiple imputation under MAR : 33.0% (95% CI: 26.4%, 39.6%) vs 44.2% (95% CI: 37.4%, 51.0%), non-inferiority proportion difference: 3.3 % (95% CI : -4.8%, 11.4%), pvalue : 0.2135
- -Modified worst-case analysis : not performed due to the lack of statistical significance in the original analysis
- -Worst-case analysis : 28.4% (95% CI: 22.5%, 35.0%) vs 52.1% (95% CI: 45.2%, 59.0%), non-inferiority proportion difference: -6.5 % (95% CI : -14.2%, 1.2%), p-value : 0.9505

<div style=\"page-break-after: always\"></div>

- -Tipping point analysis: In order to claim statistical significance for the non-inferiority test, the week 24 TSS scores of the missing MMB subjects had to be at least 8.0 points lower than those of the MMB subjects with data.
- -Best-case analysis: 43.1% vs 42.2%, non-inferiority proportion difference: 15 % (95% CI : 7%, 23%), p-value : &lt; 0.001
- SRR at W24 [Missing data at W24: MMB: 31/215 (14.4%), RUX: 13/217 (6.0%); Primary analysis: 26.5% (95% CI: 20.7%, 32.9%) vs 29.5% (95% CI: 23.5%, 36.0%), non-inferiority proportion difference: 9 % (95% CI : 2%, 16%), p-value : 0.014 ]
- -Complete case analysis under MCAR : 31.0% (95% CI: 24.4%, 38.2%) vs 31.4% (95% CI: 25.1%, 38.2%), non-inferiority proportion difference: 12.1 % (95% CI : 4.4%, 19.8%), pvalue : 0.0010
- -Multiple imputation under MAR : 30.0% (95% CI: 23.6%, 36.4%) vs 31.1% (95% CI: 24.9%, 37.4%), non-inferiority proportion difference: 11.2 % (95% CI : 3.8%, 18.6%), pvalue : 0.0015
- -Modified worst-case analysis : 26.5% (95% CI: 20.7%, 32.9%) vs 31.1% (95% CI: 24.8%, 37.4%), non-inferiority proportion difference: 7.7 % (95% CI : 0.7, 14.8%), p-value : 0.0153
- -Worst-case analysis : 26.5% (95% CI: 20.7%, 32.9%) vs 35.5% (95% CI: 29.1%, 42.2%), non-inferiority proportion difference: 5.1 % (95% CI : -1.9%, 12.2%), p-value : 0.0769
- -Tipping point analysis: No tipping point could be identified to change the statistical significance
- TI rate at W24 [Missing data at W24: MMB: 32/215 (14.9%), RUX: 12/217 (5.5%); Primary analysis: 66.5% (95% CI: 59.8%, 72.8%) vs 49.3% (95% CI: 42.5%, 56.2%), superiority proportion difference: 18 % (95% CI : 9%, 26%), p-value : &lt; 0.0001 ]
- -Modified worst-case analysis : Not performed because statistical significance was demonstrated in the more rigorous worst-case analysis.
- -Worst-case analysis : 66.5% (95% CI: 59.8%, 72.8%) vs 55.3% (95% CI: 48.4%, 62.0%), superiority proportion difference: 11.6 % (95% CI : 3.0%, 20.2%), p-value : 0.0042

<div style=\"page-break-after: always\"></div>

## Subgroup analyses in function of baseline demographics and disease characteristics

## Study SRA-MMB-301 (MOMENTUM)

## Subgroup analysis in function of baseline demographics and disease characteristics

## First primary endpoint: MFSAF TSS 24

<!-- image -->

|                                                                            | Subgroup                               | MMB                                    | DAN                                    | Difference(95%CI)                      |
|----------------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| TI/TD/TRBaselineStatus                                                     |                                        |                                        |                                        |                                        |
|                                                                            |                                        | 0.41                                   | 0.10                                   | 0.31(-0.08,0.60)                       |
| TI (MMB:N=17,DAN:N=10) TD（MMB:N=63,DAN:N=34)                               |                                        | 0.24                                   | 0.09                                   | 0.15(-0.03,0.29)                       |
| TR(MMB:N=50,DAN:N=21)                                                      |                                        | 0.20                                   | 0.10                                   | 0.10(-0.12,0.27)                       |
| TI/Non-TI BaselineStatus TI（MMB:N=17,DAN:N=10)                             |                                        | 0.41                                   | 0.10                                   | 0.31(-0.08,0.60)                       |
| Non-TI(MMB:N=113,DAN:N=55) Sex                                             |                                        | 0.22                                   | 0.09                                   | 0.13(0.00,0.24)                        |
| Male（MMB:N=79,DAN:N=44) Female(MMB:N=51,DAN:N=21)                          |                                        | 0.24 0.25                              | 0.11 0.05                              | 0.13(-0.03,0.26) 0.21(-0.01,0.36)      |
| Age <65Years(MMB:N=29,DAN:N=11)                                            |                                        | 0.17                                   | 0.00                                   | 0.17 (-0.13,0.36)                      |
| >=65Years（MMB:N=101,DAN:N=54)                                              |                                        | 0.27                                   | 0.11                                   | 0.16 (0.01,0.27)                       |
| Race                                                                       |                                        |                                        |                                        |                                        |
| Asian(MMB:N=12,DAN:N=6)                                                    |                                        | 0.33                                   | 0.00                                   | 0.33(-0.18,0.65)                       |
| BlackorAfricanAmerican（MMB:N=2,DAN:N=2） White(MMB:N=107,DAN:N=50)          |                                        | 0.00 0.22                              | 0.00 0.10                              | NC 0.12(-0.01,0.24)                    |
| Other（MMB:N=7,DAN:N=5)                                                     |                                        | 0.57                                   | 0.20                                   | 0.37(-0.24,0.80)                       |
| BaselinePlateletGroup1                                                     |                                        |                                        |                                        |                                        |
| <50x10^9/L（MMB:N=18,DAN:N=13)                                              |                                        | 0.22                                   | 0.08                                   | 0.15(-0.16,0.42)                       |
| >=50but<=150x10^9/L（MMB:N=63,DAN:N=30）                                     |                                        | 0.32                                   | 0.13                                   | 0.18(-0.02,0.35)                       |
| >150but<=300x10^9/L（MMB:N=33,DAN:N=15) >300×10^9/L（MMB:N=14,DAN:N=6)       |                                        | 0.12                                   | 0.07 0.00                              | 0.05(-0.21,0.24) 0.29(-0.20,0.58)      |
| BaselinePlateletGroup2                                                     |                                        | 0.29                                   |                                        |                                        |
| <=150x10^9/L（MMB:N=81,DAN:N=43) >150×10^9/L（MMB:N=47,DAN:N=21)             |                                        | 0.30                                   | 0.12                                   | 0.18 (0.01,0.31) 0.12(-0.08,0.27)      |
| BaselinePlateletGroup3                                                     |                                        | 0.17                                   | 0.05                                   |                                        |
| <=200×10^9/L（MMB:N=97,DAN:N=53)                                            |                                        | 0.28                                   | 0.11                                   | 0.17(0.02,0.29)                        |
| >200x10^9/L(MMB:N=31,DAN:N=11)                                             |                                        | 0.16                                   | 0.00                                   | 0.16 (-0.14,0.34)                      |
|                                                                            |                                        |                                        | 0.08                                   | 0.06(-0.13,0.20)                       |
| BaselineMFSAF TSS                                                          |                                        | 0.14                                   |                                        |                                        |
| <22（MMB:N=51,DAN:N=25)                                                     |                                        | 0.32                                   | 0.10                                   | 0.22(0.03,0.35)                        |
| >=22(MMB:N=79,DAN:N=40)                                                    |                                        | 0.22                                   | 0.13                                   | 0.15(-0.04,0.30)                       |
| BaselineSpleenVolumeMedian                                                 |                                        | 0.28                                   | 0.06                                   | 0.16 (-0.02,0.29)                      |
| <median(MMB:N=64,DAN:N=32) >=median(MMB:N=65,DAN:N=31) RBCUnitsTransferred |                                        | 0.33                                   | 0.15                                   | 0.18 (-0.14,0.43)                      |
| 0（MMB:N=27,DAN:N=13） 1-4(MMB:N=60,DAN:N=31)                                |                                        |                                        | 0.03                                   | 0.20(0.03,0.34)                        |
| 5+（MMB:N=43,DAN:N=21)                                                      |                                        | 0.23                                   |                                        |                                        |
| BaselineHGB                                                                |                                        | 0.21                                   | 0.14                                   | 0.07 (-0.17,0.26)                      |
| <8g/dL(MMB:N=62,DAN:N=32)                                                  |                                        | 0.16                                   | 0.06                                   | 0.10(-0.07,0.23)                       |
| >=8g/dL(MMB:N=67,DAN:N=33)                                                 |                                        | 0.33                                   | 0.12                                   | 0.21(0.01,0.36)                        |
| BaselineGlomelularFiltrationRate 30-60(MMB:N=51,DAN:N=31)                  |                                        | 0.25                                   | 0.03                                   | 0.22(0.05,0.37)                        |
| 60+（MMB:N=79,DAN:N=34)                                                     |                                        | 0.57                                   | 0.00                                   |                                        |
| BaselineDIPSS                                                              |                                        | 0.24                                   | 0.15                                   | 0.09(-0.09,0.24)                       |
| Intermediate-1(MMB:N=7,DAN:N=3)                                            |                                        |                                        |                                        | 0.57(-0.23,0.91)                       |
| Intermediate-2(MMB:N=72,DAN:N=40) High Risk（MMB:N=50,DAN:N=19)             |                                        | 0.21 0.26                              | 0.10 0.05                              | 0.11(-0.05,0.24) 0.21(-0.04,0.36)      |
| MyelofibrosisDiagnosis                                                     |                                        |                                        |                                        |                                        |
| PMF(MMB:N=78,DAN:N=46)                                                     |                                        |                                        | 0.09                                   | 0.16 (0.00,0.28)                       |
| post-PV MF(MMB:N=27, DAN:N=11)                                             |                                        | 0.33                                   | 0.09                                   | 0.24 (-0.11,0.48)                      |
|                                                                            |                                        | 0.24                                   |                                        |                                        |
| post-ET MF(MMB:N=25,DAN:N=8) JAK2V617Fmutationstatus                       |                                        | 0.16                                   | 0.13                                   | 0.04(-0.37,0.28)                       |
| Positive（MMB:N=97,DAN:N=51)                                                |                                        | 0.27                                   | 0.10                                   | 0.17 (0.02,0.29)                       |
| Negative(MMB:N=28,DAN:N=12)                                                |                                        | 0.21                                   | 0.08                                   | 0.13(-0.18,0.35)                       |
| Unknown（MMB:N=3,DAN:N=0)                                                   |                                        | 0.00                                   | NC                                     | NC                                     |
| PriorJAKItotaldailydose                                                    |                                        |                                        |                                        |                                        |
| 0(MMB:N=64,DAN:N=33)                                                       |                                        | 0.22                                   | 0.15                                   | 0.07 (-0.12,0.22)                      |
| <20mgBID RUX，<=200mgFED（MMB:N=29,DAN:N=17)                                 |                                        | 0.28                                   | 0.06                                   | 0.22(-0.04,0.43)                       |
| >=20mgBIDRUX,>200mgFED（MMB:N=37,DAN:N=15)                                  |                                        | 0.27                                   | 0.00                                   | 0.27(-0.00,0.44)                       |
| Geographical Region                                                        |                                        |                                        |                                        |                                        |
| Asia(MMB:N=11,DAN:N=6)                                                     |                                        | 0.36                                   | 0.00                                   | 0.36(-0.10,0.69)                       |
| Australian Asia (MMB:N=4,DAN:N=3)                                          |                                        | 0.75                                   | 0.00                                   | 0.75(-0.08,0.99)                       |
| Europe（MMB:N=98,DAN:N=44)                                                  |                                        | 0.26                                   | 0.14                                   | 0.12(-0.04,0.25)                       |
| North America (MMB:N=17,DAN:N=12) DurationofJAKItreatment                  |                                        | 0.00                                   | 0.00                                   | NC                                     |
| <12weeks (MMB:N=3,DAN:N=2)                                                 |                                        | 0.00                                   | 0.00                                   | NC                                     |
| >=12weeks（MMB:N=127,DAN:N=63)                                              |                                        | 0.25                                   | 0.10                                   | 0.16 (0.02,0.26)                       |
| OngoingJAKI atscreening                                                    |                                        |                                        |                                        |                                        |
|                                                                            |                                        | 0.28                                   | 0.03                                   | 0.24(0.05,0.38)                        |
| Yes(MMB:N=58,DAN:N=32) No（MMB:N=72,DAN:N=33)                               |                                        | 0.22                                   | 0.15                                   | 0.07 (-0.11,0.22)                      |
| -1.0-0.8-0.6-0.4-0.20.00.20.40.60.81.0                                     | -1.0-0.8-0.6-0.4-0.20.00.20.40.60.81.0 | -1.0-0.8-0.6-0.4-0.20.00.20.40.60.81.0 | -1.0-0.8-0.6-0.4-0.20.00.20.40.60.81.0 | -1.0-0.8-0.6-0.4-0.20.00.20.40.60.81.0 |

&lt;---DANFavoredMMBFavored---&gt;

Figure 26: Forest plot of MFSAF TSS response rate at Week 24 by subgroup (ITT Population, MOMENTUM)

<div style=\"page-break-after: always\"></div>

## Second primary endpoint: TI rate at Week 24

Figure 27: Forest plot of superiority difference of TI rate at Week 24 by subgroup (ITT Population, MOMENTUM)

<!-- image -->

| MMBDAN                                                 |                                                             |                                                                                                                                                                                                               |
|--------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 0.59 0.14 0.40                                         | 0.50 0.09 0.24                                              | 0.09 (-0.30, 0.47) 0.05(-0.11,0.19) 0.16 (-0.10, 0.37)                                                                                                                                                        |
| 0.59                                                   |                                                             |                                                                                                                                                                                                               |
| 0.26                                                   | 0.50 0.15                                                   | 0.09 (-0.30,0.47) 0.11 (-0.03, 0.23)                                                                                                                                                                          |
| 0.27 0.35                                              | 0.16 0.29                                                   | 0.11 (-0.06, 0.25) 0.07 (-0.19, 0.29)                                                                                                                                                                         |
| 0.48 0.25                                              | 0.18 0.20                                                   | 0.30 (-0.07,0.56) 0.04(-0.11,0.18)                                                                                                                                                                            |
| 0.58 0.00 0.29 0.14 0.17 0.37 0.18                     | 0.00 0.00 0.22 0.20 0.15 0.20                               | 0.58 (0.07, 0.85) NC 0.07 (-0.09, 0.21) -0.06 (-0.60, 0.43) 0.01 (-0.31,0.29) 0.17(-0.05,0.34) -0.08(-0.38,0.16)                                                                                              |
| 0.43 0.32 0.26 0.30 0.29 0.29 0.30 0.36 0.25 0.63 0.27 | 0.27 0.17 0.19 0.24 0.21 0.18 0.28 0.15 0.25 0.16 0.46 0.19 | 0.26 (-0.25,0.61) 0.13 (-0.04, 0.28) 0.02(-0.23,0.23) 0.09 (-0.06, 0.23) 0.11 (-0.24, 0.36) 0.01 (-0.22, 0.22) 0.15 (-0.02, 0.30) 0.11 (-0.10, 0.29) 0.08 (-0.11, 0.25) 0.17 (-0.17, 0.48) 0.07 (-0.13, 0.24) |
| 0.19 0.39                                              | 0.13                                                        | 0.07 (-0.11, 0.22) 0.12 (-0.10, 0.30)                                                                                                                                                                         |
|                                                        | 0.27                                                        |                                                                                                                                                                                                               |
| 0.63 0.35                                              | 0.33 0.13 0.26                                              | 0.29 (-0.40, 0.78) 0.23 (0.04, 0.37) -0.08 (-0.34, 0.13)                                                                                                                                                      |
| 0.20 0.37 0.18                                         | 0.10 0.29                                                   |                                                                                                                                                                                                               |
| 0.26                                                   | 0.26 0.09 0.00                                              | 0.10 (-0.08, 0.25) 0.07 (-0.13, 0.25)                                                                                                                                                                         |
|                                                        | 0.18 0.33                                                   | 0.17 (-0.17, 0.41) 0.24 (-0.13, 0.46) 0.10 (-0.05, 0.24)                                                                                                                                                      |
|                                                        | 0.06                                                        | 0.06 (-0.29, 0.36) NC 0.14 (-0.02, 0.28)                                                                                                                                                                      |
| 0.20                                                   | 0.00                                                        | -0.14 (-0.43, 0.15) 0.22 (-0.10, 0.47)                                                                                                                                                                        |
|                                                        |                                                             | 0.64 (0.08, 0.89) 0.25 (-0.49, 0.81)                                                                                                                                                                          |
|                                                        |                                                             | 0.05 (-0.13, 0.20)                                                                                                                                                                                            |
|                                                        | 0.00                                                        | NC                                                                                                                                                                                                            |
| 0.25                                                   |                                                             |                                                                                                                                                                                                               |
| 0.64                                                   |                                                             |                                                                                                                                                                                                               |
| 0.28 0.49                                              |                                                             |                                                                                                                                                                                                               |
|                                                        | NC                                                          |                                                                                                                                                                                                               |
|                                                        |                                                             | 0.07 (-0.10, 0.23)                                                                                                                                                                                            |
| 0.33                                                   |                                                             |                                                                                                                                                                                                               |
| 0.24                                                   |                                                             |                                                                                                                                                                                                               |
| 0.28                                                   |                                                             |                                                                                                                                                                                                               |
| 0.39                                                   |                                                             |                                                                                                                                                                                                               |
| 0.33                                                   |                                                             |                                                                                                                                                                                                               |
|                                                        | 0.41 0.27                                                   |                                                                                                                                                                                                               |
|                                                        | 0.00 0.25                                                   |                                                                                                                                                                                                               |
|                                                        | 0.17                                                        |                                                                                                                                                                                                               |
|                                                        |                                                             | -0.05 (-0.39, 0.23)                                                                                                                                                                                           |
|                                                        |                                                             | 0.10 (-0.04, 0.22)                                                                                                                                                                                            |
| 0.30                                                   | 0.34                                                        |                                                                                                                                                                                                               |
| 0.12                                                   |                                                             | 0.07 (-0.15, 0.27)                                                                                                                                                                                            |
| 0.00                                                   |                                                             |                                                                                                                                                                                                               |
|                                                        |                                                             | 0.15 (-0.02, 0.27)                                                                                                                                                                                            |
|                                                        | 0.06                                                        |                                                                                                                                                                                                               |
| 0.21                                                   |                                                             |                                                                                                                                                                                                               |
| 0.41                                                   |                                                             |                                                                                                                                                                                                               |
| 0.31                                                   |                                                             |                                                                                                                                                                                                               |
|                                                        | 0.21                                                        |                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

C-DAN Favored MMB Favored--

Figure 28: Forest plot of non-inferiority difference of TI rate at Week 24 by subgroup (ITT Population, MOMENTUM)

<div style=\"page-break-after: always\"></div>

## Study GU-US-352-0101 (SIMPLIFY-1)

## Pre-specified subgroup analysis for baseline demographics and disease characteristics

Primary endpoint: SRR at Week 24 based on ≥ 35 % reduction in spleen volume from baseline

Figure  29: Forest  plot  of  Splenic  Response  Rate  Based  on  ≥  35%  Reduction  in Spleen Volume From Baseline at Week 24 by subgroup (ITT Population, Noninferiority, SIMPLIFY-1)

<!-- image -->

## Secondary endpoint: MNP-SAF TSS at Week 24

Figure 30: Forest plot of MPN-SAF TSS response rate at Week 24 by subgroup (ITT Population, noninferiority, SIMPLIFY-1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Post-hoc analysis using an alternative non-inferiority margin for the secondary endpoint MPN-SAF TSS at Week 24 in SIMPLIFY-1

An alternative noninferiority margin of 0.4874 was derived in a post hoc analysis using the standard 95%-95% fixed-margin method. The lower bounds of the 95% CIs for the MMB/RUX response ratios using  the  7-item  TSS  in  the  ITT  population,  6-item  TSS  in  the  ITT  population,  and  7-item  TSS  in symptomatic subjects with baseline TSS ≥ 10 all ruled out 0.4874.

Table 75: Post-hoc analyses of MPN-SAF TSS Response Rate at Week 24 using the 95%-95% Fixed-Margin Method (ITT-population, SIMPLIFY-1)

| Analysis Population / Method   | MMB   | MMB    | RUX   | RUX    | Response Ratio (MMB/RUX)   | Response Ratio (MMB/RUX)   | Response Ratio (MMB/RUX)   |
|--------------------------------|-------|--------|-------|--------|----------------------------|----------------------------|----------------------------|
|                                | N     | TSS RR | N     | TSS RR | Ratio                      | 95% CI LB                  | 95% CI UB                  |
| ITT / 7-item TSS [1]           | 211   | 28.4%  | 211   | 42.2%  | 0.6760                     | 0.5187                     | 0.8809                     |
| ITT / 6-item TSS [2]           | 211   | 36.0%  | 211   | 48.8%  | 0.7391                     | 0.5897                     | 0.9264                     |
| Symptomatic [3] / 7-item TSS   | 152   | 32.9%  | 149   | 43.0%  | 0.7675                     | 0.5737                     | 1.0269                     |

Modified Wald response ratio and 95% CI are presented.  Noninferiority was demonstrated if the lower bound of the 95% CI for the response ratio (MMB/RUX) ruled out 0.4874 (or equivalently, 95% CI LB of p[MMB] - 0.4874 × p[RUX] &gt; 0).

[1] Original analysis.

[2] Based on the 6-item TSS used in COMFORT-I that excluded the fatigue/tiredness item.

[3] Symptomatic defined as baseline TSS ≥ 10.

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 80: Summary of efficacy for trial SRA-MMB-301 (MOMENTUM)

| Title : A Randomized, Double Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy   | Title : A Randomized, Double Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy   | Title : A Randomized, Double Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                | Protocol Identifier: SRA-MMB-301 EudraCT Number: 2019 000583 18 ClinicalTrials.gov: NCT04173494                                                                                                                                                                                                                                                 | Protocol Identifier: SRA-MMB-301 EudraCT Number: 2019 000583 18 ClinicalTrials.gov: NCT04173494                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                                                                                                                          | Phase 3, international, randomized (2:1), double blind, active controlled study comparing the efficacy and safety of MMB versus DAN in symptomatic, anemic subjects with myelofibrosis (MF) who previously received JAK inhibitor therapy.                                                                                                      | Phase 3, international, randomized (2:1), double blind, active controlled study comparing the efficacy and safety of MMB versus DAN in symptomatic, anemic subjects with myelofibrosis (MF) who previously received JAK inhibitor therapy.                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                  | 24 Weeks (randomized, double-blind period from Day 1 to Week 24) not applicable 24 weeks (open-label period from Week 24 to Week 48)                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Hypothesis                            | First primary endpoint of Total Symptom Score response rate at Week 24 was tested for superiority of MMB versus DAN. If achieved, second primary endpoint of Transfusion Independence response rate at Week 24 was tested for non- inferiority and superiority of MMB versus DAN.   | First primary endpoint of Total Symptom Score response rate at Week 24 was tested for superiority of MMB versus DAN. If achieved, second primary endpoint of Transfusion Independence response rate at Week 24 was tested for non- inferiority and superiority of MMB versus DAN.   | First primary endpoint of Total Symptom Score response rate at Week 24 was tested for superiority of MMB versus DAN. If achieved, second primary endpoint of Transfusion Independence response rate at Week 24 was tested for non- inferiority and superiority of MMB versus DAN.                          |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                       | Momelotinib (MMB)+Danazol (DAN)-matched placebo                                                                                                                                                                                                                                     | Momelotinib (MMB)+Danazol (DAN)-matched placebo                                                                                                                                                                                                                                     | 130 subjects were randomly assigned to MMB 200 mg tablets administered orally once daily (QD) plus DAN-matched placebo capsule administered orally twice daily (BID) for 24 weeks in the randomized double-blind period. MMB treatment could continue in the open- label period.                           |
| Treatments groups                     | Danazol (DAN)+ Momelotinib (MMB)-matched placebo                                                                                                                                                                                                                                    | Danazol (DAN)+ Momelotinib (MMB)-matched placebo                                                                                                                                                                                                                                    | 65 subjects were randomly assigned to DAN 300 mg capsules administered orally BID plus MMB-matched placebo tablets administered orally QD for 24 weeks in the randomized double-blind period. Crossover to MMB treatment was permitted in the open-label period.                                           |
| Endpoints and definitions             | First primary endpoint                                                                                                                                                                                                                                                              | Total Symptom Score (TSS) Response Rate at Week 24                                                                                                                                                                                                                                  | Defined as the proportion of subjects with a ≥ 50% reduction in mean Myelofibrosis Symptom Assessment Form(MFSAF)version 4.0 TSS assessed daily over the 28 days immediately before the end of week 24 compared with baseline obtained over 7 days prior to randomization.                                 |
| Endpoints and definitions             | Second primary endpoint                                                                                                                                                                                                                                                             | Transfusion Independence (TI) Rate at Week 24                                                                                                                                                                                                                                       | Defined as the proportion of subjects with TI in the terminal 12 weeks of the 24 week randomized treatment period. TI is defined as zero red blood cell transfusion (except in the case of clinically overt bleeding) and no hemoglobin value <8 g/dL for ≥ 12 weeks immediately before the week 24 visit. |
| Endpoints and definitions             | First key secondary endpoint                                                                                                                                                                                                                                                        | Splenic Response Rate (SRR) at Week 24 [ ≥ 25% reduction in spleen volume]                                                                                                                                                                                                          | Defined as the proportion of subjects who had splenic response based on ≥ 25% reduction in spleen volume from baseline.                                                                                                                                                                                    |
| Endpoints and definitions             | Second key secondary endpoint                                                                                                                                                                                                                                                       | Absolute change in MFSAF TSS from baseline at Week 24                                                                                                                                                                                                                               | Defined as the absolute change from baseline in least squares mean MFSAF TSS over the 28 days immediately before the end of week 24.                                                                                                                                                                       |
| Endpoints and definitions             | Third key secondary endpoint                                                                                                                                                                                                                                                        | SRR at Week 24 [ ≥ 35% reduction in spleen volume]                                                                                                                                                                                                                                  | Defined as the proportion of subjects who had splenic response based on ≥ 35% reduction in spleen volume from baseline.                                                                                                                                                                                    |
| Database lock                         | 03 December 2021                                                                                                                                                                                                                                                                    | 03 December 2021                                                                                                                                                                                                                                                                    | 03 December 2021                                                                                                                                                                                                                                                                                           |
| Results and Analysis                  | Results and Analysis                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                       |
| Analysis description Primary Analysis | Analysis description Primary Analysis                                                                                                                                                                                                                                               | Analysis description Primary Analysis                                                                                                                                                                                                                                               | Analysis description Primary Analysis                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24.   | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24.   | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24.   |
|--------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                              | MMB + DAN matched placebo                                                                                                                                    | DAN + MMB matched placebo                                                                                                                                    |
| Descriptive statistics and estimate variability  | Number of subject                                                                                                                                            | 130                                                                                                                                                          | 65                                                                                                                                                           |
| Descriptive statistics and estimate variability  | TSS response rate                                                                                                                                            | 24.62                                                                                                                                                        | 9.23                                                                                                                                                         |
| Descriptive statistics and estimate variability  | Percentage (%)                                                                                                                                               |                                                                                                                                                              |                                                                                                                                                              |
| Descriptive statistics and estimate variability  | 95% confidence interval (CI)                                                                                                                                 | 17.49, 32.94                                                                                                                                                 | 3.46, 19.02                                                                                                                                                  |
| Descriptive statistics and estimate variability  | TI rate,                                                                                                                                                     | 30.00                                                                                                                                                        | 20.00                                                                                                                                                        |
| Descriptive statistics and estimate variability  | Percentage (%)                                                                                                                                               |                                                                                                                                                              |                                                                                                                                                              |
| Descriptive statistics and estimate variability  | 95% CI                                                                                                                                                       | 22.28, 38.66                                                                                                                                                 | 11.10, 31.77                                                                                                                                                 |
| Descriptive statistics and estimate variability  | SRR [ ≥ 25% reduction in spleen volume]                                                                                                                      | 39.23                                                                                                                                                        | 6.15                                                                                                                                                         |
| Descriptive statistics and estimate variability  | Percentage (%)                                                                                                                                               |                                                                                                                                                              |                                                                                                                                                              |
| Descriptive statistics and estimate variability  | 95% CI                                                                                                                                                       | 30.79, 48.18                                                                                                                                                 | 1.70, 15.01                                                                                                                                                  |
| Descriptive statistics and estimate variability  | Absolute change in MFSAF TSS from baseline at Week                                                                                                           |                                                                                                                                                              |                                                                                                                                                              |
| Descriptive statistics and estimate variability  | 24 Least squares mean estimated from mixed model for repeated                                                                                                | -9.36                                                                                                                                                        | -3.13                                                                                                                                                        |
| Descriptive statistics and estimate variability  | Standard Error (SE)                                                                                                                                          |                                                                                                                                                              |                                                                                                                                                              |
| Descriptive statistics and estimate variability  |                                                                                                                                                              | 1.08                                                                                                                                                         | 1.62                                                                                                                                                         |
| Descriptive statistics and estimate variability  | SRR [ ≥ 35% reduction in spleen volume]                                                                                                                      | 22.31                                                                                                                                                        | 3.08                                                                                                                                                         |
| Descriptive statistics and estimate variability  | Percentage (%)                                                                                                                                               |                                                                                                                                                              |                                                                                                                                                              |
| Descriptive statistics and estimate variability  | 95% CI                                                                                                                                                       | 15.48, 30.44                                                                                                                                                 | 0.37, 10.68                                                                                                                                                  |
| Descriptive statistics and estimate variability  | Rate of no transfusion at Week 24 (%)                                                                                                                        | 35.38                                                                                                                                                        | 16.92                                                                                                                                                        |
| Descriptive statistics and estimate variability  | 95% CI                                                                                                                                                       | 27.20, 44.25                                                                                                                                                 | 8.76, 28.27                                                                                                                                                  |
| Effect estimate per comparison                   | First Primary endpoint: TSS response rate                                                                                                                    | Comparison groups                                                                                                                                            | MMB/placebo versus DAN/placebo                                                                                                                               |
| Effect estimate per comparison                   | First Primary endpoint: TSS response rate                                                                                                                    | Difference for superiority by stratified Cochran Mantel Haenszel (CMH) test                                                                                  | 15.67                                                                                                                                                        |
| Effect estimate per comparison                   | First Primary endpoint: TSS response rate                                                                                                                    | 95% CI                                                                                                                                                       | 5.54, 25.81                                                                                                                                                  |
| Effect estimate per comparison                   | First Primary endpoint: TSS response rate                                                                                                                    | P-value (2-sided) CMH test                                                                                                                                   | 0.0095                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Second primary endpoint: TI rate                                                     | Comparison groups                                 | MMB/placebo versus DAN/placebo   |
|--------------------------------------------------------------------------------------|---------------------------------------------------|----------------------------------|
| Second primary endpoint: TI rate                                                     | Difference for noninferiority (refer to NOTES)    | 13.58                            |
| Second primary endpoint: TI rate                                                     | 95% CI                                            | 1.86, 25.30                      |
| Second primary endpoint: TI rate                                                     | P-value (1-sided) CMH test                        | 0.0116                           |
| Second primary endpoint: TI rate                                                     | Difference for superiority by stratified CMH test | 9.80                             |
| Second primary endpoint: TI rate                                                     | 95% CI                                            | -2.03, 21.62                     |
| Second primary endpoint: TI rate                                                     | P-value                                           | 0.1265                           |
| Second primary endpoint: TI rate                                                     | (refer to NOTES)                                  |                                  |
| First key secondary endpoint : SRR [ ≥ 25% reduction in spleen volume]               | Comparison groups                                 | MMB/placebo versus DAN/placebo   |
| First key secondary endpoint : SRR [ ≥ 25% reduction in spleen volume]               | Difference by stratified CMH test                 | 33.05                            |
| First key secondary endpoint : SRR [ ≥ 25% reduction in spleen volume]               | 95% CI                                            | 22.59, 43.51                     |
| First key secondary endpoint : SRR [ ≥ 25% reduction in spleen volume]               | P-value (2-sided) CMH test                        | < 0.0001                         |
| Second key secondary endpoint: Absolute change in MFSAF TSS from baseline at Week 24 | Comparison groups                                 | MMB/placebo versus DAN/placebo   |
| Second key secondary endpoint: Absolute change in MFSAF TSS from baseline at Week 24 | Difference (SE)                                   | -6.22 (1.92)                     |
| Second key secondary endpoint: Absolute change in MFSAF TSS from baseline at Week 24 | 95% CI                                            | -10.0, -2.43                     |
| Second key secondary endpoint: Absolute change in MFSAF TSS from baseline at Week 24 | P-value (2 sided) CMH test                        | 0.0014                           |
| Third key secondary endpoint : SRR [ ≥ 35% reduction in spleen volume]               | Comparison groups                                 | MMB/placebo versus DAN/placebo   |
| Third key secondary endpoint : SRR [ ≥ 35% reduction in spleen volume]               | Difference by stratified CMH test                 | 18.18                            |
| Third key secondary endpoint : SRR [ ≥ 35% reduction in spleen volume]               | 95% CI                                            | 9.77, 26.59                      |
| Third key secondary endpoint : SRR [ ≥ 35% reduction in spleen volume]               | P-value (2-sided) CMH test                        | 0.0011                           |
| Fourth key secondary endpoint : Rate pf no transfusion at Week 24                    | Comparison groups                                 | MMB/placebo versus DAN/placebo   |
| Fourth key secondary endpoint : Rate pf no transfusion at Week 24                    | Difference by stratified CMH test                 | 17.20                            |
| Fourth key secondary endpoint : Rate pf no transfusion at Week 24                    | 95% CI                                            | 7.99, 26.40                      |
| Fourth key secondary endpoint : Rate pf no transfusion at Week 24                    | P-value (2-sided) CMH test                        | 0.0012                           |

<div style=\"page-break-after: always\"></div>

| Notes   | Week 24 TI rate non-inferiority hypothesis testing : a stratum adjusted 2 sided 95% CI based on Koch et al was calculated for the difference between the proportion of subjects with TI in the MMB group and 80% of the proportion of subjects with TI in the DAN group. If the lower bound of the CI was greater than 0, MMB was to be declared noninferior to DAN Summary of Subject Disposition during the 24 Week Period: 94 subjects (72.3%) in the MMB group and 38 subjects (58.5%) in the DAN group completed randomized treatment. For subjects who discontinued randomized treatment early, adverse event was the most common reason overall in both groups (16 subjects, 12.3% MMB; 11 subjects, 16.9% DAN) followed by subject decision (6, 4.6% MMB; 5, 7.7% DAN).   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Table 76: Summary of efficacy for trial GS-US-352-0101 (SIMPLIFY-1)

| Title : A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib versus Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)   | Title : A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib versus Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)                                                                        | Title : A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib versus Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                       | Protocol Identifier: SRA-MMB-301 EudraCT Number: 2013-002707-33 ClinicalTrials.gov: NCT01969838                                                                                                                                                                                                                             | Protocol Identifier: SRA-MMB-301 EudraCT Number: 2013-002707-33 ClinicalTrials.gov: NCT01969838                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                 | Phase 3, international, randomized (1:1), double blind, active controlled study comparing MMB versus RUX in JAK inhibitor naïve subjects with intermediate or high risk PMF or post PV/ET MF                                                                                                                                | Phase 3, international, randomized (1:1), double blind, active controlled study comparing MMB versus RUX in JAK inhibitor naïve subjects with intermediate or high risk PMF or post PV/ET MF                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                              | 24 Weeks (randomized, double-blind period, from Day 1 to Week 24) not applicable up to 5 Years (open-label period, from Week 24 to Year 5)                                                                                                                                                                                                                         |
| Hypothesis                                                                                                                                                                                                                                             | The primary endpoint of Splenic Response Rate at Week 24 was tested for non- inferiority of MMB versus RUX. If achieved, the key secondary endpoints would be tested in a hierarchical fashion to control for the overall type I error rate of 0.05. The first key secondary endpoint of Total Symptom Score was tested for | The primary endpoint of Splenic Response Rate at Week 24 was tested for non- inferiority of MMB versus RUX. If achieved, the key secondary endpoints would be tested in a hierarchical fashion to control for the overall type I error rate of 0.05. The first key secondary endpoint of Total Symptom Score was tested for                                        |
| Treatments groups                                                                                                                                                                                                                                      | Momelotinib (MMB) + Ruxolitinib (RUX)-matched placebo                                                                                                                                                                                                                                                                       | 215 subjects were randomly assigned to MMB 200 mg tablets administered orally once daily (QD) plus RUX-matched placebo tablets administered orally twice daily (BID) for 24 weeks in the randomized double-blind period. MMB treatment could continue in the open- label period.                                                                                   |
|                                                                                                                                                                                                                                                        | Ruxolitinib (RUX) + Momelotinib (MMB)-matched placebo                                                                                                                                                                                                                                                                       | 217 subjects were randomly assigned to RUX tablets (5 to 20 mg dosage depending on platelet counts) administered orally BID plus MMB-matched placebo tablets administered orally QD for 24 weeks in the randomized double-blind period. Crossover to MMB treatment was permitted in the open-label period. RUX treatment in the open-label period was not allowed. |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                       | Primary endpoint                                                                                                                                           | SRR at Week 24                                                                                                                                             | SRR at Week 24                                                                                                                                             | Defined as the proportion of subjects who had splenic response based on ≥ 35% reduction in spleen volume from baseline.                                                                                                                                                                                    | Defined as the proportion of subjects who had splenic response based on ≥ 35% reduction in spleen volume from baseline.                                                                                                                                                                                    |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                       | First key secondary endpoint                                                                                                                               | Total Symptom Score (TSS) Response Rate at Week 24                                                                                                         | Total Symptom Score (TSS) Response Rate at Week 24                                                                                                         | Defined as the proportion of subjects with a ≥ 50% reduction in mean Myeloproliferative Neoplasm Symptom Assessment Form (MPN- SAF) version 2.0 TSS assessed daily over the 28 days immediately before the end of week 24 compared with baseline.                                                          | Defined as the proportion of subjects with a ≥ 50% reduction in mean Myeloproliferative Neoplasm Symptom Assessment Form (MPN- SAF) version 2.0 TSS assessed daily over the 28 days immediately before the end of week 24 compared with baseline.                                                          |
| Endpoints and definitions                       | Second key secondary endpoint                                                                                                                              | Transfusion Independence (TI) Rate at Week 24                                                                                                              | Transfusion Independence (TI) Rate at Week 24                                                                                                              | Defined as the proportion of subjects with TI in the terminal 12 weeks of the 24 week randomized treatment period. TI is defined as zero red blood cell transfusion (except in the case of clinically overt bleeding) and no hemoglobin value <8 g/dL for ≥ 12 weeks immediately before the week 24 visit. | Defined as the proportion of subjects with TI in the terminal 12 weeks of the 24 week randomized treatment period. TI is defined as zero red blood cell transfusion (except in the case of clinically overt bleeding) and no hemoglobin value <8 g/dL for ≥ 12 weeks immediately before the week 24 visit. |
| Endpoints and definitions                       | Key exploratory endpoint                                                                                                                                   | Absolute change in TSS from baseline at Week 24                                                                                                            | Absolute change in TSS from baseline at Week 24                                                                                                            | Defined as the absolute change from baseline in least squares mean modified MPN-SAF TSS over the 28 days immediately before the end of week 24.                                                                                                                                                            | Defined as the absolute change from baseline in least squares mean modified MPN-SAF TSS over the 28 days immediately before the end of week 24.                                                                                                                                                            |
| Database lock 12 September 2016                 | Database lock 12 September 2016                                                                                                                            | Database lock 12 September 2016                                                                                                                            | Database lock 12 September 2016                                                                                                                            | Database lock 12 September 2016                                                                                                                                                                                                                                                                            | Database lock 12 September 2016                                                                                                                                                                                                                                                                            |
| Results and Analysis                            |                                                                                                                                                            |                                                                                                                                                            |                                                                                                                                                            |                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                            |
| Analysis population and time point description  | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24. | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24. | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24. | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24.                                                                                                                                                 | Intent to treat population : defined as all patients who were randomized. The 24 week timepoint for the primary analysis is defined from Day 1 to Week 24.                                                                                                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                            | Treatment group                                                                                                                                            | MMB + RUX matched                                                                                                                                          | MMB + RUX matched                                                                                                                                                                                                                                                                                          | RUX + MMB matched placebo                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                          | Number of subject                                                                                                                                          | 215                                                                                                                                                        | 215                                                                                                                                                                                                                                                                                                        | 217                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | SRR [ ≥ 35% reduction in spleen volume] Percentage (%)                                                                                                     | SRR [ ≥ 35% reduction in spleen volume] Percentage (%)                                                                                                     | 26.5                                                                                                                                                       | 26.5                                                                                                                                                                                                                                                                                                       | 29.5                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95% confidence interval (CI)                                                                                                                               | 95% confidence interval (CI)                                                                                                                               | 20.74, 32.94                                                                                                                                               | 20.74, 32.94                                                                                                                                                                                                                                                                                               | 23.51, 36.04                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | TSS response rate Percentage (%)                                                                                                                           | TSS response rate Percentage (%)                                                                                                                           | 28.4                                                                                                                                                       | 28.4                                                                                                                                                                                                                                                                                                       | 42.2                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                     | 95% CI                                                                                                                                                     | 22.45, 35.03                                                                                                                                               | 22.45, 35.03                                                                                                                                                                                                                                                                                               | 35.43, 49.15                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | TI rate                                                                                                                                                    | TI rate                                                                                                                                                    | 66.5                                                                                                                                                       | 66.5                                                                                                                                                                                                                                                                                                       | 49.3                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                     | 95% CI                                                                                                                                                     | 59.78, 72.79                                                                                                                                               | 59.78, 72.79                                                                                                                                                                                                                                                                                               | 42.48, 56.16                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|        | Absolute change in MPN- SAF TSS from baseline at Week 24 Least squares mean estimated from mixed model for repeated measures (MMRM)   | -5.87                                                                            | -7.11                          |
|--------|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------|
| Effect | Primary endpoint: SRR [ ≥ 35% reduction                                                                                               | Comparison groups                                                                | MMB/placebo versus RUX/placebo |
| Effect | in spleen volume]                                                                                                                     | Difference for non- inferiority by stratified Cochran Mantel Haenszel (CMH) test | 9                              |
| Effect | Primary endpoint: SRR [ ≥ 35% reduction                                                                                               | 95% CI                                                                           | 2, 16                          |
| Effect | Primary endpoint: SRR [ ≥ 35% reduction                                                                                               | P-value CMH test                                                                 | 0.014                          |
| Effect | First key secondary endpoint: TSS response rate                                                                                       | Comparison groups                                                                | MMB/placebo versus RUX/placebo |
| Effect | First key secondary endpoint: TSS response rate                                                                                       | Difference for non- inferiority by stratified CMH test (Refer to NOTES)          | 0                              |
| Effect | First key secondary endpoint: TSS response rate                                                                                       | 95% CI                                                                           | -8, 8                          |
| Effect | First key secondary endpoint: TSS response rate                                                                                       | P-value CMH test                                                                 | 0.98                           |
| Effect | Second key secondary endpoint: TI rate                                                                                                | Comparison groups                                                                | MMB/placebo versus RUX/placebo |
| Effect | Second key secondary endpoint: TI rate                                                                                                | Difference for superiority by stratified CMH test                                | 18                             |
| Effect | Second key secondary endpoint: TI rate                                                                                                | 95% CI                                                                           | 9, 26                          |
| Effect | Second key secondary endpoint: TI rate                                                                                                | P-value                                                                          | <0.001 (nominal)               |
| Effect | Second key secondary endpoint: TI rate                                                                                                | CMH test                                                                         |                                |
| Effect | Key exploratory endpoint: Absolute change in MPN-SAF TSS from baseline at Week 24                                                     | Comparison groups                                                                | MMB/placebo versus RUX/placebo |
| Effect | Key exploratory endpoint: Absolute change in MPN-SAF TSS from baseline at Week 24                                                     | Difference (SE)                                                                  | 1.24 (0.83)                    |
| Effect | Key exploratory endpoint: Absolute change in MPN-SAF TSS from baseline at Week 24                                                     | 95% CI                                                                           | -0.40, 2.88                    |
| Effect | Key exploratory endpoint: Absolute change in MPN-SAF TSS from baseline at Week 24                                                     | P-value                                                                          | 0.1380 (nominal)               |
| Effect | Key exploratory endpoint: Absolute change in MPN-SAF TSS from baseline at Week 24                                                     | CMH test                                                                         |                                |

<div style=\"page-break-after: always\"></div>

| Notes                                           | TSS Non-inferiority hypothesis testing : the noninferiority proportion difference calculated as p(MMB) - 0.67 × p(RUX); noninferiority was to be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | TSS Non-inferiority hypothesis testing : the noninferiority proportion difference calculated as p(MMB) - 0.67 × p(RUX); noninferiority was to be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | TSS Non-inferiority hypothesis testing : the noninferiority proportion difference calculated as p(MMB) - 0.67 × p(RUX); noninferiority was to be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Notes                                           | declared if the difference ruled out 0. Summary of Subject Disposition during the 24 Week Period: 1 subject in each treatment group was randomized but not treated. Thus, a total of 214 subjects in the MMB group and 216 subjects in the RUX group received treatment. Overall, 175 subjects (81.4%) in the MMB group and 201 subjects (92.6%) in the RUX group completed 24 weeks of double-blind study treatment. A total of 40 subjects (18.6%) in the MMB group and 16 subjects (7.4%) in the RUX group prematurely discontinued study drug, with AEs being the most common reason for discontinuing study treatment in both groups (8.8% MMB; 4.1% RUX). | declared if the difference ruled out 0. Summary of Subject Disposition during the 24 Week Period: 1 subject in each treatment group was randomized but not treated. Thus, a total of 214 subjects in the MMB group and 216 subjects in the RUX group received treatment. Overall, 175 subjects (81.4%) in the MMB group and 201 subjects (92.6%) in the RUX group completed 24 weeks of double-blind study treatment. A total of 40 subjects (18.6%) in the MMB group and 16 subjects (7.4%) in the RUX group prematurely discontinued study drug, with AEs being the most common reason for discontinuing study treatment in both groups (8.8% MMB; 4.1% RUX). | declared if the difference ruled out 0. Summary of Subject Disposition during the 24 Week Period: 1 subject in each treatment group was randomized but not treated. Thus, a total of 214 subjects in the MMB group and 216 subjects in the RUX group received treatment. Overall, 175 subjects (81.4%) in the MMB group and 201 subjects (92.6%) in the RUX group completed 24 weeks of double-blind study treatment. A total of 40 subjects (18.6%) in the MMB group and 16 subjects (7.4%) in the RUX group prematurely discontinued study drug, with AEs being the most common reason for discontinuing study treatment in both groups (8.8% MMB; 4.1% RUX). |
| Notes                                           | P-value : Nominal is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control. The summary table captures the key efficacy endpoints; not all secondary                                                                                                                                                                                                                                                                  | P-value : Nominal is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control. The summary table captures the key efficacy endpoints; not all secondary                                                                                                                                                                                                                                                                  | P-value : Nominal is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control. The summary table captures the key efficacy endpoints; not all secondary                                                                                                                                                                                                                                                                  |
| Analysis description                            | endpoints are presented. Hemoglobin <12 g/dL Subgroup Population: defined as patients with baseline hemoglobin value of <12 g/dL who were randomized. The 24 week timepoint for the secondary analysis is defined from Day 1 to Week 24. This subgroup was not prespecified.                                                                                                                                                                                                                                                                                                                                                                                    | endpoints are presented. Hemoglobin <12 g/dL Subgroup Population: defined as patients with baseline hemoglobin value of <12 g/dL who were randomized. The 24 week timepoint for the secondary analysis is defined from Day 1 to Week 24. This subgroup was not prespecified.                                                                                                                                                                                                                                                                                                                                                                                    | endpoints are presented. Hemoglobin <12 g/dL Subgroup Population: defined as patients with baseline hemoglobin value of <12 g/dL who were randomized. The 24 week timepoint for the secondary analysis is defined from Day 1 to Week 24. This subgroup was not prespecified.                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | MMB + RUX matched placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RUX + MMB matched placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 159                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 164                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | SRR [ ≥ 35% reduction in spleen volume] Percentage (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | 95% confidence interval (CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22.02, 36.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22.43, 36.87                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | TSS response rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 29.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 39.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22.62, 37.53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 32.18, 47.96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | TI rate Percentage (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 62.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 37.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 54.24, 69.82                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29.79, 45.08                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | Primary endpoint: SRR [ ≥ 35% reduction in spleen volume]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | MMB/placebo versus RUX/placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Primary endpoint: SRR [ ≥ 35% reduction in spleen volume]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Difference for non- inferiority by stratified Cochran Mantel Haenszel (CMH) test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint: SRR [ ≥ 35% reduction in spleen volume]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3, 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                  | Primary endpoint: SRR [ ≥ 35% reduction in spleen volume]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | P-value CMH test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.007 (nominal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  | First key secondary endpoint: TSS response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | MMB/placebo versus RUX/placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|       | rate                                                                                                                                                                                                                                                                                                                  | Difference for non- inferiority by stratified CMH test                                                                                                                                                                                                                                                                | 3                                                                                                                                                                                                                                                                                                                     |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | rate                                                                                                                                                                                                                                                                                                                  | 95% CI                                                                                                                                                                                                                                                                                                                | -6, 12                                                                                                                                                                                                                                                                                                                |
|       | rate                                                                                                                                                                                                                                                                                                                  | P-value CMH test                                                                                                                                                                                                                                                                                                      | 0.5 (nominal)                                                                                                                                                                                                                                                                                                         |
|       | Second key secondary endpoint: TI rate                                                                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                                                                                     | MMB/placebo versus RUX/placebo                                                                                                                                                                                                                                                                                        |
|       | Second key secondary endpoint: TI rate                                                                                                                                                                                                                                                                                | Difference for superiority by stratified CMH test                                                                                                                                                                                                                                                                     | 26                                                                                                                                                                                                                                                                                                                    |
|       | Second key secondary endpoint: TI rate                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                | 16, 36                                                                                                                                                                                                                                                                                                                |
|       | Second key secondary endpoint: TI rate                                                                                                                                                                                                                                                                                | P-value CMH test                                                                                                                                                                                                                                                                                                      | <0.01 (nominal)                                                                                                                                                                                                                                                                                                       |
| Notes | P-value : Nominal is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control. | P-value : Nominal is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control. | P-value : Nominal is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control. |

## 2.6.5.3. Clinical studies in special populations

No individual efficacy studies in specific populations were conducted. In all three controlled trials, as well as in the supportive studies, a majority of patients was ≥ 65 years (80% in MOMENTUM, 57% in SIMPLIFY-1 and 65% in SIMPLIFY-2, respectively).

|                      | Age65-74(0lder subjects number/total number)   | Age75-84(Older subjectsnumber/total number)   | Age 85+(Older subjects number/total number)   |
|----------------------|------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| ControlledTrials     |                                                |                                               |                                               |
| MOMENTUM             | 94/195(48.2%)                                  | 57/195(29.2%）                                 | 4/195 (2.1%)                                  |
| SIMPLIFY-1           | 176/432(40.7%）                                 | 69/432(16.0%)                                 | 2/432 (<1%)                                   |
| SIMPLIFY-2           | 73/156(46.8%）                                  | 27/156(17.3%)                                 | 1/156(<1%）                                    |
| Non-controlledTrials |                                                |                                               |                                               |
| GS-US-352-1672       | 19/41(46.3%）                                   | 9/41(22.0%)                                   | 2/41(4.9%)                                    |

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

Not applicable.

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

## Table 77: Overall summary of primary, key secondary and other selected secondary efficacy endpoints  for  MOMENTUM  (ITT  population)  with  corresponding  SIMPLIFY-1  results  (ITT population and anemia subgroup with baseline Hgb &lt; 10 g/dL)

|          | MOMENTUM       | MOMENTUM       | SIMPLIFY-1 [1]   | SIMPLIFY-1 [1]   | SIMPLIFY-1 [1]         | SIMPLIFY-1 [1]         |
|----------|----------------|----------------|------------------|------------------|------------------------|------------------------|
|          | ITT Population | ITT Population | ITT Population   | ITT Population   | Baseline Hgb < 10 g/dL | Baseline Hgb < 10 g/dL |
| MOMENTUM | MMB            | DAN =          | MMB =            | RUX (N =         | MMB (N =               | RUX (N =               |
| Endpoint | (N = 130)      | (N 65)         | (N 215)          | 217)             | 86)                    | 95)                    |

<div style=\"page-break-after: always\"></div>

|                                                  | MOMENTUM                 | MOMENTUM                 | SIMPLIFY-1 [1]    | SIMPLIFY-1 [1]    | SIMPLIFY-1 [1]         | SIMPLIFY-1 [1]         |
|--------------------------------------------------|--------------------------|--------------------------|-------------------|-------------------|------------------------|------------------------|
|                                                  | ITT Population           | ITT Population           | ITT Population    | ITT Population    | Baseline Hgb < 10 g/dL | Baseline Hgb < 10 g/dL |
| MOMENTUM Endpoint                                | MMB (N = 130)            | DAN (N = 65)             | MMB (N = 215)     | RUX (N = 217)     | MMB (N = 86)           | RUX (N = 95)           |
| Primary efficacy endpoints                       |                          |                          |                   |                   |                        |                        |
| MFSAF TSS response rate at week 24 [2]           |                          |                          |                   |                   |                        |                        |
| Evaluable at week 24, n                          | 130                      | 65                       | 211               | 211               | 84                     | 94                     |
| Responder, n (%)                                 | 32 (24.6%)               | 6 (9.2%)                 | 60 (28.4%)        | 89 (42.2%)        | 21 (25.0%)             | 34 (36.2%)             |
| Exact 95% CI [3]                                 | 17.49, 32.94             | 3.46, 19.02              | 22.45, 35.03      | 35.43, 49.15      | 16.19, 35.64           | 26.51, 46.73           |
| Superiority proportion difference, %(95% CI)     | 15.67 (5.54, 25.81)      | 15.67 (5.54, 25.81)      | -14 (-23, -5)     | -14 (-23, -5)     | -12 (-26, 2)           | -12 (-26, 2)           |
| p-value                                          | 0.0095                   | 0.0095                   | 0.9985 [4]        | 0.9985 [4]        | 0.089 (nominal)        | 0.089 (nominal)        |
| Noninferiority proportion difference, %(95% CI)  | na                       | na                       | 0 (-8, 8) [5]     | 0 (-8, 8) [5]     | -0 (-12, 12)           | -0 (-12, 12)           |
| p-value                                          | na                       | na                       | 0.98              | 0.98              | 1.00 (nominal)         | 1.00 (nominal)         |
| TI rate at week 24                               |                          |                          |                   |                   |                        |                        |
| Responder, n (%)                                 | 39 (30.0%)               | 13 (20.0%)               | 143 (66.5%)       | 107 (49.3%)       | 40 (46.5%)             | 26 (27.4%)             |
| Exact 95% CI [3]                                 | 22.28, 38.66             | 11.10, 31.77             | 59.78, 72.79      | 42.48, 56.16      | 35.68, 57.59           | 18.72, 37.48           |
| Superiority proportion difference, %(95% CI)     | 9.80 (-2.03, 21.62)      | 9.80 (-2.03, 21.62)      | 18 (9, 26)        | 18 (9, 26)        | 22 (9, 36)             | 22 (9, 36)             |
| p-value                                          | 0.1265                   | 0.1265                   | < 0.001 (nominal) | < 0.001 (nominal) | 0.001 (nominal)        | 0.001 (nominal)        |
| Noninferiority proportion difference, %(95% CI)  | 13.58 (1.86, 25.30) [6]  | 13.58 (1.86, 25.30) [6]  | na                | na                | na                     | na                     |
| 1-sided p-value                                  | 0.0064                   | 0.0064                   | na                | na                | na                     | na                     |
| Key secondary efficacy endpoints                 |                          |                          |                   |                   |                        |                        |
| ≥ 25% from baseline) at week 24                  |                          |                          |                   |                   |                        |                        |
| Responder, n (%)                                 | 51 (39.2%)               | 4 (6.2%)                 |                   |                   |                        |                        |
| Exact 95% CI [3]                                 | 30.79, 48.18 1.70, 15.01 | 30.79, 48.18 1.70, 15.01 |                   |                   |                        |                        |
| Superiority proportion difference, %(95% CI)     | 33.05 (22.59, 43.51)     | 33.05 (22.59, 43.51)     |                   |                   |                        |                        |
| p-value                                          | < 0.0001                 | < 0.0001                 |                   |                   |                        |                        |
| Change from baseline in MFSAF TSS at week 24 [2] |                          |                          |                   |                   |                        |                        |
| Evaluable at week 24, n                          | 92                       | 37                       | 177               | 193               |                        |                        |
| Mean (SD)                                        | -11.52 (12.86)           | -3.93 (11.94)            | -6.18 (9.985)     | -7.26 (8.533)     |                        |                        |
| Least squares mean (SE) [7]                      | -9.36 (1.08)             | -3.13 (1.62)             | -5.87 (0.93)      | -7.11 (0.91)      |                        |                        |
| Least squares mean difference (SE) [7]           | -6.22 (1.92)             | -6.22 (1.92)             | 1.24 (0.83)       | 1.24 (0.83)       |                        |                        |

<div style=\"page-break-after: always\"></div>

|                                                                                        | MOMENTUM                                                                      | MOMENTUM                                                                      | SIMPLIFY-1 [1]                                        | SIMPLIFY-1 [1]                                        | SIMPLIFY-1 [1]          | SIMPLIFY-1 [1]              |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------|-----------------------------|
| MOMENTUM                                                                               | ITT Population MMB                                                            | DAN                                                                           | ITT MMB                                               | Population RUX                                        | Baseline Hgb MMB        | < 10 g/dL RUX               |
| Endpoint                                                                               | 130) (N =                                                                     | 130) (N =                                                                     | 215) (N =                                             | 215) (N =                                             |                         |                             |
| p-value [8]                                                                            |                                                                               |                                                                               |                                                       |                                                       |                         |                             |
| SRR (reduction in spleen volume ≥ 35% from baseline) at                                | 0.0014                                                                        | 0.0014                                                                        | 0.1380 (nominal)                                      | 0.1380 (nominal)                                      |                         |                             |
| week 24                                                                                |                                                                               |                                                                               |                                                       |                                                       |                         |                             |
|                                                                                        |                                                                               |                                                                               |                                                       | 64 (29.5%)                                            | 27 (31.4%) 21.81, 42.30 |                             |
| Responder, n (%)                                                                       |                                                                               | 65)                                                                           |                                                       | 23.51,                                                |                         |                             |
|                                                                                        | (N =                                                                          |                                                                               |                                                       |                                                       | (N = 86)                | (N = 95)                    |
| 95% CI [7]                                                                             |                                                                               |                                                                               | (N =                                                  |                                                       |                         |                             |
|                                                                                        |                                                                               |                                                                               |                                                       | 217)                                                  |                         |                             |
|                                                                                        | -10.0, -2.43 29 (22.3%) 2 (3.1%) 15.48, 30.44 0.37, 10.68 18.18 (9.77, 26.59) | -10.0, -2.43 29 (22.3%) 2 (3.1%) 15.48, 30.44 0.37, 10.68 18.18 (9.77, 26.59) | -0.40, 2.88 57 (26.5%) 20.74, 32.94 36.04 -3 (-12, 5) | -0.40, 2.88 57 (26.5%) 20.74, 32.94 36.04 -3 (-12, 5) |                         |                             |
| Exact 95% CI [3] Superiority proportion difference, %(95% CI) p-value p-value          | 0.0011 na                                                                     |                                                                               |                                                       | 0.014                                                 | 0 (-13, 0.94 (nominal)  | 31 (32.6%) 23.36, 43.02 14) |
| Noninferiority proportion difference,                                                  |                                                                               |                                                                               | 0.45 9 (2, 16) [9]                                    | 0.45 9 (2, 16) [9]                                    | 13 (2, 25)              | 13 (2, 25)                  |
| %(95% CI)                                                                              | na                                                                            | na                                                                            |                                                       |                                                       |                         |                             |
| Proportion of subjects with RBC units transfused during the RT period Responder, n (%) |                                                                               |                                                                               |                                                       |                                                       | 0.026 (nominal)         | 0.026 (nominal)             |
| zero                                                                                   | 46 (35.4%)                                                                    | 11 (16.9%)                                                                    | 73%                                                   | 46%                                                   |                         |                             |
| Exact 95% CI [3]                                                                       | 27.20, 44.25                                                                  | 8.76, 28.27                                                                   | 66, 78                                                | 39, 52                                                | 41 (47.7%) 36.79,       | 50.50,                      |
| Superiority proportion difference                                                      | 17.20 (7.99, 26.40)                                                           | 17.20 (7.99, 26.40)                                                           | na                                                    | na                                                    |                         |                             |
| (95% CI)                                                                               |                                                                               |                                                                               |                                                       |                                                       |                         |                             |
| p-value Selected other secondary                                                       | 0.0012                                                                        | 0.0012                                                                        | na                                                    | na                                                    |                         |                             |
| endpoints TD rate at week 24 Dependent, n (%)                                          | 20 (15.4%)                                                                    | 16 (24.6%)                                                                    | 65 (30.2%)                                            | 87 (40.1%)                                            |                         | 58 (61.1%)                  |
| Exact 95% CI [3]                                                                       | 9.66, 22.76                                                                   | 14.77, 36.87                                                                  | 24.17, 36.85                                          | 33.52, 46.94                                          | 58.73                   | 70.89                       |
| Proportion difference                                                                  | -8.26 (-20.18, 3.66)                                                          | -8.26 (-20.18, 3.66)                                                          | -10 (-19, -2)                                         | -10 (-19, -2)                                         | -16 (-30, -2)           | -16 (-30, -2)               |
| (95% CI) p-value                                                                       |                                                                               |                                                                               |                                                       |                                                       |                         |                             |
| Overall survival, n                                                                    | 130                                                                           | 65                                                                            | 214                                                   | 216                                                   |                         |                             |
| [10]                                                                                   | 0.1602                                                                        | 0.1602                                                                        | 0.019 (nominal)                                       | 0.019 (nominal)                                       | 0.028 (nominal)         | 0.028 (nominal)             |
| Median follow-up [11]                                                                  | 275.00 days (0.75 y)                                                          | 295.00 days (0.81 y)                                                          | 3.43 y                                                | 3.47 y                                                |                         |                             |
| Death, n (%)                                                                           | 25 (19.2%)                                                                    | 16 (24.6%)                                                                    | 67 (31.3%)                                            | 73 (33.8%)                                            |                         |                             |
| Censored, n (%)                                                                        | 105 (80.8%)                                                                   | 49 (75.4%)                                                                    | 147 (68.7%)                                           | 143 (66.2%)                                           |                         |                             |
| Kaplan-Meier estimate overall Median (95% CI)                                          | NC (NC, NC)                                                                   | NC (390.00 days [1.1 y], NC)                                                  | NR (4.73 y, NR)                                       | NR (4.94 y, NR)                                       |                         |                             |
| Range                                                                                  | 41, 476+ days (0.11, 1.3 y)                                                   | 26, 523+ days (0.07, 1.4 y)                                                   | 0.06, 7.53 y                                          | 0.03, 7.35 y                                          |                         |                             |
| Hazard ratio (95% CI) [12]                                                             | 0.734 (0.382, 1.409)                                                          | 0.734 (0.382, 1.409)                                                          | 1.03 (0.74, 1.44)                                     | 1.03 (0.74, 1.44)                                     |                         |                             |
| p-value [13]                                                                           | 0.3510                                                                        | 0.3510                                                                        | 0.8646                                                | 0.8646                                                |                         |                             |

<div style=\"page-break-after: always\"></div>

|                                | MOMENTUM                     | MOMENTUM                     | SIMPLIFY-1 [1]    | SIMPLIFY-1 [1]       | SIMPLIFY-1 [1]         | SIMPLIFY-1 [1]         |
|--------------------------------|------------------------------|------------------------------|-------------------|----------------------|------------------------|------------------------|
|                                | ITT Population               | ITT Population               | ITT Population    | ITT Population       | Baseline Hgb < 10 g/dL | Baseline Hgb < 10 g/dL |
| MOMENTUM Endpoint              | MMB (N = 130)                | DAN (N = 65)                 | MMB (N = 215)     | RUX (N = 217)        | MMB (N = 86)           | RUX (N = 95)           |
| Leukemia-free survival, n [10] | 130                          | 65                           | 215               | 217                  |                        |                        |
| Median follow-up [11]          | 281.00 days (9.2 mo)         | 275.00 days (9.0 mo)         | 35.4 mo           | 35.2 mo              |                        |                        |
| Event, n (%)                   | 27 (20.8%)                   | 18 (27.7%)                   | 67 (31.2%)        | 68 (31.3%)           |                        |                        |
| Leukemic transformation        | 3 (2.3%)                     | 4 (6.2%)                     | 12 (5.6%)         | 9 (4.1%)             |                        |                        |
| Death                          | 24 (18.5%)                   | 14 (21.5%)                   | 55 (25.6%)        | 59 (27.2%)           |                        |                        |
| Censored, n (%)                | 103 (79.2%)                  | 47 (72.3%)                   | 148 (68.8%)       | 149 (68.7%)          |                        |                        |
| Kaplan-Meier estimate          |                              |                              |                   |                      |                        |                        |
| Median                         | NC (NC, NC)                  | NC (NC, NC)                  | NR (44.09, NR)    | 53.06 mo (48.72, NR) |                        |                        |
| Range                          | 41, 476+ days (1.3, 15.6 mo) | 26, 509+ days (0.9, 16.7 mo) | 0.03, 59.30 mo    | 0.36, 56.34 mo       |                        |                        |
| Hazard ratio (95% CI) [12]     | 0.650 (0.351, 1.206)         | 0.650 (0.351, 1.206)         | 1.07 (0.76, 1.50) | 1.07 (0.76, 1.50)    |                        |                        |
| p-value [13]                   | 0.1696                       | 0.1696                       | 0.70              | 0.70                 |                        |                        |

Proportion differences were analyzed using the stratified CMH method except where noted.  All p values were 2 sided unless otherwise specified.  '(nominal)' is used to indicate nominal p values for descriptive results of hypothesis tests that were included only after a hypothesis test was not rejected in a hierarchical test sequence, or when compared with p values for hypothesis tests that were included in the overall type I error rate control.  + indicates a censored observation in MOMENTUM.

- [1] Results are included for comparison with MOMENTUM and are not shown in the planned hierarchical testing order for SIMPLIFY 1.
- [2] MPN SAF TSS for SIMPLIFY 1.
- [3] Exact binomial CI for MOMENTUM and based on Clopper Pearson method without stratification for SIMPLIFY 1.  [4] One sided p value for superiority of MMB computed from the original 2 sided nondirectional p value of 0.003 as follows:  superiority p value = 1 - (0.003/2) = 0.9985.
- [5] Delta = p(MMB) - 0.67 × p(RUX), where p(MMB) was the proportion with TSS response in the MMB group and p(RUX) was the proportion with TSS response in the RUX group.
- [6] Delta = p(MMB) - 0.80 × p(DAN), where p(MMB) was the proportion with TI in the MMB group and p(DAN) was the proportion with TI in the DAN group.  The 95% CI was stratum adjusted and based on Koch et al (Chapter 13 in Berry, 1989).
- [7] MOMENTUM:  Based on MMRM adjusted for baseline MFSAF TSS (&lt; 22 vs ≥ 22), baseline palpable spleen length below the left costal margin (&lt; 12 cm vs ≥ 12 cm), and baseline RBC or whole blood units transfused in the 8-week period before randomization (0, 1-4, ≥ 5 units).  SIMPLIFY 1:  Based on MMRM that included treatment, time, treatment × time, age, race, and baseline TSS.
- [8] p value for the least squares mean difference between the 2 groups from the MMRM.
- [9] Delta = p(MMB) - 0.60 × p(RUX), where p(MMB) was the SRR in the MMB group and p(RUX) was the SRR in the RUX group.
- [10] Overall survival:  Based on the ITT population for MOMENTUM and the safety population for SIMPLIFY 1.  SIMPLIFY 1 includes follow up data from XAP as of the data cutoff date of 03 Dec 2021.  Leukemia free survival:  Based on the ITT population for both studies.
- [11] By reverse Kaplan Meier method for MOMENTUM and based on the safety population for SIMPLIFY 1.
- [12] From a stratified Cox proportional hazards model.
- [13] Nominal p value from a stratified log rank test.

CMH, Cochran Mantel Haenszel; DAN, danazol; ITT, intent to treat; MFSAF, Myelofibrosis Symptom Assessment Form; Min, max, minimum, maximum; MMB, momelotinib; MMRM, mixed model for repeated measures; mo, months; MPN SAF, Myeloproliferative Neoplasm Symptom Assessment Form; na, not applicable; NC, not computable; NR, not reached; Q1, Q3, first quartile, third quartile; RBC, red blood cell; RT, randomized treatment; RUX, ruxolitinib; SRR, splenic response rate; TD, transfusion dependence; TI, transfusion independence; TSS, total symptom score; XAP, Study SRA MMB 4365; y, years

## 2.6.5.6. Supportive studies

Main supportive study for JAKi-treated patients: Study GS-US-352-1214 (SIMPLIFY-2), a Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available

<div style=\"page-break-after: always\"></div>

## Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Postpolycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib.

SIMPLIFY-2 was an international, randomized, open-label, phase 3 study of the efficacy and safety of MMB versus BAT in subjects with PMF or post-PV/ET MF whose prior treatment with RUX was associated with anemia and/or thrombocytopenia. The primary objective was to determine the efficacy of MMB compared with BAT as measured by SRR at Week 24.

<!-- image -->

Abbreviations: LTFU, long-term follow-up; QD, once daily; RUX, ruxolitinib.

MMB was administered at a starting dose of 200 mg once daily. After completion of the randomized treatment  phase,  subjects  will  be  eligible  to  receive  MMB  for  the  duration  of  the  study  during  the extended  treatment  phase  ( up  to  168  weeks ).  until  the  termination  of  the  study.  The  maximum participation in the treatment period for any subject was 192 weeks. BAT (best available therapy) was administered at the discretion of investigator.

The primary objective was to determine the efficacy of MMB versus BAT in anemic or thrombocytopenic subjects with PMF or Post-PV/ET MF who are treated with ruxolitinib as measured by SRR24

Secondary objectives included:

- To determine the effect of MMB compared with BAT on the improvement of TSS at Week 24
- To determine the effect of MMB compared with BAT on rate of RBC transfusions through Week 24
- To determine the effect of MMB compared with BAT on RBC TI rate at Week 24
- To determine the effect of MMB compared with RUX on RBC TD rate at Week 24

A sample size of 150 subjects (2:1 randomization to MMB or BAT) was planned to provide &gt; 95% power to test the primary hypothesis that MMB was superior to BAT in SRR at week 24 at the assumed SRR of 20% for MMB and 1% for BAT. Sample size assumptions were based on data from the small subset of subjects previously treated with RUX in the MMB phase 2 studies CCL09101 and YM387-II02, and from historic data from the non-Janus kinase (JAK) inhibitor-containing BAT arm of COMFORTII, a phase 3 study of RUX versus BAT in JAK inhibitor-naïve subjects with MF that supported the initial approval of RUX for MF (Harrison, 2012). All statistical tests were 2-sided and performed at the 5% significance level unless otherwise specified.

In SIMPLIFY-2  study, data cutoff for Week 24 Interim Analysis was 28 July 2016 and data cutoff for Week 48 Interim Analysis was 12 September 2017 .

156 subjects were randomized 2:1 to either MMB (104 subjects) or BAT (52 subjects) treatment in the RT phase. 69 of the 104 subjects (66.3%) in the MMB group and 41 of the 52 subjects (78.8%) in the BAT group completed treatment in the RT phase. In the ET phase, 64 of the 104 (61.5%) MMB-treated subjects continued to receive MMB (MMB to MMB) and 40 of the 52 (76.9%) BAT-treated subjects

<div style=\"page-break-after: always\"></div>

switched to MMB (BAT to MMB). Overall, most subjects in the ET phase completed Week 48 (Week 24 in ET Phase) visits or later (49 of 64 MMB to MMB [76.6%] subjects and 20 of 40 BAT to MMB [50.0%] subjects).

Figure 31: Subject disposition flow chart (SIMPLIFY-2)

<!-- image -->

Based on the available data for subjects who entered the RT phase, 95.2% in the MMB group and 94.2% in the BAT group reported the use of any prior MF therapy. Similarly, in the ET phase, 95.3% of MMB to MMB and 100.0% of BAT to MMB subjects reported the use of prior therapy. Per inclusion criterion 4, all subjects must have been treated with ruxolitinib for at least 28 days and met treatment requirements outlined in the protocol. Five subjects did not meet this criterion. Data on initiation and duration of ruxolitinib were missing for 22 subjects (13 who were randomized to the MMB arm and 9 who were randomized to the BAT arm). Other than ruxolitinib, the most frequently reported ( ≥ 10% of total subjects in each phase) prior MF therapy was hydroxyurea (24.4% and 19.2%, respectively).

Primary Efficacy Endpoint: SRR at Week 24 based on ≥ 35% reduction in spleen volume from baseline

<div style=\"page-break-after: always\"></div>

Table 78: Analysis of Splenic Response Rate at Week 24 (Randomized Treatment Phase, Intent-to-Treat Analysis Set, SIMPLIFY-2)

|                                                           | MMB (N =104)       | BAT (N = 52)       |
|-----------------------------------------------------------|--------------------|--------------------|
| Responder, n (%)                                          | 7 (6.7%)           | 3 (5.8%)           |
| 95% exact CI                                              | 0.0275,0.1338      | 0.0121, 0.1595     |
| Proportion difference - stratified CMH method (95% CI)    | 0.01 (-0.09, 0.10) | 0.01 (-0.09, 0.10) |
| p-value                                                   | 0.90               | 0.90               |
| Proportion difference - unstratified CMH method (95% CI)  | 0.01 (-0.07, 0.09) | 0.01 (-0.07, 0.09) |
| p-value                                                   | 0.82               | 0.82               |
| Proportion difference -unstratified exact method (95% CI) | 0.01 (-0.16, 0.18) | 0.01 (-0.16, 0.18) |
| p-value                                                   | 1.00               | 1.00               |
| Non-responder, n (%)                                      | 97 (93.3%)         | 49 (94.2%)         |
| Baseline spleen volume not available                      | 0                  | 0                  |
| Spleen volume at Week 24 not available                    | 34 (32.7%)         | 13 (25.0%)         |
| Last participation date < Day 141 in RT phase             | 23 (22.1%)         | 10 (19.2%)         |
| < 35% spleen volumereduction at Week 24                   | 63 (60.6%)         | 36 (69.2%)         |
| > 0% spleen volume increase at Week 24                    | 34 (32.7%)         | 19 (36.5%)         |

Abbreviations: BAT = best available therapy; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; ITT = intent-totreat; MMB = momelotinib; RT = Randomized Treatment 95% Exact CI is based on Clopper-Pearson method without stratification

Secondary Efficacy Endpoint: MPN-SAF TSS response rate at Week 24

Table 79: Analysis of Response Rate in Total Symptom Score at Week 24 (Randomized Treatment Phase, Intent-to-Treat Analysis Set, SIMPLIFY-2)

|                                                                    | MMB (N =104)      | BAT (N = 52)      |
|--------------------------------------------------------------------|-------------------|-------------------|
| TotalSynptomScorestatusatbaseline                                  |                   |                   |
| Missing                                                            | 0                 | 0                 |
| TSS = 0                                                            | 1 (1.0%)          | 3 (5.8%)          |
| TSS >0                                                             | 103 (99.0%)       | 49 (94.2%)        |
| TSSResponseRate atWeek 24                                          |                   |                   |
| Subjects evaluable at Week 24                                      | 103               | 51                |
| TSS = 0 at baseline and TSS > 0 or missing at Week 24              | 0                 | 2 (3.9%)          |
| Responder, n (%)                                                   | 27 (26.2%)        | 3 (5.9%)          |
| 95% exact CI                                                       | 0.1804, 0.3580    | 0.0123, 0.1624    |
| Proportion difference - stratified CMH method (95% CI)             | 0.20 (0.09, 0.32) | 0.20 (0.09, 0.32) |
| P-value                                                            | <0.001            | <0.001            |
| Non-responder                                                      | 76 (73.8%)        | 48 (94.1%)        |
| Last participation date < Day 162 in RT phase                      | 28 (27.2%)        | 10 (19.6%)        |
| Last participation date ≥ Day 162 and TSS at Week 24 not available | 3 (2.9%)          | 3 (5.9%)          |
| < 50%reduction from baseline at Week 24                            | 45 (43.7%)        | 34 (66.7%)        |
| > 0% increase from baseline at Week 24                             | 25 (24.3%)        | 23 (45.1%)        |

Abbreviations: BAT = best available therapy; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; DB =double-blind; ITT = intent-to-treat; MMB = momelotinib; RT = Randomized Treatment; TSS = Total Symptom Score a 95% Exact CI is based on Clopper-Pearson method without stratification TSS rate analysis at one visit only included evaluable subjects (ie, those with TSS &gt; 0 at baseline or with TSS = 0 at baseline but with TSS &gt; 0 or missing at that visit).

Secondary Efficacy Endpoint: TI response rate at Week 24

<div style=\"page-break-after: always\"></div>

The difference was nominally significant in the SIMPLIFY-2 trial

Table 80: Analysis of RBC Transfusion Independence Response Rate at Week 24 (Randomized Treatment Phase, Intent-to-Treat Analysis Set, SIMPLIFY-2)

|                                                         | MMB (N =104)      | BAT (N = 52)      |
|---------------------------------------------------------|-------------------|-------------------|
| Responder, n (%)                                        | 45 (43.3%)        | 11 (21.2%)        |
| 95% exact CI                                            | 0.3359, 0.5335    | 0.1106, 0.3470    |
| Proportion difference - Stratified CMH method (95% CI)  | 0.23 (0.09, 0.37) | 0.23 (0.09, 0.37) |
| P-value                                                 | 0.001             | 0.001             |
| Non-responder, n (%)                                    | 59 (56.7%)        | 41 (78.8%)        |
| Transfusion (except bleeding) in the last 12 weeks      | 30 (28.8%)        | 28 (53.8%)        |
| Any hemoglobin assessment < 8 g/dL in the last 12 weeks | 23 (22.1%)        | 20 (38.5%)        |
| Last participation date prior to Day 162 in RT phase    | 28 (26.9%)        | 10 (19.2%)        |
| Other                                                   | 11 (10.6%)        | 4 (7.7%)          |

Abbreviations: BAT = best available therapy; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; ITT =intent-to-treat; MMB = momelotinib; RBC = red blood cell; RT = Randomized Treatment Note: 95% Exact CI is based on Clopper-Pearson method without stratification.

## Main supportive study for JAKi-treatment naïve patients: Study GU-US-352-1672

GS-US-352-1672 was a phase 2, open-label, single-arm, multicenter, translational biology study of the effect  of  MMB  on  TI  and  relevant  disease-specific  biomarkers  related  to  iron  metabolism  and inflammation in transfusion-dependent subjects with PMF or post-PV/ET MF. The primary objective was to determine the TI response rate in transfusion-dependent subjects with MF treated with MMB. Other secondary endpoints included no RBC transfusions for ≥ 8 weeks anytime by week 24, SRR at week 24 and TSS response rate at week 24.

The study enrolled 41 subjects aged  ≥ 18 years with PMF or post-PV/ET MF of high-risk, intermediate-2  risk,  or  intermediate-1  risk  and  TD  at  baseline.    Most  subjects  (87.8%)  were  JAK inhibitor naïve at baseline.

## Outcomes and estimations

- -TI response rate by week 24: Fourteen of 41 subjects ( 34.1% ; 90% CI: 22.0, 48.1) reached TI by week 24. Of the 14 subjects with a TI response by week 24, 11 had baseline Hgb ≥ 8 g/dL and 3 had baseline Hgb &lt;8 g/dL. Non-responders included 5 subjects (12.2%) who discontinued the study before day 84 (ie, 12 weeks before week 24).
- -Proportion of patients with no RBC transfusions for ≥ 8 weeks anytime by week 24: By week 24, 16 subjects (39.0%; 90% CI: 26.2, 53.1) had no RBC transfusion for ≥ 8 weeks at any time.
- -SRR at week 24: Five of 41 subjects ( 12.2% ; 90% CI: 4.9, 23.9) had a ≥ 35% reduction from baseline in spleen volume at week 24. Spleen volume at week 24 was not available for 15 subjects (36.6%).

<div style=\"page-break-after: always\"></div>

- -TSS response rate at week 24: Six of 38 evaluable subjects ( 15.8% ; 90% CI: 7.1, 28.8) had a ≥ 50%  reduction  from  baseline  in  TSS  at  week  24.  TSS  at  week  24  was  not  available  for  17 evaluable subjects (44.7%).
- -Hgb  levels:  MMB  induced  an  increase  in  Hgb  that  was  maintained  over  time.  In  the  overall biomarker analysis set, mean Hgb levels were 8.0 g/dL at baseline, 8.8 g/dL at week 2, and 8.9 g/dL at week 24.

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

## Study design

The applicant has submitted the results of three phase 3 randomised controlled studies and one singlearm trial to support the indications:

- in patients that have been treated with ruxolitinib:
- -MOMENTUM  with  24  weeks  randomized,  double-blind  treatment  period  and  open-label extended  treatment  phase  (up  to  180  weeks)  with  momelotinib  treatment  in  both  arms. Danazol-treated subjects who did not cross-over to momelotinib at Week 24 had the option to continue danazol as open-label treatment through week 48.
- -SIMPLIFY-2 with 24 weeks randomised open-label treatment period and open-label extended treatment phase (up to 168 weeks) with momelotinib treatment in both arms.
- in JAK inhibitor naïve patients:
- -SIMPLIFY-1  with  24  weeks  randomized,  double-blind  period  and  up  to  5  years  open-label, with momelotinib monotherapy after 24 weeks in both arms
- -GU-US-352-1672 open-label, single-arm trial with momelotinib monotherapy.

Patients have been randomised at 2:1 or 1:1 ratio to momelotinib or controls in

- -MOMENTUM trial (195 patients: 130 to momelotinib arm and 65 to danazol arm),
- -SIMPLIFY-2 trial (156 patients: 104 to momelotinib arm and 52 to best available therapy arm)
- -SIMPLIFY-1 trial (432 patients: 215 to momelotinib arm and 217 to ruxolitinib arm)

or treated in a single-arm GU-US-352-1672 trial (41 patients).

The efficacy assessment of momelotinib in patients with moderate to severe anaemia (Hgb &lt; 10 g/dL, as per eligibility criteria) in patients previously treated with ruxolitinib is mainly based on the results of the MOMENTUM trial. In the JAK inhibitor naïve setting, the efficacy of momelotinib in patients with moderate to severe anaemia is mainly based on post-hoc analysis in the subgroup of patients with Hgb &lt;10 g/dL.

## Starting dose justification and adjustments

The dose of momelotinib tablet was 200 mg once daily in all trials, supported by the results of early dose-finding  studies  with  capsule  to  tablet  formulation.  For  the  E-R  analyses  please  refer  to  PK/PD part.

Treatment was to be interrupted or reduced due to thrombocytopenia, neutropenia, or other toxicities at  investigator  discretion.  Doses  were  reduced  by  sequential  decrements  (150  mg,  100  mg  and  50

<div style=\"page-break-after: always\"></div>

mg). Patients had to permanently discontinue treatment in case of leukemic transformation, pregnancy or disease progression.

Concurrent active anti-MF therapy while on study drug was prohibited, except in the control arm of the SIMPLIFY-2 trial. Patients in the control arm were also allowed to cross-over before the end of the 24 week randomization phase in case of confirmed splenic progression (defined differently across studies).

Patients received MMB treatment as long as they benefitted and tolerated MMB. Most common reasons for MMB discontinuation during the RT and OL phases included adverse events, insufficient efficacy, disease progression and subject decision. However, many patients remained on treatment long term as evidenced by the long-term extension safety study (XAP study), with most subjects maintaining their Week 24 responses and with induction of new responses in week 24 non-responders, waiving the need for guidance on treatment duration into the SmPC.

## Targeted patient population as per eligibility criteria

All  phase  3  trials  only  included  adults  who  were  required  to  have  confirmed  diagnosis  of  PMF  in accordance with the World Health Organization (WHO) criteria, or Post-PV/ET MF in accordance with the  IWG-MRT  criteria.  In  addition,  prognostic  scoring  systems  were  considered  for  eligibility,  with haemoglobin &lt; 10 g/dL being an important variable contributing to the risk category in IPSS (1 point), DIPSS  (2  points)  and  DIPSS  plus  (1  point)  models  for  primary  MF.  The  latter  model  also  includes transfusion needs as a variable (1 point).

In MOMENTUM trial eligible subjects were required to have received prior treatment with an approved JAK inhibitor  for ≥ 90 days or less if complicated with hematologic toxicity. A wash-out period of at least  2  weeks  was  required  since  previous  JAK  inhibitor  therapy.  Eligible  patients  also  had  baseline splenomegaly (defined as palpable spleen at ≥ 5 cm below the LCM or with volume ≥ 450 cm 3 ), were symptomatic (defined as MFSAF TSS ≥ 10 and applied to overcome intra -patient variability in TSS over time) and had at least moderate anaemia (defined as Hgb &lt; 10 g/dL) at screening (within 6 weeks before  randomization).  Only  patients  with  high,  intermediate-2  or  intermediate-1  risk  (defined  by DIPSS  or  DIPSS-Plus)  were  eligible.  This  study  also  allowed  enrolment  of  patients  with  severe thrombocytopenia (defined as platelet counts ≤ 50 x 10 9 /L, however not lower than 25 x 10 9 /L).

In  supportive  SIMPLIFY-2  trial,  a  similar  population  as  in  the  MOMENTUM  study  were  included,  i.e. patients who received current or prior treatment with ruxolitinib that was complicated with hematologic toxicity. Similarly, patients were required to have baseline splenomegaly (defined as palpable spleen at ≥ 5 cm below the LCM) and had high or intermediate -2 risk (defined by DIPSS). Also intermediate-1 risk  patients  were  eligible,  provided  it  was  associated  with  symptomatic  splenomegaly  and/or hepatomegaly.

In contrast to the MOMENTUM study patients enrolled in the SIMPLIFY-2 study were not required to respect  a  wash-out  of  prior  JAK  inhibitor  therapy.  In  addition,  study  eligibility  was  not  restricted  to patients with at least moderate anaemia, although the likelihood of inclusion of anaemic patients was higher due to selection by risk. In addition, patients in the SIMPLIFY-2 study were not required to be symptomatic.

In SIMPLIFY-1 trial, only patients with no prior treatment with a JAK inhibitor were eligible. Patients were required to have high-risk or intermediate-2 risk MF (defined by IPSS), or to have intermediate-1 risk  (IPSS)  associated  with  symptomatic  splenomegaly,  hepatomegaly,  anaemia  (Hgb  &lt;  10.0  g/dL), and/or unresponsive to available therapy.

Similar  as  for  the  SIMPLIFY-2  study,  the  SIMPLIFY-1  study  was  not  designed  to  study  the  effect  of momelotinib in anaemia, with inclusion of mildly anaemic (Hgb ≥ 10 g/dL and &lt; 12 g/dL) as well as non-anaemic patients  in  the  overall  eligible  study  population.  Patients  were  also  not  required  to  be symptomatic.

In the early single-arm GU-US-352-1672 study, patients with high-risk or intermediate-2 risk (per DIPSS) or intermediate-1 risk per DIPSS with symptomatic splenomegaly and/or hepatomegaly,

<div style=\"page-break-after: always\"></div>

transfusion dependent at baseline (defined as ≥ 4 U RBC transfusion in the 8 weeks prior to the first dose of MMB) were eligible. There was no requirement with regard to prior JAK-inhibitor therapy.

## Comparators

In the MOMENTUM trial in JAKi exposed patients (first patient enrolled in April 2020), the efficacy and safety  of  momelotinib  was  compared  to  danazol.  Although  there  is  no  standard-of-care  in  patients previously treated with a JAK inhibitor, during scientific advice the use of a single orally administered comparator was supported as it allows a double-blinded study design, needed to mitigate bias in the primary  endpoint  of  TSS  response  rate.  The  choice  of  the  gonadoreline  antagonist  danazol  was supported  given  the  focus  of  the  momelotinib  development  on  the  effect  on  anaemia.  Danazol  is recommended by clinical guidelines for the management of MF-associated anaemia, mainly based on case series of 50 consecutive patients with MF and anaemia (Cervantes, 2015). The dose of danazol used in the MOMENTUM study (total daily starting dose of 600 mg with reduction to 400 mg or less from Week 48 to the minimum necessary dose to maintain response) was consistent with the dose used in the publication by Cervantes et al. (2015) and recommended in clinical guidelines.

However, up to today danazol is not approved in the EU for management of MF-associated anaemia. In 2021  fedratinib  has  received  approval  in  the  EU  for  treatment  of  disease-related  splenomegaly  or symptoms in MF patients including those patients who previously received treatment with ruxolitinib. Nevertheless, it can be taken into consideration that the MOMENTUM trial was designed and initiated before fedratinib was approved and available in the EU.

While  danazol  was  accepted  as  a  relevant  comparator  for  a  superiority  claim  (as  a  co-primary endpoint), the absence of well-controlled data supporting danazol as active comparator (e.g. versus placebo  or  other  therapies  used  for  anaemia  management  in  patients  with  MF)  is  hampering  the interpretation of the non-inferiority testing for TI rate at Week 24 this study. The clinical relevance of the selected non-inferiority margin is therefore also considered uncertain. Post-hoc baseline-matched indirect  comparison  (MAIC)  analyses  are  suggestive  for  a  benefit  in  TI  rate  of  DAN  versus  placebo [odds ratio for TI during 6 months: 5.47 (95% CI: 1.88, 15.91); placebo data retrieved from a phase 3 randomized study comparing pomalidomide and placebo in transfusion dependent MF patients, Tefferi 2017], of DAN versus BAT [odds ratio for TI rate at Week 24: 2.387 (95% CI: 0.643, 8.859)] and of MMB  versus  placebo  [odds  ratio  for  TI  during  6  months:  6.80  (95%  CI:  3.00,  15.40)],  however, limitations intrinsic to indirect comparisons, accentuated by the relatively small effective sample size after weighting in the DAN arm of the MAIC analysis compared to placebo (DAN 23.4 versus placebo 77), should be taken into consideration.

In  supportive SIMPLIFY-2 trial in ruxolitinib-treated patients (first subject enrolled in July 2014) the efficacy and safety of momelotinib was compared to best available therapy (BAT) as per investigator's discretion  in  accordance  with  standard  of  care,  given  there  were  no  approved  therapies  in  EU  for patients  with  MF  who  were  previously  treated  with  ruxolitinib  at  the  time  of  study  initiation.  In addition, sequential or concurrent administration of more than one BAT was allowed, and BAT could change anytime during the study except at screening. Hence, the study was designed as an open-label study. Although any agent(s) approved for the treatment of MF or considered standard of care were allowed  including  no  active  therapy,  the  vast  majority  of  patients  in  the  BAT  arm  was  treated  with ruxolitinib (88.5%) and only a minority (12.5%) of these received the recommended dose of ruxolitinib 20 mg twice daily (dosage range of 5 -20 mg was allowed). Other main administered treatments were hydroxyurea  (23.1%)  and  prednisone/prednisolone  (11.5%).  Only  2  subjects  (3.8%)  received  no therapy.

In SIMPLIFY-1 trial in JAKi naïve patients (first subject enrolled January 2014), the choice of ruxolitinib as  active  comparator  was  considered  acceptable,  as  it  is  current  standard  of  care  in  the  early treatment setting. The starting dose of ruxolitinib and dose modification guidelines used in the study are largely in agreement with the Jakavi (ruxolitinib) SmPC.

In the early single-arm GU-US-352-1672 translational trial in JAKi naïve patients there was no active comparator.

<div style=\"page-break-after: always\"></div>

## Choice of endpoints

Reduction of spleen volume (assessed by splenic response rate) and improvement of disease-related symptoms (assessed  by  total  symptom  score  response  rate)  has  been  assessed  as  primary  or  key secondary  endpoints.  Both  objectives  are  related  to  each  other  (i.e.  reduction  of  spleen  volume  is associated with improvement of symptoms). Symptom improvement is considered a clinically relevant treatment benefit, as symptom burden significantly contributes to the reduced health-related quality of life observed in myelofibrosis patients.

In  addition,  although  the  SIMPLIFY-1  and  SIMPLIFY-2  studies  were  not  designed  to  investigate  the effect  of  momelotinib  on  anaemia-related  outcomes  as  primary  endpoints,  the  effect  of  MMB  on transfusion requirements was also assessed in all studies. Transfusion dependency is known to impact prognosis and is considered of relevance for the momelotinib development focused in its later stage on the relieving disease-related and treatment-related anaemia. The currently approved JAK inhibitors do not address optimally disease-related cytopenias and often induce those (including anaemia).

In the phase 3 studies, a hierarchical testing approach was used for the analysis of primary and key secondary efficacy endpoints, which is considered adequate to control the study-wise type I error at 5%, also in case of more than one primary endpoint without being composite primary endpoints (cfr. MOMENTUM)

The MOMENTUM trial includes 2 primary endpoints, i.e. the assessment of improvement of symptoms, by  evaluating  the  MFSAF  total  symptom  score  (TSS)  response  rate  at  week  24,  and  assessment  of anaemia-related outcomes, by evaluating the transfusion independency (TI) response at week 24. Both primary  endpoints  were  however  not  designed  as  co-primary  endpoints,  as  recommended  during scientific advice, meaning that TSS must be positive along with transfusion independence (EMA/CHMP/SAWP/128654/2019;  EMA/CHMP/SAWP/497222/2019).  The  study  met  both  primary endpoints if superiority of TSS 24 was significant and at least non-inferiority of TI 24 was significant.

The first primary endpoint is the MFSAF v4.0 TSS response rate at week 24, defined as the proportion of patients with 50% reduction in mean TSS (calculated as the sum of the daily scores of the 7 items of the MFSAF v4.0) over the 28 days immediately prior to the end of Week 24 compared to baseline. The  Myelofibrosis  Symptom  Assessment  Form  version  4.0  Diary  (MFSAF  v4.0)  includes  7  items considered  to  be  important  symptoms  of  MF:  fatigue,  night  sweats,  pruritus,  abdominal  discomfort, pain  under  ribs  on  left  side  of  body,  early  satiety,  and  bone  pain.  An  appropriate  anchor-based meaningful change threshold (MCT) analysis has been conducted to justify the 50% MCT.

The  second  primary  endpoint  was  Transfusion  Independency  (TI)  rate  at  Week  24,  defined  as  the proportion of subjects with TI status (i.e. not requiring RBC or whole blood transfusion for ≥ 12 weeks, with all Hgb levels during the ≥ 12 -week interval of ≥ 8 g/dL) at the end of Week 24. TI rate at Week 24 was first tested for superiority, if the superiority test for TI at week 24 was not significant, a noninferiority test was to be performed. Switching of objective is considered an appropriate approach in case  of  uncertain  magnitude  of  advantage  without  adjustment  for  multiplicity,  however  the  clinical relevance  of  non-inferiority  in  transfusion  dependency  rate  is  uncertain,  considering  the  lack  of  an acceptable active comparator.

The splenic response rate (SRR) at week 24, defined as a reduction in spleen volume of ≥ 35% from baseline as measured by MRI or CT scan, was included as key secondary endpoint (third one). This criterion is in line with the IWG-MRT criteria. SRR was tested for superiority.

In SIMPLIFY-2 trial, the primary endpoint was SRR at week 24, similarly defined as the proportion of subjects with a reduction in spleen volume ≥ 35% from baseline, which was tested for superiority. TSS response rate at week 24 was the first secondary endpoint, also tested for superiority.

Although similarly defined as in the MOMENTUM study (≥ 50% reduction in TSS), assessment of TSS in this study was based on a different PRO measure, i.e. the modified MPN-SAF v2.0 TSS. TSS was based on 7 of the 8 items (excluding inactivity), which are the same items as for the MFSAF v4.0 TSS.

<div style=\"page-break-after: always\"></div>

TI  rate  at  week  24  was  also  included  as  secondary  endpoint  (third  one).  It  was  defined  as  the proportion  of  subjects  with  TI  in  the  terminal  12  before  the  Week  24  visit,  with  TI  defined  slightly different compared the MOMENTUM study, i.e. not requiring RBC transfusions and no central or local laboratory haemoglobin (Hgb) level &lt; 8 g/dL. TI rate at Week was also tested for superiority.

In the SIMPLIFY-1 trial, the endpoints were similar as in the SIMPLIFY-2 study with SRR at Week 24 being the primary endpoint. The testing strategy was however different with first non-inferiority testing for  SRR  and  TSS  response  rate  at  Week  24,  which  was  acceptable  given  the  uncertainty  on  the magnitude of advantage of momelotinib compared to ruxolitinib for these endpoints. The selected noninferiority  margins  seemed  however  to  be  arbitrarily  chosen,  without  clinical  judgement  on  the importance of loss of efficacy of MMB compared to the reference of RUX that is associated with these non-inferiority  margins [0.60 in MMB/RUX  response  ratio  scale for primary analysis of  SRR (corresponding  to  preservation  of  77%  of  the  RUX/placebo  response  ratio)  and  0.16  in  MMB-RUX response difference scale for exploratory analysis (corresponding to preservation of around 50% of the treatment effect of the ruxolitinib control compared to placebo); 0.67 in MMB/RUX response ratio for primary  analysis  TSS  response  ratio].  However  we  note  that  these  values  correspond  to  the  lower bound  of  the  95%  confidence  intervals  of  the  MMB/RUX  response  ratio  or  MMB-RUX  response difference, and that the chance of the true difference being worse than that suggested by this bound is generally considered acceptably small.

In an early single-arm GU-US-352-1672 trial, the primary objective was to determine the TI response rate in transfusion-dependent subjects with MF treated with MMB.

## Duration of trials

Week 24 data presented for the MOMENTUM study are derived from the primary analysis with data cut-off date of 03 Dec 2021 , which is also the date when the last subject reached the Week 24 time point (first subject screened: 07 Feb 2020). Week 48 analysis data presented have a cutoff date of 17 Jan 2023.

With the exception of data for OS, the data presented for the SIMPLIFY-2 study are those as of data cut-off data of 25 Apr 2019 ,  at  the moment of last subject last visit, after a follow-up of around 5 years (first subject screened: 19 Jun 2014). The data presented for OS are those derived from followup data from an MMB extension study (XAP) as of the data cutoff date of 03 Dec 2021.

The data presented for the SIMPLIFY-1 study are derived from a follow-up analysis (around 5 years of follow-up) with data cut-off date 01  Jul  2019 (first  subject screened: 06 Dec 2013). OS data were also derived as of the data cutoff date of 03 Dec 2021 (XAP). Note that the final (primary) analysis, when subjects had reached the Week 24 time point, was conducted at the data cut-off point of 12 Sep 2016, for which the corresponding CSR has been submitted.

## Data presented for the single-arm GU-US-352-1672 trial are those as of data cut-off date of 31 Oct 2017 (first subject screened: 29 Jan 2016)

## Adequacy of methods, conduct, analyses and reporting of results

The  three  phase  3  studies  of  MMB  enrolled  patients  in  Europe,  North  America,  Asia,  and  Australia/ Australasia,  with  the  majority  (approximately  70%)  enrolled  in  Europe  (72,8%,  69,5%,  72,4%  in MOMENTUM, SIMPLIFY-1  and  SIMPLIFY-2,  respectively).  The  supportive  phase  2  study  GS-US-3521672 enrolled patients in North America only.

In the MOMENTUM trial, following initial submission of the application, the applicant identified a vendor technical  error  related  to  the  MOMENTUM  anti-myelofibrosis  prohibited  medication  dataset.  Subjects which received a prohibited active anti-MF therapy during the randomized treatment period were not flagged in that prohibited anti-MF dataset owing to a dataset filter. After removal of the dataset filter, 6 subjects (5 in the MMB arm and 1 in the DAN arm) were identified as receiving prohibited active antiMF  therapy  during  the  randomized  treatment  period,  which  should  have  been  reported  as  nonresponders  in  the  primary  analysis  of  the  response-based  primary  and  key  secondary  endpoints. However, 5 of the 6 subjects were already reported as non-responders in the original analysis of each

<div style=\"page-break-after: always\"></div>

of the affected endpoints, thus requiring no corrections to their responder status. As a result, only one patient had been misclassified for the endpoints of transfusion independence status at Week 24 and splenic response rate at Week 24 (subject should be considered non-responder instead of responder). In this report, only the final corrected data are presented. The correction of data is considered not to have affected data interpretation as the affected primary efficacy endpoint (TI rate at Week 24) and 2 key secondary efficacy endpoints [SRR (reduction in spleen volume of ≥ 25% and ≥ 35%) at Week 24] tested in the prespecified hierarchical order shown were still met (non-inferiority for TI rate at Week 24 and superiority for SRR at Week 24).

In MOMENTUM and SIMPLIFY-1 studies, the SAP was finalized while the study was ongoing (SIMPLIFY1)  or  even  after  the  last  subject  last  visit  (MOMENTUM),  however  before  the  date  of  treatment unblinding  for  statistical  analyses.  Though,  due  to  unblinding  for  safety  reasons  or  because  of confirmed  splenic  progression  and  eligibility  for  early  cross-over,  a  total  of  22  subjects  in  the MOMENTUM study and 26 subjects in the SIMPLIFY-1 study were unblinded before Week 24. However, no changes on the content of the SAP were made on the basis of blinded or unblinded data review, reassuring that the studies integrity.

The MOMENTUM study protocol was globally amended twice with the first subjects only enrolled after the first global protocol amendment. With protocol amendment v2.0, important changes were however introduced in the criteria for early crossing over from DAN to open-label MMB, i.e. revision of criteria for splenic progression and allowing in exceptional circumstances, such as severe splenic progression, the short-term use of restricted anti-MF medication. However, the number of subjects with confirmed splenic progression during the randomized treatment period was low (2 MMB, 6 DAN), with most of them meeting the definition of confirmed splenic progression under both protocol v1.0 and v2.0. In addition, out of the 6 DAN subjects with confirmed splenic progression, no subject received prohibited anti-MF  therapy  during  the  randomized  treatment  period.  Therefore,  the  changes  introduced  from protocol version v1.0 to v2.0 had only limited impact on the interpretation of the results.

The rate of major protocol deviations in both treatment groups are within acceptable ranges (n = 1 MMB, n = 4 DAN) and are not considered to affect data interpretation. It was further noticed that 13 subjects  were  included  with  baseline  MFSAF  TSS  score  &lt;  10,  which  is  not  in  accordance  to  the inclusion criteria, and which have a potential to influence interpretation of study data. However, given these  deviations  were  balanced  between  both  treatment  groups  and  given  their  relevance  for  the claimed indication, this issue is not further pursued. Additional minor violations in PRO data collection were due to a cyberattack which resulted in a small amount of data loss, however the protocol included appropriate  missing  data  strategies  for  PRO-based  endpoints.  With  regard  to  the  protocol  violations related  to  manipulation  of  the  time  zones  of  completed  PRO  questionnaires  (n  =  4),  a  sensitivity analysis for the MFSAF TSS response rate at Week 24, excluding the affected PRO data, was conducted which  is  considered  acceptable.  Although  pre-specified  per  SAP,  no  further  per-protocol  sensitivity analyses  were  conducted,  which  is  considered  acceptable  given  the  low  rate  of  important  protocol deviations which are not expected to affect data interpretation.

With  regard  to  treatment  compliance,  the  proportion  of  patients  in  the  MMB  and  DAN  group  who managed to take at least 90% of their intended doses was lower in the MMB arm (76.2%) compared to the DAN arm (89.2%) in the randomized treatment phase, likely reflecting the difference in rate of dose modifications (dose reductions or interruptions) due to AEs, which was higher in the MMB arm compared to the DAN arm (34% and 29%, respectively), which was not accounted for in the planned intended cumulative dose, the denominator of the relative dose intensity. This increased rate of dose modifications due to AEs in the MMB arm is however associated with a lower discontinuation rate due to AEs compared to the DAN arm (17.7% and 23.1%, respectively), reflecting that with MMB AEs could be better managed compared to DAN.

In the SIMPLIFY-1 trial the original protocol was amended 3 times during the study, with first subjects enrolled in the study under the original study protocol. As of protocol amendment 1, in- and exclusion criteria  were  amended  to  increase  of  minimal  required  ANC  level  and  CrCl,  and  decrease  the  QTc interval above which patients were excluded. The proportion of subjects screened under the original

<div style=\"page-break-after: always\"></div>

protocol  and  who  did  not  meet  the  revised  eligibility  in  protocol  amendment  1  however  was  low relative to the overall ITT population and balanced between study treatment arms (2 patients in each arm), with limited impact on the interpretation of the results.

The rate of major protocol deviations in both treatment groups in the double-blind phase of this study was  higher  compared  to  the  MOMENTUM  study  and  was  imbalanced  (n  =  44  MMB,  n  =  32  RUX), however the imbalance was mainly driven by an imbalance in GCP violations, not considered to have an  important  impact  interpretation  of  study  data.  Other  protocol  violations  were  related  to  missing data  of  key  endpoints.  Similar  missing  data  strategies  as  for  MOMENTUM  were  also  applied  in  the SIMPLIFY-1  study.  With  regard  to  violations  in  eligibility,  these  were  mainly  related  to  the  nonexclusion  of  subjects  with  active  infection  of  carrier  of  hepatitis  or  with  non-eligible  lab  values,  not considered to have an important impact on data interpretation. In addition, two subjects, one in each treatment group, were randomized but not treated because of withdrawn consent. These 2 subjects were considered as non-responders in the analyses of primary and key secondary endpoints.

Sensitivity analysis for the per-protocol analysis set, excluding patients with major protocol deviations, were conducted.

Treatment compliance during the double-blind phase was high with 95% and 94% of patients in the MMB and RUX group, respectively, who managed to take at least 90% of their intended doses, and this proportion was still above 80% in the open-label phase.

Given  the  substantial  proportion  of  missing  data  (MOMENTUM  and  SIMPLIFY-2)  and  the  imbalances between  treatment  arms  (MOMENTUM  and  SIMPLIFY-1),  as  per  guideline  on  missing  data  in confirmatory trials (EMA/CPWP/EWP/1776/99 Rev.1, 2010), post-hoc sensitivity analyses using various missing data handling methods, including complete case (CC) analysis [discarding missing data; under missing  completely  at  random  (MCAR)  assumption],  multiple  imputation  (MI)  analysis  [under  the missing at random (MAR) assumption] and tipping point analyses [exploring the impact of Missing not at random (MNAR) data] have been conducted for all main endpoints of all 3 randomized studies. In addition, exploratory worst-case analyses (imputing non-response for MMB subjects and response for control arm subjects) and modified worst-case analyses have been conducted. These modified worstcase  analyses  used  a  conservative  imputation  mechanism  but  also  accounts  for  the  reasons  for discontinuation.  Patients  in  the  MMB  arm  with  missing  data  due  to  reasons  other  than  disease progression  were  analyzed  as  non-responders;  for  control  arm  subjects  with  missing  data  due  to reasons other than insufficient efficacy or disease progression, the more favorable treatment arm was used to impute missing data for the control arm (MMB arm for MOMENTUM and SIMPLIFY-2 for all 3 endpoints and TI rate in SIMPLIFY-1; RUX arm for TSS response and SRR in SIMPLIFY-1)

## Statistical analyses

Statistical  testing  strategy  was  overall  adequate  in  all  three  phase  3  studies.  Adjustment  for multiplicity by applying a hierarchical testing strategy has been considered appropriate. The primary analyses  were  done  on  the  ITT  population,  which  is  a  standard  approach.  For  SIMPLIFY-1  and SIMPLIFY-2, post-hoc analyses in the subgroup of patients with moderate or severe anaemia (Hgb &lt;10 g/dL) were conducted.

Missing  data  in  the  primary  and  key  secondary  response-based  endpoints  were  considered  nonresponders, which is one of approaches usually applied. For the key secondary endpoint changes from baseline  of  mean  TSS  in  the  MOMENTUM study,  missing  data  in  the  primary  analysis  were  handled using a mixed model for repeated measurements (MMRM), under the missing at random assumption (MAR). A more conservative sensitivity analysis based on the controlled multiple imputation method, which departures from an MAR (missing at random) assumption but with applying potential missing data mechanism of missing not at random (MNAR), has also been conducted.

Patients concomitantly receiving prohibited active anti-MF therapy were considered non-responders in the primary analysis of the MOMENTUM study, as they might confound the MMB and/or RUX treatment effect.  No  such  approach  however  was  applied  for  the  SIMPLIFY-1  study.  Seven  subjects  in  the

<div style=\"page-break-after: always\"></div>

SIMPLIFY-1  study  (MMB  3,  RUX  4)  were  identified  as  receiving  prohibited  active  anti-MF  therapy according to the MOMENTUM protocol at any time during the randomized treatment period. However, 4 of  these  7  SIMPLIFY-1  subjects  were  non-responders.  Given  this  low  number  of  only  3  patients  in whom effects were potentially confounded by concurrent anti-MF therapy relative to the overall ITT population, the impact on the interpretation of the results is considered limited.

The  used  sample  size  calculation  method  in  the  MOMENTUM  study  is  considered  not  cautious,  in particular due to uninformed underestimation of the DAN effect estimates for TSS response rate and SRR (justified by the applicant due to the lack of any published literature), resulting in an observed proportion difference for TSS response rate that is lower than assumed (15% vs 21%, respectively), still  superiority  of  MMB  compared  to  DAN  was  met.  Furthermore,  also  the  assumed  true  TI  rate  for MMB (45%,  based  on  SIMPLIFY-2  results)  is  an  underestimation  of  the  observed  Week  24  TI  rate (30%), likely due to a larger number of anaemic patients with a higher transfusion burden at baseline relative  to  SIMPLIFY-2,  resulting  in  a  lower  than  assumed  proportion  difference  (10%  vs  24%, respectively) with MMB considered non-inferior compared to DAN (superiority not met). Although the applicant  considers  the  observed  proportion  difference  in  TI  response  rate  of  10%  as  clinically meaningful,  this  difference  was  not  pre-specified  for  the  study  design  which  was  not  powered  to account for this assumption.

## Efficacy data and additional analyses

In general, the interpretation of the response-based primary and key secondary endpoint results of the phase  3  studies  MOMENTUM,  SIMPLIFY-2  and  SIMPLIFY-1  is  hampered  due  to  the  proportion  of missing  values  at  Week  24,  which  is  substantial  in  particular  for  the  MOMENTUM  and  SIMPLIFY-2 studies  and  which  is  not  balanced  between  the  MMB  arm  and  control  arm  in  particular  for  the MOMENTUM  and  SIMPLIFY-1  studies.  However,  in  addition  to  the  primary  analyses,  in  which  all patients with missing data at Week 24 were considered non-responders, post-hoc sensitivity analyses using  various  missing  data  handling  methods  have  been  conducted.  The  results  of  these  sensitivity analyses were overall consistent with the primary analyses. In order to overturn statistical significance, the conducted tipping point analyses identified tipping points which are considered rather implausible (for  TSS  response  and  TI  rate  in  MOMENTUM)  or  could  not  identify  a  tipping  point  (for  SRR  in MOMENTUM and SIMPLIFY-1). No tipping point analyses were conducted for TSS response rate and TI rate in SIMPLIFY-2 and for TI rate in SIMPLIFY-1 as for these endpoints even the conservative modified worst-case sensitivity analysis (TSS response rate and TI rate in SIMPLIFY-2) and/or the worst-case sensitivity analyses (TI rate in SIMPLIFY-1) showed (nominal) superiority of MMB compared to control, elevating the need to conduct less conservative sensitivity analyses.

With  regard  to  the  missed  primary  endpoint  of  SRR  in  SIMPLIFY-2,  the  applicant  did  not  conduct sensitivity analyses due to the lack of statistical significance and a small number of responders in the original analysis.

In general, the results from conducted sensitivity analyses indicate that neither the information loss nor the methods used to handle missing data had a substantial impact on the study conclusions and therefore reassure on the reliability and the validity of the primary analysis results.

Baseline characteristics, patient population (ITT and by anaemia severity)

- Treated with ruxolitinib

In the MOMENTUM trial patients with an advanced disease and unfavourable prognosis were enrolled. Given  that  a  vast  majority  of  patients  had  intermediate-2  or  high-risk  disease  according  to  DIPSS (94.9%), median survival is expected to be only a few years or less. A majority of patients was ≥ 65 years of age (79.5%) and was diagnosed with PMF (64%).

As per study eligibility criteria, all patients were symptomatic, had an enlarged spleen and had at least moderate  baseline  anaemia  (Hgb  &lt;  10  g/dL).  Around  half  of  patients  were  suffering  from  severe

<div style=\"page-break-after: always\"></div>

anaemia (Hgb &lt; 8 g/dL; 48%) with minima up to 3.8 g/dL. Therefore, some patients would have been very  vulnerable  to  further  haemoglobin  decrease  under  treatment.  Only  a  minority  of  patient  was transfusion  independent  at  baseline  (13.8%)  and  around  half  of  patients  (49.7%)  were  considered transfusion dependent, which is also known as an unfavourable risk factor and impacting quality of life of MF patients. Patients that were not meeting the definitions of TI or TD were considered transfusion requiring (but not fully dependent on transfusions). Further also note that a majority of patients had baseline thrombocytopenia (platelet counts ≤ 150 x 10 9 /L) and 15.9% of patients had baseline severe thrombocytopenia (platelet counts ≤ 50 x 10 9 /L but &gt; 25 x 10 9 /L). Based on the above characteristics and the study eligibility criteria, the majority of the MOMENTUM study population is representative for patients considered intolerant to previous JAK inhibitor therapy due to hematological complications.

Overall, the demographics and baseline disease history and characteristics are well balanced between both treatment arms.

Only a low number of patients with intermediate-1 DIPSS risk were included (n = 7 MMB, DAN = 3. More patients with intermediate-1 DIPSS risk are however included in the SIMPLIFY-2 study.

All  patients  were previously treated with ruxolitinib, only a minority of patients additionally received prior  fedratinib  [5.4%  MMB  (n  =  7)  vs  3.1%  DAN  (n  =  2)],  reflecting  that  ruxolitinib  is  currently standard  of  care  in  the  early  treatment  setting.  The  small  number  of  subjects  in  this  subgroup  of patients who received prior fedratinib do not allow to make definite conclusions on the comparison with the overall ITT group.

In the SIMPLIFY-2 trial patients seem to have a less advanced disease status as compared to patients in the MOMENTUM study with a smaller proportion of patients with intermediate-2 or high risk disease (75%), a lower median TSS (16) with 29.5% of patients with TSS &lt; 10, a higher median baseline Hgb (9.0 g/dL, range 6 - 16), a higher proportion of patients with baseline TI status (32.7%) and 64.7% of patients ≥ 65 years of age . The proportion of patients with baseline TD status was similar as compared to the MOMENTUM study (54.5%). Compared to the MOMENTUM study, the SIMPLIFY-2 study included more patients with intermediate-1 DIPSS risk [MMB: n = 23 (22%), BAT: n = 16 (31%)], however the proportion of intermediate-1 patients in the anaemia subgroups is smaller, with only 12 intermediate-1 risk patients in the post-hoc defined subgroup of patients with Hgb &lt; 10 g/dL [MMB: 5 (7.5%), BAT: 7 (17.9%)].

As  per  study  eligibility  criteria,  the  SIMPLIFY-2  study  population  is  representative  for  patients considered intolerant to previous ruxolitinib due to hematological complications. A majority of patients suffered from at least moderate baseline anaemia (Hgb &lt; 10 g/dL; 67.3%) which is the corresponding Hgb threshold used in the MOMENTUM study to select baseline moderate to severe anaemic patients. A smaller fraction of patients compared to MOMENTUM suffered from severe anaemia (Hgb &lt; 8 g/dL; 21.2%).

Although a number of treatment options were allowed, the vast majority of patients in the BAT arm were  treated  with  ruxolitinib  (88%),  with  only  a  minority  of  them  (12.5%)  having  received  the recommended dose of 20 mg twice daily.

Overall, the demographics and baseline disease history and characteristics are well balanced between both treatment arms with the exception of sex at birth.

Overall,  the  demographic  and  disease  characteristics  of  the  post-hoc  defined  subpopulation  with  at least moderate anaemia (Hgb &lt; 10 g/dL) were consistent with the overall ITT population. As expected, the  notable  differences  in  the  key  baseline  demographic  and  disease  characteristic  between  the hemoglobin subgroups and the ITT population are related to transfusion requirements (proportion of patients  transfusion  independent  at  baseline  in  Hgb  &lt;  10  g/dL  subgroup  versus  ITT:13.3%  versus

<div style=\"page-break-after: always\"></div>

32.7%) and mean hemoglobin values (in Hgb &lt; 10 g/dL subgroup: mean Hgb 8.4 versus ITT: 9.4 g/dL).

Despite a number of imbalances between both treatment arms in this subgroup (not unexpected given the lack of randomization in this particular subgroup), key baseline characteristics in both treatment arms for this subgroup were representative for a population requiring JAKi therapy (TSS ≥10: MMB: 68%, BAT: 72%; Median spleen volume: MMB: 2577 cm³, BAT: 2049 cm³; Transfusion dependency: MMB: 79%, BAT: 64%).

## · JAKi naive

In the SIMPLIFY-1 trial, patients in general have less advanced disease compared to patients included in  the  MOMENTUM  and  to  a  lesser  extent  compared  to  the  SIMPLIFY-2  study,  mainly  driven  by differences  in  study  eligibility  criteria  (JAK-inhibitor  naïve  patients  versus  JAK-inhibitor  treated patients,  no  restriction  to  patients  with  at  least  moderate  anaemia  [Hgb  &lt;  10  g/dL],  eligibility  of asymptomatic patients [TSS &lt; 10]).

Compared to the MOMENTUM study, the SIMPLIFY1 study included a lower proportion of patients ≥65 years (57%), lower proportion of patients with intermediate-2 and high risk disease (79%; however per IPSS), patients had a lower median TSS (17) with 30% of patients with TSS &lt; 10, a higher median baseline  Hgb  (10.4  g/dL,  range  6  -  19),  a  majority  of  patients  was  baseline  TI  (69%)  and  only  a minority was TD at baseline (24%). In addition, a small proportion of patients had moderate baseline thrombocytopenia (platelet counts ≤ 100 x 10 9 /L; 10%); patients suffering from severe thrombocytopenia (platelet counts ≤ 50 x 10 9 /L) were not eligible. The SIMPLIFY-1 study also included intermediate-1 IPSS risk patients (20.6%), however the proportion of intermediate-1 patients in the anaemia subgroups is smaller (13.7%), with only 5 intermediate-1 risk patients in the post-hoc defined subgroup of patients with Hgb &lt; 10 g/dL.

Overall, the demographics and baseline disease history and characteristics are well balanced between both treatment arms, however slightly more subjects had severe anemia (Hgb &lt;8 g/dL: 13.0% versus 9.7%) in the MMB group at baseline.

Only a minority of patients suffered from at least moderate baseline anaemia (Hgb &lt; 10 g/dL; 41.7%). A  small  fraction  of  patients  suffered  from  severe  anaemia  (Hgb  &lt;  8  g/dL;  11.3%).  The  baseline haemoglobin was not a stratification factor. With the exception of baseline transfusion requirements and hemoglobin values, clinically important demographic and baseline characteristics were consistent in  the  post-hoc  defined  subgroup  of  patients  with  at  least  moderate  anaemia  (Hgb  &lt;  10  g/dL) compared with the ITT population, such as proportion of patients with TSS ≥10, median spleen volume and mean platelet count. As expected, patients with at least moderate anaemia had a lower mean Hb value (8.6 g/dL versus 10.6 g/dL) and had higher transfusion requirements at baseline (proportion of patients transfusion independent at baseline: 36.7% versus 69.2%) compared to the ITT population.

Between the MMB and RUX arms within the post-hoc defined subgroup of patients with Hgb &lt; 10 g/dL, the overall demographic and disease characteristics were consistent, however small differences in key demographic and disease characteristics in the &lt; 10 g/dL subgroup may predict to favor the RUX arm as the MMB arm represent a slightly older population with more severe anemia (23.6% versus 22.1%) and transfusion dependence (57.0% versus 45.3%). Also, there were more subjects in the RUX arm with platelet counts &gt; 200 x 10 9 /L (MMB: 43.0%, RUX: 50.5%) and per the prescribing information, these subjects likely received the optimal RUX starting dose of 20 mg BID. Other differences did not appear to be substantial.

Single-arm GU-US-352-1672 trial

<div style=\"page-break-after: always\"></div>

The study enrolled 41 subjects aged  ≥ 18 years with PMF or post-PV/ET MF of high-risk, intermediate-2  risk,  or  intermediate-1  risk  and  TD  at  baseline.    Most  subjects  (87.8%)  were  JAK inhibitor naïve at baseline.

## Endpoints of symptoms response

## · Treated with ruxolitinib

The  MOMENTUM  trial  met  its  first  primary  efficacy  endpoint,  demonstrating  statistically  significant superior MFSAF TSS response rate at Week 24 for MMB over DAN [24.62% (95% CI: 17.49, 32.94) versus 9.23% (95% CI: 3.46, 19.02); p = 0.0095]. With the limits intrinsic to indirect comparison, a TSS  response  rate  at  Week  24  of  24.6%  might  be  considered  clinically  meaningful,  as  a  similar response  rate  was  observed  with  in  ruxolitinib-pretreated  patients  who  received  treatment  with fedratinib 400 mg QD in the JAKARTA-2 study (using different modified 6-item MFSAF v2.0 measure).

This primary endpoint was supported by the key secondary endpoint of change from baseline MFSAF TSS at Week 24 which demonstrated a statistically significant superior difference in LS mean change, as observed in the MMRM analysis [-9.36 (1.08) versus -3.13 (1.62); p = 0.0014]. Over time, the LS mean changes from baseline in TSS was consistently larger in the MMB group compared to the DAN group. This difference in LS mean change was consistent across all individual symptoms.

Updated follow-up data of TSS response rate at Week 48 showed that in evaluable patients MMB led to durable  TSS  responses,  with  72%  of  the  MMB → MMB  group  and  100.0%  of  the  DAN → MMB  group maintaining their TSS response at week 48, and that MMB was also able to induce new responses in week 24 TSS non-responders (28% of the MMB → MMB group and 40.0% of the DAN → MMB group). Median duration of TSS response was not reached in both treatment groups.

In the supportive SIMPLIFY-2 study, despite lack of a washout period, despite the differences in the used PRO instruments and despite the uncertainty in this endpoint due to the open-label design of this study,  the  Week  24  modified  MPN-SAF  v2.0  TSS  response  rate  observed  in  the  SIMPLIFY-2  study supports the effect of MMB on symptom response observed in the MOMENTUM study, with a similar TSS  response  rate  at  Week  24  of  26.2%  (95%  CI:  18.04,  35.80),  which  was  numerically  higher compared to the BAT control arm [5.9% (95% CI: 1.23, 16.24); p &lt; 0.001]. However, this numerical improvement in TSS is only of nominal significance due to missed statistical significance in the primary endpoint.  In  addition,  note  that  in  the  BAT  group  the  vast  majority  of  patients  (88%)  received ruxolitinib, but only a minority of them (12%) received the full recommended dose of 20 mg BID. This suboptimal  ruxolitinib  dosing  in  the  BAT  group  might  also  have  contributed  or  might  explain  the numerical improvement in TSS response rate with MMB compared to BAT. (ITT analysis)

Also in the corresponding post-hoc defined subgroup of patients with at least moderate anaemia (Hgb &lt; 10 g/dL) in the SIMPLIFY-2 study, TSS response rate at Week 24 in the MMB group (32.3%) was consistent  higher  compared  to  the  corresponding  subgroup  in  the  BAT  group  (2.6%)  (post-hoc subgroup analysis).

In addition, the SIMPLIFY-2 study also provided supportive evidence for the intermediate-1 subgroup for which only scarce data were available in the MOMENTUM study, showing a consistent meaningful benefit of MMB compared to BAT, with a response rate in the MMB arm in this subgroup (26.1%) that was consistent with the MMB arm of ITT population (26.2%) (post-hoc subgroup analysis).

However,  reliability  of  PRO  data  in  this  study  is  compromised  taking  into  account  the  open-label design. Bias in favour of the MMB group can therefore not be excluded. As TSS data were not collected after Week 24, duration of TSS response at Week 24 was not evaluable.

<div style=\"page-break-after: always\"></div>

In conclusion ,  the  benefit  of  MMB  in  JAKi  treated  patients  for  the  treatment  of  disease-related symptoms is considered justified, mainly based on the results of the pivotal MOMENTUM trial in the JAK inhibitor pre-treated patient population with haemoglobin &lt;10 g/dL per protocol eligibility.

## · JAKi naïve

The SIMPLIFY-1 trial failed to demonstrate non-inferiority of MMB over RUX in the secondary endpoint of modified MPN-SAF v2.0 TSS response rate at Week 24 with a numerical higher TSS response rate in the ruxolitinib control group [28.4% (95% CI: 22.45, 35.03) versus 42.2% (95% CI: 35.43, 49.15); p = 0.98]. The mean change in TSS from baseline at Week 24 by MMRM analysis (exploratory post-hoc analysis) showed a non-significant difference in favour of RUX (LS mean change from baseline -5.87 for MMB versus -7.11 for RUX; p = 0.1380). (ITT analysis)

Also in the post-hoc defined subgroup of subjects with at least moderate anemia (25.0% MMB, 36.2% RUX), the proportion differences were consistent with the ITT population. Though, lower TSS response rate was observed in the RUX arm for the subgroup compared to ITT, resulting in numerically smaller differential treatment effects. Consistent with the ITT, the mean within-subject improvements in each treatment arm in the Hgb &lt; 10 g/dL subgroup were however rather similar [MMB arm: -5.06 points vs RUX arm: -6.68; LS mean difference: 1.62 ((95% CI: -0.85, 4.09) (post-hoc subgroup analysis)

Also in the subgroup of intermediate-1 patients, including those with anaemia, results are generally consistent with the ITT (post-hoc subgroup analysis).

Failure to show non-inferiority of MMB compared to RUX in TSS response rate raises concerns on the robustness of analysis and on the clinically relevant magnitude of the observed MMB effect. The cause for not meeting non-inferiority was likely multifactorial, including a higher rate of early discontinuation of patients in the MMB group favouring the RUX control arm, inclusion of subjects with baseline TSS range between 0 - 10 in which there is a high intra-patient variability in TSS over time, and the not rigorously selected noninferiority margin.

The  imbalance  in  early  discontinuation  was  due  to  more  subjects  with  low-grade  adverse  events leading to discontinuation of MMB, while such patients in the RUX group underwent dose reductions or temporary dose interruptions. In the primary analysis, these patients were considered non-responders, while  they  actually  may  have  benefitted  MMB  treatment  in  terms  of  TSS  up  to  their  early discontinuation. As such, the primary analysis is expected to be a rather conservative estimate of the MMB effect on TSS response rate. However, missing data sensitivity analyses (complete case analysis, multiple imputation) consistently did not reach statistical significance of the non-inferiority treatment difference.

A best-case sensitivity analysis imputing response for the subjects who discontinued before Day 162 in the  MMB group and non-response for those in the RUX group was however able to claim statistical significance for non-inferiority of MMB compared to RUX in TSS response rate. In addition, the tipping point  analysis  showed  that  in  order  to  claim  statistical  significance,  a  theoretical  average  shift  of  at least  8  points  lower  in  patients  with  missing  TSS  response  data  at  W24  compared  to  those  with complete data would be required. Although both sensitivity analysis are considered rather implausible, they  suggest  that  the  imbalance  in  early  discontinuation  may  have  contributed  to  the  unmet  TSS response rate results in SIMPLIFY-1, as they favoured the RUX study control arm.

As  TSS  data  were  not  collected  after  Week  24,  duration  of  TSS  response  at  Week  24  was  not evaluable.

Despite the numerically lower TSS response rate for MMB compared to RUX, a clinically meaningful magnitude  of  effect  is  however  suggested  given  the  consistency  in  magnitude  of  the  MMB  TSS response within the overall ITT populations and within the Hgb &lt; 10 g/dL subpopulations with the 2 other  phase  3  studies  with  MMB  in  JAKi  treated  patients  (MOMENTUM:  24.6%;  SIMPLIFY-2:  ITT:

<div style=\"page-break-after: always\"></div>

26.2%, Hgb &lt; 10 g/dL: 32.3%). Also the LS mean change from baseline TSS at week 24 for MMB was also  similar  between  symptomatic  subjects  (defined  as  baseline  TSS ≥ 10)  in  both  SIMPLIFY-1  and MOMENTUM subjects (-8.12 vs -9.36). This provides grounds for extrapolation of the MMB benefit on symptom control in the JAKi treated patient population to the JAKi naïve patient population.

In addition, with the limits intrinsic to cross-trial comparisons, consistent low TSS response rates with placebo or non-JAK inhibitor containing controls in phase 3 studies have been observed, including with other  JAK  inhibitors  [COMFORT-1  (placebo):  5.3%;  JAKARTA-1  (placebo):  7%;  PERSIST-1  (BAT): 6.5%; MOMENTUM (DAN): 9.2%; SIMPLIFY-2 (BAT): ITT: 5.9%; Hgb &lt; 10 g/dL: 2.6%].

On the other hand, TSS response rate for the ITT reported for MMB in SIMPLIFY-1, MOMENTUM and SIMPLIFY-2  are  consistently  lower  compared  to  those  reported  for  RUX  in  SIMPLIFY-1  (42%)  and COMFORT-1 (46%) and compared to those reported for the two fedratinib groups in the JAKARTA-1 study (36% and 34%).

Further support for a clinically meaningful magnitude of effect of MMB on disease-related symptoms includes the similar mean within-subject improvements in each treatment arm in both the ITT and Hgb &lt; 10 g/dL subgroup [LS mean difference in Hgb &lt; 10 g/dL subgroup of 1.62 (95% CI: -0.85, 4.09) on a  70-point  scale]  and  the  similar  improvements  in  individual  symptom  items  with  MMB  and  RUX (analysis only conducted for ITT).

With regard to the single-arm GU-US-352-1672 trial, data on TSS response rate at Week 24 were not reliable given the high rate of missing data of TSS at Week 24.

In  conclusion ,  considering the consistency in magnitude of the MMB symptom response within the overall ITT populations and in the Hgb &lt; 10 g/dL subpopulation across MMB phase 3 trials as well as the consistent low TSS response rates reported with placebo or non-JAK inhibitor containing controls in phase  3  studies  with  other  JAK  inhibitors  in  the  JAKi  naïve  setting,  and  taking  into  account  the potential contribution of the imbalance in early discontinuation in favouring the RUX control arm in the SIMPLIFY-1  study,  the  magnitude  of  the  MMB  effect  on  symptom  improvement  can  be  considered clinically  meaningful,  particularly  in  the  subgroup  of  JAKi  naïve  patients  suffering  with  moderate  or severe anaemia, although the observed effect is lower when compared to approved JAK inhibitors.

## Endpoints of splenic response

- Treated with ruxolitinib

In the MOMENTUM trial, the key secondary endpoint of SR R at Week 24, based on ≥ 35% reduction (as well as on ≥ 25% reduction) in spleen volume from baseline, was met demonstrating statistically significant superior SRR at Week 24 for MMB over DAN [22.31% (95%CI: 15.48, 30.44) versus 3.08% (95% CI: 0.37, 10.68); p &lt; 0.0001]. With the limits intrinsic to indirect comparison, a SRR at Week 24 of  22.31%  might  be  considered  clinically  meaningful,  as  a  similar  response  rate  of  22.7%  was observed in ruxolitinib-pretreated patients who received treatment with fedratinib 400 mg QD in the JAKARTA-2 study.

Updated follow-up data of TI at Week 48 showed that in evaluable patients MMB led to durable splenic responses,  with  76%  of  the  MMB → MMB group and 50% of the  DAN → MMB group maintaining  their splenic response at week 48, and that MMB was also able to induce new splenic responses in week 24 non-responders (24% of the MMB → MMB group and 11% of the DAN → MMB group).

The SIMPLIFY-2 trial failed to demonstrate superiority of MMB over BAT in the primary endpoint of SRR at week 24 [6.7% (95%CI: 2.75, 13.38) versus 5.8% (95% CI: 1.21, 15.95); p = 0.90], and did not support the findings in JAKi treated patients in the MOMENTUM study. However, this is possibly due to confounding because, in contrast to MOMENTUM which required a wash-out period of at least 2 weeks,

<div style=\"page-break-after: always\"></div>

no wash-out period after previous anti-MF therapy was required. As a result, in the SIMPLIFY-2 study, the  majority  of  patients  in  both  treatment  arms  (MMB:  74%,  BAT:  75%)  maintained  the  effect  of ongoing JAKi therapy (however mostly low dose) while switched to MMB without washout period. This potentially confounding effect is supported by subgroup analysis of the SIMPLIFY-2 study in function of washout period and by clinical data available from the extended open-label treatment periods of the SIMPLIFY studies, which allowed immediate cross-over from RUX to MMB without washout period. (ITT analysis)

Similarly, also in the corresponding subgroup of patients with Hgb &lt; 10 g/dL a low SRR at Week 24 was observed in the MMB group (9.1%), only slightly higher as compared to that observed in the BAT group (5.1%) (post-hoc subgroup analysis).

Also  in  the  intermediate-1  risk  subgroup,  SRR  was  low  in  both  treatment  arms  (post-hoc  subgroup analysis).

In conclusion , the effect of MMB in the JAKi treated population for the treatment of disease-related splenomegaly is considered demonstrated, based on the results of the pivotal MOMENTUM trial in the JAK inhibitor pre-treated patient population with haemoglobin &lt;10 g/dL per protocol eligibility.

## · JAKi naive

In the SIMPLIFY-1 trial, the primary endpoint of non-inferiority of MMB over RUX in SRR at week 24 was met [26.5% (95%CI: 20.74, 32.94) versus 29.5% (95% CI: 23.51, 36.04); p = 0.014], though no clinical judgement for the selected non-inferiority margin has been provided. (ITT analysis)

Also in the post-hoc defined subgroup of subjects with at least moderate anemia (31.4% MMB, 32.6% RUX),  p  =  0.007),  nominal  p-values  for  non-inferiority  proportion  difference  were  statistically significant, consistent with the ITT population (post-hoc subgroup analysis).

Also in the subgroup of intermediate-1 patients, including those with anaemia, a consistent benefit of MMB over RUX has been observed compared to the ITT (post-hoc subgroup analysis).

Duration of splenic response at any time was a prespecified exploratory endpoint. Splenic responses seemed to be durable with a median duration of splenic response of 35.9 months in the MMB group and of 19.1 months in the RUX group, however a large majority of patients were censored. A smaller proportion of patients in the MMB group compared to the RUX group reported loss of response (33.3% versus 51.8%, respectively). (ITT analysis)

With the limits intrinsic to cross-trial comparison, SRR at Week 24 for the MMB group of the SIMPLIFY1 study is consistent to that of the MMB group in the MOMENTUM study (31.4% for Hgb &lt; 10 g/dL subgroup in SIMPLIFY-1, 22.3% in MOMENTUM).

Results  of  subgroup  analysis  by  baseline  platelet  count  (analysis  in  ITT  population)  suggested  a differentiated benefit of MMB compared with RUX in thrombocytopenic patients (with baseline platelet counts &lt; 150 × 10 9 /L) with better results for SRR: 11/47 (23.4%) vs 2/57 (3.5%); TI rate: 29/47 (61.7%) vs 24/57 (42.1%) and similar TSS response rate pattern 13/45 (28.9%) vs 19/57 (33.3%). The  attenuation  of  RUX  treatment  effects,  in  particular  of  TSS  and  SRR,  based  on  baseline  platelet counts  compared  with  the  overall  ITT  results  was  not  observed  with  MMB.  A  comparison  of demographics/characteristics of this subgroup with those of the ITT population suggest that the low platelet group reflects a population with more advanced disease relative to the ITT. While baseline TSS was consistent in this subgroup compared to ITT in both treatment groups, the median spleen volume in the RUX arm of the low platelet subgroup is larger than the spleen volume in the RUX arm of the overall ITT population (2240.1 vs 1910.8 cm 3 , respectively), while the median spleen volume in the MMB arm of the low platelet subgroup is smaller than that in the overall ITT population (1734.0 vs 2009.6 cm 3 , respectively). The impact of the lower spleen volume in the RUX arm compared with the

<div style=\"page-break-after: always\"></div>

MMB arm in the low platelet subgroup may have contributed to the differential treatment effects in this subgroup;  however,  the  lower  ruxolitinib  dose  in  this  population  is  also  considered  a  substantial contributing factor. (prespecified subgroup analysis)

Given the high rate of missing data of splenic volume at Week 24, the data on SRR at Week 24 for the single-arm GU-US-352-1672 trial were not reliable for evaluation of consistency with SIMPLIFY-1.

In conclusion ,  although  no  clinical  judgement  for  the  selected  non-inferiority  margins  has  been provided, both the primary (based on 0.60 non-inferiority margin in MMB/RUX response ratio scale) as well as the exploratory sensitivity analysis (based on 0.16 non-inferiority margin in MMB-RUX response difference scale) consistently showed non-inferiority of MMB compared to RUX. In addition, the point estimates, representing the best estimate of the true difference, although not positive, it is close to zero for the MMB-RUX response rate difference (-0.03) or close to 1 for the MMB/RUX response ratio (0.9),  thus  tending  towards  equally  efficacious  treatments.  Taking  this  into  account  and  considering the consistently very low splenic response rates observed with placebo (≤ 1%) in trials with other JAK inhibitors in the JAKi naïve setting as well as the inability to identify a tipping point to overturn the statistical  significance  of  the  non-inferiority  treatment  difference  in  the  tipping  point  analysis,  the magnitude of benefit of MMB on disease-related splenomegaly in JAKi naïve patients with moderate or severe anaemia can be considered clinically meaningful.

## Anaemia-related endpoints

## · Treated with ruxolitinib

In the MOMENTUM trial, TI rate at Week 24 was the second primary endpoint. Although no superiority could be demonstrated, this primary endpoint was met as MMB was considered statistically significantly non-inferior compared to DAN [30.0% (95% CI: 22.28, 38.66) versus 20.0% (95% CI: 11.10, 31.77), respectively; p = 0.0116]. Note that at baseline the proportion of patients with TI status was similar (13.1% MMB, 15.4% DAN).

In the subgroup of patients with baseline TD status (prespecified subgroup analysis), which consisted around half of patients (48.5% MMB, 52.3% DAN), a greater proportion of subjects in the MMB group converted to TI at week 24 compared with the DAN group (14.3% vs 8.8%).

Updated follow-up data  of  TI  at  Week  48  showed  that  in  evaluable  patients  MMB  led  to  durable  TI responses, with 88.2% of the MMB → MMB group and 80.0% of the DAN → MMB group maintaining their TI  response at week 48, and that MMB was also able to induce new responses in week 24 TI nonresponders (24.2% of the MMB → MMB group and 50.0% of the DAN → MMB group). Median duration of TI response was not reached in both treatment groups.

Inference of efficacy in the MOMENTUM study for anaemia-related endpoints is however complicated as the treatment effect of DAN over placebo on TI rate has not previously been demonstrated and thus DAN cannot be considered an active comparator suitable for non-inferiority analyses. In addition, the observed  treatment  difference  in  TI  rate  (10%)  is  lower  than  expected  (24%)  and  thus  there  is uncertainty on the clinical relevance of this treatment difference.

Evidence from other (key) secondary endpoints, analysing the effect on the transfusion requirements and on hemoglobin levels, is however supporting at least a protective effect of MMB on anemia:

- -With regard to transfusion requirements, a statistically significant higher proportion of patients in the  MMB  group  received  no  transfusion  units ( 35.4%  versus  16.9%)  or  ≤ 4 RBC  units  during treatment and up to Week 24, compared to the DAN group (55.4% versus 44.6%). A reduced need to RBC transfusions was also reflected by a lower cumulative transfusion risk at week 24 for MMB (HR = 0.556 for MMB versus DAN) and the longer median time to first RBC unit transfused

<div style=\"page-break-after: always\"></div>

during  randomized  treatment  phase  (HR  =  0.504  for  MMB  vs  DAN).  At  Week  24,  a  smaller proportion of patients in the MMB group was considered TD compared to the DAN group (15.4% vs 24.6%).

- -With regard to the effect on hemoglobin, during the entire 24 week treatment period, treatment with MMB led to higher proportions of patients with ≥ 1 (53.1% versus 33.8%), ≥ 1.5 (40.0% versus 23.1%), or ≥ 2 g/dL  (29.2% versus 20.0%) increases of hemoglobin levels from baseline.
- -Post-hoc  analyses  on  transfusion  intensity  and  on  anaemia  response  rates  (per  IWG-MRT/ELN) were consistent in favouring MMB over DAN.
- -A post-hoc Bayesian dynamic borrowing analysis was utilized to calculate the posterior probability of MMB to be superior to DAN in W24 TI rate, which was 93%. With augmenting the MMB arm of the MOMENTUM study with data from the Hgb &lt; 10 g/dL subgroup from the SIMPLIFY-2 study this probability increased to 96%, which supports the assumption that it is likely that superiority may have been achieved with increased sample size.

The  SIMPLIFY-2  trial  provided  supportive  data  with  regard  to  the  effect  of  MMB  on  transfusion requirements. For the secondary endpoint of TI rate at Week 24, treatment with MMB resulted in a numerical higher TI rate at Week 24 compared to treatment with BAT [(43.3% (95% CI: 33.59, 53.35) versus 21.2% (95% CI: 11.06, 34.70); nominal p = 0.001), despite a lower proportion of subjects with baseline TI status in the MMB group (30.8% vs 36.5%). However, this numerical improvement in TI rate is only of nominal significance due to missed statistical significance in the primary endpoint. The higher TI rate at Week 24 observed in the MMB group of the SIMPLIFY-2 study compared to the MMB group of the MOMENTUM study is likely due to the higher proportion of patients with baseline TI status in the SIMPLIFY-2 study (30.8% versus 13.1%). (ITT analysis)

In the corresponding subgroup of patients with Hgb &lt; 10 g/dL in the SIMPLIFY-2 study, the TI rate at week 24 obtained with MMB was consistently higher compared to the corresponding subgroup in the BAT  group  (33.3%  versus  12.8%)  and  corresponded  better  to  the  one  observed  with  MMB  in  the MOMENTUM study (post-hoc subgroup analysis).

Post-hoc subgroup analyses in intermediate-1 patients indicated a consistent treatment benefit of MMB compared to BAT, however with higher response rates in both treatment arms as compared to the ITT population, explained by the lower transfusion requirements or dependency in this lower risk subgroup. (post-hoc subgroup analysis)

Other secondary endpoints further supported the beneficial effect of MMB on transfusion requirements, i.e. TI rate at Week 24 in subjects with baseline TD (32.8% MMB versus 3.7% BAT), TD rate at Week 24  (50.0%  versus  63.5%)  and  RBC  transfusion  rate  during  the  RT  period  (0.5  versus  1.2).  (ITT analysis)

In conclusion ,  the  totality  of  evidence  in  the  MOMENTUM  study,  suggesting  a  trend  towards superiority  for  MMB  over  DAN,  is  supporting  that  MMB  does  have  at  least  a  protective  effect  on anaemia and associated RBC transfusion requirements in JAKi treated patients with haemoglobin &lt;10 g/dL  per  protocol  eligibility.  However  due  to  the  overall  non-confirmatory  nature  of  data,  anaemia treatment effect is not demonstrated. As a result, the initially claimed indication was changed.

- JAKi naive

For the secondary endpoint of TI rate at Week 24 in the SIMPLIFY-1 trial, treatment with MMB resulted in  higher  TI  rate  at  Week  24  compared  to  treatment  with  RUX  [66.5%  (95%  CI:  59.78,  72.79)  vs 49.3%  (95%  CI:  42.48,  56.16);  nominal  p &lt; 0.001].  Note  that  at  baseline  a  similar  proportion  of patients had TI status (68.4% MMB, 70.0% RUX). However, this numerical improvement in transfusion

<div style=\"page-break-after: always\"></div>

burden are only of nominal significance due to missed statistical significance in the previous endpoint in the hierarchical testing. Results should thus rather be seen as exploratory. (ITT analysis)

In the subgroup of patients with baseline TD status, which consisted only a minority of patients (24.7% MMB, 24.0% RUX), a greater proportion of subjects in the  MMB group converted to TI at week 24 compared with the RUX group (30.2 versus 17.3%) (post-hoc exploratory analysis).

In the post-hoc defined subgroup of subjects with at least moderate anemia a slightly larger treatment difference  in  favor  of  MMB  in  TI  rate  at  week  24  has  been  observed  compared  to  ITT    (MMB  46.5 versus  RUX  27.4;  superiority  %  diff:  22),  despite  fewer  subjects  in  MMB  arm  that  are  TI  (29%  vs 44%), more subjects that are TD (57% vs 46%) and more subjects that have severe anaemia (32% vs 22%). Compared to baseline, the TI rate at Week 24 increased from baseline and the TD rate at Week 24 decreased from baseline, while converse effects were observed in the RUX group with Hgb &lt; 10 g/dL. (post-hoc exploratory analysis).

Also in the subgroup of intermediate-1 patients, including those with anaemia, a consistent benefit of MMB over RUX have been observed compared to the ITT (post-hoc subgroup analysis).

The observed effect however was measured at the time of a nadir in haematology values during RUX treatment after which recovery is known to occur, raising concerns on the clinical relevance of the MMB benefit  compared  to  RUX  and  on  whether  the  advantage  of  MMB  compared  to  RUX  would  be maintained beyond week 24. Due to the option of cross-over, no data are available on the persistence of the transfusion independency effect of momelotinib compared to ruxolitinib after Week 24. Data on transfusion  intensity  up  to  Week  36  with  ruxolitinib  are  however  available  in  the  COMFORT-1  study which showed a similar transfusion intensity profile for RUX in the first 24 weeks which peaked at week 8 before declining by week 24, after which it remained relatively stable up to week 36 (no further data provided). In the course of these 36 weeks, the RUX transfusion intensity also remained consistently higher as compared to placebo. In addition, with the limits of cross-trial comparisons, MMB transfusion intensity in SIMPLIFY-1 was persistently lower compared to placebo in COMFORT-1, both for the MMB arm in the RT period as well for patients treated with MMB in both treatment arms of the open-label phase  beyond  week  24,  indirectly  supporting  the  maintenance  of  MMB's  advantage  over  RUX  in reducing  transfusion  needs  and  anemia-related  benefits.  However,  the  limitations  related  to  such indirect comparisons should be considered.

Further note that simultaneous dose reductions of RUX observed after week 8 in the SIMPLIFY-1 study were most likely responsible for the partial recovery in Hgb levels and transfusion intensity as observed with RUX after week 8, which however in turn negatively affects prognosis.

Evidence  from  other  secondary  and  exploratory  endpoints,  analysing  the  effect  on  the  transfusion requirements  and  on  hemoglobin  levels,  is  supporting  the  beneficial  effect  of  MMB  on  anemia compared to RUX (ITT analysis):

- -With  regard  to  transfusion  requirements  a  greater  proportion  of  patients  in  the  MMB  group compared to the RUX group had zero transfusions (73% vs 46%) or ≤4 RBC transfusions during the RT period (83% vs 62%). A reduced need to RBC transfusions was also reflected by a lower cumulative  transfusion  risk  at  week  24  for  MMB  (HR  =  0.522  for  MMB  versus  RUX),  a  lower median RBC transfusion rate (0 units/month vs 0.4 units/month) and by a smaller proportion of patients in the MMB group at Week 24 that was considered TD (30.2% vs 40.1%).
- -With  regard  to  the  effect  on  hemoglobin,  during  the  last  12  weeks  of  the  24  week  treatment period, treatment with MMB led to higher proportions of patients with ≥ 1 (37.2% vs 16.6%), ≥ 1.5 (23.7% v 11.5%), or ≥ 2 g/dL (16.7% vs 6.0%) increases of hemoglobin levels from baseline. While in the RUX group, mean Hgb level decreased during the first 12 weeks, MMB induced a rapid

<div style=\"page-break-after: always\"></div>

increase in mean Hgb levels that was maintained over time. A consistent increase in mean Hgb level was observed after cross-over from RUX to MMB treatment.

In addition, the improvements in transfusion requirements and hemoglobin levels with MMB compared to RUX in the Hgb &lt; 10 g/dL subgroup were consistent compared to the overall ITT population, despite the higher transfusion needs and the lower hemoglobin levels in this particular subgroup compared to the overall ITT population (post-hoc subgroup analysis).

Duration  of  TI  response  at  any  time  was  analysed  in  a  post-hoc  exploratory  analysis.  TI  responses seem to be durable in both treatment groups with median duration of TI not reached after a median follow-up  of  35  months  in  both  treatment  arms.  Most  patients  maintaining  their  response  up  to treatment  discontinuation.  The  high  rate  of  cross-over  however  confounds  any  comparison  of  data obtained after Week 24. (ITT analysis)

Single-arm GU-US-352-1672 trial, which included a patient population which is not diluted by subjects who cannot improve (only patients with TD at baseline were included), supported the beneficial effect of  MMB  on  reducing  the  need  for  RBC  transfusion  in  JAK-inhibitor  naïve  patients,  with  34.1%  of patients who were considered TI at Week 24.

In conclusion ,  the  results  with  MMB  on  anaemia-related  outcomes  are  consistent  and  indicate  a clinically meaningful magnitude of effect, though due to absence of hierarchical multiplicity control in the anaemia related endpoints (including TI rate at W24) of the SIMPLIFY-1 study, these data can only support for the time being an at least protective effect of MMB on anaemia and do not demonstrate the effect on anemia treatment. As a result, the initially claimed indication was changed.

## Overall survival and leukemia-free survival

-  Overall survival (OS):
- Treated with ruxolitinib

In the MOMENTUM study, after a median follow-up of 1.1 years for the MMB group and 1.0 years for the DAN group (including those who crossed-over to MMB), K-M estimated median OS was 1.7 y in the MMB arm and not reached the DAN arm [HR: 0.890 (95% CI: 0.504, 1.572); p = 0.69]. A sensitivity analysis of OS up to Week 24 did not demonstrate a statistical significant difference, though there was a numerical trend in favour of MMB (HR = 0.506, log-rank test p = 0.0719).

In the SIMPLIFY-2 study, after a median follow-up of 3.07 years for the MMB group and 3.22 years for the BAT group (including those who crossed-over to MMB), K-M estimated median OS was 2.86 years (95% CI: 2.28, NR) in the former randomized MMB group and 3.13 years (95% CI: 1.77, NR) in the former BAT group [HR: 1.00 (95% CI: 0.60, 1.65); p = 0.99]. (ITT analysis)

- JAKi naive

In the SIMPLIFY-1 study, after a median follow-up of 3.43 years for the MMB group and 3.47 years for the RUX group (including those who crossed-over to MMB), K-M estimated median OS was not reached in both treatment arms [HR: 1.03 (95% CI: 0.74, 1.44); p = 0.86]. (ITT analysis)

-  Leukemia-free survival (LFS):
- Treated with JAKi

In the MOMENTUM study, after a median follow-up of 1.0 years for both treatment groups (including those who crossed-over from DAN to MMB), K-M estimated median LFS was 1.7 y in the MMB arm and not reached in the DAN arm [HR: 0.81 (95% CI: 0.47, 1.39); p = 0.43].

<div style=\"page-break-after: always\"></div>

In the SIMPLIFY-2 study, after a median follow-up of 2.35 years for the MMB group and 2.27 years for the BAT group (including those who crossed-over to MMB), K-M estimated median LFS was 2.83 years in the former randomized MMB group and 3.13 years in the former BAT group [HR: 0.95 (95% CI: 0.58, 1.57); p = 0.85]. (ITT analysis)

## · JAKi naive

In the SIMPLIFY-1 study, after a median follow-up of 2.95 years for the MMB group and 2.93 years for the  RUX  group  (including  those  who  crossed-over  to  MMB),  K-M  estimated  median  LFS  was  not reached in the former randomized MMB group and 4.42 years in the former RUX group [HR: 1.07 (95% CI: 0.76, 1.50); p = 0.70]. (ITT analysis)

In conclusion ,  for  all  phase  3  studies,  no  definite  conclusion  of  the  effect  of  MMB  on  OS  and  LFS versus their respective comparator however can be drawn, as the comparisons with their respective control groups were heavily confounded by the high rate of cross-over from the control groups to the MMB group after Week 24 assessments (63.5% of patients randomized to DAN in MOMENTUM, 91.6% of patients randomized to RUX in SIMPLIFY-1, 38.5% of patients randomized to BAT in SIMPLIFY-2). In addition, the studies were not powered to assess superiority in survival analyses. In the MOMENTUM study, K-M curves started to diverge early for both OS and LFS to a maximum difference at the 24 week timepoint, which is the time points after which cross-over was allowed, however this was not confirmed in other studies. Supportive evidence based on retrospective analysis of long-term survival data in JAK-inhibitor naïve patients who participated in phase 1/2 clinical studies was provided. With the  limits  intrinsic  to  such  retrospective  analysis,  these  data  suggested  longer  median  OS  for  MMB compared to RUX.

Sensitivity analyses adjusting for the impact of cross-over (Rank Preserving Structural Failure Time, 3 approaches) further suggested an underlying trend of the survival improvement for MMB over control. The  phase  3  studies  further  consistently  suggested  that  transfusion  independence  at  week  24  was associated with improved OS in both treatment groups (Mesa et al., 2022; Verstovsek et al., 2022).

## Long term effects

Only limited data are available across the phase 3 studies on the further course of the disease in terms of  symptom  response,  spleen  response  or  transfusion  requirements  on  the  potential  for  efficacy withdrawal effects in patients who permanently discontinued MMB treatment before and after the Week 24 endpoint. Patients were only followed for survival and leukemic transformation (see above).

Although across the three phase 3 studies subsequent JAK inhibitor therapy (i.e., ruxolitinib, fedratinib) or  hydroxyurea  therapy  may  have  been  reported  after  permanent  discontinuation  of  study  drug, including MMB, efficacy outcomes on these therapies were not collected.

## 2.6.7. Conclusions on the clinical efficacy

In the JAKi  treated  setting ,  the benefit of MMB for the treatment of disease-related splenomegaly and symptoms can be considered clinically meaningful, based on the results of the pivotal MOMENTUM trial  in  the  JAK  inhibitor  pre-treated  patient  population  with  haemoglobin  &lt;10  g/dL  per  protocol eligibility.  In  addition,  the  totality  of  evidence  on  anaemia-related  outcomes  supports  at  least  a protective  effect  of  MMB  on  anaemia  and  associated  RBC  transfusion  requirements  in  JAKi  treated patients  where  both  disease-related  and  treatment-related  anaemia  are  of  significant  burden. However,  due  to  the  overall  non-confirmatory  nature  of  data,  a  claim  of  anaemia  treatment  is  not justified.  Furthermore,  the  benefit  MMB  in  patients  previously  treated  with  fedratinib  cannot  be

<div style=\"page-break-after: always\"></div>

determined given the scarce data with MMB in fedratinib pretreated patients and given the potential differences in cross-resistance mechanisms between fedratinib and ruxolitinib.

In the JAKi naïve setting , based on the totality of data, MMB is considered to provide benefits: the effect on disease-related splenomegaly is considered clinically meaningful and the magnitude of effect on  disease-related  symptoms  is  consistent  across  momelotinib  trials  and  consistent  higher  as compared  with  placebo  or  non-JAK  inhibitor  containing  controls  in  phase  3  studies  with  other  JAK inhibitors,  although  lower  when  compared  to  approved  JAK  inhibitors.  In  addition,  patients  with manifestation of at least moderate anaemia may also derive benefit at longer term, due to potentially reduced RBC transfusion requirements of particular relevance in this subgroup.

## 2.6.8. Clinical safety

## 2.6.8.1. Patient exposure

The safety profile of MMB in patients with PMF or post polycythaemia vera and post essential thrombocythemia (post PV/ET) MF is derived from the following 4 clinical studies involving 725 adults who received at least 1 dose of MMB study drug with a total follow up time of 1260.93 person years:

- One ongoing phase 3 randomized controlled study, MOMENTUM (RT complete; data cutoff 03 Dec 2021 for ongoing open label treatment with MMB)
- Two completed phase 3 randomized controlled studies, SIMPLIFY 1 and SIMPLIFY 2
- One ongoing uncontrolled long term extension safety study, XAP (subjects from phase 3 studies only, data cutoff 03 Dec 2021)

The 24 week RT periods by study include 195 treated subjects from MOMENTUM (130 MMB, 65 DAN), 430 treated subjects from SIMPLIFY 1 (214 MMB, 216 RUX), and 156 treated subjects from SIMPLIFY 2 (104 MMB, 52 BAT [46 RUX]).

The 24 week RT period for the integrated phase 3 studies includes 448 subjects treated with MMB, 262 subjects treated with RUX, and 65 subjects treated with DAN. The open label data include all 604 subjects who received open label, extended, and/or extended access treatment with MMB including the phase 3 subjects who crossed over to MMB treatment after RUX, BAT, and DAN and those who were subsequently treated in the long term extension safety study XAP. The pooled group of MMB overall includes all 725 subjects treated with MMB from the phase 3 studies, including RT and the additional open label data.

<div style=\"page-break-after: always\"></div>

Figure 32: Momelotinib Phase 3 Studies Schematic

<!-- image -->

Numbers in parentheses are for treated subjects.

- [1] BAT included ruxolitinib (88.5% of subjects).  BAT for 2 subjects randomized to BAT was no therapy.
- [2] Also enrolled subjects from phase 2 study GS US 352 1154, which included subjects from prior phase 1 2 studies.

BAT, best available therapy; DAN, danazol; ET, extended treatment; JAKi, Janus kinase inhibitor; MMB, momelotinib; OL, open label; RT, randomized treatment; RUX, ruxolitinib; XAP, extended access protocol.

A total of 725 phase 3 subjects were treated with MMB overall, including 448 during RT and 604 during open label treatment; 176 (24.3%) overall were ongoing as of the data cutoff date.  During RT, 262 subjects were treated with RUX and 65 were treated with DAN.  Of the 604 subjects treated with open label MMB, 327 subjects received MMB during RT and continued MMB treatment (MMB → MMB), and 277 subjects crossed over to MMB after RT with a comparator (40 DAN → MMB, 197 RUX → MMB, 40 BAT → MMB).

Most subjects completed the RT period (75.4% MMB, 90.5% RUX, 58.5% DAN).  The most common reasons for study drug discontinuation were adverse event (10.7% MMB, 3.4% RUX, 16.9% DAN) and subject decision (3.3% MMB, 1.9% RUX, 7.7% DAN).

Most subjects treated during RT received open label treatment with MMB (73.0% MMB, 88.9% RUX, 61.5% DAN), including early crossovers (0.8% RUX, 7.7% DAN).  No subject in MOMENTUM elected to receive open label treatment with DAN.  Of subjects treated during RT, 11.6% MMB and 33.8% DAN were continuing open label treatment with MMB in MOMENTUM as of the data cutoff date.  The most common reason for study drug discontinuation during open label treatment was study terminated by sponsor (15.0% MMB, 26.3% RUX, 0 DAN) as planned for SIMPLIFY 1 and SIMPLIFY 2 after ongoing subjects transitioned to study XAP, followed by adverse event (13.2% MMB, 24.4% RUX, 1.5% DAN), disease progression (8.7% MMB, 12.6% RUX, 0 DAN), and insufficient efficacy (6.0% MMB, 8.4% RUX, 1.5% DAN).

Subjects from all 3 studies transitioned to study XAP for extended treatment with MMB.  Approximately one fifth of subjects treated during RT received extended access MMB treatment in XAP (18.1% MMB, 23.3% RUX, 13.8% DAN) and a subset were continuing as of the cutoff date (13.4% MMB, 13.4% RUX, 10.8% DAN).  Disease progression was the most common reason for study drug discontinuation during XAP (1.6% MMB, 4.6% RUX, 0 DAN).

<div style=\"page-break-after: always\"></div>

Overall, adverse event was the most reason for study drug discontinuation in every RT group (24.6% MMB, 29.4% RUX, 20.0% DAN) and during MMB open label treatment (22.4%) and overall (25.2%). Disease progression was the next most common reason during RT (12.3% MMB, 17.9% RUX, 0 DAN) and during MMB open label treatment (15.1%) and overall (13.8%).

Table  81: Integrated Subject Disposition by Study Period and Treatment (Safety Population)

|                                          | Randomized           | Randomized        | Randomized           | Open-Label           | Overall              |
|------------------------------------------|----------------------|-------------------|----------------------|----------------------|----------------------|
|                                          | MMB (N = 448)        | RUX (N =262)      | DAN (N =65)          | MMB N=604)           | MMB (N = 725)        |
| Duration of exposure (weeks) [1]         |                      |                   |                      |                      |                      |
| n                                        | 448                  | 262               | 65                   | 604                  | 725                  |
| Mean (SD)                                | 20.7 (6.68)          | 22.7 (4.50)       | 17.3 (7.99)          | 90.5 (99.22)         | 88.1 (97.19)         |
| Median (Q1, Q3)                          | 23.9 (22.1, 24.0)    | 24.0 (23.7, 24.1) | 23.7 (10.1, 24.0)    | 47.9 (16.9, 130.4)   | 49.0 (20.1, 119.3)   |
| Minimum,maximum                          | 0.3, 26.7            | 1.3, 26.9         | 0.7,26.9             | 0.1,369.4            | 0.3,393.1            |
| Duration of exposure (months) [1]        |                      |                   |                      |                      |                      |
| n                                        | 448                  | 262               | 65                   | 604                  | 725                  |
| Mean (SD)                                | 4.8 (1.54)           | 5.2 (1.03)        | 4.0 (1.84)           | 20.8 (22.82)         | 20.3 (22.35)         |
| Median (Q1, Q3)                          | 5.5 (5.1, 5.5)       | 5.5 (5.5, 5.6)    | 5.5 (2.3, 5.5)       | 11.0 (3.9, 30.0)     | 11.3 (4.6, 27.4)     |
| Minimum,maximum                          | 0.1, 6.1             | 0.3,6.2           | 0.2,6.2              | 0.0, 85.0            | 0.1, 90.4            |
| Duration of exposure, n (%)              |                      |                   |                      |                      |                      |
| Any duration (>0 weeks)                  | 448 (100%)           | 262 (100%)        | 65 (100%)            | 604 (100%)           | 725 (100%)           |
| 2 4 weeks                                | 425 (94.9%)          | 257 (98.1%)       | 63 (96.9%)           | 565 (93.5%)          | 684 (94.3%)          |
| 28 weeks                                 | 402 (89.7%)          | 253 (96.6%)       | 52 (80.0%)           | 515 (85.3%)          | 637 (87.9%)          |
| 2 12 weeks                               | 385 (85.9%)          | 246 (93.9%)       | 45 (69.2%)           | 486 (80.5%)          | 602 (83.0%)          |
| 2 24 weeks                               | 207 (46.2%)          | 148 (56.5%)       | 22 (33.8%)           | 406 (67.2%)          | 513 (70.8%)          |
| 2 48 weeks                               | 0                    | 0                 | 0                    | 302 (50.0%)          | 367 (50.6%)          |
| ≥ 96 weeks                               | 0                    | 0                 | 0                    | 193 (32.0%)          | 213 (29.4%)          |
| 236 months                               | 0                    | 0                 | 0                    | 122 (20.2%)          | 134 (18.5%)          |
| ≥48 months                               | 0                    | 0                 | 0                    | (%791) 86            | 103 (14.2%)          |
| ≥ 60 months                              | 0                    | 0                 | 0                    | 84 (13.9%)           | 88 (12.1%)           |
| Average daily dose (mg) [2]              |                      |                   |                      |                      |                      |
| n                                        | 448                  | 259               | 65                   | 604                  | 725                  |
| Mean (SD)                                | 187.5 (26.02)        | 26.6 (11.24)      | 576.5 (65.28)        | 176.1 (45.43)        | 179.2 (34.80)        |
| Median (Q1, Q3)                          | 200.0 (185.9, 200.0) | 28.8 (17.2, 37.9) | 600.0 (600.0, 600.0) | 194.3 (161.0, 200.0) | 194.6 (168.8, 200.0) |
| Minimum,maximum                          | 0,229                | 5,48              | 242.600              | 0, 775               | 0, 494               |
|                                          | Randomized           | Randomized        | Randomized           | Open-Label           | Overall              |
|                                          | MMB (N = 448)        | RUX (N =262)      | DAN (N=65)           | MMB (N =604)         | MIMB (N = 725)       |
| Relative dose intensity(%)[3]            |                      |                   |                      |                      |                      |
| n                                        | 448                  | 259               | 65                   | 604                  | 725                  |
| Mean (SD)                                | 93.8 (13.01)         | 66.6 (28.10)      | 96.1 (10.88)         | 88.0 (22.71)         | 89.6 (17.40)         |
| Median (Q1, Q3)                          | 100.0 (92.9, 100.0)  | 71.9 (42.9, 94.7) | 100.0 (100.0, 100.0) | 97.2 (80.5, 100.0)   | 97.3 (84.4, 100.0)   |
| Minimum,maximum                          | 0, 114               | 13,121            | 40,100               | 0,387                | 0,247                |
| Subjectswith study drugmodification,n(%) | 173 (38.6%)          | 130 (60.2%) [4]   | 35 (53.8%)           | 264 (43.7%)          | 396 (54.6%)          |
| Reason for shudy drug modification       |                      |                   |                      |                      |                      |
| Adverse event                            | 73 (16.3%)           | 79 (36.6%)        | 0                    | 147 (24.3%)          | 207 (28.6%)          |
| Serious adverse event                    | 12 (2.7%)            | 0                 | 11 (16.9%)           | 6 (1.0%)             | 17 (2.3%)            |
| Per protocol                             | 35 (7.8%)            | 62 (28.7%)        | 0                    | 50 (8.3%)            | 81 (11.2%)           |
| (All others in Table 2.7.4.2.1)          |                      |                   |                      |                      |                      |

[1] Duration of exposure to study drug was calculated as the number of weeks or months between the date of the last dose of study drug minus the date of the first dose of study drug plus 1.

[2] Average daily dose was calculated as the sum of the daily dose divided by the duration of exposure.

[3] Percentage relative dose intensity was calculated as the average daily dose divided by D (mg) times 100%, where D is MMB 200 mg, RUX 40 mg, or DAN 600 mg.

[4] Summarized only for the 216 subjects in SIMPLIFY-1 who received RUX because dose modification information was not consistently collected and reported in SIMPLIFY-2.

DAN, danazol; MMB, momelotinib; Q1, Q3, first quartile, third quartile; RUX, ruxolitinib.

<div style=\"page-break-after: always\"></div>

## 2.6.8.2. Adverse events

## Overall Summary of Adverse Events

Table 82: Integrated Overall Summary of Adverse Events by Study Period and Treatment (Safety Population)

|                                   | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|-----------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| AdverseEventCategory              | MMB (N = 448)         | RUX (N = 262)         | DAN (N = 65)          | MMB (N =604) | MMB (N = 725) |
| Any adverse event,n(%)            | 420 (93.8%)           | 248 (94.7%)           | 62 (95.4%)            | 547 (90.6%)  | 696 (96.0%)   |
| Related                           | 290 (64.7%)           | 161 (61.5%)           | 29 (44.6%)            | 328 (54.3%)  | 497 (68.6%)   |
| Grade ≥3                          | 207 (46.2%)           | 113 (43.1%)           | 42 (64.6%)            | 357 (59.1%)  | 484 (66.8%)   |
| Related                           | 109 (24.3%)           | 70 (26.7%)            | 16 (24.6%)            | 146 (24.2%)  | 230 (31.7%)   |
| Grade3or4                         | 194 (43.3%)           | 113 (43.1%)           | 41 (63.1%)            | 342 (56.6%)  | 460 (63.4%)   |
| Related                           | 107 (23.9%)           | 70 (26.7%)            | 16 (24.6%)            | 145 (24.0%)  | 227 (31.3%)   |
| Serious                           | 131 (29.2%)           | 48 (18.3%)            | 26 (40.0%)            | 257 (42.5%)  | 347 (47.9%)   |
| Related                           | 38 (8.5%)             | 15 (5.7%)             | 5 (7.7%)              | 59 (9.8%)    | 93 (12.8%)    |
| Fatal                             | 29 (6.5%)             | 9 (3.4%)              | 11 (16.9%)            | 73 (12.1%)   | 102 (14.1%)   |
| Leadingtostudydrugmodification    | 100 (22.3%)           | 87 (33.2%)            | 19 (29.2%)            | 185 (30.6%)  | 262 (36.1%)   |
| Leadingtostudydrugdiscontinuation | 72 (16.1%)            | 13 (5.0%)             | 15 (23.1%)            | 157 (26.0%)  | 229 (31.6%)   |
| Grade ≥ 3                         | 56 (12.5%)            | 13 (5.0%)             | 11 (16.9%)            | 120 (19.9%)  | 176 (24.3%)   |

Shading indicates adverse events ≥ 5 percentage points higher than 1 or more other treatment group during RT. DAN, danazol; MMB, momelotinib; RT, randomized treatment; RUX, ruxolitinib.

<div style=\"page-break-after: always\"></div>

## Common Adverse Events

## Table 83: Integrated Commonly Reported Adverse Events in ≥ 5% of Subjects in Any Group by Preferred Term by Study Period and Treatment (Safety Population)

|                                   | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|-----------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| Preferred Term                    | MMB (N = 448)         | RUX (N = 262)         | DAN (N = 65)          | MMB (N= 604) | MMB (N = 725) |
| Any adverse event, n (%)          | 420 (93.8%)           | 248 (94.7%)           | 62 (95.4%)            | 547 (90.6%)  | 696 (96.0%)   |
| Diarrhoea                         | 102 (22.8%)           | 50 (19.1%)            | 6 (9.2%)              | 120 (19.9%)  | 194 (26.8%)   |
| Thrombocytopenia                  | 87 (19.4%)            | 69 (26.3%)            | 7 (10.8%)             | 106 (17.5%)  | 170 (23.4%)   |
| Anaemia                           | 62 (13.8%)            | 90 (34.4%)            | 10 (15.4%)            | 125 (20.7%)  | 167 (23.0%)   |
| Nausea                            | 75 (16.7%)            | 13 (5.0%)             | 6 (9.2%)              | 81 (13.4%)   | 141 (19.4%)   |
| Fatigue                           | 55 (12.3%)            | 36 (13.7%)            | 7 (10.8%)             | 77 (12.7%)   | 127 (17.5%)   |
| Cough                             | 45 (10.0%)            | 23 (8.8%)             | 2 (3.1%)              | 88 (14.6%)   | 126 (17.4%)   |
| Dizziness                         | 58 (12.9%)            | 27 (10.3%)            | 1 (1.5%)              | 62 (10.3%)   | 112 (15.4%)   |
| Abdominal pain                    | 48 (10.7%)            | 32 (12.2%)            | 5 (7.7%)              | 57 (9.4%)    | 102 (14.1%)   |
| Pyrexia                           | 41 (9.2%)             | 21 (8.0%)             | 5 (7.7%)              | 71 (11.8%)   | 102 (14.1%)   |
| Headache                          | 60 (13.4%)            | 46 (17.6%)            | 1 (1.5%)              | 50 (8.3%)    | 101 (13.9%)   |
| Asthenia                          | 49 (10.9%)            | 25 (9.5%)             | 6 (9.2%)              | 57 (9.4%)    | 96 (13.2%)    |
| Pruritus                          | 40 (8.9%)             | 17 (6.5%)             | 7 (10.8%)             | 60 (9.9%)    | 90 (12.4%)    |
| Dyspnoca                          | 42 (9.4%)             | 24 (9.2%)             | 9 (13.8%)             | 52 (8.6%)    | 89 (12.3%)    |
| Peripheral sensory neuropathy     | 31 (6.9%)             | 12 (4.6%)             | 1 (1.5%)              | 62 (10.3%)   | 89 (12.3%)    |
| Urinary tract infection           | 27 (6.0%)             | 15 (5.7%)             | 3 (4.6%)              | 70 (11.6%)   | 88 (12.1%)    |
| Pneumonia                         | 16 (3.6%)             | 6 (2.3%)              | 6 (9.2%)              | 68 (11.3%)   | 83 (11.4%)    |
| Constipation                      | 43 (9.6%)             | 17 (6.5%)             | 5 (7.7%)              | 41 (6.8%)    | 81 (11.2%)    |
| Oedema peripheral                 | 31 (6.9%)             | 18 (6.9%)             | 9 (13.8%)             | 50 (8.3%)    | 75 (10.3%)    |
| Arthralgia                        | 34 (7.6%)             | 17 (6.5%)             | 2 (3.1%)              | 45 (7.5%)    | 73 (10.1%)    |
| Upper respiratory tract infection | 22 (4.9%)             | 17 (6.5%)             | 1 (1.5%)              | 53 (8.8%)    | 73 (10.1%)    |
| Decreased appetite                | 27 (6.0%)             | 15 (5.7%)             | 6 (9.2%)              | 45 (7.5%)    | 69 (9.5%)     |
| Vomiting                          | 36 (8.0%)             | 8 (3.1%)              | 0                     | 36 (6.0%)    | 66 (9.1%)     |
| Pain in extremity                 | 24 (5.4%)             | 23 (8.8%)             | 1 (1.5%)              | 42 (7.0%)    | 65 (9.0%)     |
| Hypertension                      | 24 (5.4%)             | 22 (8.4%)             | 6 (9.2%)              | 44 (7.3%)    | 64 (8.8%)     |
| Back pain                         | 21 (4.7%)             | 14 (5.3%)             | 3 (4.6%)              | 48 (7.9%)    | 64 (8.8%)     |

|                                   | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|-----------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| Preferred Term                    | MMB (N =448)          | RUX (N = 262)         | DAN (N = 65)          | MMB (N =604) | MMB (N = 725) |
| Hyperuricaemia                    | 25 (5.6%)             | 9 (3.4%)              | 4 (6.2%)              | 41 (6.8%)    | 62 (8.6%)     |
| Weight decreased                  | 30 (6.7%)             | 4 (1.5%)              | 4 (6.2%)              | 35 (5.8%)    | 60 (8.3%)     |
| Night sweats                      | 20 (4.5%)             | 13 (5.0%)             | 3 (4.6%)              | 43 (7.1%)    | 60 (8.3%)     |
| Blood creatinine increased        | 26 (5.8%)             | 2 (0.8%)              | 10 (15.4%)            | 35 (5.8%)    | 54 (7.4%)     |
| Paraesthesia                      | 31 (6.9%)             | 8 (3.1%)              | 1 (1.5%)              | 25 (4.1%)    | 51 (7.0%)     |
| Hypotension                       | 27 (6.0%)             | 3 (1.1%)              | 2 (3.1%)              | 26 (4.3%)    | 50 (6.9%)     |
| Epistaxis                         | 24 (5.4%)             | 19 (7.3%)             | 4 (6.2%)              | 27 (4.5%)    | 49 (6.8%)     |
| Contusion                         | 26 (5.8%)             | 12 (4.6%)             | 0                     | 19 (3.1%)    | 44 (6.1%)     |
| Rash                              | 14 (3.1%)             | 6 (2.3%)              | 4 (6.2%)              | 31 (5.1%)    | 44 (6.1%)     |
| Bronchitis                        | 11 (2.5%)             | 7 (2.7%)              | 0                     | 35 (5.8%)    | 44 (6.1%)     |
| Hyperkalaemia                     | 21 (4.7%)             | 6 (2.3%)              | 6 (9.2%)              | 26 (4.3%)    | 43 (5.9%)     |
| Fall                              | 15 (3.3%)             | 5 (1.9%)              | 4 (6.2%)              | 29 (4.8%)    | 43 (5.9%)     |
| Acute kidney injury               | 12 (2.7%)             | 1 (0.4%)              | 8 (12.3%)             | 32 (5.3%)    | 43 (5.9%)     |
| Abdominalpain upper               | 21 (4.7%)             | 12 (4.6%)             | 5 (7.7%)              | 24 (4.0%)    | 42 (5.8%)     |
| Alanine aminotransferaseincreased | 21 (4.7%)             | 11 (4.2%)             | 5 (7.7%)              | 22 (3.6%)    | 42 (5.8%)     |
| Neutropenia                       | 23 (5.1%)             | 15 (5.7%)             | 2 (3.1%)              | 26 (4.3%)    | 41 (5.7%)     |
| Nasopharyngitis                   | 13 (2.9%)             | 18 (6.9%)             | 2 (3.1%)              | 29 (4.8%)    | 40 (5.5%)     |
| Insomnia                          | 10 (2.2%)             | 10 (3.8%)             | 3 (4.6%)              | 30 (5.0%)    | 38 (5.2%)     |
| VitaminB1 deficiency              | 14 (3.1%)             | 14 (5.3%)             | 0                     | 26 (4.3%)    | 37 (5.1%)     |
| Bone pain                         | 9 (2.0%)              | 21 (8.0%)             | 3 (4.6%)              | 22 (3.6%)    | 31 (4.3%)     |
| Hyponatraemia                     | 9 (2.0%)              | 1 (0.4%)              | 4 (6.2%)              | 16 (2.6%)    | 23 (3.2%)     |

Shading indicates events that met the ≥ 5% threshold. DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

<div style=\"page-break-after: always\"></div>

## Treatment-Related Adverse Events

Table 84: Integrated Commonly Reported Treatment-Related Adverse Events in ≥ 5% of Subjects in Any Group by Preferred Term by Study Period and Treatment (Safety Population)

|                                       | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|---------------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| PreferredTerm                         | MMB (N = 448)         | RUX (N =262)          | DAN (N =65)           | MMB (N=604)  | MMB (N = 725) |
| Anytreatment-relatedadverseevent,n(%) | 290 (64.7%)           | 161 (61.5%)           | 29 (44.6%)            | 328 (54.3%)  | 497 (68.6%)   |
| Thrombocytopenia                      | 69 (15.4%)            | 59 (22.5%)            | 3 (4.6%)              | 74 (12.3%)   | 127 (17.5%)   |
| Diarrhoea                             | 53 (11.8%)            | 20 (7.6%)             | 2 (3.1%)              | 33 (5.5%)    | 83 (11.4%)    |
| Nausea                                | 49 (10.9%)            | 3 (1.1%)              | 3 (4.6%)              | 29 (4.8%)    | 75 (10.3%)    |
| Peripheral sensory neuropathy         | 24 (5.4%)             | 5 (1.9%)              | 1 (1.5%)              | 46 (7.6%)    | 68 (9.4%)     |
| Anaemia                               | 29 (6.5%)             | 69 (26.3%)            | 1 (1.5%)              | 44 (7.3%)    | 63 (8.7%)     |
| Dizziness                             | 40 (8.9%)             | 9 (3.4%)              | 0                     | 21 (3.5%)    | 60 (8.3%)     |
| Headache                              | 38 (8.5%)             | 19 (7.3%)             | 0                     | 19 (3.1%)    | 55 (7.6%)     |
| Fatigue                               | 23 (5.1%)             | 10 (3.8%)             | 1 (1.5%)              | 22 (3.6%)    | 45 (6.2%)     |
| Paraesthesia                          | 26 (5.8%)             | 5 (1.9%)              | 0                     | 14 (2.3%)    | 38 (5.2%)     |
| Asthenia                              | 14 (3.1%)             | 4 (1.5%)              | 1 (1.5%)              | 23 (3.8%)    | 36 (5.0%)     |
| Alanineaminotransferaseincreased      | 14 (3.1%)             | 4 (1.5%)              | 5 (7.7%)              | 9 (1.5%)     | 23 (3.2%)     |

Source: Table 2.7.4.2.5.2

Shading indicates events that met the ≥ 5% threshold.

DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

## All Grade ≥ 3 Adverse Events

Table 85: Integrated Adverse Events of Grade ≥ 3 Severity in ≥ 5% of Subjects in Any Group by System Organ Class and Preferred Term by Study Period and Treatment (Safety Population)

|                                  | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|----------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| SystemOrganClass PreferredTerm   | MMB (N=448)           | RUX (N=262)           | DAN (N =65)           | MMB (N =604) | MMB (N = 725) |
| Anygrade≥3adverseevent.n(%)      | 207 (46.2%)           | 113 (43.1%)           | 42 (64.6%)            | 357 (59.1%)  | 484 (66.8%)   |
| Bloodandlymphaticsystemdisorders | 92 (20.5%)            | 70 (26.7%)            | 16 (24.6%)            | 156 (25.8%)  | 221 (30.5%)   |
| Thrombocytopenia                 | 48 (10.7%)            | 13 (5.0%)             | 5 (7.7%)              | 70 (11.6%)   | 110 (15.2%)   |
| Anaemia                          | 37 (8.3%)             | 57 (21.8%)            | 7 (10.8%)             | 77 (12.7%)   | 105 (14.5%)   |
| Infectionsandinfestations        | 47 (10.5%)            | 11 (4.2%)             | 11 (16.9%)            | 112 (18.5%)  | 154 (21.2%)   |
| Pneumonia                        | 12 (2.7%)             | 4 (1.5%)              | 6 (9.2%)              | 49 (8.1%)    | 61 (8.4%)     |
| Renalandurinarydisorders         | 13 (2.9%)             | 5 (1.9%)              | 8 (12.3%)             | 42 (7.0%)    | 52 (7.2%)     |
| Acutekidneyinjury                | 4 (0.9%)              | 1 (0.4%)              | 6 (9.2%)              | 13 (2.2%)    | 17 (2.3%)     |

Shading indicates events that met the ≥ 5% threshold.

DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

<div style=\"page-break-after: always\"></div>

## 2.6.8.3. Serious adverse event/deaths/other significant events

## 2 Subjects in Any Group by System Organ

Deaths Table 86: Integrated Fatal Adverse Events in ≥ Class and Preferred Term by Study Period and Treatment (Safety Population)

|                                                                         | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|-------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| SystemOrganClass PreferredTerm                                          | MMB (N =448)          | RUX (N= 262)          | DAN (N = 65)          | MMB (N =604) | MMB (N = 725) |
| Any fatal adverse event,n(%)                                            | 29 (6.5%)             | 9 (3.4%)              | 11 (16.9%)            | 73 (12.1%)   | 102 (14.1%)   |
| Infections and infestations                                             | 10 (2.2%)             | 3 (1.1%)              | 0                     | 22 (3.6%)    | 32 (4.4%)     |
| Pneumonia                                                               | 1 (0.2%)              | 1 (0.4%)              | 0                     | 8 (1.3%)     | 9 (1.2%)      |
| Sepsis                                                                  | 1 (0.2%)              | 2 (0.8%)              | 0                     | 4 (0.7%)     | 5 (0.7%)      |
| COVID-19                                                                | 3 (0.7%)              | 0                     | 0                     | 0            | 3 (0.4%)      |
| COVID-19 pneumonia                                                      | 3 (0.7%)              | 0                     | 0                     | 0            | 3 (0.4%)      |
| Septic shock                                                            | 1 (0.2%)              | 0                     | 0                     | 1 (0.2%)     | 2 (0.3%)      |
| Neoplasms benign,malignant,and unspecified (including cysts and polyps) | 5 (1.1%)              | 3 (1.1%)              | 2 (3.1%)              | 9 (1.5%)     | 14 (1.9%)     |
| Acutemyeloidleukaemia                                                   | 3 (0.7%)              | 1 (0.4%)              | 1 (1.5%)              | 3 (0.5%)     | 6 (0.8%)      |
| Transformation to acutemyeloidleukaemia                                 | 2 (0.4%)              | 0                     | 1 (1.5%)              | 1 (0.2%)     | 3 (0.4%)      |
| Generaldisordersandadministrationsiteconditions                         | 4 (0.9%)              | 0                     | 2 (3.1%)              | 10 (1.7%)    | 14 (1.9%)     |
| Death                                                                   | 1 (0.2%)              | 0                     | 1 (1.5%)              | 3 (0.5%)     | 4 (0.6%)      |
| Sudden death                                                            | 2 (0.4%)              | 0                     | 0                     | 1 (0.2%)     | 3 (0.4%)      |
| Disease progression                                                     | 0                     | 0                     | 1 (1.5%)              | 3 (0.5%)     | 3 (0.4%)      |
| Multiple organ dysfunction syndrome                                     | 0                     | 0                     | 0                     | 2 (0.3%)     | 2 (0.3%)      |
| Cardiac disorders                                                       | 1 (0.2%)              | 0                     | 2 (3.1%)              | 10 (1.7%)    | 11 (1.5%)     |
| Cardiac arrest                                                          | 1 (0.2%)              | 0                     | 0                     | 3 (0.5%)     | 4 (0.6%)      |
| Cardiac failure                                                         | 0                     | 0                     | 0                     | 4 (0.7%)     | 4 (0.6%)      |
| Myocardial infarction                                                   | 0                     | 0                     | 0                     | 2 (0.3%)     | 2 (0.3%)      |
| Respiratory, thoracic and mediastinal disorders                         | 2 (0.4%)              | 0                     | 0                     | 7 (1.2%)     | 9 (1.2%)      |
| Respiratory failure                                                     | 2 (0.4%)              | 0                     | 0                     | 2 (0.3%)     | 4 (0.6%)      |
| Renal and urinary disorders                                             | 1 (0.2%)              | 0                     | 0                     | 4 (0.7%)     | 5 (0.7%)      |
| Renal failure                                                           | 1 (0.2%)              | 0                     | 0                     | 1 (0.2%)     | 2 (0.3%)      |

|                                  | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label    | Overall       |
|----------------------------------|-----------------------|-----------------------|-----------------------|---------------|---------------|
| System Organ Class PreferredTerm | MIMB (N =448)         | RUX (N = 262)         | DAN (N =65)           | MMB (N = 604) | MMB (N = 725) |
| Bloodandlymphaticsystemdisorders | 0                     | 0                     | 3 (4.6%)              | 3 (0.5%)      | 3 (0.4%)      |
| Anaemia                          | 0                     | 0                     | 3 (4.6%)              | 1 (0.2%)      | 1 (0.1%)      |

Shading indicates events that met the ≥ 2 subjects threshold. DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

<div style=\"page-break-after: always\"></div>

Table 87: Summary of Related Treatment-Emergent Adverse Events Leading to Death by System Organ Class and Preferred Term (Safety Population)

| SystemOrganClass Preferred Term                      | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label    | Overall      |
|------------------------------------------------------|-----------------------|-----------------------|-----------------------|---------------|--------------|
| SystemOrganClass Preferred Term                      | MMB (N= 448)          | RUX (N = 262)         | DAN (N=65)            | MMB (N = 607) | MMB (N= 726) |
| Any related TEAE leading to death, n (%)             | 2 (0.4)               | 0                     | 2 (3.1)               | 5 (0.8)       | 7 (1.0)      |
| Infections and infestations                          | 0                     | 0                     | 0                     | 3 (0.5)       | 3 (0.4)      |
| Gastroenteritis rotavirus                            | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Infection                                            | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Pneumonia staphylococcal                             | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Cardiac disorders                                    | 1 (0.2)               | 0                     | 1 (1.5)               | 0             | 1 (0.1)      |
| Cardiac alrest                                       | 1 (0.2)               | 0                     | 0                     | 0             | 1 (0.1)      |
| Cardiogenic shock                                    | 0                     | 0                     | 1 (1.5)               | 0             | 0            |
| Respiratory, thoracic and mediastinal disorders      | 1 (0.2)               | 0                     | 0                     | 0             | 1 (0.1)      |
| Respiratory failure                                  | 1 (0.2)               | 0                     | 0                     | 0             | 1 (0.1)      |
| General disorders and administration site conditions | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Death                                                | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Renal and urinary disorders                          | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Nephritis                                            | 0                     | 0                     | 0                     | 1 (0.2)       | 1 (0.1)      |
| Injury,poisoning and procedural complications        | 0                     | 0                     | 1 (1.5)               | 0             | 0            |
| Subdural haematoma                                   | 0                     | 0                     | 1 (1.5)               | 0             | 0            |

Note: DAN, danazol; MMB, momelotinib; OL, open labell/extended treatment; RT, randomized treatment, RUX, ruxolinib.

- Adverse event was coded to system organ class and preferred term using MedDRA coding dictionary version 24.0

- Exposure-adjusted event rate in 100 person years Was calculated as 100-number of AEs/total person-time follow-up in years.

Abbreviations: DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

Source:Table 40.005

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events

Table 88: Integrated Serious Adverse Events Reported in ≥ 2 Subjects in Any Group During Randomized Treatment by System Organ Class and Preferred Term by Study Period and Treatment (Safety Population)

|                                                                           | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label         | Overall            |
|---------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|--------------------|--------------------|
| System Organ Class                                                        | MMIB                  | RUX                   | DAN                   | MIMB               | MIMB               |
| Preferred Term                                                            | (N = 448)             | (N =262)              | (N = 65)              | (N=604)            | (N = 725)          |
| Any serious adverse event, n (%)                                          | 131 (29.2%)           | 48 (18.3%)            | 26 (40.0%)            | 257 (42.5%)        | 347 (47.9%)        |
| Infections and infestations                                               | 44 (9.8%)             | 12 (4.6%)             | 11 (16.9%)            | 111 (18.4%)        | 148 (20.4%)        |
| Pneumonia                                                                 | 10 (2.2%)             | 3 (1.1%)              | (%76) 9               | 44 (7.3%)          | 54 (7.4%)          |
| Sepsis                                                                    | 4 (0.9%)              | 2 (0.8%)              | 0                     | 13 (2.2%)          | 15 (2.1%)          |
| Urinary tract infection                                                   | 2 (0.4%)              | 2 (0.8%)              | 0                     | 13 (2.2%)          | 15 (2.1%)          |
| Cellulitis                                                                | 4 (0.9%)              | 0                     | 1 (1.5%)              | 5 (0.8%)           | 8 (1.1%)           |
| COVID-19pneumonia                                                         | 3 (0.7%)              | 0                     | 0                     | 3 (0.5%)           | 6 (0.8%)           |
| COVID-19                                                                  | 3 (0.7%)              | 0                     | 0                     | 0                  | 3 (0.4%)           |
| Cystitis                                                                  | 3 (0.7%)              | 0                     | 1 (1.5%)              | 0                  | 3 (0.4%)           |
| Gastroenteritis                                                           | 0                     | 2 (0.8%)              | 0                     | 3 (0.5%)           | 3 (0.4%)           |
| Cardiac disorders                                                         | 21 (4.7%)             | 7 (2.7%)              | 3 (4.6%)              | 46 (7.6%)          | 65 (9.0%)          |
| Atrialfibrillation                                                        | 7 (1.6%)              | 1 (0.4%)              | 0                     | 10 (1.7%)          | 17 (2.3%)          |
| Cardiac failure                                                           | 5 (1.1%)              | 2 (0.8%)              | 0                     | 12 (2.0%)          | 17 (2.3%)          |
| Cardiacfailurecongestive                                                  | 2 (0.4%)              | 1 (0.4%)              | 0                     | 7 (1.2%)           | (%7 1) 6           |
| Acute myocardial infarction                                               | 3 (0.7%)              | 0                     | 0                     | 4 (0.7%)           | 7 (1.0%)           |
| Angina unstable                                                           | 2 (0.4%)              | 0                     | 0                     | 1 (0.2%)           | 3 (0.4%)           |
| Supraventricular tachycardia                                              | 2 (0.4%)              | 0                     | 0                     | 0                  | 2 (0.3%)           |
| Gastrointestinal disorders                                                | 24 (5.4%)             | 10 (3.8%)             | 0                     | 39 (6.5%)          | 58 (8.0%)          |
| Diarrhoea                                                                 | 5 (1.1%)              | 1 (0.4%)              | 0                     | 4 (0.7%)           | (%7 1) 6           |
| Upper gastrointestinal haemorrhage                                        | 3 (0.7%)              | 0                     | 0                     | 3 (0.5%)           | 6 (0.8%)           |
| Ascites                                                                   | 1 (0.2%)              | 2 (0.8%)              | 0                     | 5 (0.8%)           | 5 (0.7%)           |
| Gastrointestinal haemorrhage                                              | 2 (0.4%)              | 0                     | 0                     | 3 (0.5%)           | 3 (0.4%)           |
| Smallintestinalobstruction                                                | 2 (0.4%)              | 0                     | 0                     | 1 (0.2%)           | 3 (0.4%)           |
| Abdominal pain                                                            | 1 (0.2%)              | 3 (1.1%)              | 0                     | 2 (0.3%)           | 3 (0.4%)           |
|                                                                           | RandomizedTreatment   |                       |                       | Open-Label         | Overall            |
| System Organ Class                                                        | MMB                   | RUX                   | DAN                   | MMB                | MMB                |
| Preferred Term                                                            | (N= 448)              | (N =262)              | (N= 65)               | (N= 604)           | (N = 725)          |
| Blood and lymphatic system disorders                                      | 21 (4.7%)             | 9 (3.4%)              | 6 (9.2%)              | 34 (5.6%)          | 54 (7.4%)          |
| Anaemia                                                                   | 13 (2.9%)             | 8 (3.1%)              | 3 (4.6%)              | 20 (3.3%)          | 32 (4.4%)          |
| Splenic infarction                                                        | 2 (0.4%)              | 0                     | 2 (3.1%)              | (%0: 1) 9          | 8 (1.1%)           |
| Thrombocytopenia                                                          | 3 (0.7%)              | 3 (1.1%)              | 0                     | 4 (0.7%)           | 7 (1.0%)           |
| Renal andurinarydisorders                                                 | 16 (3.6%)             | 2 (0.8%)              | 3 (4.6%)              | 41 (6.8%)          | 53 (7.3%)          |
| Acute kidney injury                                                       | 7 (1.6%)              | 1 (0.4%)              | 3 (4.6%)              | 18 (3.0%)          | 25 (3.4%)          |
| Renal failure                                                             | 4 (0.9%)              | 0                     | 0                     | 5 (0.8%)           | (%7 1) 6           |
| Nephrolithiasis                                                           | 2 (0.4%)              | 1 (0.4%)              | 0                     | 1 (0.2%)           | 3 (0.4%)           |
| Respiratory, thoracic and mediastinal disorders                           | 12 (2.7%)             | 5 (1.9%)              | 1 (1.5%)              | 38 (6.3%)          | 49 (6.8%)          |
| Dyspnoea                                                                  | 2 (0.4%)              | 0                     | 0                     | 7 (1.2%)           | (%7 1) 6           |
| Respiratory failure                                                       | 3 (0.7%)              | 0                     | 0                     | 4 (0.7%)           | 7 (1.0%)           |
| Pneumonia aspiration                                                      | 2 (0.4%)              | 0                     | 0                     | 4 (0.7%)           | 5 (0.7%)           |
| Chronic obstructive pulmonary disease                                     | 2 (0.4%)              | 0                     | 0                     | 1 (0.2%)           | 3 (0.4%)           |
| Generaldisordersandadministrationsite conditions                          | 15 (3.3%)             | 8 (3.1%)              | 5 (7.7%)              | 33 (5.5%)          | 47 (6.5%)          |
| Pyrexia                                                                   | 7 (1.6%)              | 3 (1.1%)              | 0                     | 12 (2.0%)          | 18 (2.5%)          |
| General physical health deterioration                                     | 4 (0.9%)              | 2 (0.8%)              | 2 (3.1%)              | 2 (0.3%)           | 6 (0.8%)           |
| Sudden death                                                              | 2 (0.4%)              | 0                     | 0                     | 1 (0.2%)           | 3 (0.4%)           |
| Neoplasms benign, malignant, and unspecified (including cysts and polyps) | 10 (2.2%)             | 2 (0.8%)              | 4 (6.2%)              | 29 (4.8%)          | 38 (5.2%)          |
| Transformationtoacute myeloid leukaemia                                   | 2 (0.4%)              | 0                     | 2 (3.1%)              | 1 (0.2%)           | 3 (0.4%)           |
| Acute myeloid leukaemia                                                   | 2 (0.4%)              | 0                     | 1 (1.5%)              | 1 (0.2%)           | 3 (0.4%)           |
| Syncope                                                                   | 10 (2.2%)             | 1 (0.4%)              | 2 (3.1%)              | 25 (4.1%)          | 35 (4.8%)          |
| Nervous system disorders                                                  | 4 (0.9%)              | 0                     | 0                     | 4 (0.7%)           | 8 (1.1%)           |
| Presyncope                                                                | 2 (0.4%) 6 (1.3%)     | 0                     | 0                     | 1 (0.2%) 19 (3.1%) | 3 (0.4%) 25 (3.4%) |
| Metabolism and nutrition disorders Hyperkalaemia                          | 2 (0.4%)              | 3 (1.1%) 1 (0.4%)     | 2 (3.1%) 1 (1.5%)     | 3 (0.5%)           | 5 (0.7%)           |

<div style=\"page-break-after: always\"></div>

|                                | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall        |
|--------------------------------|-----------------------|-----------------------|-----------------------|--------------|----------------|
| SystemOrganClass PreferredTern | MIMIB (N =448)        | RUX (N = 262)         | DAN (N =65)           | MMB (N= 604) | MIMB (N = 725) |
| Fluidoverload                  | 2 (0.4%)              | 0                     | 0                     | 0            | 2 (0.3%)       |
| Vasculardisorders              | 8 (1.8%)              | 3 (1.1%)              | 1 (1.5%)              | 14 (2.3%)    | 22 (3.0%)      |
| Hypotension                    | 2 (0.4%)              | 0                     | 0                     | 3 (0.5%)     | 5 (0.7%)       |
| Investigations                 | 3 (0.7%)              | 1 (0.4%)              | 1 (1.5%)              | 1 (0.2%)     | 4 (0.6%)       |
| Bloodcreatinineincreased       | 2 (0.4%)              | 0                     | 0                     | 0            | 2 (0.3%)       |
| Immunesystemdisorders          | 2 (0.4%)              | 0                     | 0                     | 1 (0.2%)     | 3 (0.4%)       |
| Hypersensitivity               | 2 (0.4%)              | 0                     | 0                     | 0            | 2 (0.3%)       |
| Earandlabyrinthdisorders       | 0                     | 3 (1.1%)              | 0                     | 1 (0.2%)     | 1 (0.1%)       |
| Vertigo                        | 0                     | 2 (0.8%)              | 0                     | 1 (0.2%)     | 1 (0.1%)       |

Shading indicates events that met the ≥ 2 subjects threshold in any group. DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

Adverse Events of Clinical Importance

Table 89: Integrated Overall Summary of All Adverse Events of Clinical Importance by Study Period and Treatment (Safety Population)

|                         | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|-------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| Important Event, n (%)  | MB (N=448)            | RUX (N=262)           | DAN (N=65)            | MIIB (N=604) | MIIB (N =725) |
| Infections              | 178 (39.7%)           | 112 (42.7%)           | 23 (35.4%)            | 299 (49.5%)  | 402 (55.4%)   |
| Malignancies            | 25 (5.6%)             | 15 (5.7%)             | 5 (7.7%)              | 77 (12.7%)   | 97 (13.4%)    |
| Opportunisticinfections | 10 (2.2%)             | 11 (4.2%)             | 1 (1.5%)              | 31 (5.1%)    | 40 (5.5%)     |
| AML/transformation      | 8 (1.8%)              | 3 (1.1%)              | 3 (4.6%)              | 14 (2.3%)    | 22 (3.0%)     |
| Nonmelanomaskincancer   | 6 (1.3%)              | 8 (3.1%)              | 0                     | 31 (5.1%)    | 35 (4.8%)     |
| MACE                    | 14 (3.1%)             | 7 (2.7%)              | 4 (6.2%)              | 46 (7.6%)    | 57 (7.9%)     |
| Thrombocytopenia        | 94 (21.0%)            | 69 (26.3%)            | 10 (15.4%)            | 114 (18.9%)  | 181 (25.0%)   |
| Neutropenia             | 27 (6.0%)             | 15 (5.7%)             | 3 (4.6%)              | 30 (5.0%)    | 49 (6.8%)     |
| Anemia                  | 63 (14.1%)            | 92 (35.1%)            | 11 (16.9%)            | 128 (21.2%)  | 170 (23.4%)   |
| Peripheral neuropathy   | 39 (8.7%)             | 12 (4.6%)             | 1 (1.5%)              | 74 (12.3%)   | 107 (14.8%)   |
| Thromboembolism         | 15 (3.3%)             | 2 (0.8%)              | 6 (9.2%)              | 51 (8.4%)    | 64 (8.8%)     |
| Hemomhage               | 95 (21.2%)            | 52 (19.8%)            | 12 (18.5%)            | 136 (22.5%)  | 207 (28.6%)   |

Shading indicates adverse events ≥ 5 percentage points higher than 1 or more group during randomized treatment. AML, acute myeloid leukemia; DAN, danazol; MACE, major adverse cardiovascular events; MMB, momelotinib; RUX, ruxolitinib.

<div style=\"page-break-after: always\"></div>

## 2.6.8.4. Laboratory findings

Parameter During 24 Weeks of Randomized Treatment (Safety Population)

Table 90: Integrated Hematology - Shift From Baseline Grade 0, 1, or 2 to Worst Postbaseline Grade 3 or 4 by Key abnormality

| Laboratory Abnornality     | Shift FromBaseline to Worst Postbaseline   | MMB (N=448)   | RUX (N= 262)   | DAN (N = 65)   |
|----------------------------|--------------------------------------------|---------------|----------------|----------------|
| Anemia                     | 0to3                                       | 1 (0.2%)      | 5 (1.9%)       | 0              |
| Anemia                     | 1 to 3                                     | 5 (1.1%)      | 22 (8.4%)      | 0              |
| Anemia                     | 2 to3                                      | 48 (10.7%)    | 59 (22.5%)     | 10 (15.4%)     |
| Lymphocyte count decreased | 0 to 3                                     | 11 (2.5%)     | 14 (5.3%)      | 4 (6.2%)       |
| Lymphocyte count decreased | 1 to 3                                     | 5 (1.1%)      | 2 (0.8%)       | 2 (3.1%)       |
| Lymphocyte count decreased | 2 to 3                                     | 25 (5.6%)     | 14 (5.3%)      | 14 (21.5%)     |
| Lymphocyte count decreased | 0 to 4                                     | 3 (0.7%)      | 0              | 0              |
| Neutrophilcountdecreased   | 0 to 3                                     | 6 (1.3%)      | 4 (1.5%)       | 1 (1.5%)       |
| Neutrophilcountdecreased   | 1to3                                       | 7 (1.6%)      | 4 (1.5%)       | 0              |
| Neutrophilcountdecreased   | 2 to 3                                     | 7 (1.6%)      | (%61) s        | 2 (3.1%)       |
| Neutrophilcountdecreased   | 0 to 4                                     | 0             | 2 (0.8%)       | 0              |
| Neutrophilcountdecreased   | 2 to 4                                     | 2 (0.4%)      | 0              | 1 (1.5%)       |
| Plateletcount decreased    | 0 to 3                                     | 11 (2.5%)     | 3 (1.1%)       | 0              |
| Plateletcount decreased    | 1 to 3                                     | 11 (2.5%)     | 6 (2.3%)       | 1 (1.5%)       |
| Plateletcount decreased    | 2 to 3                                     | 23 (5.1%)     | 3 (1.1%)       | 5 (7.7%)       |
| Plateletcount decreased    | 0to 4                                      | 1 (0.2%)      | 1 (0.4%)       | 0              |
| Plateletcount decreased    | 1 to 4                                     | 3 (0.7%)      | 0              | 0              |
| Plateletcount decreased    | 2 to 4                                     | 6 (1.3%)      | 2 (0.8%)       | 1 (1.5%)       |
| WBCcountdecreased          | 0 to3                                      | 7 (1.6%)      | 7 (2.7%)       | 0              |
| WBCcountdecreased          | 1 to 3                                     | 4 (0.9%)      | 2 (0.8%)       | 1 (1.5%)       |
| WBCcountdecreased          | 2 to 3                                     | 5 (1.1%)      | 12 (4.6%)      | 2 (3.1%)       |
| WBCcountdecreased          | 0 to 4                                     | 1 (0.2%)      | 0              | 0              |

Baseline was the most recent assessment prior to or on the first dose date during randomized treatment. DAN, danazol; MMB, momelotinib; RUX, ruxolitinib; WBC, white blood cell.

<div style=\"page-break-after: always\"></div>

Abnormal Liver Function Laboratory Findings

Table 91: Integrated Summary of Abnormal Liver Function Laboratory Findings by Study Period and Treatment (Safety Population)

|                                                     | Randomized   | Randomized   | Randomized   | Open-Label   | Overall     |
|-----------------------------------------------------|--------------|--------------|--------------|--------------|-------------|
| LaboratoryAbnormality                               | MMB          | RUX          | DAN          | MMB          | MMB         |
| ALT, n                                              | 443          | 259          | 64           | 579          | 710         |
| ≥3 x ULN                                            | 16 (3.6%)    | 7 (2.7%)     | 4 (6.3%)     | 29 (5.0%)    | 41 (5.8%)   |
| ≥5 x ULN                                            | 8 (1.8%)     | 1 (0.4%)     | 2 (3.1%)     | 11 (1.9%)    | 17 (2.4%)   |
| ≥ 10 x ULN                                          | 1 (0.2%)     | 0            | 0            | 5 (0.9%)     | 6 (0.8%)    |
| ≥20 x ULN                                           | 1 (0.2%)     | 0            | 0            | 1 (0.2%)     | 2 (0.3%)    |
| AST, n                                              | 442          | 259          | 63           | 579          | 709         |
| ≥3 x ULN                                            | 7 (1.6%)     | 2 (0.8%)     | 1 (1.6%)     | 12 (2.1%)    | 17 (2.4%)   |
| ≥5 x ULN                                            | 1 (0.2%)     | 0            | 1 (1.6%)     | 6 (1.0%)     | 7 (1.0%)    |
| ≥10 x ULN                                           | 1 (0.2%)     | 0            | 0            | 3 (0.5%)     | 4 (0.6%)    |
| ≥ 20 x ULN                                          | 0            | 0            | 0            | 2 (0.3%)     | 2 (0.3%)    |
| AST or ALT, n                                       | 443          | 259          | 64           | 579          | 710         |
| ≥3 x ULN                                            | 17 (3.8%)    | 8 (3.1%)     | 4 (6.3%)     | 29 (5.0%)    | 42 (5.9%)   |
| ≥5 x ULN                                            | 8 (1.8%)     | 1 (0.4%)     | 2 (3.1%)     | 11 (1.9%)    | 17 (2.4%)   |
| ≥ 10 x ULN                                          | 1 (0.2%)     | 0            | 0            | 5 (0.9%)     | 6 (0.8%)    |
| ≥20 x ULN                                           | 1 (0.2%)     | 0            | 0            | 2 (0.3%)     | 3 (0.4%)    |
| Total bilirubin, n                                  | 443          | 259          | 64           | 579          | 710         |
| >2 x ULN                                            | 15 (3.4%)    | 10 (3.9%)    | 3 (4.7%)     | 24 (4.1%)    | 33 (4.6%)   |
| Alkaline phosphatase, n                             | 443          | 259          | 64           | 579          | 711         |
| >1.5 x ULN                                          | 75 (16.9%)   | 31 (12.0%)   | 4 (6.3%)     | 88 (15.2%)   | 142 (20.0%) |
| Elevated ALT or AST and elevated total bilirubin,n  | 433          | 259          | 64           | 579          | 710         |
| ALT or AST ≥3 x ULN and total bilirubin > 1.5 x ULN | 0            | 0            | 0            | 7 (1.2%)     | 7 (1.0%)    |
| ALT or AST ≥ 3x ULN and total bilirubin > 2.0 x ULN | 0            | 0            | 0            | 2 (0.3%)     | 2 (0.3%)    |
| Hy's Law, n [1]                                     | 433          | 259          | 64           | 578          | 710         |
|                                                     | 0            | 0            | 0            | 2 (0.3%)     | 2 (0.3%)    |

Denominators were the number of subjects with nonmissing postbaseline values for a parameter. [1] ALT or AST ≥ 3 × ULN, total bilirubin &gt; 2 × ULN, and alkaline phosphatase &lt; 2 × ULN. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAN, danazol; MMB, momelotinib; RUX, ruxolitinib, ULN, upper limit of normal.

## 2.6.8.5. In vitro biomarker test for patient selection for safety

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.6.8.6. Safety in special populations

Table 92: Integrated Overall Summary of Adverse Events by Sex (Male, Female; Randomized Treatment)

|                                   | MMB          | MMB             | RUX           | RUX             | DAN          | DAN           |
|-----------------------------------|--------------|-----------------|---------------|-----------------|--------------|---------------|
| AdverseEventCategory              | Male (N=271) | Female (N =177) | Male (N =141) | Female (N =121) | Male (N =44) | Female (N=21) |
| Anyadverseevent,n(%)              | 257 (94.8%)  | 163 (92.1%)     | 133 (94.3%)   | 115 (95.0%)     | 43 (97.7%)   | 19 (90.5%)    |
| Related                           | 171 (63.1%)  | 119 (67.2%)     | 86 (61.0%)    | 75 (62.0%)      | 22 (50.0%)   | 7 (33.3%)     |
| Grade3or4                         | 133 (49.1%)  | 61 (34.5%)      | 59 (41.8%)    | 54 (44.6%)      | 29 (65.9%)   | 12 (57.1%)    |
| Related                           | 65 (24.0%)   | 42 (23.7%)      | 38 (27.0%)    | 32 (26.4%)      | 12 (27.3%)   | 4 (19.0%)     |
| Serious                           | 93 (34.3%)   | 38 (21.5%)      | 29 (20.6%)    | 19 (15.7%)      | 16 (36.4%)   | 10 (47.6%)    |
| Related                           | 30 (11.1%)   | 8 (4.5%)        | 9 (6.4%)      | 6 (5.0%)        | 4 (9.1%)     | 1 (4.8%)      |
| Fatal                             | 22 (8.1%)    | 7 (4.0%)        | 6 (4.3%)      | 3 (2.5%)        | 6 (13.6%)    | 5 (23.8%)     |
| Leadingtostudydrugmodification    | 57 (21.0%)   | 43 (24.3%)      | 44 (31.2%)    | 43 (35.5%)      | 15 (34.1%)   | 4 (19.0%)     |
| Leadingtostudydrugdiscontinuation | 46 (17.0%)   | 26 (14.7%)      | 8 (5.7%)      | 5 (4.1%)        | 11 (25.0%)   | 4 (19.0%)     |

DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

Table 93: Integrated Overall Summary of Adverse Events by Age (18-64, ≥ 65, 18-74, ≥ 75 Years; Randomized Treatment)

|                                       | MMB             | MMB          | MMB             | MMB         | RUX        | RUX                        | RUX         | RUX         | DAN            | DAN         | DAN           | DAN         |
|---------------------------------------|-----------------|--------------|-----------------|-------------|------------|----------------------------|-------------|-------------|----------------|-------------|---------------|-------------|
| AdverseEvent Category                 | 18-64 (N = 159) | ≥65 (N=289)( | 18-74 (N = 353) | ≥75 (N =95) | 18-64      | ≥65 (N=106)(N =156)(N=218) | 18-74       | ≥75 (N =44) | 18-64 (N = 11) | ≥65 (N =54) | 18-74 (N =44) | ≥75 (N =21) |
| Any adverse event,n(%)                | 144 (90.6%)     | 276 (95.5%)  | 329 (93.2%)     | 91 (95.8%)  | 95 (89.6%) | 153 (98.1%)                | 205 (94.0%) | 43 (97.7%)  | 11 (100%)      | 51 (94.4%)  | 41 (93.2%)    | 21 (100%)   |
| Related                               | 104 (65.4%)     | 186 (64.4%)  | 225 (63.7%)     | 65 (68.4%)  | 63 (59.4%) | 98 (62.8%)                 | 136 (62.4%) | 25 (56.8%)  | 9 (81.8%)      | 20 (37.0%)  | 22 (50.0%)    | 7 (33.3%)   |
| Grade3or 4                            | 59 (37.1%)      | 135 (46.7%)  | 146 (41.4%)     | 48 (50.5%)  | 36 (34.0%) | 77 (49.4%)                 | 88 (40.4%)  | 25 (56.8%)  | 8 (72.7%)      | 33 (61.1%)  | 28 (63.6%)    | 13 (61.9%)  |
| Related                               | 31 (19.5%)      | 76 (26.3%)   | 77 (21.8%)      | 30 (31.6%)  | 29 (27.4%) | 41 (26.3%)                 | 54 (24.8%)  | 16 (36.4%)  | 5 (45.5%)      | 11 (20.4%)  | 12 (27.3%)    | 4 (19.0%)   |
| Serious                               | 33 (20.8%)      | 98 (33.9%)   | 98 (27.8%)      | 33 (34.7%)  | 13 (12.3%) | 35 (22.4%)                 | 36 (16.5%)  | 12 (27.3%)  | 4 (36.4%)      | 22 (40.7%)  | 16 (36.4%)    | 10 (47.6%)  |
| Related                               | 5 (3.1%)        | 33 (11.4%)   | 25 (7.1%)       | 13 (13.7%)  | 6 (5.7%)   | 9 (5.8%)                   | 13 (6.0%)   | 2 (4.5%)    | 1 (9.1%)       | 4 (7.4%)    | 2 (4.5%)      | 3 (14.3%)   |
| Fatal                                 | 7 (4.4%)        | 22 (7.6%)    | 23 (6.5%)       | 6 (6.3%)    | 2 (1.9%)   | 7 (4.5%)                   | 7 (3.2%)    | 2 (4.5%)    | 1 (9.1%)       | 10 (18.5%)  | 5 (11.4%)     | 6 (28.6%)   |
| Leading to study drug modification    | 26 (16.4%)      | 74 (25.6%)   | 73 (20.7%)      | 27 (28.4%)  | 31 (29.2%) | 56 (35.9%)                 | 73 (33.5%)  | 14 (31.8%)  | 4 (36.4%)      | 15 (27.8%)  | 14 (31.8%)    | 5 (23.8%)   |
| Leading to study drug discontinuation | 21 (13.2%)      | 51 (17.6%)   | 56 (15.9%)      | 16 (16.8%)  | 4 (3.8%)   | 9 (5.8%)                   | 11 (5.0%)   | (4.5%)      | 4 (36.4%)      | 11 (20.4%)  | 10 (22.7%)    | 5 (23.8%)   |

DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

Table 94: Integrated Overall Summary of Adverse Events by Baseline Prognostic Score (Intermediate 1, Intermediate 2, High Risk; Randomized Treatment

|                                       | MMIB           | MMIB           | MMIB          | RUX           | RUX           | RUX           | DAN          | DAN           | DAN           |
|---------------------------------------|----------------|----------------|---------------|---------------|---------------|---------------|--------------|---------------|---------------|
| AdverseEventCategory                  | Int-1 (N = 70) | Int-2 (N =201) | High (N =177) | Int-1 (N =55) | Int-2 (N =92) | High (N =115) | Int-1 (N =1) | Int-2 (N =31) | High (N = 32) |
| Any adverse event,n(%)                | 66 (94.3%)     | 184 (91.5%)    | 170 (96.0%)   | 49 (89.1%)    | 88 (95.7%)    | 111 (96.5%)   | 1 (100%)     | 29 (93.5%)    | 31 (96.9%)    |
| Related                               | 53 (75.7%)     | 128 (63.7%)    | 109 (61.6%)   | 28 (50.9%)    | 58 (63.0%)    | 75 (65.2%)    | 0            | 16 (51.6%)    | 13 (40.6%)    |
| Grade3or4                             | 23 (32.9%)     | 84 (41.8%)     | 87 (49.2%)    | 12 (21.8%)    | 39 (42.4%)    | 62 (53.9%)    | 0            | 22 (71.0%)    | 19 (59.4%)    |
| Related                               | 15 (21.4%)     | 48 (23.9%)     | 44 (24.9%)    | 7 (12.7%)     | 28 (30.4%)    | 35 (30.4%)    | 0            | 10 (32.3%)    | 6 (18.8%)     |
| Serious                               | 17 (24.3%)     | 56 (27.9%)     | 58 (32.8%)    | 5 (9.1%)      | 16 (17.4%)    | 27 (23.5%)    | 0            | 15 (48.4%)    | 11 (34.4%)    |
| Related                               | 5 (7.1%)       | 21 (10.4%)     | 12 (6.8%)     | 1 (1.8%)      | 5 (5.4%)      | 9 (7.8%)      | 0            | 4 (12.9%)     | 1 (3.1%)      |
| Fatal                                 | (1.4%)         | 13 (6.5%)      | 15 (8.5%)     | 1 (1.8%)      | 5 (5.4%)      | 3 (2.6%)      | 0            | 7 (22.6%)     | 4 (12.5%)     |
| Leading to study drug modification    | 10 (14.3%)     | 44 (21.9%)     | 46 (26.0%)    | 16 (29.1%)    | 27 (29.3%)    | 44 (38.3%)    | 0            | 10 (32.3%)    | 9 (28.1%)     |
| Leading to study drug discontinuation | 9 (12.9%)      | 30 (14.9%)     | 33 (18.6%)    | 1 (1.8%)      | 6 (6.5%)      | 6 (5.2%)      | 0            | 12 (38.7%)    | 3 (9.4%)      |

DIPSS scores were used for the analysis of baseline prognostic risk.

<div style=\"page-break-after: always\"></div>

DAN, danazol; DIPSS, Dynamic International Prognostic Scoring System; Int-1, intermediate-1; Int-2, intermediate-2; MMB, momelotinib; RUX, ruxolitinib.

Table 95: Integrated Overall Summary of Adverse Events by Baseline Hemoglobin Value (&lt; 8 g/dL, ≥ 8 g/dL, &lt; 10 g/dL, ≥ 10 g/dL; Randomized Treatment)

|                                       | MMB            | MMB            | MMB             | MMB              | RUX            | RUX             | RUX               | RUX               | DAN            | DAN             | DAN              | DAN            |
|---------------------------------------|----------------|----------------|-----------------|------------------|----------------|-----------------|-------------------|-------------------|----------------|-----------------|------------------|----------------|
| AdverseEventCategory                  | <8g/dL (N=100) | ≥8g/dL (N=347) | <10g/dL (N=275) | ≥10g/dL (N =172) | <8 g/dL (N=24) | ≥8g/dL (N =237) | <10 g/dL (N =130) | ≥10 g/dL (N =131) | <8g/dL (N =32) | ≥8 g/dL (N =33) | <10g/dL (N = 65) | ≥10g/dL (N =0) |
| Any adverse event,n(%)                | 94 (94.0%)     | 325 (93.7%)    | 262 (95.3%)     | 157 (91.3%)      | 22 (91.7%)     | 225 (94.9%)     | 123 (94.6%)       | 124 (94.7%)       | 31 (96.9%)     | 31 (93.9%)      | 62 (95.4%)       | 0              |
| Related                               | 59 (59.0%)     | 230 (66.3%)    | 176 (64.0%)     | 113 (65.7%)      | 13 (54.2%)     | 148 (62.4%)     | 73 (56.2%)        | 88 (67.2%)        | 14 (43.8%)     | 15 (45.5%)      | 29 (44.6%)       | 0              |
| Grade3or4                             | 52 (52.0%)     | 141 (40.6%)    | 137 (49.8%)     | 56 (32.6%)       | 13 (54.2%)     | 100 (42.2%)     | 68 (52.3%)        | 45 (34.4%)        | 19 (59.4%)     | 22 (66.7%)      | 41 (63.1%)       | 0              |
| Related                               | 24 (24.0%)     | 83 (23.9%)     | 71 (25.8%)      | 36 (20.9%)       | 6 (25.0%)      | 64 (27.0%)      | 39 (30.0%)        | 31 (23.7%)        | 7 (21.9%)      | 9 (27.3%)       | 16 (24.6%)       | 0              |
| Serious                               | 37 (37.0%)     | 94 (27.1%)     | 91 (33.1%)      | 40 (23.3%)       | 5 (20.8%)      | 43 (18.1%)      | 30 (23.1%)        | 18 (13.7%)        | 11 (34.4%)     | 15 (45.5%)      | 26 (40.0%)       | 0              |
| Related                               | 9 (9.0%)       | 29 (8.4%)      | 27 (9.8%)       | 11 (6.4%)        | 2 (8.3%)       | 13 (5.5%)       | 10 (7.7%)         | 5 (3.8%)          | 2 (6.3%)       | 3 (9.1%)        | 5 (7.7%)         | 0              |
| Fatal                                 | 11 (11.0%)     | 18 (5.2%)      | 21 (7.6%)       | 8 (4.7%)         | 3 (12.5%)      | 6 (2.5%)        | 6 (4.6%)          | 3 (2.3%)          | 5 (15.6%)      | 6 (18.2%)       | 11 (16.9%)       | 0              |
| Leading to study drug modification    | 24 (24.0%)     | 76 (21.9%)     | 69 (25.1%)      | 31 (18.0%)       | 7 (29.2%)      | 80 (33.8%)      | 41 (31.5%)        | 46 (35.1%)        | 7 (21.9%)      | 12 (36.4%)      | 19 (29.2%)       | 0              |
| Leading to study drug discontinuation | 21 (21.0%)     | 51 (14.7%)     | 52 (18.9%)      | 20 (11.6%)       | 4 (16.7%)      | 9 (3.8%)        | 7 (5.4%)          | 6 (4.6%)          | 10 (31.3%)     | 5 (15.2%)       | 15 (23.1%)       | 0              |

DAN, danazol; MMB, momelotinib; RUX, ruxolitinib.

## 2.6.8.7. Immunological events

Not applicable.

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

## Potential for Other Medicinal Products to Affect MMB Exposure

MMB is not a sensitive substrate of cytochrome P450 (CYP) 3A, P glycoprotein (P gp), or breast cancer resistance protein (BCRP) and can be coadministered with inhibitors of CYP3A without dose modification.

Coadministration of single dose rifampin (600 mg), a potent inhibitor of the hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1/1B3, and MMB resulted in a moderate increase in MMB plasma exposure in a study of healthy adult volunteers; however, the extent of this interaction does not suggest dose modification of MMB is warranted when coadministered with inhibitors of OATP1B1/1B3.

Coadministration of multiple dose rifampin treatment (600 mg once daily), a strong inducer of CYP3A/2C8/2C19, and MMB (200 mg single dose) resulted in a slight decrease in MMB plasma exposure in a study of healthy adult volunteers; thus, MMB can be coadministered with rifampin without dose modification.  However, coadministration of other strong CYP3A inducers may decrease MMB exposure, and therefore result in reduced effective drug exposure.  If coadministration of other strong CYP3A inducers is necessary, the patient should be monitored frequently.

Coadministration of multiple dose omeprazole (20 mg once daily), a proton pump inhibitor, resulted in a moderate decrease in MMB exposure in a study of healthy adult volunteers administered MMB 200 mg single dose.  However, the extent of this interaction does not suggest that dose modification is warranted when MMB is coadministered with an acid reducing agent.

<div style=\"page-break-after: always\"></div>

## Potential for MMB to Affect Exposure to Other Medicinal Products

MMB did not alter the PK of midazolam (a sensitive probe CYP3A substrate), and no dose modification is needed for sensitive CYP3A substrates when coadministered with MMB.

MMB is a BCRP inhibitor in vitro and significantly increased the plasma exposure of the BCRP substrate rosuvastatin 10 mg when coadministered with a single dose of MMB 200 mg (3.2 fold increase in maximum plasm concentration [Cmax] and 2.7 fold increase in area under the concentration time curve [AUCinf]) in a study of healthy adult volunteers.  When clinically appropriate, dose modification or alternative medications for rosuvastatin should be considered when coadministered with MMB.

## 2.6.8.9. Discontinuation due to adverse events

Table 96: Integrated Grade ≥ 3 Adverse Events Leading to Study Drug Discontinuation in ≥ 1% of Subjects in Any Group by System Organ Class and Preferred Term by Study Period and Treatment (Safety Population)

|                                                                         | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
|-------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|--------------|---------------|
| System Organ Class PreferredTerm                                        | MIMB (N = 448)        | RUX (N = 262)         | DAN (N = 65)          | MMB (N= 604) | MMB (N = 725) |
| Any adverse event leading to study drug discontinuation, n (%)          | 56 (12.5%)            | 13 (5.0%)             | 11 (16.9%)            | 120 (19.9%)  | 176 (24.3%)   |
| Blood and lymphatic system disorders                                    | 17 (3.8%)             | 4 (1.5%)              | 4 (6.2%)              | 31 (5.1%)    | 48 (6.6%)     |
| Thrombocytopenia                                                        | 10 (2.2%)             | 3 (1.1%)              | 0                     | 16 (2.6%)    | 26 (3.6%)     |
| Anaemia                                                                 | 2 (0.4%)              | 0                     | 2 (3.1%)              | 5 (0.8%)     | 7 (1.0%)      |
| Splenomegaly                                                            | 2 (0.4%)              | 0                     | 1 (1.5%)              | 4 (0.7%)     | 6 (0.8%)      |
| Neutropenia                                                             | 0                     | 0                     | 1 (1.5%)              | 4 (0.7%)     | 4 (0.6%)      |
| Neoplasms benign,malignant,and unspecified (ineluding cysts and polyps) | 10 (2.2%)             | 3 (1.1%)              | 2 (3.1%)              | 18 (3.0%)    | 28 (3.9%)     |
| Acute myeloid leukaemia                                                 | 4 (0.9%)              | 1 (0.4%)              | 1 (1.5%)              | 7 (1.2%)     | 11 (1.5%)     |
| Transformation to acute myeloid leukaemia                               | 1 (0.2%)              | 1 (0.4%)              | 1 (1.5%)              | 2 (0.3%)     | 3 (0.4%)      |
| Infections and infestations                                             | 8 (1.8%)              | 2 (0.8%)              | 0                     | 20 (3.3%)    | 28 (3.9%)     |
| Pneumonia                                                               | 2 (0.4%)              | 1 (0.4%)              | 0                     | 6 (1.0%)     | 8 (1.1%)      |
| Generaldisordersand administration site conditions                      | 5 (1.1%)              | 0                     | 2 (3.1%)              | 13 (2.2%)    | 18 (2.5%)     |
| Disease progression                                                     | 1 (0.2%)              | 0                     | 0                     | 6 (1.0%)     | 7 (1.0%)      |
| Death                                                                   | 1 (0.2%)              | 0                     | 1 (1.5%)              | 1 (0.2%)     | 2 (0.3%)      |
| Chest pain                                                              | 0                     | 0                     | 1 (1.5%)              | 0            | 0             |
| Nervous system disorders                                                | 1 (0.2%)              | 0                     | 1 (1.5%)              | 11 (1.8%)    | 12 (1.7%)     |
| Cerebrovascular accident                                                | 0                     | 0                     | 1 (1.5%)              | 2 (0.3%)     | 2 (0.3%)      |
| Cardiac disorders                                                       | 2 (0.4%)              | 0                     | 1 (1.5%)              | 5 (0.8%)     | 7 (1.0%)      |
| Coronary artery stenosis                                                | 0                     | 0                     | 1 (1.5%)              | 0            | 0             |
|                                                                         | RandomizedTreatment   | RandomizedTreatment   | RandomizedTreatment   | Open-Label   | Overall       |
| System Organ Class Preferred Term                                       | MMB (N = 448)         | RUX (N = 262)         | DAN (N = 65)          | MMB (N=604)  | MMB (N = 725) |
| Hepatobiliary disorders                                                 | 1 (0.2%)              | 0                     | 1 (1.5%)              | 3 (0.5%)     | 4 (0.6%)      |
| Jaundice                                                                | 0                     | 0                     | 1 (1.5%)              | 0            | 0             |

Shading indicates events that met the ≥ 1% threshold.

## UPDATED INFORMATION:

Updated overall AE summaries are presented for the subjects participating in the MOMENTUM OLE treatment period in tables below. For MOMENTUM, the data cut for this updated analysis was based on the overall study last patient last visit date of 29 December 2022, when all subjects had discontinued treatment or had transitioned to XAP after at least 24 weeks of participation in the OLE treatment phase of the study. The updated analysis of the XAP study, with a data cut of 02 September 2022, included subjects who entered this long-term extension study after initiating momelotinib on one of the Phase 3 studies (SIMPLIFY-1, SIMPLIFY-2, or MOMENTUM).

<div style=\"page-break-after: always\"></div>

Table 97: Updated Overall Summary of Treatment-emergent Adverse Events Over the MOMENTUM OLE Treatment Period (Safety Analysis Set)

<!-- image -->

## Adverse events

## MOMENTUM OLE

The most commonly reported adverse events during MOMENTUM OLE are summarized by preferred term in table below. Commonly reported adverse events are defined as those reported in ≥ 5% of subjects in any group. Shading indicates events that met the ≥ 5% threshold.

Certain adverse events met the ≥ 5% incidence threshold in both subjects who continued MMB from randomized treatment (MMB to MMB) and subjects who started MMB after randomized treatment with DAN (DAN to MMB), including diarrhea, thrombocytopenia, pyrexia, weight decreased, anemia, asthenia, blood creatinine increased, and fatigue, consistent with underlying MF disease signs and symptoms. The only PT with a difference ≥ 10% between treatment groups was asthenia (MMB to MMB 12/93 [12.9%]; DANto MMB 0/41).

During the MOMENTUM OLE treatment period, the updated exposure-adjusted incidence of subjects with at least one TEAE was 176.65 per 100 person-years overall; in the treatment groups, the incidence was 176.60 per 100 person-years in MMB to MMB and 176.77 per 100 person-years in DAN to MMB.

<div style=\"page-break-after: always\"></div>

Table 98: Commonly Reported Treatment-emergent Adverse Events in ≥ 5% of Subjects in Any Group by Preferred Term During OLE Treatment Period (Safety Analysis Set)

|                                         | MMB-→MMB (N=93)   | DAN-→MMB (N=41)   | Total (N=134)   |
|-----------------------------------------|-------------------|-------------------|-----------------|
| Subjects with at least one event, n (%) | 83(89.2)          | 35 (85.4)         | 118 (88.1)      |
| Diarrhoea                               | 16 (17.2)         | 5 (12.2)          | 21 (15.7)       |
| Thrombocytopenia                        | 13 (14.0)         | 7 (17.1)          | 20 (14.9)       |
| Pyrexia                                 | 13 (14.0)         | 4 (9.8)           | 17 (12.7)       |
| Weight decreased                        | 9 (9.7)           | 7 (17.1)          | 16 (11.9)       |
| Anaemia                                 | 10 (10.8)         | 4 (9.8)           | 14 (10.4)       |
| Asthenia                                | 12 (12.9)         | 0                 | 12 (9.0)        |
| Blood creatinine increased              | 7 (7.5)           | 4 (9.8)           | 11 (8.2)        |
| Cough                                   | 8(8.6)            | 2 (4.9)           | 10 (7.5)        |
| Fatigue                                 | 6 (6.5)           | 3(7.3)            | 9(6.7)          |
| COVID-19                                | 8 (8.6)           | 0                 | 8 (6.0)         |
| Hypertension                            | 3 (3.2)           | 5 (12.2)          | 8(6.0)          |
| Nausea                                  | 8 (8.6)           | 0                 | 8 (6.0)         |
| Dyspnoea                                | 7 (7.5)           | 0                 | 7 (5.2)         |
| Neutropenia                             | 5(5.4)            | 2 (4.9)           | 7 (5.2)         |
| Pruritus                                | 6 (6.5)           | 1 (2.4)           | 7 (5.2)         |
| Acute kidney injury                     | 3 (3.2)           | 3 (7.3)           | 6 (4.5)         |
| Hyperuricaemia                          | 3 (3.2)           | 3 (7.3)           | 6 (4.5)         |
| Urinary tract infection                 | 5 (5.4)           | 1 (2.4)           | 6 (4.5)         |
| Dizziness                               | 1 (1.1)           | 4 (9.8)           | 5 (3.7)         |
| Hyperkalaemia                           | 2 (2.2)           | 3 (7.3)           | 5 (3.7)         |
| Arthralgia                              | 1 (1.1)           | 3 (7.3)           | 4 (3.0)         |
| Epistaxis                               | 1 (1.1)           | 3 (7.3)           | 4 (3.0)         |

Source:Table14.3.1.2c

## XAP

The most commonly reported adverse events during the long-term extension study XAP are summarized by parent Phase 3 study and preferred term in below. The overall TEAE rate was lower in the MOMENTUM study (44.7%) than in SIMPLIFY-1 and SIMPLIFY-2 (82.3% and 90.9%, respectively), likely due to the shorter duration of follow up.

Commonly reported adverse events are defined as those reported in ≥ 5% of subjects in any group. Shading indicates events that met the ≥ 5% threshold. Anemia and COVID-19 were observed in ≥ 5% of subject across studies. There were no notable differences in the types of common AEs between groups during the XAP.

<div style=\"page-break-after: always\"></div>

Table 99: Commonly Reported Adverse Events in ≥ 5% of Subjects in Any Group by Preferred Term During XAP Treatment (Safety Population)

| Preferred Term                              |   SIMPLIFY-1 (N=96) n (%) | SIMPLIFY-1 (N=96) n (%)   |   SIMPLIFY-2 (N=22) n (%) | SIMPLIFY-2 (N=22) n (%)   |   MOMENTUM (N=85) n (%) | MOMENTUM (N=85) n (%)   |   Overall (N=203) n (%) | Overall (N=203) n (%)   |
|---------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Any Treatment-Emergent Adverse Event (TEAE) |                        79 | (82.3)                    |                        20 | (90.9)                    |                      38 | (44.7)                  |                     137 | (67.5)                  |
| Anaemia                                     |                        22 | (22.9)                    |                         4 | (18.2)                    |                       6 | (7.1)                   |                      32 | (15.8)                  |
| COVID-19                                    |                        10 | (10.4)                    |                         2 | (9.1)                     |                       7 | (8.2)                   |                      19 | (9.4)                   |
| Thrombocytopenia                            |                         8 | (8.3)                     |                         1 | (4.5)                     |                       4 | (4.7)                   |                      13 | (6.4)                   |
| Diarrhoea                                   |                         4 | (4.2)                     |                         4 | (18.2)                    |                       2 | (2.4)                   |                      10 | (4.9)                   |
| Platelet count decreased                    |                         5 | (5.2)                     |                         2 | (9.1)                     |                       3 | (3.5)                   |                      10 | (4.9)                   |
| Pneumonia                                   |                         6 | (6.3)                     |                         3 | (3.6)                     |                       1 | (1.2)                   |                      10 | (4.9)                   |
| Urinary tract infection                     |                         7 | (7.3)                     |                         3 | (13.6)                    |                       0 |                         |                      10 | (4.9)                   |
| Asthenia                                    |                         2 | (2.1)                     |                         3 | (13.6)                    |                       4 | (4.7)                   |                       9 | (4.4)                   |
| Abdominal pain                              |                         4 | (4.2)                     |                         2 | (9.1)                     |                       2 | (2.4)                   |                       8 | (3.9)                   |
| Acute kidney injury                         |                         6 | (6.3)                     |                         2 | (9.1)                     |                       0 |                         |                       8 | (3.9)                   |
| Cough                                       |                         6 | (6.3)                     |                         2 | (9.1)                     |                       0 |                         |                       8 | (3.9)                   |
| Arthralgia                                  |                         3 | (3.1)                     |                         3 | (13.6)                    |                       1 | (1.2)                   |                       7 | (3.4)                   |
| COVID-19 pneumonia                          |                         3 | (3.1)                     |                         2 | (9.1)                     |                       2 | (2.4)                   |                       7 | (3.4)                   |
| Disease progression                         |                         3 | (3.1)                     |                         1 | (4.5)                     |                       3 | (3.5)                   |                       7 | (3.4)                   |
| Dizziness                                   |                         3 | (3.1)                     |                         2 | (9.1)                     |                       2 | (2.4)                   |                       7 | (3.4)                   |
| Nausea                                      |                         4 | (4.2)                     |                         2 | (9.1)                     |                       1 | (1.2)                   |                       7 | (3.4)                   |
| Pruritus                                    |                         3 | (3.1)                     |                         4 | (18.2)                    |                       0 |                         |                       7 | (3.4)                   |
| Pyrexia                                     |                         5 | (5.2)                     |                         2 | (9.1)                     |                       0 |                         |                       7 | (3.4)                   |
| Upper respiratory tract infection           |                         6 | (6.3)                     |                         1 | (4.5)                     |                       0 |                         |                       7 | (3.4)                   |
| Back pain                                   |                         5 | (5.2)                     |                         0 |                           |                       1 | (1.2)                   |                       6 | (3.0)                   |
| Fatigue                                     |                         4 | (4.2)                     |                         2 | (9.1)                     |                       0 |                         |                       6 | (3.0)                   |
| Peripheral sensory neuropathy               |                         4 | (4.2)                     |                         2 | (9.1)                     |                       0 |                         |                       6 | (3.0)                   |
| Squamous cell carcinoma of skin             |                         5 | (5.2)                     |                         1 | (4.5)                     |                       0 |                         |                       6 | (3.0)                   |
| Abdominal pain upper                        |                         1 | (1.0)                     |                         4 | (18.2)                    |                       0 |                         |                       5 | (2.5)                   |
| Bronchitis                                  |                         3 | (3.1)                     |                         2 | (9.1)                     |                       0 |                         |                       5 | (2.5)                   |
| Decreased appetite                          |                         0 |                           |                         2 | (9.1)                     |                       3 | (3.5)                   |                       5 | (2.5)                   |
| Insomnia                                    |                         3 | (3.1)                     |                         2 | (9.1)                     |                       0 |                         |                       5 | (2.5)                   |
| Pain in extremity                           |                         1 | (1.0)                     |                         3 | (13.6)                    |                       1 | (1.2)                   |                       5 | (2.5)                   |
| Paraesthesia                                |                         2 | (2.1)                     |                         2 | (9.1)                     |                       1 | (1.2)                   |                       5 | (2.5)                   |
| Vomiting                                    |                         2 | (2.1)                     |                         3 | (13.6)                    |                       0 |                         |                       5 | (2.5)                   |
| Constipation                                |                         0 |                           |                         3 | (13.6)                    |                       1 | (1.2)                   |                       4 | (2.0)                   |
| Fall                                        |                         0 |                           |                         3 | (13.6)                    |                       1 | (1.2)                   |                       4 | (2.0)                   |
| Gout                                        |                         2 | (2.1)                     |                         2 | (9.1)                     |                       0 |                         |                       4 | (2.0)                   |
| Oedema peripheral                           |                         2 | (2.1)                     |                         2 | (9.1)                     |                       0 |                         |                       4 | (2.0)                   |
| Oropharyngeal pain                          |                         1 | (1.0)                     |                         2 | (9.1)                     |                       1 | (1.2)                   |                       4 | (2.0)                   |
| Sinusitis                                   |                         0 |                           |                         3 | (13.6)                    |                       0 |                         |                       3 | (1.5)                   |
| Skin laceration                             |                         0 |                           |                         3 | (13.6)                    |                       0 |                         |                       3 | (1.5)                   |
| Subdural haematoma                          |                         0 |                           |                         2 | (9.1)                     |                       1 | (1.2)                   |                       3 | (1.5)                   |
| Oral herpes                                 |                         0 |                           |                         2 | (9.1)                     |                       0 |                         |                       2 | (1.0)                   |
| Rhinitis                                    |                         0 |                           |                         2 | (9.1)                     |                       0 |                         |                       2 | (1.0)                   |
| Stomatitis                                  |                         0 |                           |                         2 | (9.1)                     |                       0 |                         |                       2 | (1.0)                   |

Source: Table 14.3.2.11

## First Dose Effects

During the MOMENTUM OLE, AEs occurring within 24 hours after the first dose of study drug were reported for 21.6% of subjects overall. As the MMB to MMB group continued treatment with momelotinib into the OLE, only AEs occurring in the DAN to MMB will be considered here. In the DAN to MMB group, there were 10/41 subjects (24.4%) who experienced at least one AE in the first 24 hours

<div style=\"page-break-after: always\"></div>

after the first dose of momelotinib in the OLE period. Diarrhea, dizziness, and hypocalcemia were reported in 2/41 subjects (4.9%) each; all other PTs were reported in single subjects.

During the MOMENTUM OLE, AEs considered related to study drug and occurring within the 24 hours after the first dose of open label MMB were reported for 3.7% of subjects overall. In the DAN to MMB group, there were 3/41 subjects (7.3%) who experienced at least one AE in the first 24 hours after the first dose of open-label MMB; 2 subjects experienced diarrhea and 1 subject each experienced vomiting, dizziness, headache, and hypertension.

## Treatment-related adverse events

## MOMENTUM OLE

Overall, 38.8% of subjects in OLE experienced at least 1 related TEAE. The most commonly reported treatment related AEs during MOMENTUM OLE were thrombocytopenia in 11.2% (MMB to MMB 10/93 [10.8%]; DAN to MMB 5/41 [12.2%]) and diarrhea in 6.7% (MMB to MMB 6/93 [6.5%]; DAN to MMB 3/41 [7.3%]).

During the MOMENTUM OLE treatment period, the incidence of subjects with at least one TEAE assessed as related to study drug was 77.84 per 100 person-years overall; in the treatment groups, the incidence was 74.47 per 100 person-years in MMB to MMB and 85.86 per 100 person-years in DAN to MMB.

## XAP

Overall, 50 subjects (24.6%) experienced a treatment-related AE during XAP (SIMPLIFY-1 33/96 [34.4%]; SIMPLIFY2 7/22 [31.8%]; MOMENTUM 10/85 [11.8%]). No PT was experienced by ≥ 5% of subjects overall. The only PTs experienced by ≥ 5% of subjects by study were anemia (SIMPLIFY -1 6/96 [6.3%]; SIMPLIFY-2 1/22 [4.5%]; MOMENTUM 1/85 [1.2%]), paresthesia (SIMPLIFY-1 1/96 [1.0%]; SIMPLIFY-2 2/22 [9.1%]; MOMENTUM 1/85 [1.2%]), and stomatitis (SIMPLIFY-1 0; SIMPLIFY-2 2/22 [9.1%]; MOMENTUM 0).

## Grade ≥ 3 adverse events

## MOMENTUM OLE

During the MOMENTUM OLE, 68 subjects overall (50.7%) experienced at least one Grade ≥  3 AE; these occurred with similar frequency between treatment groups (MMB to MMB 48/93 [51.6%]; DAN to MMB 20/41 [48.8%]). Grade ≥ 3 AEs by PT occurring in ≥  5% subjects overall included thrombocytopenia in 10.4% (MMB to MMB 8/93 [8.6%]; DAN to MMB 6/41 [14.6%]) and anemia in 6.7% (MMB to MMB 8/93 [8.6%]; DAN to MMB 1/41 [2.4%]). Grade ≥ 3 AEs that occurred in ≥ 5% subjects in either treatment group included Grade  ≥ 3 acute kidney injury(MMB to MMB 2/93 [2.2%]; DAN to MMB 3/41 [7.3%]) and neutropenia (MMB to MMB 5/93 [5.4%]; DAN to MMB 0).

The exposureadjusted incidence of Grade ≥  AEs during the MOMENTUM OLE was 101.80 per 100 person-years overall: 102.13 per 100 personyears in the MMB ≥ MMB group and 101.01 per 100 person-years in the DAN  MMB group.

During the MOMENTUM OLE, Grade ≥ 3 adverse events assessed as related to study treatment were reported in 16/93 subjects (17.2%) in the MMB to MMB treatment group and in 10/41 subjects (24.4%) in the DAN  MMB treatment group.

The most frequently reported PTs with Grade ≥ 3 related AEs were thrombocytopenia (MMB to MMB 6/93 [6.5%]; DAN to MMB 5/41 [12.2%]), neutropenia (MMB to MMB 3/93 [3.2%]; DAN to MMB 0/41), platelet count decreased (MMB to MMB 3/93 [3.2%];DAN to MMB 0/41), and anemia (MMB  MMB 3/93 [3.2%]; DAN to MMB 1/41 [2.4]).

<div style=\"page-break-after: always\"></div>

The exposureadjusted incidence of Grade ≥ 3 AEs assessed as related to study treatment during the MOMENTUM OLE was 26 per 100 personyears overall: 16 per 100 person years in the MMB ≥ MMB group and 10 per 100 person-years in the DAN to MMB group.

## XAP

During the XAP, 39.9% of subjects overall experienced a Grade ≥ 3 AE; 47 subjects (49.0%) from SIMPLIFY-1, 13 subjects (59.1%) from SIMPLIFY-2, and 21 subjects (24.7%) from MOMENTUM. The only PT occurring in ≥  5% subjects overall was anemia in 7.9% of subjects (SIMPLIFY -1, 8/96 [8.3%]; SIMPLIFY-2, 3/22 [13.6%]; and MOMENTUM, 5/85 [5.9%]).

Overall, 8.9% of subjects in XAP experienced a Grade ≥3 AE assessed as related by the investigator. Thrombocytopenia was the only PT occurring in more than 1 subject per study group, occurring in 6 subjects (3.0%) overall (SIMPLIFY-1, 3/96 [3.1%]; SIMPLIFY-2, 1/22 [4.5%]; and MOMENTUM, 2/85 [2.4%]).

## Serious adverse events

## MOMENTUM OLE

During treatment in the OLE period, 31.3% of subjects overall experienced at least 1 SAE (MMB to MMB 30/93 [32.3%]; DAN to MMB 12/41 [29.3%]). The SAEs by PT experienced by ≥2 subjects overall were: COVID-19 pneumonia 4/134 subjects (MMB to MMB 4/93 [4.3%]; DAN to MMB 0); acute kidney injury 4/134 subjects (MMB to MMB 2/93 [2.2%]; DAN to MMB 2/41 [4.9%]); urinary tract infection 3/134 subjects (MMB to MMB 2/93 [2.2%]; DAN to MMB 1/41 [2.4%]); febrile neutropenia and squamous cell carcinoma of the skin 2/134 subjects each (MMB to MMB 2/93 [2.2%]; DAN to MMB 0); and anemia, pneumonia, basal cell carcinoma, and pulmonary edema in 2/134 subjects each (MMB to MMB 1/93 [1.1%]; DAN to MMB 1/41 [2.4%]).Four subjects experienced SAEs assessed as related to study treatment. In the MMB to MMB group, related SAEs of edema peripheral, gastroenteritis rotavirus, and pneumonia staphylococcal were experienced in 1 subject each. In the DAN to MMB group, 1 subject experienced a related SAE of anemia.

Over the MOMENTUM OLE treatment period, the exposure-adjusted incidence of SAEs was 62.87 per 100 person-years overall: 63.83 per 100 person-years in the MMB to MMB group and 60.61 per 100 person-years in the DAN to MMB group. The exposureadjusted incidence of SAEs assessed as Grade ≥ 3 was 55.39 per 100 person-years overall: 55.32 per 100 person-years in the MMB to MMB group and 55.56 per 100 person-years in the DAN to MMB group. The exposure-adjusted incidence of SAEs considered to be related to study drug was 5.99 per 100 person-years: 6.38 per 100 person-years in the MMB to MMB group and 5.05 per 100 person-years in the DAN to MMB group.

## XAP

During treatment in XAP, 63 subjects (31.0%) overall experienced an SAE. SAEs occurring in 2 or more subjects overall are presented in Table below.

<div style=\"page-break-after: always\"></div>

Table 100: Serious Adverse Events occurring in ≥ 2 subjects overall in the XAP

| Preferred Term Any Serious Treatment-Emergent Adverse   | SIMPLIFY-1 (96=N) n (%).   | SIMPLIFY-1 (96=N) n (%).   | SIMPLIFY-2 (N=22) n (%).   | SIMPLIFY-2 (N=22) n (%).   | MOMENTUM (N=85) n (%)   | MOMENTUM (N=85) n (%)   | Overall (N=203) n (%)   | Overall (N=203) n (%)   |
|---------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Preferred Term Any Serious Treatment-Emergent Adverse   | 35                         | (36.5)                     | 11                         | (50.0)                     | 17                      | (20.0)                  | 63                      | (31.0)                  |
| Event (TEAE)                                            |                            |                            |                            |                            |                         |                         |                         |                         |
| Pneumonia                                               | 5                          | (5.2)                      | 2                          | (9.1)                      | 1                       | (1.2)                   | 8                       | (3.9)                   |
| CovID-19 pneumonia                                      | 2                          | (2.1)                      | 2                          | (9.1)                      | 2                       | (2.4)                   | 6                       | (3.0)                   |
| Acute kidney injury                                     | 3                          | (3.1)                      | 2                          | (9.1)                      | 0                       |                         | 5                       | (2.5)                   |
| Anaemia                                                 | 1                          | (1.0)                      | 1                          | (4.5)                      | 2                       | (2.4)                   | 4                       | (2.0)                   |
| Cellulitis                                              | 1                          | (1.0)                      | 1                          | (4.5)                      | 2                       | (2.4)                   | 4                       | (2.0)                   |
| Septic shock                                            | 2                          | (2.1)                      | 1                          | (4.5)                      | 0                       |                         | 3                       | (1.5)                   |
| Subdural haematoma                                      | 0                          |                            | 2                          | (9.1)                      | 1                       | (1.2)                   | 3                       | (1.5)                   |
| Abdominal pain                                          | 1                          | (1.0)                      | 0                          |                            | 1                       | (1.2)                   | 2                       | (1.0)                   |
| Ascites                                                 | 2                          | (2.1)                      | 0                          |                            | 0                       |                         | 2                       | (1.0)                   |
| Atrial fibrillation                                     | 2                          | (2.1)                      | 0                          |                            | 0                       |                         | 2                       | (1.0)                   |
| COVID-19                                                | 0                          |                            | 0                          |                            | 2                       | (2.4)                   | 2                       | (1.0)                   |
| Cardiac failure congestive                              | 0                          |                            | 0                          |                            | 2                       | (2.4)                   | 2                       | (1.0)                   |
| Death                                                   | 2                          | (2.1)                      | 0                          |                            | 0                       |                         | 2                       | (1.0)                   |
| Dyspnoea                                                | 1                          | (1.0)                      | 0                          |                            | 1                       | (1.2)                   | 2                       | (1.0)                   |
| Pneumonia bacterial                                     | 1                          | (1.0)                      | 0                          |                            | 1                       | (1.2)                   | 2                       | (1.0)                   |
| Pyrexia                                                 | 1                          | (1.0)                      | 1                          | (4.5)                      | 0                       |                         | 2                       | (1.0)                   |
| Sepsis                                                  | 2                          | (2.1)                      | 0                          |                            | 0                       |                         | 2                       | (1.0)                   |
| Squamous cell carcinoma of skin                         | 2                          | (2.1)                      | 0                          |                            | 0                       |                         | 2                       | (1.0)                   |
| Urinary tract infection                                 | 1                          | (1.0)                      | 1                          | (4.5)                      | 0                       |                         | 2                       | (1.0)                   |

Four subjects experienced SAEs that were assessed as related to study treatment. All of the SAEs assessed as related to study treatment were reported in subjects from SIMPLIFY-1. PTs include squamous cell carcinoma of the skin in 2 subjects; and dehydration, hyperkalemia, infection, and skin lesion in 1 subject each.

## Deaths

## MOMENTUM OLE

During treatment in the MOMENTUM OLE treatment period, there were 15 fatal AEs overall (MMB to MMB 10/93 [10.8%]; DAN to MMB 5/41 [12.2%]).

No PT occurred in more than 1 subject. In the MMB to MMB group, fatal AEs occurred in the PTs of anemia, arrhythmia, cerebral hemorrhage, Escherichia infection, gastroenteritis rotavirus, general physical health deterioration, multiple organ dysfunction syndrome, pneumonia staphylococcal, splenic abscess, and urosepsis; gastroenteritis rotavirus and pneumonia staphylococcal were assessed by the investigator to be related to study treatment. In the DAN to MMB group, fatal AEs occurred in the PTs of adenocarcinoma, cardiac arrest, Enterobacter sepsis, sudden death, and transformation to AML; no event was considered to be related to study treatment.

During the MOMENTUM OLE treatment period, fatal AEs occurred at an exposure-adjusted incidence rate of 22.46 events per 100 person-years. Fatal AEs considered to be related to study drug occurred at an exposure-adjusted incidence rate of 2.99 events per 100 person-years.

## XAP

During treatment in the XAP, there were 25 deaths, including 21 on-study deaths (SIMPLIFY-1, 14/96 [14.6%]; SIMPLIFY-2, 4/22 [18.2%]; and MOMENTUM, 3/85 [3.5%]). Adverse event was listed as the most frequent cause of death for each study group (21 subjects [10.3%] overall; 13 subjects [13.5%]

<div style=\"page-break-after: always\"></div>

in SIMPLIFY-1; 5 subjects [22.7%] in SIMPLIFY-2; and 3 subjects [3.5%] in MOMENTUM). Two subject deaths in SIMPLIFY-1 were due to progressive disease, 1 subject in SIMPLIFY-1 had an unexpected sudden death, and 1 subject in SIMPLIFY-2 had a death due to worsening of a medical condition. The only death considered by the investigator to be related to study treatment was in MOMENTUM due to infection.

## Adverse events leading to study treatment discontinuation

## MOMENTUM OLE

During the OLE treatment period, 16.4% of subjects overall experienced an AE leading to discontinuation. In the MMB to MMB group, 17 subjects (18.3%) reported AEs leading to discontinuation. The only PT occurring in &gt;1 subject was anemia (2 subjects [2.2%]). In the DAN to MMB group, 5 subjects (12.2%) experienced an AE leading to treatment discontinuation; no PT was reported in more than 1 subject.

Over the MOMENTUM OLE treatment period, the incidence of subjects with at least 1 exposureadjusted TEAE leading to study drug discontinuation was 32.93 per 100 person-years overall; in the treatment groups, the incidence was 36.17 per 100 person-years in MMB to MMB and 25.25 per 100 person-years in DAN to MMB.

## XAP

During the XAP, 13.3 % of subjects overall experienced a TEAE leading to study drug discontinuation; (SIMPLIFY-1, 16 subjects [16.7%]; SIMPLIFY-2, 5 subjects [22.7%]; MOMENTUM, 6 subjects [7.1%]). Of these, 9 (4.4%) were due to Grade 3 or 4 events. The most common PT leading to study drug discontinuation was disease progression (SIMPLIFY-1, 3 subjects [3.1%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 3 subjects [3.5%]).

## Adverse events leading to study drug modification

## MOMENTUM OLE

During the OLE treatment period, 30.6% of subjects overall experienced an AE leading to  dose modification (MMB to MMB 26 subjects [28.0%]; DAN to MMB 15 subjects [36.6%]). PTs occurring in 2 or more subjects per treatment group included: thrombocytopenia (6 subjects each), neutropenia and platelet count decreased (MMB to MMB 2 subjects; DAN to MMB 0 subjects each), chronic kidney disease (MMB to MMB 2 subjects; DAN to MMB 1 subject), and diarrhea (MMB to MMB 1 subject; DAN to MMB 2 subjects).

During the MOMENTUM OLE treatment period, the incidence of subjects with at least 1 exposureadjusted TEAE leading to dose modification was 61.38 per 100 person-years overall; in the treatment groups, the incidence was 55.32 per 100 person-years in MMB to MMB and 75.76 per 100 person-years in DAN to MMB.

## XAP

During the XAP, 19.7 % of subjects overall experienced a TEAE leading to study drug interruption and/or dose modification; (SIMPLIFY-1, 25 subjects [26.0%]; SIMPLIFY-2, 7 subjects [31.8%]; MOMENTUM, 8 subjects [9.4%]). Of these, 28 subjects (13.8%) experienced Grade 3 or 4 events. The most common PTs leading to study drug interruption and/or dose modification were thrombocytopenia (SIMPLIFY-1, 3 subjects [3.1%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 2 subjects [2.4%]); COVID-19 (SIMPLIFY-1, 1 subject [1.0%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 2 subjects [2.4%]); and platelet count decreased (SIMPLIFY-1, 2 subjects [2.1%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 1 subject [1.2%]).

<div style=\"page-break-after: always\"></div>

## XAP

During the XAP, 13.3 % of subjects overall experienced a TEAE leading to study drug discontinuation; (SIMPLIFY-1, 16 subjects [16.7%]; SIMPLIFY-2, 5 subjects [22.7%]; MOMENTUM, 6 subjects [7.1%]). Of these, 9 (4.4%) were due to Grade 3 or 4 events. The most common PT leading to study drug discontinuation was disease progression (SIMPLIFY-1, 3 subjects [3.1%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 3 subjects [3.5%]).

## Adverse events leading to study drug modification

## MOMENTUM OLE

During the OLE treatment period, 30.6% of subjects overall experienced an AE leading to dose modification (MMB to MMB 26 subjects [28.0%]; DAN to MMB 15 subjects [36.6%]). PTs occurring in 2 or more subjects per treatment group included: thrombocytopenia (6 subjects each), neutropenia and platelet count decreased (MMB to MMB 2 subjects; DAN to MMB 0 subjects each), chronic kidney disease (MMB to MMB 2 subjects; DAN to MMB 1 subject), and diarrhea (MMB to MMB 1 subject; DAN  MMB 2 subjects).

During the MOMENTUM OLE treatment period, the incidence of subjects with at least 1 exposureadjusted TEAE leading to dose modification was 61.38 per 100 person-years overall; in the treatment groups, the incidence was 55.32 per 100 person-years in MMB to MMB and 75.76 per 100 person-years in DAN to MMB.

## XAP

During the XAP, 19.7 % of subjects overall experienced a TEAE leading to study drug interruption and/or dose modification; (SIMPLIFY-1, 25 subjects [26.0%]; SIMPLIFY-2, 7 subjects [31.8%]; MOMENTUM, 8 subjects [9.4%]). Of these, 28 subjects (13.8%) experienced Grade 3 or 4 events. The most common PTs leading to study drug interruption and/or dose modification were thrombocytopenia (SIMPLIFY-1, 3 subjects [3.1%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 2 subjects [2.4%]); COVID-19 (SIMPLIFY-1, 1 subject [1.0%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 2 subjects [2.4%]); and platelet count decreased (SIMPLIFY-1, 2 subjects [2.1%]; SIMPLIFY-2, 1 subject [4.5%]; MOMENTUM, 1 subject [1.2%]).

## COVID-19 Adverse Events MOMENTUM OLE

During the MOMENTUM OLE, 12 subjects (MMB to MMB 11 subjects; DAN to MMB 1 subject) were diagnosed with COVID-19 infection. Of those, 8/12 subjects (66.7%) experienced an SAE. All subjects with COVID19 with reported SAEs were in the MMB to MMB treatment group. All events were Grade ≥ 3. COVID-19 pneumonia was reported in 4/12 subjects (33.3%); all other events were reported in single subjects (abscess limb, coronary artery stenosis, depression, dyspnoea, febrile neutropenia, gastroenteritis rotavirus, haemorrhagic erosive gastritis, infective exacerbation of chronic obstructive airways disease, periprosthetic fracture, pneumonia bacterial, pulmonary embolism, pulmonary oedema, restrictive pulmonary disease, splenic infarction, and upper gastrointestinal haemorrhage).

## XAP

During treatment in the XAP, 19 subjects (9.4%) were diagnosed with COVID-19 (10 subjects [10.4%] in SIMPLIFY-1; 2 subjects [9.1%] in SIMPLIFY-2, and 7 subjects [8.2%] in MOMENTUM) and 7 subjects (3.4%) were diagnosed with COVID-19 pneumonia (3 subjects [3.1%] in SIMPLIFY-1; 2 subjects in SIMPLIFY-2; and 2 subjects [2.4%] in MOMENTUM). No COVID-19 events were considered to be related to study treatment. Two subjects experienced COVID-19 events in MOMENTUM and 6 subjects experienced COVID-19 pneumonia events (2 subjects in each study) that were considered to be SAEs.

<div style=\"page-break-after: always\"></div>

## 2.6.8.10. Post marketing experience

Not applicable.

## 2.6.9. Discussion on clinical safety

The clinical safety data of MMB in patients with PMF or post polycythaemia vera and post essential thrombocythemia MF is derived for 4 clinical studies (the phase 3 program including 3 RCTs: MOMENTUM, SIMPLIFY-1 and SIMPLIFY-2, and a long term safety study XAP which rolled-over patients from Ph 3 program). The cut-off for MOMENTUM and XAP is 03 Dec 2021.

The safety database includes 725 adults with a total follow-up of 1260.93 person-years. The randomized 24 week MMB treatment period includes 448 subjects. Open label data include 604 subjects who crossed over to MMB after RUX, BAT or DAN treatment in the context of the respective Phase 3 studies or those who received MMB in the long term extension safety study XAP.

In the integrated safety analysis, the median duration of exposure to MMB in the open-label period and overall is approximately double (11.3 months and 11.0 months) than the duration of exposure to RUX and DAN (5.5 months each).

In all Phase 3 studies all patients received at least 1 dose of study drug. In the MMB arms, the majority of patients completed the RT period i.e. 72.3 %, 81.8 % and 66.3 % in MOMENTUM, SIMPLIFY-1 and SIMPLIFY-2 respectively. The main reason for discontinuation of MMB in the RT period across all three studies are adverse events. The rate of adverse events leading to discontinuation is higher in the MMB RT than in control arm in SIMPLIFY-1 (8.9% in MMB vs 4.2% RUX) and SIMPLIFY-2 (12.5% in MMB vs 0% in BAT). In MOMENTUM study, the discontinuation due to AEs in the RT period is lower in MMB than in DAN while in the open-label period there is an inverse trend. In the open-label period the main reason for discontinuation is 'study terminated by sponsor' in SIMPLIFY-1 and SIMPLIFY-2.

Overall approximately a third (28.6%) of patients who received MMB (during RT and in the open-label period/roll-over in the XAP) discontinued the treatment due to adverse events.

The majority of patients in the phase 3 studies had at least one AE.

During RT, the incidence of all SAEs were higher in MMB than in the control arm in SIMPLIFY-1 (22.9% MMB vs 18.1% RUX) and in SIMPLIFY-2 (35.6% in MMB vs 23.18% BAT). In MOMENTUM the SAEs incidence was lower in MMB than in DAN (34.6% vs 40.0%).

However, the incidence for related SAEs was higher in MMB arms than in the control (8.5% vs 7.7% in MOMENTUM, 7.0% vs 6.0% in SIMPLIFY-1 and 11.5% vs 3.8% in SIMPLIFY-2, the latter not being subject to the current application).

In MOMENTUM study (open-label phase), the rate of fatal adverse events is higher in the patient population who switched from DAN to MMB (7.5%) than for patients who continued MMB (5.4%). In SIMPLIFY-1 study, the rate of TEAEs, G3 or 4 AEs, SAEs are higher in patients who switched from RUX to MMB than in patients who continued MMB in the open label phase. Similarly, in study SIMPLIFY-2, the rate of AEs are higher in patients who switched from BAT to MMB than those who continued treatment with MMB. Overall in the three studies, 7 patients had fatal AEs considered related to MMB by the investigator (including RT and open label period).

Diarrhoea, nausea, cough and dizziness incidence was higher in MMB RT group than in RUX or DAN.

<div style=\"page-break-after: always\"></div>

Of note, the incidence of anaemia was lower during the RT period in patients receiving MMB (13.8%) than those receiving RUX (34.4%) or DAN (15.4%). All grade thrombocytopenia incidence was lower in MMB group (19.4%) than in RUX (26.3%) but higher than in DAN (10.8%).

During the RT period the most frequent AEs reported as related to treatment were thrombocytopenia, diarrhoea and nausea for MMB, anaemia and thrombocytopenia for RUX and ALT increased for DAN.

Peripheral sensory neuropathy, dizziness and paresthesia considered related to treatment were also more frequent during MMB RT period than in RUX and DAN.

The most frequent Grade 3 adverse events in the RT period were thrombocytopenia and anaemia for MMB and RUX, and for DAN anaemia, pneumonia and acute kidney injury.

The incidence of Grade 3 thrombocytopenia in the MMB RT period was approximately two times higher than in RUX while anaemia incidence was approximately half in MMB than in RUX in the RT period.

Although thrombocytopenia (all grades) marginally less frequent in MMB RT period than in RUX, the severity of thrombocytopenia appears to be higher in MMB than in RUX.

Death rate due to AEs was low during the MMB RT treatment, however it was higher in the MMB RT period (6.5%) than in RUX (3.4%) and lower than in DAN (16.6%), the latter probably associated with more advanced comorbidities and disease.

Deaths due to infection and infestations were higher in the MMB RT period (2.2%) than in both RUX (1.1%) and DAN (0%). There were 6 deaths associated with COVID-19 infection

Seven cases of sudden, unexplained or unspecified death occurred in the clinical trials with MMB. For some of the cases, risk factors associated with cardiovascular events were described in the clinical history; the age of these patients was overall low, however all had 65 years of age or more, male and female. Two cases had no known risk factors associated with cardiovascular events. Some cases are insufficiently documented to unequivocally assess causality.

The most frequent SAEs during the MMB RT were in the SOC Infections and infestations'. Pneumonia was the most frequent PT infection in the MMB RT period and was higher than in RUX but lower than the rate observed in DAN.

SAEs in SOC 'Cardiac disorders' were higher during the RT period in MMB than in RUX or DAN; the most frequent PT in cardiac disorders is atrial fibrillation. Considering risk factors associated with myelofibrosis population and the class effect of JAK inhibitors, MACE are a topic of concern for momelotinib and will need to be closely monitored in post-marketing provided favourable outcome of the marketing authorisation from the CHMP. MACE has been added as requested in the RMP as important potential risk. The majority of patients with MACE had over 60 years of age and had associated cardiovascular conditions (including but not limited to hypertension, ischemia) however for several patients there was no known pre-existent risk factors or cardiovascular known condition associated with MACE. The causality of the event was considered possibly related to trial medication by the investigator in few patients.

Of note, more frequent severe haemorrhages of gastrointestinal origin (including one fatal event in SIMPLIFY-1 study) were reported in the MMB arm during RT period (n=5) than in either RUX or DAN (no cases). It cannot be excluded that patients with haemorrhages may have had low thrombocyte levels. The frequency of thrombocyte count monitoring during the clinical trials, the threshold selected for stopping the treatment, or the low adherence to the stopping rules could explain the incidence of serious haemorrhagic events during the MMB RT.

Broad 'gastrointestinal haemorrhages' SMQ term AE analysis has been performed by the applicant in response to question. In overall incidence of GI haemorrhages are higher in the MMB arm than in the

<div style=\"page-break-after: always\"></div>

control arm in all of the 3 studies. Although there is a numerical difference in term of AEs between MMB and control arms, the overall incidence is low and multiple factors may have contributed to the haemorrhages and among these severe thrombocytopenia is a key factor. Thrombocytopenia, anaemia and haemorrhage were the most frequent (&gt;10%) AEs of clinical significance during the MMB treatment period

Despite the fact that anaemia is a common toxicity of JAK inhibitors, including momelotinib, the latter could also improve anaemia by inhibiting hepcidin production which promote erythropoiesis and by decreasing inflammation via inhibition of inflammatory cytokines signaling which improve anaemia.

The incidence of peripheral neuropathy was higher in MMB during the RT than in RUX and DAN. During RT period, the incidence of adverse events of clinical significance were generally similar between MMB and DAN with the exception of thrombocytopenia (higher incidence in RUX than in MMB). The incidence of thromboembolism was higher in MMB RT than in RUX.

With regard to time to onset, generally the adverse events of clinical importance occurred more frequently during the first 24 weeks of treatment and the incidence decreased after. When adjusted per exposure, the rate of AEs of clinical importance were lower during the open label treatment than in the randomized treatment period.

Peripheral neuropathy incidence is higher in MMB than in RUX and DAN during the RT. The most frequently reported preferred term is peripheral sensory neuropathy however a small percentage is specifically reported as peripheral motor or sensorimotor neuropathy.

Overall, the majority of the events are grade 1 and 2 in severity, however there were 9 cases of grade 3 peripheral neuropathy and discontinuations did occur in 18 patients overall. There were no fatal cases, however two cases were considered serious.

Adverse events occurring in the MMB RT appear to resolve in approximately half of the patients. The average duration of the events is around 100 days (1-471 days).

The incidence of peripheral neuropathy is higher in open-label period though the exposure-adjusted event rate in 100 person years is higher in the RT period than in open label period. During the clinical development of with MMB, peripheral neuropathy has been reported in clinical studies in up to 58.3% eg in study CCL09101E.

Peripheral neuropathy was included the list of adverse events of clinical importance in the MMB due to an early signal in early clinical development (as of phase I/II dose escalation trial).

Neurologic adverse events have been reported with JAK inhibitors, including acute neurological adverse events (Wernicke's encephalopathy), however peripheral neuropathy is not considered as an ADR for other JAK inhibitors in the respective SmPCs (e.g. tofacitinib, ruxolitinib). Anecdotal case reports of peripheral neuropathy to other JAK inhibitors are described in the literature.

The mechanistic rationale is not elucidated. In contrast to other JAK inhibitors, MMB has an inhibitory activity against ACVR1. ACVR1 is a member of the type I bone morphogenetic protein (BMP) receptors and is involved in a wide variety of biological processes, including nervous system development and regulation.

Overall, the total incidence of peripheral neuropathy reported in the clinical trials as PT/narrow SMQ grouping might be underestimated.

Safety data on peripheral neuropathy according to a broad SMQ definition shown that the preferred term for AES according to the broad SMQ definition is peripheral sensory neuropathy. The next most frequent AEs are paraesthesia and muscle weakness, respectively. It appears that peripheral neuropathy reported in MMB trials can be either sensory, motor or both, without a clear dominance for

<div style=\"page-break-after: always\"></div>

either sensory or motor. Of note, muscle atrophy has also been reported. Nevertheless, the majority of the events were mild and moderate in severity.

The incidence of infections were overall comparable during the RT with MMB, RUX and DAN; the rate of infections leading to death was low, a slightly higher incidence of infections leading to death were observed in MMB (2.2%) than in RUX (1.1%) or DAN (0%). With regards to opportunistic infections, no prominent difference was observed during the RT for MMB and RUX and DAN, respectively.

The incidence of malignancies is overall similar between MMB, RUX and DAN during RT. The most frequent malignancy was AML/transformation were reported for 1.8% MMB, 1.1% RUX, and 4.6% DAN. The greatest proportions of subjects had grade ≥ 3 events and were fatal.

According to literature, the frequency of leukemic evolution varies according to myeloproliferative neoplasms subtype. It is highest in primary myelofibrosis, where it is estimated to be approximately 10-20% at 10 years, following by polycythemia vera, with a risk of 2.3% at 10 years. The rate of transformation or survival does not appear to be influenced by JAK inhibitors treatment. With regard to malignancy and AML transformation; the data presented are in line with what has been previously reported in the literature for patients with MF and JAKi.

There is a prominent difference in term of COVID-19 AEs, including fatal events incidence, between MMB and DAN during the RT period in MOMENTUM STUDY.

There is no known potential mechanism to explain a higher risk of severe disease or death due to COVID-19 in patients receiving MMB. The majority of COVID-19 cases had pre-existing comorbidities commonly associated with risk of developing more severe COVID-19 disease and were not vaccinated against COVID-19.

Due to prominent imbalance of COVID-19 cases in MMB vs DAN, it cannot be excluded that MMB treatment may be associated with a higher risk of SARS-CoV-2 infection and a more severe risk of severe COVID-19. One of the possible mechanisms cited by the applicant in RTQ is that JAK inhibition can block the production of certain cytokines, such as type I interferons and interferon γ, which may interfere with the natural immune response (Adas, 2022). At longer term, vaccines may have had a mitigating effect in all patients since few serious/fatal COVID-19 infection cases were reported after the vaccination became widespread.

Shift from baseline of haematology parameters in the MMB RT period are similar to RUX and DAN with the exception of platelet decreased with a more prominent trend toward shift from grade 0 to 2 at baseline to grade 3 to 4 in the MMB compared with RUX and DAN. This is consistent with observations regarding the increased incidence in thrombocytopenia grade 3 and 4 adverse events and SAEs in MMB RT period.

DILI cases occurred in the phase 3 studied with MMB. The SmPC includes elevated liver enzymes as ADRs. Healthy volunteer QT study has been performed and no indication of MMB effect on QTcF has been reported. Routine postbaseline ECGs were discontinued in SIMPLIFY-1 and SIMPLIFY-2 studies and not formally analysed. In MOMENTUM ECGs were read locally and assessed predose and post baseline.

Overall, the rate of AEs are similar in males vs females who received either MMB, RUX or DAN in the RT period. In DAN treatment, males have higher incidence of G3 and G4 AES and fatal AEs than females. In MMB RT group; males had higher number of certain adverse vents than females as following: Grade 3 or 4 49.1% vs 34.5%, SAEs 34.3% vs 21.5%, SAE related 11.1% vs 4.5% and fatal 8.1% vs 4.0%.

Overall, patients who received MMB in the RT period and who were aged 65 or 75 and above years old have slightly higher incidence of grade 3 or 4, serious, fatal and adverse events leading to drug

<div style=\"page-break-after: always\"></div>

modification and discontinuation that patients between 18-64 and 18-74 years old. This trend is also observed in patients receiving DAN or RUX and may be due to comorbidities, disease progression associated with age rather than with study medication.

The majority of patients in the Ph III clinical program with MMB were White, followed by Asians and Blacks. Due to the low number of patients in the different race subgroups (ie each group includes less than 10% of the total population) no strong conclusion can be made regarding a different safety profile in Asians or Black than in White population.

For patients with creatinine clearance lower than 60 mL/min the incidence of adverse events (grade 3 or 4, serious, fatal or leading to drug discontinuation) were higher than for in patients with ≥ 60 mL/min for MMB, RUX and DAN.

For patients Grade 3 or 4, serious, fatal and AEs leading to drug discontinuation, the proportions of the MMB and RUX groups were consistently smaller for the higher baseline Hgb subgroups ( ≥ 8 and ≥ 10 g/dL) compared with the lower subgroups (&lt; 8 and &lt; 10 g/dL).

In the MMB RT group, the proportion of native and previously treated patients are similar. There is clear trend toward a higher incidence of Grade 3 or 4 (overall and related), serious (overall and related), fatal and who lead to study discontinuation/study drug modification. There is no such trend in the RUX treated patients for whom the rate of above mentioned types of adverse events in previously treated patients are similar or lower than in treatment-naïve patients in the MMB RT period.

DDI have been addressed in the PK section of the report. More patients in MMB received PPIs during treatment when compared to control treatment (RUX, DAN).

The rate of discontinuations due to G3 or above AEs in the MMB RT group was higher than RUX and lower than in DAN. The most frequent adverse events leading to discontinuation of MMB are haematology AE, namely thrombocytopenia.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics

## 2.6.10. Conclusions on the clinical safety

The safety profile of momelotinib has been characterised across a number of studies in patients with myeloproliferative disorders and healthy volunteers. A total of 725 patients have been exposed to momelotinib in these studies.

The information for safety assessment includes patients from three randomised controlled studies in patients with no prior JAK inhibitor treatment (SIMPLIFY-1), prior treatment with ruxolitinib (SIMPLIFY2), and prior treatment with an approved JAK inhibitor (ruxolitinib or fedratinib) in MOMENTUM study.

The safety profile is characterised by haematological adverse events (thrombocytopenia, anaemia) and gastrointestinal adverse events (diarrhoea, nausea), in line with the underlying disease and other JAK inhibitors. The incidence of thrombocytopenia is comparable with control (RUX, DAN), however it appears more severe with momelotinib.

Peripheral neuropathy was an adverse event of clinical importance and has been identified early in the clinical development of momelotinib. Infections and infestations are not unexpected in patients with the underlying disease or treatment.

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

Table 101: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                 |
|------------------------------|--------------------------------------------|
| Important identified risks   | Serious Infections                         |
| Important potential risks    | Major Adverse Cardiovascular Events (MACE) |
| Important potential risks    | Thromboembolism                            |
| Important potential risks    | Secondary Malignancies                     |
| Missing information          | None                                       |

## 2.7.2. Pharmacovigilance plan

No additional pharmacovigilance activities.

## 2.7.3. Risk minimisation measures

Table 102: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern     | Risk minimisation measures                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                       |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Serious Infections | Routine risk minimisation measures: SmPC sections 4.4 and 4.8 SmPC section 4.4 - recommendation on patient selection, patient observation and initiating appropriate treatment promptly PL sections 2 and 4 Legal status: Prescription only medicine Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None   |
| MACE               | Routine risk minimisation measures: SmPC section 4.4 Legal status: Prescription only medicine Additional risk minimisation measures: None                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None. |

<div style=\"page-break-after: always\"></div>

| Thromboembolism        | Routine risk minimisation measures: SmPC section 4.4 Legal status: Prescription only medicine Additional risk minimisation measures: None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None.   |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Secondary Malignancies | Routine risk minimisation measures: SmPC section 4.4 Legal status: Prescription only medicine Additional risk minimisation measures: None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None.   |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 0.2 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 15.09.2023. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Omjjara (momelotinib) is included in the

<div style=\"page-break-after: always\"></div>

additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

## 3.1.2. Available therapies and unmet medical need

MF is a rare, chronic, life-threatening disease that may arise de novo as primary (PMF) belonging to the group of myeloproliferative neoplasms (MPN) or develop from other pre-existing MPNs, namely PV or ET (post PV or post ET MF) grouped to secondary MF (SMF).  MF is a heterogeneous disease with key clinical  features  that  include  anaemia,  constitutional  symptoms, and splenomegaly.  All patients eventually become anaemic due to ineffective haematopoiesis, often associated with RBC transfusion dependency and worsening of thrombocytopenia.

The aim of therapy with JAK inhibitors is mainly symptomatic, there is currently no evidence regarding disease-modifying effects and impact on long-term efficacy outcomes such as overall survival.

The etiology of anaemia in MF is multifactorial, that could be distinguished as MF-associated anaemia with contributions from bone marrow fibrosis, direct effects of inflammation on the bone marrow microenvironment, splenomegaly with splenic sequestration; anaemia due to other causes than MF, such as indirect effects due to elevated hepcidin or concomitant factors or deficiencies that contribute to anaemia, and treatment-related anaemia (e.g., following treatment with JAK inhibitors). Anaemia is cardinal feature of this progressive disease and an important risk factor for poor survival at diagnosis, as determined by prognostic scores in patients not previously treated with JAK inhibitors. The impact of anaemia management on prognosis in JAK inhibitor-treated patients remains uncertain. Ruxolitinib and fedratinib are thought to exacerbate disease-related cytopenias (thrombocytopenia, anaemia, neutropenia) due to their myelosuppressive effect attributed mainly to JAK2 inhibition mechanism, necessitating dose modification, interruption, or discontinuation.  Compromised dose intensity can limit treatment effects on disease related splenomegaly and symptoms.  Therapies with a distinct safety profile potentially improving anaemia specific outcomes, along with control and alleviation of symptoms and reduction in spleen volume in patients with MF, may address a medical need for MF patients with anaemia, in particular in patients requiring RBC transfusions or being defined as transfusiondependent. There are currently no approved options for patients with MF who have moderate to severe anaemia.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The  main  evidence  of  efficacy  submitted  in  patients  with  primary  and  secondary  myelofibrosis  is coming from two phase 3 randomised controlled studies (MOMENTUM and SIMPLIFY-1), supported by the results of one additional randomised phase 3 trial (SIMPLIFY-2) and one single-arm Phase 2 trial (GU-US-352-1672).

These trials support respectively the indications:

- in patients that have been treated with ruxolitinib
- -SRA-MMB-301 (MOMENTUM) study with 24 weeks randomized, double-blind treatment period and 24 weeks open-label period, with cross-over allowed after 24 weeks
- -GS-US-352-1214  (SIMPLIFY-2)  with  24  weeks  randomised  open-label  treatment  period  and open-label extended treatment phase (up to 168 weeks) with momelotinib treatment in both arms
- in JAK inhibitor naïve patients
- -GU-US-352-0101 (SIMPLIFY-1) with  24  weeks  randomized,  double-blind  period  and  up  to  5 years open-label, with momelotinib monotherapy after 24 weeks in both arms
- -GU-US-352-1672 open-label, single-arm trial with momelotinib monotherapy.

Patients have been randomised at 2:1 or 1:1 ratio to momelotinib or active controls in

- -MOMENTUM trial (195 patients: 130 to momelotinib arm and 65 to danazol arm),
- -SIMPLIFY-2 trial (156 patients: 104 to momelotinib arm and 52 to best available therapy arm)
- -SIMPLIFY-1 trial (432 patients: 215 to momelotinib arm and 217 to ruxolitinib arm)

or treated in a single-arm GU-US-352-1672 trial (41 patients).

SRA-MMB-301  (MOMENTUM)  study  is  the  main  pivotal  trial  in  patients  previously  treated  with  JAK inhibitors while GS-US-352-1214 (SIMPLIFY-2) is the supportive study. In JAK inhibitor naïve patients GU-US-352-0101 (SIMPLIFY-1) is the main study supported by data from GU-US-352-1672 trial.

The primary and secondary endpoints differed in SRA-MMB-301 (MOMENTUM) study from SIMPLIFY-1 and SIMPLIFY-2 studies. MOMENTUM has two primary endpoints, i.e. the assessment of improvement of  symptoms,  by  evaluating  the  MFSAF  total  symptom  score  (TSS)  response  rate  at  week  24,  and assessment of anaemia-related outcomes, by evaluating the transfusion independency (TI) response at week 24. These two primary endpoints were however not co-primary endpoints. The study considered meeting both primary endpoints if superiority of TSS 24 was significant and at least non-inferiority of TI 24 was significant.

Both  GS-US-352-1214  (SIMPLIFY-2)  and  GU-US-352-0101  (SIMPLIFY-1)  studies  had  a  primary endpoint of Spleen response rate at week 24 (defined as the proportion of subjects who achieves a ≥ 35% reduction in spleen volume at wk 24 from baseline as measured by MRI or CT) and 4 secondary endpoints: response rate in TSS at Week 24, rate of RBC transfusion in the RT phase, RBC transfusion independence  (TI)  rate  at  Week  24  and  RBC  transfusion  dependence  (TD)  rate  at  Week  24  as secondary  endpoints.  The  SIMPLIFY-1  study  was  designed  to  demonstrate  non-inferiority  in  the primary endpoint of splenic response rate (compared to ruxolitinib), while the SIMPLIFY-2 study was designed to demonstrate superiority in that endpoint (compared to best available therapy).

All phase 3 trials included adults who were required to have confirmed diagnosis of PMF in accordance with the World Health Organization (WHO) criteria, or Post-PV/ET MF in accordance with the IWG-MRT

<div style=\"page-break-after: always\"></div>

criteria. In addition, prognostic scoring systems were considered for eligibility, with haemoglobin &lt; 10 g/dL  being  an  important  variable  contributing  to  the  score  (1  or  2  points)  and  to  the  consequently defined prognostic risk category. In MOMENTUM trial, eligible patients were required to having received prior  treatment with an approved JAK inhibitor after a wash-out period of at least 2 weeks. Eligible patients also had baseline splenomegaly, were symptomatic [defined as total symptom score ≥ 10 (on a total score of 70)] and had at least moderate anaemia (defined as haemoglobin &lt; 10 g/dL). This study also allowed enrolment of patients with severe thrombocytopenia (defined as platelet counts ≤ 50 x  10 9 /L,  however  not  lower  than  25  x  10 9 /L).  In  SIMPLIFY-2  trial,  a  similar  population  as  in  the MOMENTUM study was included, i.e. patients who received current or prior treatment with ruxolitinib that  was  complicated  with  hematologic  toxicity.  However,  patients  were  not  required  to  respect  a wash-out of prior JAK inhibitor therapy.

In SIMPLIFY-1 trial, only patients with no prior treatment with a JAK inhibitor were eligible. Similar as for  the  SIMPLIFY-2  study,  inclusion  of  non-anaemic  patients  was  allowed.  Patients  were  also  not required to be symptomatic.

## 3.2. Favourable effects

## Symptom response

In the MOMENTUM study, the MFSAF TSS response rate at 24 weeks was 24.62% (95% CI: 17.49, 32.94) for the momelotinib group and 9.23% (95% CI: 3.46, 19.02) for the danazol group, with a treatment difference of 15.67% (95% CI: 5.54, 25.81), p &lt;0.001.

This  result  for  a  primary  endpoint  in  the  MOMENTUM  study  was  supported  by  the  results  from  a secondary endpoint of change in MFSAF Total Symptom Score From Baseline at week 24. The absolute mean (SD) change from baseline in MFSAF TSS at week 24 was respectively -11.52 (12.86) and -3.93 (11.94) for the MMB and DAN group, with an LS (least squares) mean difference of -6.22 (95% CI: 10.0, -2.43), p &lt;0.01.

In the SIMPLIFY-1 study, in the post-hoc defined subgroup of patients with at least moderate anaemia, TSS  response  rate  was  consistent  (25.0%).  In  the  overall  population,  the  TSS  response  rate  was 28.4%, consistently with 24.6% and 26.2% in the MOMENTUM and SIMPLIFY-2, respectively.

## Spleen volume response

In SRA-MMB-301 (MOMENTUM) study, as the results for secondary endpoint measured at 24 weeks, 22.31% of patients treated with momelotinib reached a reduction in spleen volume of ≥ 35%. In the DAN group,  3.08%  reached  a  reduction  in  spleen  volume  of ≥ 35%.  The  treatment  difference  was 18.18% (95% CI: 9.77, 26.59; p =0.0011).

In the SIMPLIFY-1 trial, in the post-hoc defined subgroup of JAK inhibitor naïve patients with at least moderate anaemia, the SRR at Week 24 was numerically similar for MMB compared to RUX (31.4% versus 32.6% RUX). In the overall population, the primary endpoint of non-inferiority of MMB over RUX in SRR at week 24 was met [26.5% (95%CI: 20.74, 32.94) versus 29.5% (95% CI: 23.51, 36.04); p = 0.014].

## Anaemia-related outcomes

Results  for  anaemia-related  outcomes  are  considered  as  supportive.  In  the  MOMENTUM  study,  a numerically  higher  percent  of  patients  treated  with  Omjjara  (30%;  39/130)  achieved  transfusion independence (defined as no transfusions and all Hgb values ≥ 8 g/dL in the 12 weeks prior to week 24) compared with 20% (13/65) for danazol at week 24.

<div style=\"page-break-after: always\"></div>

In the SIMPLIFY-1 trial, in the post-hoc defined subgroup of patients with at least moderate anaemia, a numerically higher TI rate at week 24 has been observed for MMB (46.5%) versus RUX (27.4%).

Follow-up  data  of  TSS  response  rate,  TI  rate  and  SRR  at  Week  48  from  the  MOMENTUM  study supported the results at 24 weeks, with the majority of patients maintaining their response to MMB (72% for symptom response, 76% for splenic response and 88.2% for TI response).

## 3.3. Uncertainties and limitations about favourable effects

The proportion of missing data at Week 24 was substantial in the MOMENTUM and SIMPLIFY-2 studies in  JAKi-treated  patients,  mainly  due  to  early  discontinuation  of  treatment  before  completing  the double-blind phase at Week 24, while such proportion is lower in SIMPLIFY-1 in JAKi naïve patients (MOMENTUM: 26.2% MMB, 40.0% DAN; SIMPLIFY-2: 22.1% MMB, 19.2% BAT, SIMPLIFY-1: 12.6% MMB,  4.1%  RUX).  In  the  primary  analyses,  these  patients  with  missing  data  at  Week  24  were considered non-responders, which introduces uncertainty on the estimation of MMB treatment effects, in particular in case of important imbalances in proportion of missing data at Week 24 (MOMENTUM and  SIMPLIFY-1).  Post-hoc  sensitivity  analyses  using  various  missing  data  handling  methods  and assumptions were, however, overall consistent with the primary analyses and indicated that neither the  information  loss  nor  the  methods  used  to  handle  missing  data  had  a  substantial  impact  on  the study  conclusions  and  therefore  are  reassuring  for  the  reliability  and  the  validity  of  the  primary analysis results.

The  data  for  the  duration  of  symptom  response,  splenic  response  and  for  longer-term  data  for anaemia-related endpoints across the studies are confounded by the cross-over of patients from the control groups to MMB after week 24, not allowing to draw conclusions on comparisons for response durations.

In the SIMPLIFY-1 study, although double-blinded, the frequent protocol-mandated dose modifications for  ruxolitinib  compared  to  momelotinib  and  investigator  experience  with  ruxolitinib  may  have confounded assessments, in particular for symptom response.

## Symptom response

In the SIMPLIFY-1, non-inferiority of MMB over RUX in the secondary endpoint of modified MPN-SAF v2.0 TSS response rate at Week 24 could not be demonstrated, it was 28.4% (95% CI: 22.45, 35.03) versus 42.2% (95% CI: 35.43, 49.15) for ruxolitinib. A similar observation was made in the post-hoc defined subgroup of subjects with at least moderate anaemia (25.0% MMB, 36.2% RUX), hence lower TSS response rates were observed in the RUX arm for this subgroup compared to ITT, resulting in numerically  smaller  differential  treatment  effects  in  favour  of  ruxolitinib.  Several  limitations  to  the SIMPLIFY-1  design  might  have  contributed  in  failing  to  meet  non-inferiority,  however  missing  data sensitivity analyses suggest an important contribution of the imbalance in early discontinuation to the unmet TSS response rate results in SIMPLIFY-1, as they favoured the RUX study control arm.

## Spleen volume response

There was inconsistency in splenic response between two phase 3 studies in patients treated with JAK inhibitors. In the SIMPLIFY-2 study, the primary efficacy endpoint of superiority of MMB over BAT in SRR at week 24 was not met in ruxolitinib-treated patients which were exposed to momelotinib without a wash-out period after ruxolitinib exposure, and explained by maintenance of the effect of ongoing JAKi therapy. Lack of wash-out period for patients receiving MF therapy at screening was reported as 74% for MMB and 75% for BAT. The proportion of subjects with a ≥ 35% reduction from baseline in spleen volume at week 24 was 6.7% for the MMB group and 5.8% for the BAT group.

<div style=\"page-break-after: always\"></div>

## Anaemia-related outcomes

In  the  MOMENTUM  study,  superiority  could  not  be  demonstrated  for  a  second  primary  endpoint  of transfusion independency rate at week 24, which was 30.00% (95% CI: 22.28, 38.66) for the MMB group and 20.00% (95% CI: 11.10, 31.77) for the DAN group, with a treatment difference of 9.80% (95% CI: -2.03, 21.62). Moreover, given the absence of well-controlled data supporting danazol as active comparator, inference of efficacy based on non-inferiority with respect to transfusion independency rate is not supported. In addition, the observed treatment difference in TI rate (10%) is lower than expected (24%) and thus the clinical relevance of data for transfusion dependency rate is uncertain.

The  numerical  improvements  in  transfusion  burden  endpoints  reported  in  the  SIMPLIFY-1  and SIMPLIFY-2  studies  are  only  of  nominal  significance  due  to  missed  statistical  significance  in  the previous endpoint in the hierarchical testing. Results should thus be seen as exploratory.

In  addition,  the  clinical  relevance  of  the  observed  effects  on  anaemia-related  endpoints  in  the SIMPLIFY-1 study are uncertain. Transfusion independency endpoint was measured at the time of a nadir in haematology values during ruxolitinib treatment in the comparator arm, after which recovery is  known  to  occur.  Due  to  the  option  of  cross-over,  no  data  is  available  on  the  persistence  of  the transfusion independency effect of momelotinib compared to ruxolitinib after Week 24. Though crosstrial  comparisons  support  the  maintenance  of  momelotinib  advantage  over  ruxolitinib  in  reducing transfusion needs and anemia-related benefits after Week 24, the limitations related to such indirect comparisons should be considered.

## Survival

No definite conclusion of the effect of MMB on overall survival (OS) and leukemia-free survival (LFS) versus their respective comparator can be drawn across the three phase 3 studies, as the comparisons with their respective control groups were heavily confounded because of the high rate of cross-over from the control groups to the MMB group after Week 24 assessments.

## 3.4. Unfavourable effects

## Non-haematological toxicity

Peripheral sensory neuropathy was overall reported in 6.9% of patients in the pooled safety analyses, with  4.6%  and  1.5%  of  patients  experiencing  this  AE  when  treated  with  ruxolitinib  and  danazol, respectively. The elevated incidence of peripheral neuropathy events was reported in the early openlabel phase studies and about 50% of cases were irreversible/unresolved.

Anaemia all grades was reported as AE in 13.8% of patients in MMB during RT period; of these, 8.5% were AEs of grade 3 or more in severity.

Infections: the incidence of all grade infections in RT was 39% in MMB (42.7% in RUX and 35.4% in DAN). Of these, 9.8% were SAEs (comparing to 4.6% for RUX and 16.9% for DAN) and 2.2% were fatal events (comparing to 1.1% for RUX and 0 for DAN). Of note, 6/10 cases of fatal infections were related to COVID-19 infection.

## Haematological toxicity

Thrombocytopenia was reported in 19.4% treated with MMB versus 26.3% for ruxolitinib and 10.8% for  danazol.  Frequent  G3  and  G4  were  reported  and  thrombocytopenia  was  the  most  frequent  AE leading to discontinuation of treatment. This AE is related to mechanism of action of JAK inhibitors.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

## Peripheral sensory neuropathy

An uncertainty remains as regards the incidence which reported to be higher in the earlier studies (up to 50% in different trials).

## Hy's law criteria

There were 2 cases meeting Hy's law criteria; there is uncertainty on a potentially increased risk of serious hepatotoxic effects.

## Upper GI haemorrhages

Five SAEs of upper GI/GI haemorrhage were reported in the MMB, none for RUX or DAN.

## Severe hepatic impairment

As hepatic elimination is a major route of excretion for momelotinib, hepatic impairment may result in increased plasma momelotinib concentrations. In this context, the applicant provided the results of a dedicated study of momelotinib and its main metabolites in patients with moderate and severe hepatic impairment. The applicant considered the reduced exposure of the pharmacologically active metabolite, M21, to guide the dose adjustment recommendation. The overall 37% (based on geometric mean ratio) increase of AUC for the combined exposure justifies the recommended dose reduction of 25% of  the  starting  dose  from  200mg  to  150mg  once  daily  to  account  for  the  increase  in  plasma exposures  of  momelotinib  and  the  decrease  in  plasma  exposures  of  M21  in  subjects  with  severe hepatic impairment.

## Drug-drug interactions

Without an in vivo dedicated DDI study studying the impact of momelotinib on oral contraceptives, a risk  of  induction  of  other  non-CYP3A  enzymes  cannot  be  completely  excluded.  The  effectiveness  of concomitant  administration  of  oral  contraceptives  may  be  reduced  and  given  that  embryo-foetal toxicity  has  been  shown  with  momelotinib  in  studies  in  animals,  female  patients  of  child-bearing potential receiving momelotinib must use highly effective contraceptive methods during treatment. In this context, The applicant agreed to update sections 4.4, 4.6, and 5.2 to reflect that women using oral hormonal contraceptives should add an additional barrier method during OMJJARA treatment and for at least one week after the last dose. The updates were also made in the product information leaflet.

## Cardiac disorders

This is a class effect, incidence of serious cardiac disorders was 4.7% with the most frequent is atrial fibrillation. The incidence of 2.7% and 4.6% was reported for RUX and DAN respectively.

In addition, imbalance in frequency of COVID-19 cases in MMB was reported compared with DAN. In addition, there is no known mechanism to explain the higher incidence of COVID-19 in patients receiving MMB.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Effects Table for Omjjara in primary and secondary myelofibrosis (for favourable effects the data cut-off for MOMENTUM trial is 03 Dec 2021 and for SIMPLIFY-1 trial is 01 Jul 2019. For unfavourable effects the data cut-off is 03 Dec 2021)

| Effect                                                                                                             | Short Description                                                                                                        | Unit                                                                                                               | Treatme nt                                                                                                         | Control                                                                                                            | Uncertainties/ Strength of evidence                                                                                | Ref                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                    | Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                          | Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                    | Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                    | Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                    | Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                    | Favourable Effects Study SRA-MMB-301 (MOMENTUM) - prior JAK inhibitor treatment                                    |
|                                                                                                                    |                                                                                                                          |                                                                                                                    | MMB + DAN matched placebo n = 130                                                                                  | DAN + MMB matche d placebo n = 65                                                                                  |                                                                                                                    |                                                                                                                    |
| Symptom RR                                                                                                         | proportion of subjects with a ≥ 50% reduction in mean Myelofibrosis Symptom Assessment Form(MFSAF)version 4.0 TSS at w24 | % (95% CI)                                                                                                         | 24.62% (17.49, 32.94)                                                                                              | 9.23% (3.46, 19.02)                                                                                                |                                                                                                                    |                                                                                                                    |
| SRR at Week 24 [ ≥ 35% reduction in spleen volume]                                                                 | proportion of subjects who had splenic response based on ≥ 35% reduction in spleen volume from baseline                  | % (95% CI)                                                                                                         | 22.31 (15.48, 30.44)                                                                                               | 3.08 (0.37, 10.68)                                                                                                 |                                                                                                                    |                                                                                                                    |
| Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL) | Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL)       | Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL) | Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL) | Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL) | Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL) | Favourable Effects Study GU-US-352-0101 (SIMPLIFY-1) - JAK inhibitor naïve, anaemic subgroup (Hgb values <10 g/dL) |
|                                                                                                                    |                                                                                                                          |                                                                                                                    | MMB + RUX matched placebo n = 86                                                                                   | RUX + MMB matche d placebo n = 95                                                                                  |                                                                                                                    |                                                                                                                    |
| Spleen RR                                                                                                          | proportion of subjects who had splenic response based on ≥ 35% reduction in spleen volume from baseline at 24w           | % (95% CI)                                                                                                         | 31.4 (21.81, 42.30)                                                                                                | 32.6 (23.36, 43.02)                                                                                                | Post-hoc subgroup analysis                                                                                         |                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Effect                        | Short Description                                                                                                                   | Unit                 | Treatme nt           | Control              | Uncertainties/ Strength of evidence                                                                                                                                                                                     | Ref                  |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Symptom RR                    | proportion of subjects with a ≥ 50% reduction in mean Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) version 2.0 TSS | % (95% CI)           | 25.0 (16.19, 35.64)  | 36.2 (26.51, 46.73)  | Post-hoc subgroup analysis Non-inferiority compared to RUX not demonstrated in the overall population                                                                                                                   |                      |
| Unfavourable Effects          | Unfavourable Effects                                                                                                                | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                    | Unfavourable Effects |
|                               |                                                                                                                                     |                      | MMB n=448            | RUX n=262 DAN n=65   |                                                                                                                                                                                                                         |                      |
| Peripheral sensory neuropathy | Incidence of peripheral sensory neuropathy                                                                                          | %                    | 6.9                  | 4.6 1.5              | Infrequent G3 and G4, two serious cases                                                                                                                                                                                 |                      |
| Thrombocytop enia             | Incidence of thrombocytopenia                                                                                                       | %                    | 19.4                 | 26.3 10.8            | Frequent G3 and G4, related to MoA; thrombocytopenia was the most frequent AE leading to discontinuation of treatment                                                                                                   |                      |
| Anaemia                       | Incidence of anaemia                                                                                                                | %                    | 18.4                 | 34.4 15.4            | Grade 3 and above anaemia in MMB RT group was 8.3% (21.8 in RUX and 10.8% in DAN)                                                                                                                                       |                      |
| Upper GI haemorrhages         | Cases of upper GI bleeding                                                                                                          | n                    | 5                    | 0 0                  | 5 SAEs of upper GI/GI hemorrhage in the MMB, none in RUX or DAN                                                                                                                                                         |                      |
| Infections                    | Infections incidence                                                                                                                | %                    | 39.7                 | 42.7 35.4            | 9.8 were SAEs (comparing to 4.6% for RUX and 16.9% for DAN) 2.2% were fatal events (comparing to 1.1% for RUX and 0% for DAN); 6/10 cases of fatal infections were related to COVID-19 infection of uncertain causality |                      |
| Hy's law cases                | Cases of Hy's law                                                                                                                   | n                    | 2                    | 0 0                  | ALT/AST increases are known JAKi effect                                                                                                                                                                                 |                      |
| Cardiac disorders             | Serious cardiac disorders incidence                                                                                                 | %                    | 4.7                  | 2.7 4.6              | Known JAKi effect                                                                                                                                                                                                       |                      |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The alleviation of symptoms associated with MF, either constitutional or related to organomegaly is of clinical relevance for patients and are of direct benefit.

In the JAK inhibitor pretreated patient population, the benefit of momelotinib on disease-related symptoms is considered clinically meaningful, mainly based on the results of the MOMENTUM trial in the JAK inhibitor pre-treated patient population with at least moderate anemia (haemoglobin &lt;10 g/dL, per protocol eligibility).

The results of the MOMENTUM trial are also in favor of momelotinib for disease-related splenomegaly. However, a lower magnitude of response was observed in the SIMPLIFY-2 trial compared to the MOMENTUM trial. This may be explained by differences in wash-out period after prior JAK inhibitor therapy (absent in SIMPLIFY-2), likely resulting in confounded treatment effect due maintenance of the effect of ongoing JAKi therapy in the majority of patients in both treatment arms. Superiority for MMB vs BAT was not met for SRR, although splenic volume control was maintained.

In JAK inhibitor naïve patients, while non-inferiority of MMB to RUX was met for the primary endpoint of splenic response rate, it was not met for the first secondary endpoint of TSS response rate. Missing data sensitivity analyses conducted post hoc suggest an important contribution of the imbalance in the proportion of patients who early discontinued study treatment due to protocol defined safety-based dose modification scheme differences. These imbalances were favouring the RUX study control arm. In addition, with the limits intrinsic to cross-trial comparisons, consistency in magnitude of the MMB TSS response across phase 3 studies suggests a clinically meaningful magnitude of effect for MMB. Although this effect is numerically lower for MMB compared to that reported for the other JAK inhibitors as ruxolitinib (SIMPLIFY-1 and COMFORT-1) and fedratinib (JAKARTA-1) in JAKi naïve patients, it supports the overall effect of MMB on other clinically relevant endpoints and contributes to the totality of supportive data.

As regards the anaemia-related outcomes, it is acknowledged that overall consistent results were observed across studies and that overall data support the reduced requirements for transfusions. Moreover, the myelosuppressive effects of prior JAK inhibitors might be counteracted by additional mechanisms. While inhibiting JAK2, momelotinib appears to have less worsening effect for cytopenias. Its distinct mechanism of action through inhibiting the ACVR1 SMAD signaling pathway was associated with reduced hepcidin levels, thus potentially increasing iron availability for erythropoiesis.

However, the evidence supporting the anaemia-related outcomes can only be considered of nonconfirmatory nature in both the JAKi treated and JAKi naïve population, mainly due to methodological issues, either for non-inferiority testing for TI rate over danazol or hierarchical multiplicity control, respectively. Hence, the claim of 'anaemia treatment' was not supported. The restricted indication for adult patients with moderate to severe anaemia in both JAKi treated and JAKi naïve patients relies, respectively, on the results of the pivotal MOMENTUM trial in patients with at least moderate anaemia per eligibility criteria (ITT population) and on post-hoc subgroup analysis of the SIMPLIFY-1 trial in anaemic patients with more advanced disease, progressively compromised erythropoiesis and in need of therapy not worsening and potentially counteracting anaemia .

As regards the observed safety profile, derived in a relatively large number of patients with rare disease and with longer follow-up data from earlier studies available, it does no outweigh the clinically meaningful effects and allows treatment in more advanced patients. Manageable safety profile was observed with acceptable incidence and severity of adverse events in the intended clinical setting.

<div style=\"page-break-after: always\"></div>

Some non-hematologic toxicities were reported, mainly known JAK inhibitor class effects and were either of relatively low incidence or with high grade in a limited proportion of patients. Some haematological toxicities were observed, such as thrombocytopenia, which could result in early treatment discontinuations of this long-term treatment. However patients with low platelet counts (until 25x10 9 ) could be treated in the MOMENTUM trial, with few serious adverse events of bleeding reported. One of the notable toxicities is peripheral sensory neuropathy, which is generally of low grade but irreversible or reported as ongoing in about half of patients, it resulted in treatment discontinuation in early studies. Inconsistent incidence was reported peripheral sensory neuropathy between early and later trials. Class effects of JAK inhibitors include among others risk of severe infections and secondary malignancies, but overall safety profile show some differences with other JAK inhibitors. There is an uncertainty on the MACE incidence and severity, it is considered as important potential risk.

The effect of momelotinib on disease-related splenomegaly (SRR of 22.3%) and symptoms (TSS response rate of 24.6%) in JAK inhibitor treated patients as demonstrated in the MOMENTUM study is considered of clinical relevance in this advanced myelofibrosis setting. With the limits intrinsic to indirect comparison, the observed splenic and symptom response rates are in the same order of magnitude as that of the 22.7% and 21.5% reported respectively for similar endpoints in ruxolitinibpretreated patients who received treatment with fedratinib 400 mg QD in the JAKARTA-2 study.

With  regard  to  the  JAK  inhibitor  treated  population,  all  patients  in  the  SIMPLIFY-2  study  and MOMENTUM  previously  received  ruxolitinib.  Only  few  patients  in  the  MOMENTUM  study  (n  =  9) additionally  received  prior  fedratinib,  not  allowing  to  make  definite  conclusions  on  the  benefit  of momelotinib  in  the  subgroup  of  patients  previously  treated  with  fedratinib  and  not  supporting extrapolation to the entire pharmaceutical class, taking into account differential targeting of kinases with  differences  in  underlying  mechanism  of  action,  with  potential  differences  in  cross-resistance mechanisms.

Based on the totality of data, MMB is considered to provide benefits in the JAKi naïve setting: the effect on  disease-related  splenomegaly  is  considered  clinically  meaningful  and  the  magnitude  of  effect  on disease-related symptoms is consistent across momelotinib trials, although lower when compared to approved JAK inhibitors.

In addition, in the JAKi pretreated setting, momelotinib might be a valuable treatment option in MF patients with moderate or severe anaemia, where both disease-related and treatment-related anaemia are of significant burden for patients as it is frequently associated with requirements for RBC transfusions and transfusion dependency. In JAKi-naïve setting, patients with manifestation of at least moderate anaemia may also derive benefit at longer term, due to potentially reduced RBC transfusion requirements of particular relevance in this subgroup. The totality of evidence suggests a relevant safety and efficacy profile, with sparing and potentially improving effect on erythropoiesis.

## 3.7.2. Balance of benefits and risks

The benefit-risk for the indications 'for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib ' is positive.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall benefit/risk balance of Omjjara is positive.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Omjjara is not similar to Inrebic within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Omjjara is favourable in the following indication:

for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;

<div style=\"page-break-after: always\"></div>

- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that momelotinib is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.